PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
7712016-2	1995	Our previous work has shown that injection into mice of lipopolysaccharide (LPS) and the cytokines interleukin 1 (IL-1) and tumour necrosis factor (TNF) induces histidine decarboxylase (HDC), the enzyme forming histamine, in various tissues such as liver, lung, spleen and bone marrow, but not in the blood.	Histamine	211-220	interleukin 1 complex	Mus musculus	99-118
8770556-4	1995	We found that poly(A)+ mRNAs for IL-1, IL-3, IL-6, IL-7, and TNF alpha are differentially expressed at several stages of mouse preimplantation development, including unfertilized oocytes.	Poly A	14-21	interleukin 1 complex	Mus musculus	33-37
7526541-8	1994	Blockade of TNF-alpha by a pentoxifylline treatment led to the decrease of IL-1 and iNOS expression accompanied by a reduction of the volume of the lesions indicating that the Tat-induced lesions might be mediated by TNF production.	Pentoxifylline	27-41	interleukin 1 complex	Mus musculus	75-79
7705961-3	1994	Supernatants collected from macrophages treated with cisplatin and EGTA, nifedipine, TMB-8 or W-7 demonstrated decreased tumor necrosis factor (TNF) and interleukin-1 (IL-1) activity in comparison to supernatants collected from macrophages treated with cisplatin alone.	Cisplatin	53-62	interleukin 1 complex	Mus musculus	153-172
7705961-3	1994	Supernatants collected from macrophages treated with cisplatin and EGTA, nifedipine, TMB-8 or W-7 demonstrated decreased tumor necrosis factor (TNF) and interleukin-1 (IL-1) activity in comparison to supernatants collected from macrophages treated with cisplatin alone.	Egtazic Acid	67-71	interleukin 1 complex	Mus musculus	153-172
7705961-3	1994	Supernatants collected from macrophages treated with cisplatin and EGTA, nifedipine, TMB-8 or W-7 demonstrated decreased tumor necrosis factor (TNF) and interleukin-1 (IL-1) activity in comparison to supernatants collected from macrophages treated with cisplatin alone.	Nifedipine	73-83	interleukin 1 complex	Mus musculus	153-172
7705961-3	1994	Supernatants collected from macrophages treated with cisplatin and EGTA, nifedipine, TMB-8 or W-7 demonstrated decreased tumor necrosis factor (TNF) and interleukin-1 (IL-1) activity in comparison to supernatants collected from macrophages treated with cisplatin alone.	8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate	85-90	interleukin 1 complex	Mus musculus	153-172
7947614-9	1994	Inhibition of IL-1 activity with IL-1 receptor antagonist partially inhibited the increase in serum triglycerides; however, the ability of LPS to decrease LPL activity in either adipose or muscle tissue was not affected.	Triglycerides	100-113	interleukin 1 complex	Mus musculus	14-18
7947614-9	1994	Inhibition of IL-1 activity with IL-1 receptor antagonist partially inhibited the increase in serum triglycerides; however, the ability of LPS to decrease LPL activity in either adipose or muscle tissue was not affected.	Triglycerides	100-113	interleukin 1 complex	Mus musculus	33-37
7947614-10	1994	These data indicate that although TNF and IL-1 play a role in mediating the increase in serum triglyceride levels, these cytokines do not play a crucial role in the inhibition of either adipose or muscle LPL activity.	Triglycerides	94-106	interleukin 1 complex	Mus musculus	42-46
7877456-6	1994	Oligonucleotide probes were then synthesized and used in RT-PCR followed by Southern blotting to show that the whole brain expresses transcripts for both the type I and type II IL-1 receptors.	Oligonucleotides	0-15	interleukin 1 complex	Mus musculus	177-181
7852051-1	1994	Macrophages from SJL and DBA mice incubated with mercuric chloride (HgCl2) in vitro for 24-72 h secreted an increased amount of interleukin 1 (IL-1) to the supernatant compared with control-incubated macrophages, as determined by a sensitive thymocyte proliferation assay.	1,2,5,6-dibenzanthracene	25-28	interleukin 1 complex	Mus musculus	128-147
7858871-2	1994	The non-steroidal anti-inflammatory drugs (NSAIDs) indomethacin, 10 and 100 microM, piroxicam, 100 microM, and sodium meclofenamate, 1 and 100 microM, potentiated the lipopolysaccharide (LPS)-stimulated release of interleukin-1 (IL-1)-like activity from mouse peritoneal macrophages.	Meclofenamic Acid	111-131	interleukin 1 complex	Mus musculus	214-227
7858871-2	1994	The non-steroidal anti-inflammatory drugs (NSAIDs) indomethacin, 10 and 100 microM, piroxicam, 100 microM, and sodium meclofenamate, 1 and 100 microM, potentiated the lipopolysaccharide (LPS)-stimulated release of interleukin-1 (IL-1)-like activity from mouse peritoneal macrophages.	Meclofenamic Acid	111-131	interleukin 1 complex	Mus musculus	229-233
7858871-8	1994	The potentiation of LPS-stimulated release of IL-1-like activity produced by indomethacin, 100 microM, piroxicam, 100 microM, or sodium meclofenamate, 10 microM, was inhibited by prostaglandin E2, (PGE2) 10 ng ml-1.	Indomethacin	77-89	interleukin 1 complex	Mus musculus	46-50
7858871-8	1994	The potentiation of LPS-stimulated release of IL-1-like activity produced by indomethacin, 100 microM, piroxicam, 100 microM, or sodium meclofenamate, 10 microM, was inhibited by prostaglandin E2, (PGE2) 10 ng ml-1.	Piroxicam	103-112	interleukin 1 complex	Mus musculus	46-50
7858871-8	1994	The potentiation of LPS-stimulated release of IL-1-like activity produced by indomethacin, 100 microM, piroxicam, 100 microM, or sodium meclofenamate, 10 microM, was inhibited by prostaglandin E2, (PGE2) 10 ng ml-1.	Meclofenamic Acid	129-149	interleukin 1 complex	Mus musculus	46-50
7858871-8	1994	The potentiation of LPS-stimulated release of IL-1-like activity produced by indomethacin, 100 microM, piroxicam, 100 microM, or sodium meclofenamate, 10 microM, was inhibited by prostaglandin E2, (PGE2) 10 ng ml-1.	Dinoprostone	179-195	interleukin 1 complex	Mus musculus	46-50
7858871-8	1994	The potentiation of LPS-stimulated release of IL-1-like activity produced by indomethacin, 100 microM, piroxicam, 100 microM, or sodium meclofenamate, 10 microM, was inhibited by prostaglandin E2, (PGE2) 10 ng ml-1.	Dinoprostone	198-202	interleukin 1 complex	Mus musculus	46-50
7858871-10	1994	Aspirin, 100 microM, indomethacin, 100 nM to 10 microM, piroxicam, 1 to 100 microM, and sodium meclofenamate, 10 nM, all potentiated cell-associated IL-1-like activity in LPS- stimulated macrophages.	Aspirin	0-7	interleukin 1 complex	Mus musculus	149-153
7858871-10	1994	Aspirin, 100 microM, indomethacin, 100 nM to 10 microM, piroxicam, 1 to 100 microM, and sodium meclofenamate, 10 nM, all potentiated cell-associated IL-1-like activity in LPS- stimulated macrophages.	Indomethacin	21-33	interleukin 1 complex	Mus musculus	149-153
7858871-10	1994	Aspirin, 100 microM, indomethacin, 100 nM to 10 microM, piroxicam, 1 to 100 microM, and sodium meclofenamate, 10 nM, all potentiated cell-associated IL-1-like activity in LPS- stimulated macrophages.	Piroxicam	56-65	interleukin 1 complex	Mus musculus	149-153
7858871-10	1994	Aspirin, 100 microM, indomethacin, 100 nM to 10 microM, piroxicam, 1 to 100 microM, and sodium meclofenamate, 10 nM, all potentiated cell-associated IL-1-like activity in LPS- stimulated macrophages.	Meclofenamic Acid	88-108	interleukin 1 complex	Mus musculus	149-153
7858871-13	1994	Exogenous PGE2, 2 to 30 ng ml-1, inhibited the cell-accumulation of IL-1-like activity stimulated by LPS in the presence of indomethacin, 1 microM, or sodium meclofenamate, 0.1 microM.	Dinoprostone	10-14	interleukin 1 complex	Mus musculus	68-72
7858871-13	1994	Exogenous PGE2, 2 to 30 ng ml-1, inhibited the cell-accumulation of IL-1-like activity stimulated by LPS in the presence of indomethacin, 1 microM, or sodium meclofenamate, 0.1 microM.	Indomethacin	124-136	interleukin 1 complex	Mus musculus	68-72
7858871-13	1994	Exogenous PGE2, 2 to 30 ng ml-1, inhibited the cell-accumulation of IL-1-like activity stimulated by LPS in the presence of indomethacin, 1 microM, or sodium meclofenamate, 0.1 microM.	Meclofenamic Acid	151-171	interleukin 1 complex	Mus musculus	68-72
7874076-4	1994	The protein kinase C (PKC) activator phorbol myristic acid (PMA) stimulated PGE2 production in both strains but not IL-1 production, suggesting that signalling pathways other than PKC may be involved in IL-1 production.	phorbol-12-myristate	37-58	interleukin 1 complex	Mus musculus	203-207
7874076-4	1994	The protein kinase C (PKC) activator phorbol myristic acid (PMA) stimulated PGE2 production in both strains but not IL-1 production, suggesting that signalling pathways other than PKC may be involved in IL-1 production.	phorbol-12-myristate	60-63	interleukin 1 complex	Mus musculus	203-207
7868298-0	1994	Suramin blocks the binding of interleukin-1 to its receptor and neutralizes IL-1 biological activities.	Suramin	0-7	interleukin 1 complex	Mus musculus	76-80
7868298-1	1994	This report demonstrates the ability of the anti-cancer drug suramin to interfere with the binding of interleukin (IL)-1 to its receptor and to inhibit IL-1-induced biological activities.	Suramin	61-68	interleukin 1 complex	Mus musculus	152-156
7868298-2	1994	In a radioreceptor cell based assay, suramin inhibits the binding of IL-1 alpha to several murine cell lines expressing predominantly type I and type II IL-1 receptors.	Suramin	37-44	interleukin 1 complex	Mus musculus	69-73
7868298-3	1994	Affinity cross-linking experiments using IL-1 alpha and EL-4.6.1 cells confirms that suramin inhibits the binding of the ligand to the 80 kDa IL-1 type I receptor.	Suramin	85-92	interleukin 1 complex	Mus musculus	41-45
7868298-5	1994	In a cell-free system, suramin prevents the binding of IL-1 alpha and IL-1 beta to murine and human recombinant soluble type I IL-1 receptors.	Suramin	23-30	interleukin 1 complex	Mus musculus	55-59
7868298-6	1994	For example, the IC50 for suramin inhibiting IL-1 alpha and IL-1 beta binding to soluble human IL-1 receptor were 204 microM and 186 microM, respectively.	Suramin	26-33	interleukin 1 complex	Mus musculus	45-49
7868298-7	1994	The suramin analogues, NF-058 and NF-103 (which bear the same number of sulfate groups as suramin), are between three- and ten-fold less active than suramin in inhibiting IL-1 binding to EL-4.6.1 cells, and to recombinant soluble IL-1 receptor.	Suramin	4-11	interleukin 1 complex	Mus musculus	171-175
7868298-7	1994	The suramin analogues, NF-058 and NF-103 (which bear the same number of sulfate groups as suramin), are between three- and ten-fold less active than suramin in inhibiting IL-1 binding to EL-4.6.1 cells, and to recombinant soluble IL-1 receptor.	Suramin	4-11	interleukin 1 complex	Mus musculus	230-234
7868298-8	1994	Furthermore, in a dose-dependent manner suramin prevents several IL-1 mediated biological responses, including thymocyte proliferation, PGE-2 synthesis and IL-6 production.	Suramin	40-47	interleukin 1 complex	Mus musculus	65-69
7852051-1	1994	Macrophages from SJL and DBA mice incubated with mercuric chloride (HgCl2) in vitro for 24-72 h secreted an increased amount of interleukin 1 (IL-1) to the supernatant compared with control-incubated macrophages, as determined by a sensitive thymocyte proliferation assay.	Mercuric Chloride	49-66	interleukin 1 complex	Mus musculus	128-147
7868298-10	1994	Taken together, the results indicate that suramin is a competitive IL-1 receptor antagonist.	Suramin	42-49	interleukin 1 complex	Mus musculus	67-71
7868298-11	1994	Because IL-1 participates in a broad range of immunological and inflammatory functions, the data suggest that suramin administration may influence important activities beyond those associated strictly with tumor inhibition.	Suramin	110-117	interleukin 1 complex	Mus musculus	8-12
7852051-1	1994	Macrophages from SJL and DBA mice incubated with mercuric chloride (HgCl2) in vitro for 24-72 h secreted an increased amount of interleukin 1 (IL-1) to the supernatant compared with control-incubated macrophages, as determined by a sensitive thymocyte proliferation assay.	Mercuric Chloride	68-73	interleukin 1 complex	Mus musculus	128-147
7852051-5	1994	Topical application of HgCl2 in a mixture of acetone-olive oil on the external ear of SJL mice induced a dose- and time-dependent increase in IL-1 activity.	Mercuric Chloride	23-28	interleukin 1 complex	Mus musculus	142-146
7852051-5	1994	Topical application of HgCl2 in a mixture of acetone-olive oil on the external ear of SJL mice induced a dose- and time-dependent increase in IL-1 activity.	Acetone	45-52	interleukin 1 complex	Mus musculus	142-146
7852051-6	1994	A maximal increase was seen after application of 1% HgCl2 for 24 h with lower IL-1 activity after 48 and 72 h. Application of 5%, but not 1% or 0.1%, slightly increased the IL-1 activity in the contralateral ear treated with acetone-olive oil only, as compared with the activity in ears from animals given no mercury treatment, suggesting a systemic effect by application of 5% HgCl2.	Mercuric Chloride	52-57	interleukin 1 complex	Mus musculus	78-82
7852051-6	1994	A maximal increase was seen after application of 1% HgCl2 for 24 h with lower IL-1 activity after 48 and 72 h. Application of 5%, but not 1% or 0.1%, slightly increased the IL-1 activity in the contralateral ear treated with acetone-olive oil only, as compared with the activity in ears from animals given no mercury treatment, suggesting a systemic effect by application of 5% HgCl2.	Mercuric Chloride	52-57	interleukin 1 complex	Mus musculus	173-177
7852051-6	1994	A maximal increase was seen after application of 1% HgCl2 for 24 h with lower IL-1 activity after 48 and 72 h. Application of 5%, but not 1% or 0.1%, slightly increased the IL-1 activity in the contralateral ear treated with acetone-olive oil only, as compared with the activity in ears from animals given no mercury treatment, suggesting a systemic effect by application of 5% HgCl2.	Mercury	309-316	interleukin 1 complex	Mus musculus	173-177
7852051-6	1994	A maximal increase was seen after application of 1% HgCl2 for 24 h with lower IL-1 activity after 48 and 72 h. Application of 5%, but not 1% or 0.1%, slightly increased the IL-1 activity in the contralateral ear treated with acetone-olive oil only, as compared with the activity in ears from animals given no mercury treatment, suggesting a systemic effect by application of 5% HgCl2.	Mercuric Chloride	378-383	interleukin 1 complex	Mus musculus	173-177
7524369-4	1994	However, combinations of IFN with either TNF or IL-1 resulted in significant nitrite production; simultaneous stimulation of cells with all three cytokines resulted in significantly increased nitrite production compared with any combination of two cytokines.	Nitrites	77-84	interleukin 1 complex	Mus musculus	48-52
8068940-5	1994	As expected, IL-1 increased white blood cell counts, splenic granulocyte-macrophage colony-forming units, and spleen cell number, and protected mice from lethal doses of carboplatin (200 mg/kg; Paraplatin, Bristol Laboratories, Evansville, IN) administered the day after completion of the 7 days of IL-1 administration.	Carboplatin	170-181	interleukin 1 complex	Mus musculus	13-17
7879702-3	1994	Human recombinant tumour necrosis factor-alpha (TNF-alpha) and the calcium ionophores A23187 and ionomycin induced a concentration-dependent increase of cell-associated IL-1 but failed to cause release of IL-1 at concentrations producing maximal stimulation of cell-associated IL-1.	Calcium	67-74	interleukin 1 complex	Mus musculus	169-173
7879702-3	1994	Human recombinant tumour necrosis factor-alpha (TNF-alpha) and the calcium ionophores A23187 and ionomycin induced a concentration-dependent increase of cell-associated IL-1 but failed to cause release of IL-1 at concentrations producing maximal stimulation of cell-associated IL-1.	Calcimycin	86-92	interleukin 1 complex	Mus musculus	169-173
7879702-3	1994	Human recombinant tumour necrosis factor-alpha (TNF-alpha) and the calcium ionophores A23187 and ionomycin induced a concentration-dependent increase of cell-associated IL-1 but failed to cause release of IL-1 at concentrations producing maximal stimulation of cell-associated IL-1.	Ionomycin	97-106	interleukin 1 complex	Mus musculus	169-173
7879702-4	1994	The phorbol ester, 4 beta-phorbol dibutyrate, stimulated the release of IL-1 from mouse macrophages but failed to induce an increase in cell-associated IL-1.	Phorbol Esters	4-17	interleukin 1 complex	Mus musculus	72-76
7879702-4	1994	The phorbol ester, 4 beta-phorbol dibutyrate, stimulated the release of IL-1 from mouse macrophages but failed to induce an increase in cell-associated IL-1.	4 beta-phorbol dibutyrate	19-44	interleukin 1 complex	Mus musculus	72-76
7879702-7	1994	It appears that a calcium signal is sufficient for the transcription and translation of IL-1 mRNA but does not result in the secretion of biologically active forms of IL-1.	Calcium	18-25	interleukin 1 complex	Mus musculus	88-92
7523795-3	1994	Using PCR, we demonstrated GM-CSF and IL-1 expression by adherent cells taken from marrow fibroblast layers following Ara-C-induced hematopoietic damage and during marrow regeneration, while expression in control layers was not detected.	Cytarabine	118-123	interleukin 1 complex	Mus musculus	38-42
7523795-7	1994	While IL-3 and GM-CSF were not present in the conditioned medium of marrow fibroblast layers either from Ara-C-treated mice or controls, IL-1 was found in low concentrations in cultures from Ara-C-treated animals.	Cytarabine	191-196	interleukin 1 complex	Mus musculus	137-141
8080048-1	1994	By administering physiological doses of interleukin-1 (IL-1) concurrently with multiple low doses of the beta cell toxin streptozotocin (MSZ), we observed an augmentation of diabetes by IL-1 in four different strains of mice.	Streptozocin	121-135	interleukin 1 complex	Mus musculus	186-190
8080048-1	1994	By administering physiological doses of interleukin-1 (IL-1) concurrently with multiple low doses of the beta cell toxin streptozotocin (MSZ), we observed an augmentation of diabetes by IL-1 in four different strains of mice.	CHEMBL4458573	137-140	interleukin 1 complex	Mus musculus	186-190
8080048-2	1994	Augmentation of hyperglycemia by IL-1 was most prominent in the two MSZ-resistant mouse strains Balb/cJ and A/J.	CHEMBL4458573	68-71	interleukin 1 complex	Mus musculus	33-37
8080048-3	1994	Furthermore, concurrent treatment with IL-1 and MSZ rendered these MSZ-resistant mice susceptible to the development of significant insulitis when compared to mice treated with MSZ alone.	CHEMBL4458573	67-70	interleukin 1 complex	Mus musculus	39-43
8080048-3	1994	Furthermore, concurrent treatment with IL-1 and MSZ rendered these MSZ-resistant mice susceptible to the development of significant insulitis when compared to mice treated with MSZ alone.	CHEMBL4458573	67-70	interleukin 1 complex	Mus musculus	39-43
8080048-7	1994	We conclude that IL-1 synergizes with MSZ to augment diabetes in mice that are normally resistant to the diabetogenic effects of MSZ.	CHEMBL4458573	129-132	interleukin 1 complex	Mus musculus	17-21
8068940-5	1994	As expected, IL-1 increased white blood cell counts, splenic granulocyte-macrophage colony-forming units, and spleen cell number, and protected mice from lethal doses of carboplatin (200 mg/kg; Paraplatin, Bristol Laboratories, Evansville, IN) administered the day after completion of the 7 days of IL-1 administration.	Carboplatin	194-204	interleukin 1 complex	Mus musculus	13-17
7948065-4	1994	When the islets of NOD mice were incubated with the IL-1 (10, 100 U/ml) under condition of high glucose, IAP and endogenous retrovirus type C frequently appeared in the beta-cells.	Glucose	96-103	interleukin 1 complex	Mus musculus	52-56
7827288-9	1994	Because IL-1 synthesis was inducible in spleen cells following actinomycin D treatment, the results indicate that at distant sites of infection IL-1 (alpha and beta) mRNA is expressed but not translated into protein.	Dactinomycin	63-76	interleukin 1 complex	Mus musculus	8-12
7827288-9	1994	Because IL-1 synthesis was inducible in spleen cells following actinomycin D treatment, the results indicate that at distant sites of infection IL-1 (alpha and beta) mRNA is expressed but not translated into protein.	Dactinomycin	63-76	interleukin 1 complex	Mus musculus	144-148
8051402-8	1994	Finally, the cells responding to IL-1 + IL-7 were identified as mature CD4-CD8-TCR+ thymocytes by the use of bromodeoxyuridine (BrdUrd), suggesting that the GM-CSF produced by thymic accessory cells in response to IL-1 participates in IL-7-dependent, intrathymic expansion of the CD4-CD8-TCR+ compartment.	Bromodeoxyuridine	109-126	interleukin 1 complex	Mus musculus	33-37
7932187-2	1994	Because delta 9-tetrahydrocannabinol (THC) treatment also has been reported to affect these physiological responses, we tested the drug effect on IL1 production and secretion.	Dronabinol	8-36	interleukin 1 complex	Mus musculus	146-149
7932187-2	1994	Because delta 9-tetrahydrocannabinol (THC) treatment also has been reported to affect these physiological responses, we tested the drug effect on IL1 production and secretion.	Dronabinol	38-41	interleukin 1 complex	Mus musculus	146-149
7932187-3	1994	Addition of THC to endotoxin (ETX)-treated murine, resident peritoneal macrophage cultures increased, in a dose-dependent manner, supernatant IL1 activity over ETX only treatment.	Dronabinol	12-15	interleukin 1 complex	Mus musculus	142-145
7932187-10	1994	These results suggest THC augments the ETX-induced processing of IL1 beta and release of IL1 alpha rather than increasing the cellular production of IL1 protein.	Dronabinol	22-25	interleukin 1 complex	Mus musculus	65-68
7842348-0	1994	[Effects of calcitonin and indomethacin on bone resorption mediated by interleukin-1].	Indomethacin	27-39	interleukin 1 complex	Mus musculus	71-84
7842348-2	1994	The results showed that calcium release from cultured calvariae was significantly increased after adding 20 ng/ml IL-1 (P < 0.01).	Calcium	24-31	interleukin 1 complex	Mus musculus	114-118
7842348-3	1994	The increase of calcium release stimulated by IL-1 was blocked by both calcitonin at the concentration of 10, 100, 1,000 ng/ml and indomethacin (10(-6), 10(-5) mol/L).	Calcium	16-23	interleukin 1 complex	Mus musculus	46-50
7842348-3	1994	The increase of calcium release stimulated by IL-1 was blocked by both calcitonin at the concentration of 10, 100, 1,000 ng/ml and indomethacin (10(-6), 10(-5) mol/L).	Indomethacin	131-143	interleukin 1 complex	Mus musculus	46-50
7842348-4	1994	The stimulation of calcium release by IL-1 was also blocked even adding 10 mol/L indomethacin 5 hours after adding IL-1 into the culture.	Calcium	19-26	interleukin 1 complex	Mus musculus	38-42
7842348-4	1994	The stimulation of calcium release by IL-1 was also blocked even adding 10 mol/L indomethacin 5 hours after adding IL-1 into the culture.	Calcium	19-26	interleukin 1 complex	Mus musculus	115-119
7842348-4	1994	The stimulation of calcium release by IL-1 was also blocked even adding 10 mol/L indomethacin 5 hours after adding IL-1 into the culture.	Indomethacin	81-93	interleukin 1 complex	Mus musculus	38-42
7842348-4	1994	The stimulation of calcium release by IL-1 was also blocked even adding 10 mol/L indomethacin 5 hours after adding IL-1 into the culture.	Indomethacin	81-93	interleukin 1 complex	Mus musculus	115-119
7842348-5	1994	These data showed that both calcitonin and indomethacin can inhibit bone resorption stimulated by IL-1.	Indomethacin	43-55	interleukin 1 complex	Mus musculus	98-102
7842348-6	1994	Thus, it is possible that calcitonin and indomethacin may be used as a therapeutic agent to block inflammatory bone resorption mediated by IL-1.	Indomethacin	41-53	interleukin 1 complex	Mus musculus	139-143
7527776-0	1994	Measurement of interleukin-1 stimulated constitutive prostaglandin G/H synthase (cyclooxygenase) mRNA levels in osteoblastic MC3T3-E1 cells using competitive reverse transcriptase polymerase chain reaction.	Prostaglandins	53-66	interleukin 1 complex	Mus musculus	15-28
7527776-1	1994	To assess regulation of constitutive prostaglandin G/H synthase (PGHS-1) by interleukin-1 (IL-1) in osteoblastic MC3T3-E1 cells, we compared analysis by competitive reverse transcriptase-polymerase chain reaction (RT-PCR) with Northern blot analysis.	Prostaglandins	37-50	interleukin 1 complex	Mus musculus	76-89
7527776-1	1994	To assess regulation of constitutive prostaglandin G/H synthase (PGHS-1) by interleukin-1 (IL-1) in osteoblastic MC3T3-E1 cells, we compared analysis by competitive reverse transcriptase-polymerase chain reaction (RT-PCR) with Northern blot analysis.	Prostaglandins	37-50	interleukin 1 complex	Mus musculus	91-95
8062890-2	1994	Previously, we reported that increased intracellular cAMP levels inhibited bioactive granulocyte-macrophage colony-stimulatory factor (GM-CSF) production stimulated by IL-1 or by the synergistic stimulus of IL-1 plus TNF-alpha.	Cyclic AMP	53-57	interleukin 1 complex	Mus musculus	168-172
8062890-2	1994	Previously, we reported that increased intracellular cAMP levels inhibited bioactive granulocyte-macrophage colony-stimulatory factor (GM-CSF) production stimulated by IL-1 or by the synergistic stimulus of IL-1 plus TNF-alpha.	Cyclic AMP	53-57	interleukin 1 complex	Mus musculus	207-211
8062890-8	1994	Addition to stromal cells of the soluble cAMP agonist 8-bromo-cAMP (8BrcAMP) at 0.5 to 1 mM stimulated IL-6 mRNA expression acting alone, and it was additive with IL-1 or IL-1 plus TNF-alpha in stimulating IL-6 expression.	Cyclic AMP	41-45	interleukin 1 complex	Mus musculus	163-167
8062890-8	1994	Addition to stromal cells of the soluble cAMP agonist 8-bromo-cAMP (8BrcAMP) at 0.5 to 1 mM stimulated IL-6 mRNA expression acting alone, and it was additive with IL-1 or IL-1 plus TNF-alpha in stimulating IL-6 expression.	8-Bromo Cyclic Adenosine Monophosphate	54-66	interleukin 1 complex	Mus musculus	163-167
8062890-8	1994	Addition to stromal cells of the soluble cAMP agonist 8-bromo-cAMP (8BrcAMP) at 0.5 to 1 mM stimulated IL-6 mRNA expression acting alone, and it was additive with IL-1 or IL-1 plus TNF-alpha in stimulating IL-6 expression.	8-Bromo Cyclic Adenosine Monophosphate	54-66	interleukin 1 complex	Mus musculus	171-175
8062890-8	1994	Addition to stromal cells of the soluble cAMP agonist 8-bromo-cAMP (8BrcAMP) at 0.5 to 1 mM stimulated IL-6 mRNA expression acting alone, and it was additive with IL-1 or IL-1 plus TNF-alpha in stimulating IL-6 expression.	8-Bromo Cyclic Adenosine Monophosphate	68-75	interleukin 1 complex	Mus musculus	163-167
8062890-8	1994	Addition to stromal cells of the soluble cAMP agonist 8-bromo-cAMP (8BrcAMP) at 0.5 to 1 mM stimulated IL-6 mRNA expression acting alone, and it was additive with IL-1 or IL-1 plus TNF-alpha in stimulating IL-6 expression.	8-Bromo Cyclic Adenosine Monophosphate	68-75	interleukin 1 complex	Mus musculus	171-175
8062890-9	1994	On the other hand, 8BrcAMP inhibited GM-CSF mRNA expression stimulated by IL-1 or IL-1 plus TNF-alpha.	8-Bromo Cyclic Adenosine Monophosphate	19-26	interleukin 1 complex	Mus musculus	74-78
8062890-9	1994	On the other hand, 8BrcAMP inhibited GM-CSF mRNA expression stimulated by IL-1 or IL-1 plus TNF-alpha.	8-Bromo Cyclic Adenosine Monophosphate	19-26	interleukin 1 complex	Mus musculus	82-86
8039254-6	1994	IL-1 receptor blockade quite significantly diminished lung tissue damage and granuloma formation, judging from morphometric index and lung hydroxyproline measurements.	Hydroxyproline	139-153	interleukin 1 complex	Mus musculus	0-4
7948065-7	1994	When the islets of NON mice were incubated with or without IL-1 (10 U/ml) in the presence of high glucose, IAP was rarely found in beta-cells and retrovirus type C was undetectable in beta-cells.	Glucose	98-105	interleukin 1 complex	Mus musculus	59-63
8048000-2	1994	In this study we tested the hypothesis that pentoxifylline improves survival after CLP, not by inhibiting TNF synthesis but by exerting its effect on leukocyte adhesiveness, neutrophil sequestration, recruitment of cells into the focus of sepsis, and interleukin-1 (IL-1) expression.	Pentoxifylline	44-58	interleukin 1 complex	Mus musculus	251-270
7959870-5	1994	Treatment of the carrageenin-injected mice with L-NMMA had little effect on the proliferative response of the DLN cells, but significantly reduced the production of IL-1, IL-2, IL-6 and IFN-gamma, and increased the secretion of IL-10.	omega-N-Methylarginine	48-54	interleukin 1 complex	Mus musculus	165-169
8048078-4	1994	In the present studies, the role of the proinflammatory cytokines interleukin 1 (IL-1) and tumor necrosis factor (TNF) in TCDD-induced hyperinflammation was examined.	Polychlorinated Dibenzodioxins	122-126	interleukin 1 complex	Mus musculus	66-85
7959870-4	1994	The draining lymph node (DLN) cells from mice injected 48 hr previously with carrageenin produced significantly higher levels of proliferation and interleukin-1 (IL-1), IL-2, IL-6 and interferon-gamma (IFN-gamma), but less IL-10, compared to cells from saline-injected controls, when stimulated with concanavalin A (Con A) in vitro.	Carrageenan	77-88	interleukin 1 complex	Mus musculus	162-166
8037760-5	1994	Thus, the results indicate that sustained administration of IL-1ra can prevent the diabetogenic process elicited by low dose STZ treatment, suggesting that IL-1 may have a role in the pathogenesis of this form of diabetes.	Streptozocin	125-128	interleukin 1 complex	Mus musculus	60-64
7948425-0	1994	Activation of the mouse IL-2 gene by okadaic acid: synergy with interleukin-1.	Okadaic Acid	37-49	interleukin 1 complex	Mus musculus	64-77
7959870-5	1994	Treatment of the carrageenin-injected mice with L-NMMA had little effect on the proliferative response of the DLN cells, but significantly reduced the production of IL-1, IL-2, IL-6 and IFN-gamma, and increased the secretion of IL-10.	Carrageenan	17-28	interleukin 1 complex	Mus musculus	165-169
7831195-6	1994	In keeping with these observations, the inhibitory action exerted by dexamethasone, in both IL-1- and IL-8-induced cell infiltration, was abrogated by passive immunisation of mice with specific anti-lipocortin 1 antibodies.	Dexamethasone	69-82	interleukin 1 complex	Mus musculus	92-106
7927490-5	1994	Both DEX and CPZ inhibited TNF production, whereas induction of IL-1 and IL-6 was inhibited by DEX but not by CPZ.	Dexamethasone	95-98	interleukin 1 complex	Mus musculus	64-68
7948425-5	1994	We found that the protein phosphatase PP1 and PP2A inhibitor okadaic acid (OA) alone was able to significantly stimulate IL-2 production by the IL-1-responsive EL4 subline EL4 5D3 and also by the IL-1-nonresponsive EL4 subline EL4D6/76.	Okadaic Acid	61-73	interleukin 1 complex	Mus musculus	144-148
7948425-5	1994	We found that the protein phosphatase PP1 and PP2A inhibitor okadaic acid (OA) alone was able to significantly stimulate IL-2 production by the IL-1-responsive EL4 subline EL4 5D3 and also by the IL-1-nonresponsive EL4 subline EL4D6/76.	Okadaic Acid	61-73	interleukin 1 complex	Mus musculus	196-200
8168971-3	1994	Since IL-1 induces production of tumor necrosis factor alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF), platelet-activating factor (PAF), and arachidonic acid metabolites, we investigated the potential role of these substances in IL-1-induced protection.	Arachidonic Acid	171-187	interleukin 1 complex	Mus musculus	6-10
7948425-5	1994	We found that the protein phosphatase PP1 and PP2A inhibitor okadaic acid (OA) alone was able to significantly stimulate IL-2 production by the IL-1-responsive EL4 subline EL4 5D3 and also by the IL-1-nonresponsive EL4 subline EL4D6/76.	Okadaic Acid	75-77	interleukin 1 complex	Mus musculus	144-148
7948425-5	1994	We found that the protein phosphatase PP1 and PP2A inhibitor okadaic acid (OA) alone was able to significantly stimulate IL-2 production by the IL-1-responsive EL4 subline EL4 5D3 and also by the IL-1-nonresponsive EL4 subline EL4D6/76.	Okadaic Acid	75-77	interleukin 1 complex	Mus musculus	196-200
7948425-6	1994	In the IL-1-responsive cell line OA strongly synergized with phorbol myristate acetate (PMA) and IL-1.	Tetradecanoylphorbol Acetate	61-86	interleukin 1 complex	Mus musculus	7-11
7948425-6	1994	In the IL-1-responsive cell line OA strongly synergized with phorbol myristate acetate (PMA) and IL-1.	Tetradecanoylphorbol Acetate	88-91	interleukin 1 complex	Mus musculus	7-11
7948425-7	1994	In the IL-1-nonresponsive cell line OA synergized with PMA but not with IL-1.	Tetradecanoylphorbol Acetate	55-58	interleukin 1 complex	Mus musculus	7-11
8168971-0	1994	Roles of tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, platelet-activating factor, and arachidonic acid metabolites in interleukin-1-induced resistance to infection in neutropenic mice.	Arachidonic Acid	120-136	interleukin 1 complex	Mus musculus	152-165
7919139-7	1994	IL-1 in the supernate was greater with CU than with either tubing alone or PAN (P < 0.005; analysis of variance), which showed comparable values.	Cellulose	39-41	interleukin 1 complex	Mus musculus	0-4
7518332-3	1994	IL-1 induced the broadest range of neurochemical changes, affecting central norepinephrine (NE), serotonin (5-HT) and dopamine (DA) activity.	Norepinephrine	76-90	interleukin 1 complex	Mus musculus	0-4
8176939-3	1994	This antitumor effect was abolished when administration of CPA preceded that of IL-1.	Cyclophosphamide	59-62	interleukin 1 complex	Mus musculus	80-84
7518332-3	1994	IL-1 induced the broadest range of neurochemical changes, affecting central norepinephrine (NE), serotonin (5-HT) and dopamine (DA) activity.	Serotonin	97-106	interleukin 1 complex	Mus musculus	0-4
7518332-3	1994	IL-1 induced the broadest range of neurochemical changes, affecting central norepinephrine (NE), serotonin (5-HT) and dopamine (DA) activity.	Dopamine	118-126	interleukin 1 complex	Mus musculus	0-4
7518332-3	1994	IL-1 induced the broadest range of neurochemical changes, affecting central norepinephrine (NE), serotonin (5-HT) and dopamine (DA) activity.	Dopamine	128-130	interleukin 1 complex	Mus musculus	0-4
7518332-4	1994	In particular, IL-1 enhanced NE turnover in the hypothalamus and hippocampus, 5-HT turnover in the hippocampus and prefrontal cortex (owing to increased utilization and reduced content of the transmitters in these brain regions), and enhanced DA utilization in the prefrontal cortex.	Dopamine	243-245	interleukin 1 complex	Mus musculus	15-19
7518332-8	1994	In addition to the neurochemical changes, plasma corticosterone concentrations were profoundly enhanced in IL-1-treated animals, but not significantly altered by IL-2 or IL-6 treatment.	Corticosterone	49-63	interleukin 1 complex	Mus musculus	107-111
7518332-9	1994	The IL-1-induced corticosterone elevations did not significantly correlate with alterations of hypothalamic NE activity.	Corticosterone	17-31	interleukin 1 complex	Mus musculus	4-8
8045669-2	1994	LPS-stimulated TNF and IL-1 secretion were suppressed by cocaine in higher dosages.	Cocaine	57-64	interleukin 1 complex	Mus musculus	23-27
7956562-4	1994	(2) PGE1 suppressed the release of tumor necrosis factor (TNF) and secreted-interleukin-1 (SIL-1) in culture supernatants of P.acnes-elicited kupffer cells and membrane IL-1 (mIL-1) in kupffer cells in a dose-dependent manner in vitro.	Alprostadil	4-8	interleukin 1 complex	Mus musculus	92-96
8163655-6	1994	Further, an antibody neutralizing IL-11 suppressed osteoclast development induced by either 1,25-dihydroxyvitamin D3, parathyroid hormone, interleukin-1, or tumor necrosis factor; whereas inhibitors of IL-1 or TNF had no effect on IL-11-stimulated osteoclast formation.	Calcitriol	92-116	interleukin 1 complex	Mus musculus	34-38
7956562-4	1994	(2) PGE1 suppressed the release of tumor necrosis factor (TNF) and secreted-interleukin-1 (SIL-1) in culture supernatants of P.acnes-elicited kupffer cells and membrane IL-1 (mIL-1) in kupffer cells in a dose-dependent manner in vitro.	Alprostadil	4-8	interleukin 1 complex	Mus musculus	175-180
7956562-5	1994	These results strongly suggest that PGE1 can prevent liver cell necrosis in the animal model and the mechanism of curative effect of PGE1 in massive liver cell necrosis may result from inhibition of the activity of TNF, sIL-1 and mIL-1 in the kupffer cells.	Alprostadil	36-40	interleukin 1 complex	Mus musculus	230-235
7956562-5	1994	These results strongly suggest that PGE1 can prevent liver cell necrosis in the animal model and the mechanism of curative effect of PGE1 in massive liver cell necrosis may result from inhibition of the activity of TNF, sIL-1 and mIL-1 in the kupffer cells.	Alprostadil	133-137	interleukin 1 complex	Mus musculus	230-235
7510523-1	1994	Human recombinant interleukin-1 alpha (IL-1) stimulated the mouse osteoblast-like cell line, MC3T3-E1, to produce prostaglandin E2 (PGE2).	Dinoprostone	114-130	interleukin 1 complex	Mus musculus	39-43
8014027-4	1994	When these mice were also given levamisole (2.5 mg/kg, po) on days 0-2 the mean time to ANC recovery greater than 100/microliters was 7.7 +/- 0.3 days, (p < 0.05 vs. controls), while IL-1 (2 micrograms/day, ip) positive controls yielded a mean time to > 100 ANC of 6.5 +/- 0.2 days.	Levamisole	32-42	interleukin 1 complex	Mus musculus	186-190
7510523-1	1994	Human recombinant interleukin-1 alpha (IL-1) stimulated the mouse osteoblast-like cell line, MC3T3-E1, to produce prostaglandin E2 (PGE2).	Dinoprostone	132-136	interleukin 1 complex	Mus musculus	39-43
7510523-3	1994	The protein kinase A (PKA)-specific inhibitor, KT5720, also inhibited the IL-1-induced PGE2 production in MC3T3-E1 cells, as did staurosporine, a potent inhibitor of protein kinase C (PKC).	KT 5720	47-53	interleukin 1 complex	Mus musculus	74-78
7510523-3	1994	The protein kinase A (PKA)-specific inhibitor, KT5720, also inhibited the IL-1-induced PGE2 production in MC3T3-E1 cells, as did staurosporine, a potent inhibitor of protein kinase C (PKC).	Dinoprostone	87-91	interleukin 1 complex	Mus musculus	74-78
7510523-3	1994	The protein kinase A (PKA)-specific inhibitor, KT5720, also inhibited the IL-1-induced PGE2 production in MC3T3-E1 cells, as did staurosporine, a potent inhibitor of protein kinase C (PKC).	Staurosporine	129-142	interleukin 1 complex	Mus musculus	74-78
7510523-5	1994	However, 8-Br-cAMP and TPA acted synergistically to induce PGE2 production equal to that of IL-1.	Tetradecanoylphorbol Acetate	23-26	interleukin 1 complex	Mus musculus	92-96
7510523-6	1994	These observations suggest that activation of both PKA and PKC are involved in IL-1-induced PGE2 production in MC3T3-E1 cells.	Dinoprostone	92-96	interleukin 1 complex	Mus musculus	79-83
8283056-5	1994	However, GM-CSF increased IL-1 binding to BMC both in vivo and in vitro after 8 h. Further studies showed that in vitro GM-CSF and dexamethasone synergistically increased IL-1 binding to BMC in a time- and dose-dependent manner.	Dexamethasone	131-144	interleukin 1 complex	Mus musculus	26-30
8182644-2	1994	ICA is characterized by early production of IL-1, pronounced influx of PMN and marked cartilage degradation within one day.	ica	0-3	interleukin 1 complex	Mus musculus	44-48
8079830-0	1994	Measurement of interleukin-1 liberation in zymosan air-pouch exudate in mice.	Zymosan	43-50	interleukin 1 complex	Mus musculus	15-28
8079830-1	1994	The aim of the present study was to examine whether interleukin-1 (IL-1) production is involved in the pathology of inflammation induced by zymosan in the air-pouch of mice.	Zymosan	140-147	interleukin 1 complex	Mus musculus	52-65
8079830-1	1994	The aim of the present study was to examine whether interleukin-1 (IL-1) production is involved in the pathology of inflammation induced by zymosan in the air-pouch of mice.	Zymosan	140-147	interleukin 1 complex	Mus musculus	67-71
8079830-7	1994	Orally administered dexamethasone induced a dose-dependent reduction in IL-1 alpha, whereas indomethacin and IX 207-887, an IL-1-release inhibitor, failed to reduce the IL-1 alpha content in this model.	Dexamethasone	20-33	interleukin 1 complex	Mus musculus	72-76
8283056-5	1994	However, GM-CSF increased IL-1 binding to BMC both in vivo and in vitro after 8 h. Further studies showed that in vitro GM-CSF and dexamethasone synergistically increased IL-1 binding to BMC in a time- and dose-dependent manner.	Dexamethasone	131-144	interleukin 1 complex	Mus musculus	171-175
8572893-5	1994	B cells from normal, but not immunodeficient mice, prefixed with glutaraldehyde and cultured with thymocytes or a T cell line BK33, induce in T cells production of a factor which causes release of IL-1 by macrophages.	Glutaral	65-79	interleukin 1 complex	Mus musculus	197-201
8032958-2	1994	On days 20 and 30 following S180 challenge, a decrease in this effect on IL-1 production in treated and untreated SMAc was observed.	smac	114-118	interleukin 1 complex	Mus musculus	73-77
8032958-3	1994	Concomitantly with the alterations in the regulation of IL-1 production during tumor growth, an increase in the levels of prostaglandin E2 and serum immune complexes could be detected.	Dinoprostone	122-138	interleukin 1 complex	Mus musculus	56-60
7509645-3	1993	Naloxone injected with saline or D prior to IL 1, prevented IL-1-induced rise in CRP level.	Naloxone	0-8	interleukin 1 complex	Mus musculus	60-64
7509141-3	1993	Inhibition of liver protein synthesis with D-galactosamine (GALN) completely inhibited the IL-1-induced synthesis of acute-phase proteins.	Galactosamine	43-58	interleukin 1 complex	Mus musculus	91-95
7509141-3	1993	Inhibition of liver protein synthesis with D-galactosamine (GALN) completely inhibited the IL-1-induced synthesis of acute-phase proteins.	Galactosamine	60-64	interleukin 1 complex	Mus musculus	91-95
7509141-4	1993	GALN pretreatment abolished the protective effect of IL-1 on survival completely (neutropenic mice infected with Pseudomonas aeruginosa) or partially (nonneutropenic mice infected with Klebsiella pneumoniae).	Galactosamine	0-4	interleukin 1 complex	Mus musculus	53-57
7509141-6	1993	A protective effect of IL-1 via effects on glucose homeostasis during the acute-phase response was investigated by comparing plasma glucose levels in IL-1-treated mice and control mice before and during infection.	Glucose	43-50	interleukin 1 complex	Mus musculus	23-27
7509141-7	1993	Although glucose levels in IL-1-pretreated mice were somewhat higher in the later stages of infection, no significant differences from levels in control mice were present, and the glucose levels in control-treated animals never fell to hypoglycemic values.	Glucose	9-16	interleukin 1 complex	Mus musculus	27-31
7509141-7	1993	Although glucose levels in IL-1-pretreated mice were somewhat higher in the later stages of infection, no significant differences from levels in control mice were present, and the glucose levels in control-treated animals never fell to hypoglycemic values.	Glucose	180-187	interleukin 1 complex	Mus musculus	27-31
8153057-4	1993	Lipopolysaccharide-stimulated release of macrophage-derived IL-1 by spleen cells, determined on D10.G4.1 cells, remained in the control range during the preweaning period (postnatal day 6-28), then decreased in prenatally diazepam-exposed offspring, significantly in males during the postweaning period (postnatal day 34-61) and in both sexes in adults (postnatal day 62-83).	Diazepam	222-230	interleukin 1 complex	Mus musculus	60-64
8153057-7	1993	From these and our earlier data it is evident that prenatal exposure to low doses of benzodiazepines can result in long-lasting alterations of the cytokine network, as indicated by reduced release of TNF-alpha, IL-1, IL-6, IL-2 and interferon-gamma.	Benzodiazepines	85-100	interleukin 1 complex	Mus musculus	211-215
8282136-2	1993	The effect of IL-1 has been shown to be mediated, at least in part, by IL-1-induced prostaglandin (PG) E2 production in osteoblasts.	Dinoprostone	84-105	interleukin 1 complex	Mus musculus	14-18
8282136-2	1993	The effect of IL-1 has been shown to be mediated, at least in part, by IL-1-induced prostaglandin (PG) E2 production in osteoblasts.	Dinoprostone	84-105	interleukin 1 complex	Mus musculus	71-75
8282136-3	1993	The intracellular signal transduction mechanism of IL-1 in the PG production, however, is unknown.	Prostaglandins	63-65	interleukin 1 complex	Mus musculus	51-55
8282136-5	1993	MC produced PGE2 30 min after the IL-1 stimulation.	Methylcholanthrene	0-2	interleukin 1 complex	Mus musculus	34-38
8282136-7	1993	The IL-1-induced PGE2 production was inhibited by H-7 in a dose dependent manner.	Dinoprostone	17-21	interleukin 1 complex	Mus musculus	4-8
8282136-9	1993	KT5720 inhibited the IL-1-induced PGE2 production in MC in a dose dependent fashion.	Dinoprostone	34-38	interleukin 1 complex	Mus musculus	21-25
8282136-9	1993	KT5720 inhibited the IL-1-induced PGE2 production in MC in a dose dependent fashion.	Methylcholanthrene	53-55	interleukin 1 complex	Mus musculus	21-25
8282136-10	1993	Similarly, staurosporin inhibited the IL-1-induced PGE2 production in MC in a dose dependent manner.	Staurosporine	11-23	interleukin 1 complex	Mus musculus	38-42
8282136-10	1993	Similarly, staurosporin inhibited the IL-1-induced PGE2 production in MC in a dose dependent manner.	Dinoprostone	51-55	interleukin 1 complex	Mus musculus	38-42
8282136-10	1993	Similarly, staurosporin inhibited the IL-1-induced PGE2 production in MC in a dose dependent manner.	Methylcholanthrene	70-72	interleukin 1 complex	Mus musculus	38-42
8190019-0	1994	Effect of combination interleukin-1 and erythropoietin in ameliorating the hematopoietic toxicity associated with the use of zidovudine administered to normal mice.	Zidovudine	125-135	interleukin 1 complex	Mus musculus	22-35
8190019-3	1994	We report results describing the effect of combination interleukin-1 (IL-1) and erythropoietin (Epo) in their ability to modulate the hematopoietic toxicity associated with dose-escalation zidovudine administered in normal mice.	Zidovudine	189-199	interleukin 1 complex	Mus musculus	55-68
8190019-3	1994	We report results describing the effect of combination interleukin-1 (IL-1) and erythropoietin (Epo) in their ability to modulate the hematopoietic toxicity associated with dose-escalation zidovudine administered in normal mice.	Zidovudine	189-199	interleukin 1 complex	Mus musculus	70-74
8190019-4	1994	When administered over a six-week period, IL-1 and Epo raised the packed red cell volume, white blood cell and platelet counts in control mice and mice receiving dose-escalation zidovudine.	Zidovudine	178-188	interleukin 1 complex	Mus musculus	42-46
8190019-6	1994	These results indicate that use of combined IL-1 and Epo may be efficacious in ameliorating the hematopoietic toxicity associated with the use of zidovudine.	Zidovudine	146-156	interleukin 1 complex	Mus musculus	44-48
8123802-3	1993	The use of Wilcoxon rank T-test demonstrated that alpha-adrenergic antagonist (dihydroergotaminum, 3.9 mg/kg) injection to stressed mice suppressed exclusively IL-1 activities production.	Dihydroergotamine	79-97	interleukin 1 complex	Mus musculus	160-164
8115027-7	1993	In the anterior pituitary, a significant increase in the density of basal IL-1 receptors was observed 6 h following immobilization stress or after 7 days of DEX treatment while short-term DEX treatments are ineffective.	Dexamethasone	157-160	interleukin 1 complex	Mus musculus	74-78
8115027-7	1993	In the anterior pituitary, a significant increase in the density of basal IL-1 receptors was observed 6 h following immobilization stress or after 7 days of DEX treatment while short-term DEX treatments are ineffective.	Dexamethasone	188-191	interleukin 1 complex	Mus musculus	74-78
7509645-6	1993	The preinjection of naloxone blocked these phenomenon and pyrogenic effect of IL-1 in the rabbits.	Naloxone	20-28	interleukin 1 complex	Mus musculus	78-82
8396935-1	1993	High affinity "peripheral-type" benzodiazepine binding sites were detected in an interleukin-1 (IL-1) responsive murine thymoma cell line EL4.NOB-1.	Benzodiazepines	32-46	interleukin 1 complex	Mus musculus	81-94
8407943-3	1993	Staurosporine abolished the enhanced phosphorylation in response to IL-1 for some of these proteins, suggesting that protein kinase C (PKC) was at least partially responsible.	Staurosporine	0-13	interleukin 1 complex	Mus musculus	68-72
8407943-7	1993	On the other hand, okadaic acid also led to elevation of IL-1-induced trans/autophosphorylation of PKC-beta.	Okadaic Acid	19-31	interleukin 1 complex	Mus musculus	57-61
8407943-8	1993	Accordingly, IL-1 induction of interleukin-2 synthesis was markedly enhanced by okadaic acid in EL-4 cells.	Okadaic Acid	80-92	interleukin 1 complex	Mus musculus	13-17
8396935-1	1993	High affinity "peripheral-type" benzodiazepine binding sites were detected in an interleukin-1 (IL-1) responsive murine thymoma cell line EL4.NOB-1.	Benzodiazepines	32-46	interleukin 1 complex	Mus musculus	96-100
8396935-4	1993	Phorbol myristate acetate (PMA), another activator of EL4.NOB-1 cells, had an opposite effect to IL-1 in that it increased binding site expression dramatically suggesting different mechanisms of action for these two effectors.	Tetradecanoylphorbol Acetate	0-25	interleukin 1 complex	Mus musculus	97-101
8399854-5	1993	Oil-induced decidualization was associated with increased and prolonged production of IL-1 and IL-6 and decreased production of TNF alpha relative to these values in uninjected controls.	Oils	0-3	interleukin 1 complex	Mus musculus	86-90
8393776-5	1993	In line with this finding, addition of 17 beta-estradiol to calvaria cell cultures followed by withdrawal of the steroid caused an increase in the amount of IL-6 produced in response to the subsequent stimulation of these cultures with IL-1 or PTH compared to that in cultures that had never been treated with estradiol; when the inactive isomer 17 alpha-estradiol was used, no change in IL-6 production was observed.	alfatradiol	349-364	interleukin 1 complex	Mus musculus	236-240
8117933-1	1993	Sexual steroids are involved in the regulation of the immune system and modulate directly the synthesis of interleukin-1 (IL-1) by macrophages.	Steroids	7-15	interleukin 1 complex	Mus musculus	107-120
8117933-1	1993	Sexual steroids are involved in the regulation of the immune system and modulate directly the synthesis of interleukin-1 (IL-1) by macrophages.	Steroids	7-15	interleukin 1 complex	Mus musculus	122-126
8393776-5	1993	In line with this finding, addition of 17 beta-estradiol to calvaria cell cultures followed by withdrawal of the steroid caused an increase in the amount of IL-6 produced in response to the subsequent stimulation of these cultures with IL-1 or PTH compared to that in cultures that had never been treated with estradiol; when the inactive isomer 17 alpha-estradiol was used, no change in IL-6 production was observed.	Estradiol	39-56	interleukin 1 complex	Mus musculus	236-240
8393776-5	1993	In line with this finding, addition of 17 beta-estradiol to calvaria cell cultures followed by withdrawal of the steroid caused an increase in the amount of IL-6 produced in response to the subsequent stimulation of these cultures with IL-1 or PTH compared to that in cultures that had never been treated with estradiol; when the inactive isomer 17 alpha-estradiol was used, no change in IL-6 production was observed.	Steroids	113-120	interleukin 1 complex	Mus musculus	236-240
8393776-5	1993	In line with this finding, addition of 17 beta-estradiol to calvaria cell cultures followed by withdrawal of the steroid caused an increase in the amount of IL-6 produced in response to the subsequent stimulation of these cultures with IL-1 or PTH compared to that in cultures that had never been treated with estradiol; when the inactive isomer 17 alpha-estradiol was used, no change in IL-6 production was observed.	Estradiol	47-56	interleukin 1 complex	Mus musculus	236-240
7690078-4	1993	Cell-associated IL-1 activity was measured after fixation by paraformaldehyde (PFA).	paraform	61-77	interleukin 1 complex	Mus musculus	16-20
8318028-6	1993	Estradiol and progesterone reduced both spontaneous and IL-1-induced cartilage degradation in vitro.	Estradiol	0-9	interleukin 1 complex	Mus musculus	56-60
8318028-6	1993	Estradiol and progesterone reduced both spontaneous and IL-1-induced cartilage degradation in vitro.	Progesterone	14-26	interleukin 1 complex	Mus musculus	56-60
8318028-7	1993	Testosterone antagonized the effects of IL-1 on both proteoglycan loss and proteoglycan synthesis.	Testosterone	0-12	interleukin 1 complex	Mus musculus	40-44
8325323-6	1993	Thus, deletion or mutation of TCEd within a complete IL-2 promoter abrogated IL-1 costimulation in the IL-1 responsive EL4 subclone.	tced	30-34	interleukin 1 complex	Mus musculus	77-81
8325323-6	1993	Thus, deletion or mutation of TCEd within a complete IL-2 promoter abrogated IL-1 costimulation in the IL-1 responsive EL4 subclone.	tced	30-34	interleukin 1 complex	Mus musculus	103-107
8325323-7	1993	Therefore, the TCEd element is functionally essential for the effect of IL-1.	tced	15-19	interleukin 1 complex	Mus musculus	72-76
8325323-8	1993	We also identified a nuclear factor (NF), IL-1 NF, that binds to the TCEd site after IL-1 stimulation.	tced	69-73	interleukin 1 complex	Mus musculus	42-46
8325323-8	1993	We also identified a nuclear factor (NF), IL-1 NF, that binds to the TCEd site after IL-1 stimulation.	tced	69-73	interleukin 1 complex	Mus musculus	85-89
8325323-10	1993	Binding of IL-1 NF to the TCEd site was competed by a typical chi B oligonucleotide, suggesting that it is similar to NF-chi B in its DNA-binding properties.	tced	26-30	interleukin 1 complex	Mus musculus	11-15
8325323-10	1993	Binding of IL-1 NF to the TCEd site was competed by a typical chi B oligonucleotide, suggesting that it is similar to NF-chi B in its DNA-binding properties.	Oligonucleotides	68-83	interleukin 1 complex	Mus musculus	11-15
8325323-11	1993	However, the TCEd element was only activated by costimulation with PHA and IL-1 whereas a typical chi B element was already activated by IL-1 alone.	tced	13-17	interleukin 1 complex	Mus musculus	75-79
8260598-8	1993	This and other data suggest that components of the IL-1 RNA catabolic pathway are labile and sensitive to treatment with actinomycin D.	Dactinomycin	121-134	interleukin 1 complex	Mus musculus	51-55
7690078-4	1993	Cell-associated IL-1 activity was measured after fixation by paraformaldehyde (PFA).	paraform	79-82	interleukin 1 complex	Mus musculus	16-20
7690078-6	1993	On the other hand, cell-associated IL-1 was detected in AM fixed by PFA on days 1, 3, 6 and 9 after administration.	paraform	68-71	interleukin 1 complex	Mus musculus	35-39
8381071-3	1993	IL-1 significantly (P < 0.05) elevated ACTH release after incubation periods of 4, 8, and 24 h. IL-1-induced ACTH release was not additive to that of CRF, cholera toxin, 8-bromo-cAMP, or forskolin.	8-Bromo Cyclic Adenosine Monophosphate	173-185	interleukin 1 complex	Mus musculus	0-4
8514539-3	1993	METHODS AND MATERIALS: IL-1 was administered to C3H/Km mice in combination with fractionated irradiation, or with cyclophosphamide, cisplatin, or 5-fluorouracil (5FU) followed by irradiation.	Cisplatin	132-141	interleukin 1 complex	Mus musculus	23-27
8514539-3	1993	METHODS AND MATERIALS: IL-1 was administered to C3H/Km mice in combination with fractionated irradiation, or with cyclophosphamide, cisplatin, or 5-fluorouracil (5FU) followed by irradiation.	Fluorouracil	146-160	interleukin 1 complex	Mus musculus	23-27
8514539-3	1993	METHODS AND MATERIALS: IL-1 was administered to C3H/Km mice in combination with fractionated irradiation, or with cyclophosphamide, cisplatin, or 5-fluorouracil (5FU) followed by irradiation.	Fluorouracil	162-165	interleukin 1 complex	Mus musculus	23-27
8514539-7	1993	IL-1 was protective when injected intraperitoneally 24 hr before CY or c-DDP, which were given immediately before the first of five daily radiation dose fractions.	Cysteine	65-67	interleukin 1 complex	Mus musculus	0-4
8514539-7	1993	IL-1 was protective when injected intraperitoneally 24 hr before CY or c-DDP, which were given immediately before the first of five daily radiation dose fractions.	Cisplatin	71-76	interleukin 1 complex	Mus musculus	0-4
8477669-2	1993	To determine the role of cytokines in mediating these changes, we studied the effects of endotoxin (LPS), tumor necrosis factor-alpha (TNF) and interleukin-1 beta (IL-1) on cholesterol and TG metabolism in C57Bl/6 (LPS-sensitive) mice and in C3H/HeJ (LPS-resistant) mice whose macrophages do not produce TNF and IL-1 in response to LPS.	Cholesterol	173-184	interleukin 1 complex	Mus musculus	164-168
8477669-7	1993	As seen with LPS, TNF and IL-1 also increased serum cholesterol and TG levels in C57Bl/6 mice.	Cholesterol	52-63	interleukin 1 complex	Mus musculus	26-30
8477669-7	1993	As seen with LPS, TNF and IL-1 also increased serum cholesterol and TG levels in C57Bl/6 mice.	Triglycerides	68-70	interleukin 1 complex	Mus musculus	26-30
8511985-5	1993	The initial transient decrease in blood ionized calcium observed following an injection of IL-1 was also abrogated.	Calcium	48-55	interleukin 1 complex	Mus musculus	91-95
7678812-6	1993	Interleukin-1 (IL-1) treatment to the same recovery group of AZT-exposed mice also resulted in an improvement of CFU-GM growth in LTBMC that was not seen in the nonrecovered group.	Zidovudine	61-64	interleukin 1 complex	Mus musculus	0-13
7678812-6	1993	Interleukin-1 (IL-1) treatment to the same recovery group of AZT-exposed mice also resulted in an improvement of CFU-GM growth in LTBMC that was not seen in the nonrecovered group.	Zidovudine	61-64	interleukin 1 complex	Mus musculus	15-19
7678814-8	1993	These results suggest that the ability of IL-1 to enhance granulocyte differentiation in vivo is partly due to its ability to induce a cascade of cytokines and steroids which in turn regulate IL-1 receptor expression.	Steroids	160-168	interleukin 1 complex	Mus musculus	42-46
7678814-8	1993	These results suggest that the ability of IL-1 to enhance granulocyte differentiation in vivo is partly due to its ability to induce a cascade of cytokines and steroids which in turn regulate IL-1 receptor expression.	Steroids	160-168	interleukin 1 complex	Mus musculus	192-196
8237606-7	1993	Addition of normal splenic macrophages to in vitro cultures restored immune responses, as did IL-1, IL-6 and IFN-gamma, suggesting that morphine-induced immunosuppression is due to a deficit in macrophage function.	Morphine	136-144	interleukin 1 complex	Mus musculus	94-98
8141647-8	1993	We, thus, suggest that in nude mice the reduced plasma and HDL cholesterol levels are probably due to increased HDL degradation, which may be secondary to IL-1 and TGF deficiency.	Cholesterol	63-74	interleukin 1 complex	Mus musculus	155-159
8018447-5	1993	In vitro IL-1 induced proliferative responses of mouse thymocytes, human T cells and fibroblasts and IL-1 stimulated PGE2 secretion from fibroblasts, were all inhibited by the M20 IL-1 Inhibitor.	Dinoprostone	117-121	interleukin 1 complex	Mus musculus	9-13
8440487-3	1993	IL-1 levels were measured in the urine of 33 healthy, ambulatory, elderly subjects (ages 83-95 years), using both a murine thymocyte bioassay, measuring activation by the incorporation of tritiated thymidine and an MTT dye reduction assay.	Tritiated thymidine	188-207	interleukin 1 complex	Mus musculus	0-4
8440487-3	1993	IL-1 levels were measured in the urine of 33 healthy, ambulatory, elderly subjects (ages 83-95 years), using both a murine thymocyte bioassay, measuring activation by the incorporation of tritiated thymidine and an MTT dye reduction assay.	monooxyethylene trimethylolpropane tristearate	215-218	interleukin 1 complex	Mus musculus	0-4
1473014-1	1992	Both interleukin-1 (IL-1) and endotoxin (lipopolysaccharide, LPS) are potent activators of the hypothalamo-pituitary-adrenal (HPA) axis, and they also increase cerebral norepinephrine metabolism and tryptophan.	Norepinephrine	169-183	interleukin 1 complex	Mus musculus	20-24
1473014-1	1992	Both interleukin-1 (IL-1) and endotoxin (lipopolysaccharide, LPS) are potent activators of the hypothalamo-pituitary-adrenal (HPA) axis, and they also increase cerebral norepinephrine metabolism and tryptophan.	Tryptophan	199-209	interleukin 1 complex	Mus musculus	20-24
1431123-6	1992	These cell mixing experiments revealed that cLC are the major source of the IL-6 bioactivity, whereas IL-1, GM-CSF, and TNF-alpha are predominantly generated by cKC.	CKC	161-164	interleukin 1 complex	Mus musculus	102-106
1428234-12	1992	We conclude that exogenous administration of IL-1 enhances experimental bone/bone-marrow metastases, and that this phenomenon is mediated through prostaglandins.	Prostaglandins	146-160	interleukin 1 complex	Mus musculus	45-49
1472981-21	1992	These results suggest that suppression of the induction of ODC by GalN may be one cause of the sensitization to LPS, IL-1 or TNF, and that the induction of HDC, i.e. histamine formation, may not be involved in this sensitization.9.	Galactosamine	66-70	interleukin 1 complex	Mus musculus	117-121
1423638-3	1992	Low molecular weight (8000 Da) dextran sulfate also enhanced the T cell responses and synergized with IL-1, whereas, de-N-sulfated heparin was devoid of both of these activities.	Dextran Sulfate	31-46	interleukin 1 complex	Mus musculus	102-106
1423638-7	1992	Heparin enhanced the growth-promoting effect of IL-1 on the IL-1-dependent helper T cell clone, D10.G4.1, and enhanced IL-1 receptor expression on these cells.	Heparin	0-7	interleukin 1 complex	Mus musculus	48-52
1423638-7	1992	Heparin enhanced the growth-promoting effect of IL-1 on the IL-1-dependent helper T cell clone, D10.G4.1, and enhanced IL-1 receptor expression on these cells.	Heparin	0-7	interleukin 1 complex	Mus musculus	60-64
1423638-7	1992	Heparin enhanced the growth-promoting effect of IL-1 on the IL-1-dependent helper T cell clone, D10.G4.1, and enhanced IL-1 receptor expression on these cells.	Heparin	0-7	interleukin 1 complex	Mus musculus	60-64
1423638-8	1992	These data indicate that heparin acts directly on the T cells and enhances their responsiveness to IL-1 by up-regulating IL-1 receptor expression.	Heparin	25-32	interleukin 1 complex	Mus musculus	99-103
1423638-8	1992	These data indicate that heparin acts directly on the T cells and enhances their responsiveness to IL-1 by up-regulating IL-1 receptor expression.	Heparin	25-32	interleukin 1 complex	Mus musculus	121-125
1425417-5	1992	Treatment with 8-Br-cAMP plus 0.2 and 2 U/ml IL-1 decreased testosterone production to 63 +/- 14% and 41 +/- 19%, respectively, while 5, 10, and 20 U/ml IL-1 decreased testosterone production to less than 5% that of cells treated with 8-Br-cAMP alone.	Testosterone	60-72	interleukin 1 complex	Mus musculus	45-49
1425417-5	1992	Treatment with 8-Br-cAMP plus 0.2 and 2 U/ml IL-1 decreased testosterone production to 63 +/- 14% and 41 +/- 19%, respectively, while 5, 10, and 20 U/ml IL-1 decreased testosterone production to less than 5% that of cells treated with 8-Br-cAMP alone.	Testosterone	168-180	interleukin 1 complex	Mus musculus	45-49
1425417-5	1992	Treatment with 8-Br-cAMP plus 0.2 and 2 U/ml IL-1 decreased testosterone production to 63 +/- 14% and 41 +/- 19%, respectively, while 5, 10, and 20 U/ml IL-1 decreased testosterone production to less than 5% that of cells treated with 8-Br-cAMP alone.	Testosterone	168-180	interleukin 1 complex	Mus musculus	153-157
1425417-5	1992	Treatment with 8-Br-cAMP plus 0.2 and 2 U/ml IL-1 decreased testosterone production to 63 +/- 14% and 41 +/- 19%, respectively, while 5, 10, and 20 U/ml IL-1 decreased testosterone production to less than 5% that of cells treated with 8-Br-cAMP alone.	8-Bromo Cyclic Adenosine Monophosphate	235-244	interleukin 1 complex	Mus musculus	45-49
1425417-5	1992	Treatment with 8-Br-cAMP plus 0.2 and 2 U/ml IL-1 decreased testosterone production to 63 +/- 14% and 41 +/- 19%, respectively, while 5, 10, and 20 U/ml IL-1 decreased testosterone production to less than 5% that of cells treated with 8-Br-cAMP alone.	8-Bromo Cyclic Adenosine Monophosphate	235-244	interleukin 1 complex	Mus musculus	153-157
1425417-6	1992	Chronic treatment with IL-1 plus 8-Br-cAMP caused a shift in steroid production from testosterone to progesterone, but total steroid production (the sum of testosterone plus progesterone) was unaffected by IL-1 treatment.	Steroids	61-68	interleukin 1 complex	Mus musculus	23-27
1425417-6	1992	Chronic treatment with IL-1 plus 8-Br-cAMP caused a shift in steroid production from testosterone to progesterone, but total steroid production (the sum of testosterone plus progesterone) was unaffected by IL-1 treatment.	Testosterone	85-97	interleukin 1 complex	Mus musculus	23-27
1425417-6	1992	Chronic treatment with IL-1 plus 8-Br-cAMP caused a shift in steroid production from testosterone to progesterone, but total steroid production (the sum of testosterone plus progesterone) was unaffected by IL-1 treatment.	Progesterone	101-113	interleukin 1 complex	Mus musculus	23-27
1425417-6	1992	Chronic treatment with IL-1 plus 8-Br-cAMP caused a shift in steroid production from testosterone to progesterone, but total steroid production (the sum of testosterone plus progesterone) was unaffected by IL-1 treatment.	Testosterone	156-168	interleukin 1 complex	Mus musculus	23-27
1425417-8	1992	IL-1 caused a dose-dependent decrease in 8-Br-cAMP-stimulated P450c17 levels (0.2 U/ml by 31 +/- 9%, 2 U/ml by 82 +/- 12%, and 10 or 20 U/ml by 100% compared to that in cells treated with 8-Br-cAMP alone).	8-br	41-45	interleukin 1 complex	Mus musculus	0-4
1425417-8	1992	IL-1 caused a dose-dependent decrease in 8-Br-cAMP-stimulated P450c17 levels (0.2 U/ml by 31 +/- 9%, 2 U/ml by 82 +/- 12%, and 10 or 20 U/ml by 100% compared to that in cells treated with 8-Br-cAMP alone).	Cyclic AMP	46-50	interleukin 1 complex	Mus musculus	0-4
1425417-8	1992	IL-1 caused a dose-dependent decrease in 8-Br-cAMP-stimulated P450c17 levels (0.2 U/ml by 31 +/- 9%, 2 U/ml by 82 +/- 12%, and 10 or 20 U/ml by 100% compared to that in cells treated with 8-Br-cAMP alone).	8-Bromo Cyclic Adenosine Monophosphate	41-50	interleukin 1 complex	Mus musculus	0-4
1425417-10	1992	The inhibitory effect of IL-1 on 8-Br-cAMP-stimulated P450c17 expression was reversible.	8-br	33-37	interleukin 1 complex	Mus musculus	25-29
1425417-10	1992	The inhibitory effect of IL-1 on 8-Br-cAMP-stimulated P450c17 expression was reversible.	Cyclic AMP	38-42	interleukin 1 complex	Mus musculus	25-29
1425417-11	1992	Within 12 h after the removal of IL-1, P450c17 mRNA was restored to 24%; after 24 h, to 36%; after 36 h, to 65%; and after 48 h, to 84% of that with 8-Br-cAMP alone.	8-Bromo Cyclic Adenosine Monophosphate	149-158	interleukin 1 complex	Mus musculus	33-37
1490727-6	1992	In the absence of a direct and lasting effect on TNF-producing cells, the host reaction responsible for the inhibitory effect of IL-1 could be related to the overproduction of corticosterone that occurred after IL-1 injection, since it was not observed in adrenalectomized animals.	Corticosterone	176-190	interleukin 1 complex	Mus musculus	129-133
1490727-6	1992	In the absence of a direct and lasting effect on TNF-producing cells, the host reaction responsible for the inhibitory effect of IL-1 could be related to the overproduction of corticosterone that occurred after IL-1 injection, since it was not observed in adrenalectomized animals.	Corticosterone	176-190	interleukin 1 complex	Mus musculus	211-215
1490727-7	1992	Indeed the blockade of corticoid secretion by indomethacin prevented the inhibition of TNF production induced by IL-1 administration before LPS challenge.	Indomethacin	46-58	interleukin 1 complex	Mus musculus	113-117
1514611-5	1992	LPS, IL-1, and TNF increased hepatic malonyl-CoA levels.	Malonyl Coenzyme A	37-48	interleukin 1 complex	Mus musculus	5-9
1638511-3	1992	Thioglycollate-elicited macrophages required only LPS plus IFN-gamma for cytostatic activity which was expressed concomitantly with the release of high levels of TNF, IL-1 and IL-6, whereas C3H/HeJ macrophages produced low levels of monokines and were not cytostatic.	Thioglycolates	0-14	interleukin 1 complex	Mus musculus	167-171
1405592-5	1992	However, ibuprofen treatment increased (P less than 0.05) SPL proliferation, lymphokine (IL-2, IFN-gamma, and IL-6) synthesis, and IL-1 release by sM phi compared to hemorrhage alone.	Ibuprofen	9-18	interleukin 1 complex	Mus musculus	131-135
1338333-0	1992	Elevated cAMP is required for stimulation of eicosanoid synthesis by interleukin 1 and bradykinin in BALB/c 3T3 fibroblasts.	Cyclic AMP	9-13	interleukin 1 complex	Mus musculus	69-82
1338333-0	1992	Elevated cAMP is required for stimulation of eicosanoid synthesis by interleukin 1 and bradykinin in BALB/c 3T3 fibroblasts.	Eicosanoids	45-55	interleukin 1 complex	Mus musculus	69-82
1338333-1	1992	In Swiss 3T3 murine fibroblasts, interleukin 1 (IL-1) and bradykinin stimulate prostaglandin E2 (PGE2) synthesis.	Dinoprostone	79-95	interleukin 1 complex	Mus musculus	33-53
1338333-1	1992	In Swiss 3T3 murine fibroblasts, interleukin 1 (IL-1) and bradykinin stimulate prostaglandin E2 (PGE2) synthesis.	Dinoprostone	97-101	interleukin 1 complex	Mus musculus	33-53
1338333-3	1992	When BALB/c 3T3 cells were preincubated with cAMP analogs, both IL-1 and bradykinin stimulated PGE2 synthesis to levels similar to those observed in Swiss 3T3 cells.	Cyclic AMP	45-49	interleukin 1 complex	Mus musculus	64-68
1338333-3	1992	When BALB/c 3T3 cells were preincubated with cAMP analogs, both IL-1 and bradykinin stimulated PGE2 synthesis to levels similar to those observed in Swiss 3T3 cells.	Dinoprostone	95-99	interleukin 1 complex	Mus musculus	64-68
1338333-4	1992	Similarly, when the cells were preincubated with forskolin, which activates the catalytic subunit of adenylate cyclase directly, or NECA, which stimulates cellular cAMP accumulation by activating adenosine receptors, IL-1 and bradykinin stimulated PGE2 synthesis.	Colforsin	49-58	interleukin 1 complex	Mus musculus	217-221
1338333-4	1992	Similarly, when the cells were preincubated with forskolin, which activates the catalytic subunit of adenylate cyclase directly, or NECA, which stimulates cellular cAMP accumulation by activating adenosine receptors, IL-1 and bradykinin stimulated PGE2 synthesis.	Cyclic AMP	164-168	interleukin 1 complex	Mus musculus	217-221
1338333-5	1992	Rp-cAMPS, an inhibitor of cAMP-dependent protein kinase, blocked the ability of cAMP or NECA to render cells responsive to IL-1 and bradykinin.	Cyclic AMP	3-7	interleukin 1 complex	Mus musculus	123-127
1338333-5	1992	Rp-cAMPS, an inhibitor of cAMP-dependent protein kinase, blocked the ability of cAMP or NECA to render cells responsive to IL-1 and bradykinin.	Adenosine-5'-(N-ethylcarboxamide)	88-92	interleukin 1 complex	Mus musculus	123-127
1338333-6	1992	In basal BALB/c 3T3 cells, bradykinin and IL-1 stimulated arachidonate release in the absence of cAMP, but little conversion of released arachidonate to PGE2 occurred.	Arachidonic Acid	58-70	interleukin 1 complex	Mus musculus	42-46
1338333-9	1992	In these cells, IL-1 and bradykinin stimulated PGE2 synthesis despite basal intracellular cAMP concentrations similar to BALB/c, and cAMP only modestly potentiated the response.	Dinoprostone	47-51	interleukin 1 complex	Mus musculus	16-20
1338333-9	1992	In these cells, IL-1 and bradykinin stimulated PGE2 synthesis despite basal intracellular cAMP concentrations similar to BALB/c, and cAMP only modestly potentiated the response.	Cyclic AMP	90-94	interleukin 1 complex	Mus musculus	16-20
1602402-1	1992	Administration of either endotoxin (lipopolysaccharide, LPS) or interleukin-1 (IL-1) activates the hypothalamic-pituitary-adrenal axis and cerebral catecholamine systems.	Catecholamines	148-161	interleukin 1 complex	Mus musculus	64-83
1535214-0	1992	Retinoid augmentation of bioactive interleukin-1 production by murine keratinocytes.	Retinoids	0-8	interleukin 1 complex	Mus musculus	35-48
1535214-1	1992	The effect of retinoids on the production of interleukin-1 (IL-1) by murine epidermal keratinocytes was investigated.	Retinoids	14-23	interleukin 1 complex	Mus musculus	45-58
1535214-1	1992	The effect of retinoids on the production of interleukin-1 (IL-1) by murine epidermal keratinocytes was investigated.	Retinoids	14-23	interleukin 1 complex	Mus musculus	60-64
1535214-3	1992	Exposure of keratinocytes to retinoids increased IL-1 bioactivity in culture supernatants and cell extracts at concentrations as low as 8 x 10(-9) mol/l, as assessed by T-cell proliferation.	Retinoids	29-38	interleukin 1 complex	Mus musculus	49-53
1535214-5	1992	All-trans retinoic acid and 13-cis retinoic acid had a greater ability to induce IL-1 production than the two aromatic retinoids, etretinate and acitretin.	Tretinoin	0-23	interleukin 1 complex	Mus musculus	81-85
1535214-5	1992	All-trans retinoic acid and 13-cis retinoic acid had a greater ability to induce IL-1 production than the two aromatic retinoids, etretinate and acitretin.	Isotretinoin	28-48	interleukin 1 complex	Mus musculus	81-85
1535214-6	1992	Treatment with 8-methoxypsoralen plus ultraviolet A radiation and treatment with triamcinolone acetonide both reduced the effect of retinoids on the production of bioactive IL-1.	Methoxsalen	15-32	interleukin 1 complex	Mus musculus	173-177
1535214-6	1992	Treatment with 8-methoxypsoralen plus ultraviolet A radiation and treatment with triamcinolone acetonide both reduced the effect of retinoids on the production of bioactive IL-1.	Triamcinolone Acetonide	81-104	interleukin 1 complex	Mus musculus	173-177
1535214-6	1992	Treatment with 8-methoxypsoralen plus ultraviolet A radiation and treatment with triamcinolone acetonide both reduced the effect of retinoids on the production of bioactive IL-1.	Retinoids	132-141	interleukin 1 complex	Mus musculus	173-177
8327661-7	1993	For example, if protection was determined as a ratio of D10"s or LD50/10, a bigger DMF was obtained for BALB/c mice than C3H mice with the same IL-1 dose, suggesting that C3H mice were not as well protected.	Dimethylformamide	83-86	interleukin 1 complex	Mus musculus	144-148
8510131-2	1993	M1Av stimulated thioglycolate-induced peritoneal macrophages from C3H/HeN and C3H/HeJ mice to release cell-free tumour necrosis factor (TNF) and interleukin (IL)-6, and a cell-associated thymocyte activating factor, probably IL-1.	Thioglycolates	16-29	interleukin 1 complex	Mus musculus	225-229
8482848-7	1993	Northern blot analysis revealed that IL-1 and TNF-alpha stimulated MCP-1 mRNA expression in a dose-dependent manner, whereas dexamethasone blocked MCP-1 expression by cells stimulated with IL-1.	Dexamethasone	125-138	interleukin 1 complex	Mus musculus	189-193
8218930-4	1993	Pretreatment with IL-1 significantly increased the synthesis of prostaglandin E2 (PGE2) in samples of liver tissue from AAP-treated mice, but had no effect on the synthesis of leukotriene C4 (LTC4).	Dinoprostone	64-80	interleukin 1 complex	Mus musculus	18-22
8218930-4	1993	Pretreatment with IL-1 significantly increased the synthesis of prostaglandin E2 (PGE2) in samples of liver tissue from AAP-treated mice, but had no effect on the synthesis of leukotriene C4 (LTC4).	Dinoprostone	82-86	interleukin 1 complex	Mus musculus	18-22
8461477-4	1993	IL-1 pretreatment significantly accelerated hematopoietic recovery versus transplanted saline-treated controls with a pronounced enhancement of peripheral leukocyte, platelet, and erythrocyte recovery.	Sodium Chloride	87-93	interleukin 1 complex	Mus musculus	0-4
8473513-0	1993	IL-1-induced murine osteoblast IL-6 production is mediated by the type 1 IL-1 receptor and is increased by 1,25 dihydroxyvitamin D3.	Calcitriol	107-131	interleukin 1 complex	Mus musculus	0-4
8473513-5	1993	Vitamin D3 increases IL-1R expression dose- and metabolite-dependently, with 1,25-(OH)2D3 having the greatest potency, and also enhances IL-1"s capacity to stimulate IL-6 production at low IL-1 levels.	Cholecalciferol	0-10	interleukin 1 complex	Mus musculus	21-25
8473513-5	1993	Vitamin D3 increases IL-1R expression dose- and metabolite-dependently, with 1,25-(OH)2D3 having the greatest potency, and also enhances IL-1"s capacity to stimulate IL-6 production at low IL-1 levels.	Cholecalciferol	0-10	interleukin 1 complex	Mus musculus	137-141
8427959-5	1993	Similarly, in vitro treatment with IL-1 of bone marrow cells isolated from 5-fluorouracil-treated mice results in elevated levels of MnSOD RNA.	Fluorouracil	75-89	interleukin 1 complex	Mus musculus	35-39
8423349-0	1993	Modulation of IL-1-induced neutrophil migration by dexamethasone and lipocortin 1.	Dexamethasone	51-64	interleukin 1 complex	Mus musculus	14-18
8423349-6	1993	The glucocorticoid dexamethasone (0.015 to 1.5 mg/kg) potently inhibited the elicitation of neutrophils induced by IL-1 when given systemically 2 h before the cytokine.	Dexamethasone	19-32	interleukin 1 complex	Mus musculus	115-119
8392161-2	1993	In recent years, many studies have addressed the effects of IL-1 on carbohydrate metabolism.	Carbohydrates	68-80	interleukin 1 complex	Mus musculus	60-64
8392161-5	1993	In vitro, beta-islet cells incubated briefly with IL-1 produced insulin; incubation for longer periods of time or with high levels of IL-1 induced cytotoxic effects for which suggested mechanisms include production of free radicals, alterations in mitochondrial function, increased production of phosphoinositide second messenger, accumulation of prostaglandins, alterations in ion fluxes or changes in gene transcription.	Phosphatidylinositols	296-312	interleukin 1 complex	Mus musculus	50-54
8392161-5	1993	In vitro, beta-islet cells incubated briefly with IL-1 produced insulin; incubation for longer periods of time or with high levels of IL-1 induced cytotoxic effects for which suggested mechanisms include production of free radicals, alterations in mitochondrial function, increased production of phosphoinositide second messenger, accumulation of prostaglandins, alterations in ion fluxes or changes in gene transcription.	Phosphatidylinositols	296-312	interleukin 1 complex	Mus musculus	134-138
8392161-5	1993	In vitro, beta-islet cells incubated briefly with IL-1 produced insulin; incubation for longer periods of time or with high levels of IL-1 induced cytotoxic effects for which suggested mechanisms include production of free radicals, alterations in mitochondrial function, increased production of phosphoinositide second messenger, accumulation of prostaglandins, alterations in ion fluxes or changes in gene transcription.	Prostaglandins	347-361	interleukin 1 complex	Mus musculus	50-54
8392161-5	1993	In vitro, beta-islet cells incubated briefly with IL-1 produced insulin; incubation for longer periods of time or with high levels of IL-1 induced cytotoxic effects for which suggested mechanisms include production of free radicals, alterations in mitochondrial function, increased production of phosphoinositide second messenger, accumulation of prostaglandins, alterations in ion fluxes or changes in gene transcription.	Prostaglandins	347-361	interleukin 1 complex	Mus musculus	134-138
8399976-0	1993	Effect of alginate and calcium on secretion of IL-1 by immobilized Swiss peritoneal macrophages.	Alginates	10-18	interleukin 1 complex	Mus musculus	47-51
8399976-0	1993	Effect of alginate and calcium on secretion of IL-1 by immobilized Swiss peritoneal macrophages.	Calcium	23-30	interleukin 1 complex	Mus musculus	47-51
8399976-3	1993	Calcium and alginate individually enhance production of IL-1 by macrophages and act in synergy when macrophages are immobilized in calcium alginate matrix.	Calcium	0-7	interleukin 1 complex	Mus musculus	56-60
8399976-3	1993	Calcium and alginate individually enhance production of IL-1 by macrophages and act in synergy when macrophages are immobilized in calcium alginate matrix.	Alginates	12-20	interleukin 1 complex	Mus musculus	56-60
8374514-5	1993	In addition, the secretion of cytokines involved in host defence mechanisms--IL-1, TNF-alpha, and IL-2--was investigated upon incubation of J774-1 cells with arglabin.	arglabin	158-166	interleukin 1 complex	Mus musculus	77-81
8374514-10	1993	Using either method, lower concentrations of arglabin (ranging from 12.5 micrograms/mL to 0.125 micrograms/mL) were the most effective in inducing IL-1, TNF-alpha, or IL-2 secretion.	arglabin	45-53	interleukin 1 complex	Mus musculus	147-151
8458231-7	1993	Suppression of MTT reduction in murine thymocytes and splenocytes by intact FLE cells could be reversed by the addition of interleukin-1 (IL-1).	monooxyethylene trimethylolpropane tristearate	15-18	interleukin 1 complex	Mus musculus	123-143
8219776-5	1993	Recombinant IL-1 also induced a drastic increase in plasma corticosterone levels in various strains of normal mice.	Corticosterone	59-73	interleukin 1 complex	Mus musculus	12-16
8219776-7	1993	However, in young lupus-prone (NZB/W)F1 and MRL/MP-lpr mice, a significantly lower increase in plasma corticosterone levels was observed after injection of recombinant IL-1, suggesting a deficient immuno-endocrine communication via the HPA loop in this instance as well.	Corticosterone	102-116	interleukin 1 complex	Mus musculus	168-172
8432622-4	1993	The level of Interleukin-1 (IL-1) secreted in the culture supernatant of peritoneal macrophages of DEODAN-treated mice was found to be slightly increased only when the mice were treated with 150 mg/kg DEODAN for 10 days.	deodan	99-105	interleukin 1 complex	Mus musculus	13-26
8432622-4	1993	The level of Interleukin-1 (IL-1) secreted in the culture supernatant of peritoneal macrophages of DEODAN-treated mice was found to be slightly increased only when the mice were treated with 150 mg/kg DEODAN for 10 days.	deodan	99-105	interleukin 1 complex	Mus musculus	28-32
8432622-4	1993	The level of Interleukin-1 (IL-1) secreted in the culture supernatant of peritoneal macrophages of DEODAN-treated mice was found to be slightly increased only when the mice were treated with 150 mg/kg DEODAN for 10 days.	deodan	201-207	interleukin 1 complex	Mus musculus	13-26
8432622-4	1993	The level of Interleukin-1 (IL-1) secreted in the culture supernatant of peritoneal macrophages of DEODAN-treated mice was found to be slightly increased only when the mice were treated with 150 mg/kg DEODAN for 10 days.	deodan	201-207	interleukin 1 complex	Mus musculus	28-32
8108271-0	1993	Effects of RRR-alpha-tocopheryl succinate on IL-1 and PGE2 production by macrophages.	alpha-Tocopherol	15-41	interleukin 1 complex	Mus musculus	45-49
8108271-1	1993	Vitamin E is thought to enhance immunity by increasing interleukin-1 (IL-1) production and by downregulating prostaglandin E2 (PGE2) synthesis.	Vitamin E	0-9	interleukin 1 complex	Mus musculus	70-74
8108271-2	1993	In an effort to understand the mechanism(s) whereby the form of vitamin E known as RRR-alpha-tocopheryl succinate [also called vitamin E succinate (VES)] ameliorates retrovirus-induced immune dysfunctions, peritoneal exudate cells (PECs) derived from normal chickens and avian and murine macrophage cell lines were used as in vitro model systems to test the effects of VES treatments on PGE2 and IL-1 production.	Vitamin E	64-73	interleukin 1 complex	Mus musculus	396-400
8108271-2	1993	In an effort to understand the mechanism(s) whereby the form of vitamin E known as RRR-alpha-tocopheryl succinate [also called vitamin E succinate (VES)] ameliorates retrovirus-induced immune dysfunctions, peritoneal exudate cells (PECs) derived from normal chickens and avian and murine macrophage cell lines were used as in vitro model systems to test the effects of VES treatments on PGE2 and IL-1 production.	alpha-Tocopherol	87-113	interleukin 1 complex	Mus musculus	396-400
8108271-2	1993	In an effort to understand the mechanism(s) whereby the form of vitamin E known as RRR-alpha-tocopheryl succinate [also called vitamin E succinate (VES)] ameliorates retrovirus-induced immune dysfunctions, peritoneal exudate cells (PECs) derived from normal chickens and avian and murine macrophage cell lines were used as in vitro model systems to test the effects of VES treatments on PGE2 and IL-1 production.	alpha-Tocopherol	127-146	interleukin 1 complex	Mus musculus	396-400
8108271-2	1993	In an effort to understand the mechanism(s) whereby the form of vitamin E known as RRR-alpha-tocopheryl succinate [also called vitamin E succinate (VES)] ameliorates retrovirus-induced immune dysfunctions, peritoneal exudate cells (PECs) derived from normal chickens and avian and murine macrophage cell lines were used as in vitro model systems to test the effects of VES treatments on PGE2 and IL-1 production.	alpha-Tocopherol	148-151	interleukin 1 complex	Mus musculus	396-400
1482145-3	1992	IL-1 induced a dose-dependent increase in corticosterone levels in plasma.	Corticosterone	42-56	interleukin 1 complex	Mus musculus	0-4
1482145-5	1992	Although corticosterone levels induced by pretreatment with IL-1 or ACTH were virtually identical, the ACTH-induced corticosterone peak was not associated with protection against Klebsiella pneumoniae infection in normal mice and Pseudomonas aeruginosa infection in neutropenic mice.	Corticosterone	9-23	interleukin 1 complex	Mus musculus	60-64
1482145-7	1992	In addition, we found that plasma corticosterone concentrations during K. pneumoniae infection were significantly lower after pretreatment with IL-1 than after pretreatment with ACTH or vehicle, probably reflecting the better physical condition of IL-1-treated mice.	Corticosterone	34-48	interleukin 1 complex	Mus musculus	144-148
1482145-7	1992	In addition, we found that plasma corticosterone concentrations during K. pneumoniae infection were significantly lower after pretreatment with IL-1 than after pretreatment with ACTH or vehicle, probably reflecting the better physical condition of IL-1-treated mice.	Corticosterone	34-48	interleukin 1 complex	Mus musculus	248-252
1451333-4	1992	Although IL-1 production by poly(I:C)-treated M phi was comparable to the level produced by saline-treated, KLH-pulsed M phi controls, addition of exogenous rIL-1 was still examined to explore the possibility that a greater amount of IL-1 may be needed to induce T cell proliferation with poly(I:C)-treated, KLH-pulsed M phi.	Poly I-C	28-37	interleukin 1 complex	Mus musculus	9-13
1451333-6	1992	Interestingly, the addition of combinations of IL-1 and IL-6 increased the proliferation of T cells in response to KLH presented by either saline- or poly(I:C)-treated M phi.	Sodium Chloride	139-145	interleukin 1 complex	Mus musculus	47-51
1451333-6	1992	Interestingly, the addition of combinations of IL-1 and IL-6 increased the proliferation of T cells in response to KLH presented by either saline- or poly(I:C)-treated M phi.	Poly I-C	150-159	interleukin 1 complex	Mus musculus	47-51
1431289-1	1992	This work was devoted to clarify the changes in interleukin-1 (IL-1) activity of peritoneal macrophages in mice experimentally infected with S. mansoni before and after praziquantel administration.	Praziquantel	169-181	interleukin 1 complex	Mus musculus	48-67
1431289-2	1992	A significant increase in (IL-1) activity after praziquantel administration was detected.	Praziquantel	48-60	interleukin 1 complex	Mus musculus	27-31
22217835-12	1992	In parallel, in vitro treatment of Leydig cells with recombinant IL-1 resulted in a dose-dependent inhibition of P450c17 mRNA expression and testosterone production.	Testosterone	141-153	interleukin 1 complex	Mus musculus	65-69
22217835-13	1992	These data demonstrate that LPS treatment, in vivo and in vitro, induced IL-1 gene expression in TIMs, and that IL-1 inhibits P450c17 mRNA in vitro.	tims	97-101	interleukin 1 complex	Mus musculus	73-77
1428234-8	1992	Many of the biologic effects of IL-1 are mediated by prostaglandins.	Prostaglandins	53-67	interleukin 1 complex	Mus musculus	32-36
1472981-0	1992	Ornithine and histidine decarboxylase activities in mice sensitized to endotoxin, interleukin-1 or tumour necrosis factor by D-galactosamine.	Ornithine	0-9	interleukin 1 complex	Mus musculus	82-95
1472981-2	1992	An injection of D-galactosamine (GalN) into mice together with a lipopolysaccharide (LPS or endotoxin), interleukin-1 (IL-1) or tumour necrosis factor (TNF), sensitized the mice and induced fulminant hepatitis with severe congestion resulting in rapid death.	Galactosamine	16-31	interleukin 1 complex	Mus musculus	104-117
1384992-0	1992	IL-1-induced prostacyclin production by cerebral vascular endothelial cells inhibits myelin basic protein-specific lymphocyte proliferation.	Epoprostenol	13-25	interleukin 1 complex	Mus musculus	0-4
1384992-6	1992	Additional experiments indicated that EC were required for the generation of PGI2 and that either macrophages (M phi), or recombinant murine IL-1 were able to replace LNC in cocultures with EC in order to generate PGI2.	Epoprostenol	214-218	interleukin 1 complex	Mus musculus	141-145
1384992-7	1992	The ability of IL-1 to stimulate EC-derived PGI2 synthesis was dose dependent with maximal stimulation observed at 50 U/ml IL-1.	Epoprostenol	44-48	interleukin 1 complex	Mus musculus	15-19
1384992-7	1992	The ability of IL-1 to stimulate EC-derived PGI2 synthesis was dose dependent with maximal stimulation observed at 50 U/ml IL-1.	Epoprostenol	44-48	interleukin 1 complex	Mus musculus	123-127
1384992-8	1992	The IL-1-induced production of PGI2 by EC as well as PGI2 production in cultures containing EC and either LNC or M phi was inhibited by treatment with anti-IL-1 antibody.	Epoprostenol	31-35	interleukin 1 complex	Mus musculus	4-8
1384992-8	1992	The IL-1-induced production of PGI2 by EC as well as PGI2 production in cultures containing EC and either LNC or M phi was inhibited by treatment with anti-IL-1 antibody.	Epoprostenol	31-35	interleukin 1 complex	Mus musculus	156-160
1384992-8	1992	The IL-1-induced production of PGI2 by EC as well as PGI2 production in cultures containing EC and either LNC or M phi was inhibited by treatment with anti-IL-1 antibody.	Epoprostenol	53-57	interleukin 1 complex	Mus musculus	156-160
1384992-9	1992	These results indicate that EC are capable of inhibiting antigen-specific lymphocyte proliferation by producing PGI2, which can be induced by the lymphokine, IL-1.	Epoprostenol	112-116	interleukin 1 complex	Mus musculus	158-162
1425417-3	1992	Addition of IL-1 to macrophage-depleted primary cultures of mouse Leydig cells caused a dose-dependent decrease in cAMP-dependent testosterone production and 17 alpha-hydroxylase/C17-20 lyase (P450c17) mRNA levels.	Cyclic AMP	115-119	interleukin 1 complex	Mus musculus	12-16
1425417-3	1992	Addition of IL-1 to macrophage-depleted primary cultures of mouse Leydig cells caused a dose-dependent decrease in cAMP-dependent testosterone production and 17 alpha-hydroxylase/C17-20 lyase (P450c17) mRNA levels.	Testosterone	130-142	interleukin 1 complex	Mus musculus	12-16
1425428-12	1992	These results suggest that the effects of IL-1 on resorption and release of IGF-I may be mediated in part by a prostaglandin-dependent mechanism.	Prostaglandins	111-124	interleukin 1 complex	Mus musculus	42-46
1425428-15	1992	The results are consistent with the hypotheses that 1) IL-1 stimulates IGF-I production by bone cells, in part by PG-dependent mechanisms; 2) the effects of IL-1 and PGs on bone formation and resorption may be mediated by locally induced secretion of IGF-I and other growth factors in bone.	Prostaglandins	114-116	interleukin 1 complex	Mus musculus	55-59
1290956-7	1992	While IL-1 and TNF-alpha stimulate both of these enzymes, other mechanisms are probably also operative for other forms of chemotherapy, i.e. IL-1 and TNF-alpha were shown to protect hematopoietic progenitors from phenylketophosphamide, a cyclophosphamide derivative that is not metabolized by the enzyme aldehyde dehydrogenase.	phenylketophosphamide	213-234	interleukin 1 complex	Mus musculus	6-10
1290956-7	1992	While IL-1 and TNF-alpha stimulate both of these enzymes, other mechanisms are probably also operative for other forms of chemotherapy, i.e. IL-1 and TNF-alpha were shown to protect hematopoietic progenitors from phenylketophosphamide, a cyclophosphamide derivative that is not metabolized by the enzyme aldehyde dehydrogenase.	phenylketophosphamide	213-234	interleukin 1 complex	Mus musculus	141-145
1290956-7	1992	While IL-1 and TNF-alpha stimulate both of these enzymes, other mechanisms are probably also operative for other forms of chemotherapy, i.e. IL-1 and TNF-alpha were shown to protect hematopoietic progenitors from phenylketophosphamide, a cyclophosphamide derivative that is not metabolized by the enzyme aldehyde dehydrogenase.	Cyclophosphamide	238-254	interleukin 1 complex	Mus musculus	6-10
1290956-7	1992	While IL-1 and TNF-alpha stimulate both of these enzymes, other mechanisms are probably also operative for other forms of chemotherapy, i.e. IL-1 and TNF-alpha were shown to protect hematopoietic progenitors from phenylketophosphamide, a cyclophosphamide derivative that is not metabolized by the enzyme aldehyde dehydrogenase.	Cyclophosphamide	238-254	interleukin 1 complex	Mus musculus	141-145
1282723-2	1992	The tumor necrosis factor-alpha- (TNF-alpha) and interleukin-1 (IL-1)-stimulated ICAM-1 expression in TEC is blocked with the PKC/PKA inhibitor staurosporine, and also with the PKC-selective inhibitor calphostin C.	Staurosporine	144-157	interleukin 1 complex	Mus musculus	49-68
1282723-2	1992	The tumor necrosis factor-alpha- (TNF-alpha) and interleukin-1 (IL-1)-stimulated ICAM-1 expression in TEC is blocked with the PKC/PKA inhibitor staurosporine, and also with the PKC-selective inhibitor calphostin C.	calphostin C	201-213	interleukin 1 complex	Mus musculus	49-68
1282723-4	1992	The TNF-alpha- and IL-1-stimulated ICAM-1 expression is also inhibited with the transcriptional inhibitor actinomycin D and with the protein synthesis inhibitor cycloheximide.	Dactinomycin	106-119	interleukin 1 complex	Mus musculus	19-23
1282723-4	1992	The TNF-alpha- and IL-1-stimulated ICAM-1 expression is also inhibited with the transcriptional inhibitor actinomycin D and with the protein synthesis inhibitor cycloheximide.	Cycloheximide	161-174	interleukin 1 complex	Mus musculus	19-23
1527422-3	1992	When added concomitantly with lipopolysaccharide, pentoxifylline blocked the release of TNF and IL-1 but not IL-6, while dexamethasone inhibited the release of TNF and IL-6.	Pentoxifylline	50-64	interleukin 1 complex	Mus musculus	96-100
1444208-1	1992	The induction of interleukin-1 (IL-1) by agrimoniin, a tannin of Agrimonia pilosa Ledeb., in human peripheral blood mononuclear cells (PBMC) in vitro and in mouse adherent peritoneal exudate cells (PEC) in vivo was studied.	agrimoniin	41-51	interleukin 1 complex	Mus musculus	32-36
1444208-4	1992	The adherent PEC from mice intraperitoneally injected with agrimoniin (10 mg/kg) also secreted IL-1 4 days later.	agrimoniin	59-69	interleukin 1 complex	Mus musculus	95-99
1396414-0	1992	Inhibitory action of tetrandrine on macrophage production of interleukin-1 (IL-1)-like activity and thymocyte proliferation.	tetrandrine	21-32	interleukin 1 complex	Mus musculus	61-80
1396414-8	1992	In experiments where thymocytes were directly treated with tetrandrine, a dose-dependent inhibition of thymocyte proliferation was noted with both interleukin-1-(IL-1) specific and nonspecific mitogenic (concanavalin A) actions.	tetrandrine	59-70	interleukin 1 complex	Mus musculus	162-166
1522390-2	1992	Macrophages from mice administered a single oral dose of levamisole (3 mg/kg) 1 to 4 days prior to macrophage harvest demonstrated a twofold enhancement of IL-1 production compared to vehicle-treated mice.	Levamisole	57-67	interleukin 1 complex	Mus musculus	156-160
1522390-4	1992	Similar results were observed when IL-1 production and TNF production were followed in peritoneal exidate cells directly stimulated with levamisole in vitro.	Levamisole	137-147	interleukin 1 complex	Mus musculus	35-39
1522390-8	1992	Immunoprecipitation studies of supernatants from biosynthetically labeled macrophages also revealed augmented IL-1 production and decreased IL-6 and TNF, indicating that levamisole may have affected cytokine production at the translational level.	Levamisole	170-180	interleukin 1 complex	Mus musculus	110-114
1337557-0	1992	Cyclic AMP mimics IL-1 action in augmenting the differentiation of a mouse myeloid leukemic cell line (M1).	Cyclic AMP	0-10	interleukin 1 complex	Mus musculus	18-22
1641758-6	1992	Treatment with ATP-MgCl2 after hemorrhage restored macrophage ATP levels (p less than 0.05) and significantly increased (p less than 0.05) macrophage AP, IL-1, IL-6, and TNF release by 110% +/- 21%, 130% +/- 38%, 124% +/- 17%, and 66% +/- 24%, respectively.	atp-mgcl2	15-24	interleukin 1 complex	Mus musculus	154-158
1641758-6	1992	Treatment with ATP-MgCl2 after hemorrhage restored macrophage ATP levels (p less than 0.05) and significantly increased (p less than 0.05) macrophage AP, IL-1, IL-6, and TNF release by 110% +/- 21%, 130% +/- 38%, 124% +/- 17%, and 66% +/- 24%, respectively.	Adenosine Triphosphate	15-18	interleukin 1 complex	Mus musculus	154-158
1353517-7	1992	Induction of TNF mRNA by 10 microM taxol was detectable at 45 min of stimulation, maximal at 90 min, and evident for at least 8 h. The same low concentration of taxol also induced interleukin 1 (IL-1) alpha and beta mRNA expression.	Paclitaxel	35-40	interleukin 1 complex	Mus musculus	180-193
1353517-7	1992	Induction of TNF mRNA by 10 microM taxol was detectable at 45 min of stimulation, maximal at 90 min, and evident for at least 8 h. The same low concentration of taxol also induced interleukin 1 (IL-1) alpha and beta mRNA expression.	Paclitaxel	161-166	interleukin 1 complex	Mus musculus	180-193
1353517-8	1992	We conclude that taxol triggers macrophages for TNF and IL-1 production.	Paclitaxel	17-22	interleukin 1 complex	Mus musculus	56-60
1605310-11	1992	We further investigated whether IL-1 and complement factors were involved in the onset of this ICA.	ica	95-98	interleukin 1 complex	Mus musculus	32-36
1605310-15	1992	In this study, the authors show a synergistic action of IL-1 and complement in the onset of cationic ICA.	ica	101-104	interleukin 1 complex	Mus musculus	56-60
1587307-2	1992	Murine bone marrow (BM) harvested 24 h after 5-fluorouracil (5-FU) administration (d1 5-FU BM) was stimulated with IL-1 and IL-3 to expand its progenitor pool during 7 days of suspension culture (delta-culture), and this in vitro expanded BM was compared to fresh d1 5-FU BM in its ability to reconstitute lethally irradiated or high-dose 5-FU-treated hosts.	Fluorouracil	61-65	interleukin 1 complex	Mus musculus	115-119
1587307-2	1992	Murine bone marrow (BM) harvested 24 h after 5-fluorouracil (5-FU) administration (d1 5-FU BM) was stimulated with IL-1 and IL-3 to expand its progenitor pool during 7 days of suspension culture (delta-culture), and this in vitro expanded BM was compared to fresh d1 5-FU BM in its ability to reconstitute lethally irradiated or high-dose 5-FU-treated hosts.	Fluorouracil	86-90	interleukin 1 complex	Mus musculus	115-119
1587307-2	1992	Murine bone marrow (BM) harvested 24 h after 5-fluorouracil (5-FU) administration (d1 5-FU BM) was stimulated with IL-1 and IL-3 to expand its progenitor pool during 7 days of suspension culture (delta-culture), and this in vitro expanded BM was compared to fresh d1 5-FU BM in its ability to reconstitute lethally irradiated or high-dose 5-FU-treated hosts.	Fluorouracil	86-90	interleukin 1 complex	Mus musculus	115-119
1587307-2	1992	Murine bone marrow (BM) harvested 24 h after 5-fluorouracil (5-FU) administration (d1 5-FU BM) was stimulated with IL-1 and IL-3 to expand its progenitor pool during 7 days of suspension culture (delta-culture), and this in vitro expanded BM was compared to fresh d1 5-FU BM in its ability to reconstitute lethally irradiated or high-dose 5-FU-treated hosts.	Fluorouracil	86-90	interleukin 1 complex	Mus musculus	115-119
1602402-11	1992	The MHPG responses to IL-1 were substantially greater in hypothalamus than in other brain regions, whereas those to LPS were less regionally specific.	Methoxyhydroxyphenylglycol	4-8	interleukin 1 complex	Mus musculus	22-26
1599392-7	1992	In rats fed ad libitum, treatment with TNF plus IL-1 increased the contribution of hepatic lipogenesis to circulating TG to 550% of control values (P = 0.03) and plasma TG concentrations to 159% (P = 0.02), whereas PDHa increased slightly to 120% (P = 0.02) and liver glycogen content fell to 45.8% (P = 0.05) of control values.	Triglycerides	118-120	interleukin 1 complex	Mus musculus	48-52
1599392-7	1992	In rats fed ad libitum, treatment with TNF plus IL-1 increased the contribution of hepatic lipogenesis to circulating TG to 550% of control values (P = 0.03) and plasma TG concentrations to 159% (P = 0.02), whereas PDHa increased slightly to 120% (P = 0.02) and liver glycogen content fell to 45.8% (P = 0.05) of control values.	Triglycerides	169-171	interleukin 1 complex	Mus musculus	48-52
1599392-7	1992	In rats fed ad libitum, treatment with TNF plus IL-1 increased the contribution of hepatic lipogenesis to circulating TG to 550% of control values (P = 0.03) and plasma TG concentrations to 159% (P = 0.02), whereas PDHa increased slightly to 120% (P = 0.02) and liver glycogen content fell to 45.8% (P = 0.05) of control values.	Glycogen	268-276	interleukin 1 complex	Mus musculus	48-52
8381071-3	1993	IL-1 significantly (P < 0.05) elevated ACTH release after incubation periods of 4, 8, and 24 h. IL-1-induced ACTH release was not additive to that of CRF, cholera toxin, 8-bromo-cAMP, or forskolin.	Colforsin	190-199	interleukin 1 complex	Mus musculus	0-4
8381071-3	1993	IL-1 significantly (P < 0.05) elevated ACTH release after incubation periods of 4, 8, and 24 h. IL-1-induced ACTH release was not additive to that of CRF, cholera toxin, 8-bromo-cAMP, or forskolin.	Colforsin	190-199	interleukin 1 complex	Mus musculus	99-103
1560050-1	1992	EL 4-6.1 cells, variants of the murine EL4 thymoma cell line, can be activated by interleukin 1 (IL-1) or phorbol 12-myristate-13-acetate (PMA), or PMA+IL-1 to secrete interleukin 2 (IL-2) and interleukin 4 (IL-4) and to express the IL-2 receptor (IL-2R).	Tetradecanoylphorbol Acetate	139-142	interleukin 1 complex	Mus musculus	152-156
1572101-3	1992	Macrophages treated with cisplatin, LPS, IL-1 and TNF produced released and membrane-associated IL-1 and TNF activity which was significantly enhanced after priming with IFN-gamma.	Cisplatin	25-34	interleukin 1 complex	Mus musculus	41-53
1572101-3	1992	Macrophages treated with cisplatin, LPS, IL-1 and TNF produced released and membrane-associated IL-1 and TNF activity which was significantly enhanced after priming with IFN-gamma.	Cisplatin	25-34	interleukin 1 complex	Mus musculus	41-45
1532365-10	1992	Using a monoclonal anti-IL-1R antibody, we finally observed that the effects of RU38486 were most probably not mediated by IL-1.	Mifepristone	80-87	interleukin 1 complex	Mus musculus	24-28
1521932-3	1992	Besides confirming the finding that exogenous IL-1 leads to a rapid increase in CSF detection, we obtained evidence that IL-1 may also result in the production of cyclo-oxygenase pathway products that down-regulate the IL-1-induced burst in CSA and CSF-1 levels.	Cyclosporine	241-244	interleukin 1 complex	Mus musculus	46-50
1521932-3	1992	Besides confirming the finding that exogenous IL-1 leads to a rapid increase in CSF detection, we obtained evidence that IL-1 may also result in the production of cyclo-oxygenase pathway products that down-regulate the IL-1-induced burst in CSA and CSF-1 levels.	Cyclosporine	241-244	interleukin 1 complex	Mus musculus	121-125
1521932-3	1992	Besides confirming the finding that exogenous IL-1 leads to a rapid increase in CSF detection, we obtained evidence that IL-1 may also result in the production of cyclo-oxygenase pathway products that down-regulate the IL-1-induced burst in CSA and CSF-1 levels.	Cyclosporine	241-244	interleukin 1 complex	Mus musculus	121-125
1521932-4	1992	While co-treatment of mice with indomethacin led to a further increase in CSF detection, the combined exposure to IL-1 and PGE2 resulted in a significant impairment of the stimulatory activity of IL-1.	Dinoprostone	123-127	interleukin 1 complex	Mus musculus	196-200
1533794-5	1992	Cross-linking studies demonstrated that the 125I-labeled IL-1/IL-1R complex on B cells and 70Z/3 IL-1R was found to block binding of IL-1 to IL-1R on 70Z/3 and splenic B cells, but not to type I IL-1R on murine EL4 thymoma cells.	Iodine-125	44-48	interleukin 1 complex	Mus musculus	57-61
1533794-5	1992	Cross-linking studies demonstrated that the 125I-labeled IL-1/IL-1R complex on B cells and 70Z/3 IL-1R was found to block binding of IL-1 to IL-1R on 70Z/3 and splenic B cells, but not to type I IL-1R on murine EL4 thymoma cells.	Iodine-125	44-48	interleukin 1 complex	Mus musculus	62-66
1561635-3	1992	In the present studies we analyzed the effects of benzene treatment of mice on the production of interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) by bone marrow leukocytes.	Benzene	50-57	interleukin 1 complex	Mus musculus	112-116
1314278-7	1992	In addition, synergistic activity of B-FGF on zidovudine-induced hematopoietic stem cell toxicity was observed in the presence of interleukin 1 (IL-1) (30 ng/ml).	Zidovudine	46-56	interleukin 1 complex	Mus musculus	130-150
1621110-2	1992	The activity of IL-1 was expressed as its ability to stimulate 3H-TdR incorporation in the thymocytes of C57 mice.	Tritium	63-65	interleukin 1 complex	Mus musculus	16-20
1739981-6	1992	Sephadex G-75 chromatography of pooled, concentrated LPS culture supernatant resolved into two peaks of IL-1 activity at 13-17 and at 45-70 kDa, respectively.	sephadex	0-13	interleukin 1 complex	Mus musculus	104-108
1561635-9	1992	Benzene treatment was also found to induce a small but significant (p less than or equal to 0.02) increase in the production of IL-1 by bone marrow leukocytes.	Benzene	0-7	interleukin 1 complex	Mus musculus	128-132
1739981-11	1992	The inability to detect IL-1 by the thymocyte assay is due to the presence of a chondrocyte inhibitor of IL-1 that can be demonstrated in cell sonicates, supernatants, and on paraformaldehyde-fixed chondrocytes.	paraform	175-191	interleukin 1 complex	Mus musculus	105-109
1545136-5	1992	GM-CSF bioactivity increased in cell supernatants from keratinocytes exposed in vitro to 1 microgram/ml cyclosporin for up to 24 h. GM-CSF and IL-1 mRNA levels in keratinocytes cultured under similar conditions or in the presence of lipopolysaccharide also increased.	Cyclosporine	104-115	interleukin 1 complex	Mus musculus	143-147
1311561-0	1992	Investigation of guanine-nucleotide-binding protein involvement and regulation of cyclic AMP metabolism in interleukin 1 signal transduction.	Guanine Nucleotides	17-35	interleukin 1 complex	Mus musculus	107-120
1373685-3	1992	Furthermore, IL-1, IL-6, and KL, alone or in combination, synergized with the colony-stimulating factors (CSFs) granulocyte CSF (G-CSF), macrophage CSF (M-CSF), granulocyte-macrophage CSF (GM-CSF), or interleukin 3 (IL-3) in clonal and liquid cultures of 5-FU-purged bone marrow.	Fluorouracil	255-259	interleukin 1 complex	Mus musculus	13-17
1311561-5	1992	In EL4-cell membrane preparations the kinetics of 125I-IL1 binding were altered in the presence of guanosine 5"-[beta gamma-imido]triphosphate, resulting in the formation of a higher-affinity state for IL1 binding.	Guanylyl Imidodiphosphate	99-142	interleukin 1 complex	Mus musculus	55-58
1311561-5	1992	In EL4-cell membrane preparations the kinetics of 125I-IL1 binding were altered in the presence of guanosine 5"-[beta gamma-imido]triphosphate, resulting in the formation of a higher-affinity state for IL1 binding.	Guanylyl Imidodiphosphate	99-142	interleukin 1 complex	Mus musculus	202-205
1311561-7	1992	These results suggest that IL1 receptor function may be regulated by guanine nucleotides; however, the mechanism appears to differ from that exhibited by conventional G-protein-linked receptors.	Guanine Nucleotides	69-88	interleukin 1 complex	Mus musculus	27-30
1311561-0	1992	Investigation of guanine-nucleotide-binding protein involvement and regulation of cyclic AMP metabolism in interleukin 1 signal transduction.	Cyclic AMP	82-92	interleukin 1 complex	Mus musculus	107-120
1311561-1	1992	The involvement of guanine-nucleotide-binding proteins (G-proteins) and regulation of cyclic AMP (cAMP) in interleukin 1 (IL1) signal transduction has been investigated in EL4 and 7OZ/3 cells expressing Type 1 and Type 2 IL1 receptors respectively.	Cyclic AMP	98-102	interleukin 1 complex	Mus musculus	107-120
1624215-4	1992	In non-immunized animals retinoic acid stimulated the production of IL-1 but not of IL-2.	Tretinoin	25-38	interleukin 1 complex	Mus musculus	68-72
1311550-7	1992	Pretreatment with IL-1 or LPS significantly increased superoxide anion production, C albicans phagocytosis, and survival compared with pretreatment with phosphate-buffered solution.	Superoxides	54-70	interleukin 1 complex	Mus musculus	18-22
1729374-3	1992	In the present study it was investigated whether endogenously produced TNF-alpha and IL-1 are involved in the activation of peritoneal macrophages by rIFN-gamma leading to toxoplasmastatic activity and the production of reactive nitrogen intermediates.	reactive nitrogen	220-237	interleukin 1 complex	Mus musculus	85-89
1431555-2	1992	The effect of heat shock (HS) on the synthesis of the monokines tumor necrosis factor (TNF) and interleukin 1 (IL-1) by endotoxin-stimulated thioglycollate-elicited peritoneal macrophages was investigated.	Thioglycolates	141-155	interleukin 1 complex	Mus musculus	96-115
1728297-5	1992	Treatment of challenged mice with cyclosporin A (CyA) led to an abrogation of the disease as seen by an abrogation of the increase in lung index, lack of IL-1 and TNF-alpha release in the BAL.	Cyclosporine	34-47	interleukin 1 complex	Mus musculus	154-158
1319175-2	1992	Maximal expression of Ia antigen and release of interleukin 1 (IL1) were observed during the first week of pregnancy (implantation), when the highest peak of estradiol was produced.	Estradiol	158-167	interleukin 1 complex	Mus musculus	22-66
1350792-5	1992	But Taxol seemed to be a weak inducer of the two interleukins IL-1 and IL-2, since their detection occurred late in the cell culture supernatants.	Paclitaxel	4-9	interleukin 1 complex	Mus musculus	62-66
1510786-7	1992	Thus, IL-1 treatment could clinically be an effective immunotherapeutic modality for autoimmune diabetes mellitus by suppressing early disease progression or normalize plasma glucose levels when insulin is present.	Glucose	175-182	interleukin 1 complex	Mus musculus	6-10
1319763-5	1992	Hydrocortisone in concentrations as low as 10 ng/ml had dramatic inhibitory effects on supernatant levels of TNF and IL-1 and on TNF, IL-1 and IL-6 transcript number.	Hydrocortisone	0-14	interleukin 1 complex	Mus musculus	117-121
1319763-5	1992	Hydrocortisone in concentrations as low as 10 ng/ml had dramatic inhibitory effects on supernatant levels of TNF and IL-1 and on TNF, IL-1 and IL-6 transcript number.	Hydrocortisone	0-14	interleukin 1 complex	Mus musculus	134-138
1319763-11	1992	Thus, physiological and pharmacological concentrations of hydrocortisone had dramatic inhibitory effects on the supernatant levels of TNF and IL-1, and on the number of available TNF, IL-1 and IL-6 transcripts in PEC exposed to LPS, but had minimal effects on supernatant levels of IL-6 bioactivity.	Hydrocortisone	58-72	interleukin 1 complex	Mus musculus	142-146
1319763-11	1992	Thus, physiological and pharmacological concentrations of hydrocortisone had dramatic inhibitory effects on the supernatant levels of TNF and IL-1, and on the number of available TNF, IL-1 and IL-6 transcripts in PEC exposed to LPS, but had minimal effects on supernatant levels of IL-6 bioactivity.	Hydrocortisone	58-72	interleukin 1 complex	Mus musculus	184-188
1319763-12	1992	This hydrocortisone action may be a specific negative feedback system for IL-1 and TNF, with relative sparing of IL-6.	Hydrocortisone	5-19	interleukin 1 complex	Mus musculus	74-86
1530793-0	1992	IL-1 increases phospholipase A2 activity, expression of phospholipase A2-activating protein, and release of linoleic acid from the murine T helper cell line EL-4.	Linoleic Acid	108-121	interleukin 1 complex	Mus musculus	0-4
1727430-2	1992	After in vitro activation by lipopolysaccharide acid (LPS), these macrophages hyperexpress IL-1 beta mRNA and hyperproduce IL-1 protein in comparison with +/+ controls.	lipopolysaccharide acid	29-52	interleukin 1 complex	Mus musculus	91-95
1727430-2	1992	After in vitro activation by lipopolysaccharide acid (LPS), these macrophages hyperexpress IL-1 beta mRNA and hyperproduce IL-1 protein in comparison with +/+ controls.	lps	54-57	interleukin 1 complex	Mus musculus	91-95
1541679-3	1992	Addition of 17 beta-estradiol in the cultures exerted a dose-dependent inhibition of IL-1-, TNF-, and IL-1 + TNF-induced production of bioassayable IL-6.	Estradiol	12-29	interleukin 1 complex	Mus musculus	85-89
1541679-3	1992	Addition of 17 beta-estradiol in the cultures exerted a dose-dependent inhibition of IL-1-, TNF-, and IL-1 + TNF-induced production of bioassayable IL-6.	Estradiol	12-29	interleukin 1 complex	Mus musculus	102-106
1530793-7	1992	The consequence of the elevated PLA2 activity was examined by analysis of the fatty acids released from IL-1-treated cells.	Fatty Acids	78-89	interleukin 1 complex	Mus musculus	104-108
1530793-10	1992	In EL-4 cells, IL-1 potentiates PMA-mediated release of IL-2 at suboptimal concentrations of PMA.	Tetradecanoylphorbol Acetate	32-35	interleukin 1 complex	Mus musculus	15-19
1530793-10	1992	In EL-4 cells, IL-1 potentiates PMA-mediated release of IL-2 at suboptimal concentrations of PMA.	Tetradecanoylphorbol Acetate	93-96	interleukin 1 complex	Mus musculus	15-19
1530793-15	1992	Furthermore, the release of the unsaturated fatty acid linoleic acid or its metabolites may be of functional importance in IL-1-mediated IL-2 production by EL-4 cells.	Fatty Acids, Unsaturated	32-54	interleukin 1 complex	Mus musculus	123-127
1530793-15	1992	Furthermore, the release of the unsaturated fatty acid linoleic acid or its metabolites may be of functional importance in IL-1-mediated IL-2 production by EL-4 cells.	Linoleic Acid	55-68	interleukin 1 complex	Mus musculus	123-127
1614286-1	1992	Interleukin-1 (IL-1) has been shown to activate the hypothalamic-pituitary-adrenal (HPA) axis, and to elevate cerebral concentrations of tryptophan and the norepinephrine catabolite, 3-methoxy,4-hydroxyphenylethyleneglycol (MHPG).	Methoxyhydroxyphenylglycol	224-228	interleukin 1 complex	Mus musculus	15-19
1614286-1	1992	Interleukin-1 (IL-1) has been shown to activate the hypothalamic-pituitary-adrenal (HPA) axis, and to elevate cerebral concentrations of tryptophan and the norepinephrine catabolite, 3-methoxy,4-hydroxyphenylethyleneglycol (MHPG).	Methoxyhydroxyphenylglycol	224-228	interleukin 1 complex	Mus musculus	0-13
1614286-1	1992	Interleukin-1 (IL-1) has been shown to activate the hypothalamic-pituitary-adrenal (HPA) axis, and to elevate cerebral concentrations of tryptophan and the norepinephrine catabolite, 3-methoxy,4-hydroxyphenylethyleneglycol (MHPG).	Tryptophan	137-147	interleukin 1 complex	Mus musculus	0-13
1614286-1	1992	Interleukin-1 (IL-1) has been shown to activate the hypothalamic-pituitary-adrenal (HPA) axis, and to elevate cerebral concentrations of tryptophan and the norepinephrine catabolite, 3-methoxy,4-hydroxyphenylethyleneglycol (MHPG).	Tryptophan	137-147	interleukin 1 complex	Mus musculus	15-19
1614286-1	1992	Interleukin-1 (IL-1) has been shown to activate the hypothalamic-pituitary-adrenal (HPA) axis, and to elevate cerebral concentrations of tryptophan and the norepinephrine catabolite, 3-methoxy,4-hydroxyphenylethyleneglycol (MHPG).	norepinephrine catabolite	156-181	interleukin 1 complex	Mus musculus	0-13
1614286-1	1992	Interleukin-1 (IL-1) has been shown to activate the hypothalamic-pituitary-adrenal (HPA) axis, and to elevate cerebral concentrations of tryptophan and the norepinephrine catabolite, 3-methoxy,4-hydroxyphenylethyleneglycol (MHPG).	norepinephrine catabolite	156-181	interleukin 1 complex	Mus musculus	15-19
1614286-1	1992	Interleukin-1 (IL-1) has been shown to activate the hypothalamic-pituitary-adrenal (HPA) axis, and to elevate cerebral concentrations of tryptophan and the norepinephrine catabolite, 3-methoxy,4-hydroxyphenylethyleneglycol (MHPG).	Methoxyhydroxyphenylglycol	183-222	interleukin 1 complex	Mus musculus	0-13
1614286-2	1992	Eicosanoids have been shown to be involved in a number of the effects of IL-1, but their role in the activation of the HPA axis is controversial.	Eicosanoids	0-11	interleukin 1 complex	Mus musculus	73-77
1614286-1	1992	Interleukin-1 (IL-1) has been shown to activate the hypothalamic-pituitary-adrenal (HPA) axis, and to elevate cerebral concentrations of tryptophan and the norepinephrine catabolite, 3-methoxy,4-hydroxyphenylethyleneglycol (MHPG).	Methoxyhydroxyphenylglycol	183-222	interleukin 1 complex	Mus musculus	15-19
1614286-6	1992	However, the cyclo-oxygenase inhibitor, diclofenac, did attenuate the IL-1-induced elevation of plasma corticosterone and the neurochemical changes.	Diclofenac	40-50	interleukin 1 complex	Mus musculus	70-74
1614286-6	1992	However, the cyclo-oxygenase inhibitor, diclofenac, did attenuate the IL-1-induced elevation of plasma corticosterone and the neurochemical changes.	Corticosterone	103-117	interleukin 1 complex	Mus musculus	70-74
1614286-7	1992	To resolve the conflicting data on the effect of indomethacin on the IL-1-induced elevation of plasma concentration, we studied the effects of indomethacin on the response to IL-1 injected intravenously (IV).	Indomethacin	49-61	interleukin 1 complex	Mus musculus	69-73
1614286-7	1992	To resolve the conflicting data on the effect of indomethacin on the IL-1-induced elevation of plasma concentration, we studied the effects of indomethacin on the response to IL-1 injected intravenously (IV).	Indomethacin	143-155	interleukin 1 complex	Mus musculus	175-179
1614286-8	1992	By contrast with the response to IP IL-1, that to IV IL-1 was attenuated by indomethacin.	Indomethacin	76-88	interleukin 1 complex	Mus musculus	53-57
1614286-10	1992	Forty min following IP IL-1, the corticosterone response to IL-1 was markedly attenuated.	Corticosterone	33-47	interleukin 1 complex	Mus musculus	23-27
1614286-10	1992	Forty min following IP IL-1, the corticosterone response to IL-1 was markedly attenuated.	Corticosterone	33-47	interleukin 1 complex	Mus musculus	60-64
1757129-4	1991	After normal mice were injected intraperitoneally with NBCS or 10(7) CFU heat-killed or viable C. albicans, the number of peritoneal granulocytes rose sharply within 6 h. Pretreatment of mice with a single intraperitoneal dose of 80 ng IL-1 24 h before injection of an inflammatory stimulus did not influence the course of the numbers of leukocytes in the circulation or in the peritoneal cavity.	nbcs	55-59	interleukin 1 complex	Mus musculus	236-240
1455368-4	1992	The activity of IL-1 in supernatants of peripheral blood monocytes (PBM) was measured by bioassay resting on co-stimulation of mouse thymocytes; quantitative determination of tumor necrosis factor-alpha (TNF-alpha) was made by ELISA, PGE2 was determined by RIA.	Dinoprostone	234-238	interleukin 1 complex	Mus musculus	16-20
1814758-4	1991	Enhanced sensitivity to IL-1-induced suppression of food and water intake were observed in obese yellow mice compared to lean mice (food intake suppression: lean 29.92%, obese 88.48%; water intake suppression: lean 25.18%, obese 71.56% of respective controls).	Water	61-66	interleukin 1 complex	Mus musculus	24-28
1814758-4	1991	Enhanced sensitivity to IL-1-induced suppression of food and water intake were observed in obese yellow mice compared to lean mice (food intake suppression: lean 29.92%, obese 88.48%; water intake suppression: lean 25.18%, obese 71.56% of respective controls).	Water	184-189	interleukin 1 complex	Mus musculus	24-28
1565842-6	1992	Synthetic molecules (muramyl dipeptides) like MDP or murabutide (Mu), known as macrophage activators, were also efficient in inducing IL1 hyperexpression in sg/sg macrophages.	Acetylmuramyl-Alanyl-Isoglutamine	21-39	interleukin 1 complex	Mus musculus	134-137
1565842-6	1992	Synthetic molecules (muramyl dipeptides) like MDP or murabutide (Mu), known as macrophage activators, were also efficient in inducing IL1 hyperexpression in sg/sg macrophages.	Acetylmuramyl-Alanyl-Isoglutamine	46-49	interleukin 1 complex	Mus musculus	134-137
1565842-6	1992	Synthetic molecules (muramyl dipeptides) like MDP or murabutide (Mu), known as macrophage activators, were also efficient in inducing IL1 hyperexpression in sg/sg macrophages.	murabutide	53-63	interleukin 1 complex	Mus musculus	134-137
1565842-6	1992	Synthetic molecules (muramyl dipeptides) like MDP or murabutide (Mu), known as macrophage activators, were also efficient in inducing IL1 hyperexpression in sg/sg macrophages.	murabutide	65-67	interleukin 1 complex	Mus musculus	134-137
1834470-6	1991	Recombinant mIL 1Ra competitively inhibited 125I-labeled IL 1 alpha binding to murine type I IL 1R present on EL4 6.1 cells (Ki value of 0.21 nM) and antagonized IL 1-stimulated co-mitogenesis in murine thymocytes (0.7 x 10(6)-1.1 x 10(6) units/mg).	Iodine-125	44-48	interleukin 1 complex	Mus musculus	13-17
1838853-6	1991	The PGE2 response to IL-1 and PTH was not affected by 1,25-(OH)2D3 at 24 h, but at 48 h 1,25-(OH)2D3 (10(-8) M) increased the PGE2 response to both IL-1 and PTH.	Dinoprostone	4-8	interleukin 1 complex	Mus musculus	21-25
1838853-6	1991	The PGE2 response to IL-1 and PTH was not affected by 1,25-(OH)2D3 at 24 h, but at 48 h 1,25-(OH)2D3 (10(-8) M) increased the PGE2 response to both IL-1 and PTH.	Dinoprostone	4-8	interleukin 1 complex	Mus musculus	21-33
1838853-6	1991	The PGE2 response to IL-1 and PTH was not affected by 1,25-(OH)2D3 at 24 h, but at 48 h 1,25-(OH)2D3 (10(-8) M) increased the PGE2 response to both IL-1 and PTH.	Calcitriol	88-100	interleukin 1 complex	Mus musculus	21-25
1838853-6	1991	The PGE2 response to IL-1 and PTH was not affected by 1,25-(OH)2D3 at 24 h, but at 48 h 1,25-(OH)2D3 (10(-8) M) increased the PGE2 response to both IL-1 and PTH.	Dinoprostone	126-130	interleukin 1 complex	Mus musculus	21-25
1838853-6	1991	The PGE2 response to IL-1 and PTH was not affected by 1,25-(OH)2D3 at 24 h, but at 48 h 1,25-(OH)2D3 (10(-8) M) increased the PGE2 response to both IL-1 and PTH.	Dinoprostone	126-130	interleukin 1 complex	Mus musculus	21-33
1658005-15	1991	Since both the 43- and 45-kDa proteins, immunoprecipitated from [32P]phosphate-labeled cells, demonstrated a dramatic increase in their levels of serine, threonine, and tyrosine phosphorylation after brief treatment with IL-1, we conclude that IL-1 modulates the activity of these extracellular signal-regulated kinase/microtubule-associated protein-2 kinases by altering the level of their phosphorylation.	Phosphorus-32	65-68	interleukin 1 complex	Mus musculus	221-225
1658005-15	1991	Since both the 43- and 45-kDa proteins, immunoprecipitated from [32P]phosphate-labeled cells, demonstrated a dramatic increase in their levels of serine, threonine, and tyrosine phosphorylation after brief treatment with IL-1, we conclude that IL-1 modulates the activity of these extracellular signal-regulated kinase/microtubule-associated protein-2 kinases by altering the level of their phosphorylation.	Phosphorus-32	65-68	interleukin 1 complex	Mus musculus	244-248
1658005-15	1991	Since both the 43- and 45-kDa proteins, immunoprecipitated from [32P]phosphate-labeled cells, demonstrated a dramatic increase in their levels of serine, threonine, and tyrosine phosphorylation after brief treatment with IL-1, we conclude that IL-1 modulates the activity of these extracellular signal-regulated kinase/microtubule-associated protein-2 kinases by altering the level of their phosphorylation.	Phosphates	69-78	interleukin 1 complex	Mus musculus	221-225
1658005-15	1991	Since both the 43- and 45-kDa proteins, immunoprecipitated from [32P]phosphate-labeled cells, demonstrated a dramatic increase in their levels of serine, threonine, and tyrosine phosphorylation after brief treatment with IL-1, we conclude that IL-1 modulates the activity of these extracellular signal-regulated kinase/microtubule-associated protein-2 kinases by altering the level of their phosphorylation.	Phosphates	69-78	interleukin 1 complex	Mus musculus	244-248
1658005-15	1991	Since both the 43- and 45-kDa proteins, immunoprecipitated from [32P]phosphate-labeled cells, demonstrated a dramatic increase in their levels of serine, threonine, and tyrosine phosphorylation after brief treatment with IL-1, we conclude that IL-1 modulates the activity of these extracellular signal-regulated kinase/microtubule-associated protein-2 kinases by altering the level of their phosphorylation.	Tyrosine	169-177	interleukin 1 complex	Mus musculus	221-225
1658005-15	1991	Since both the 43- and 45-kDa proteins, immunoprecipitated from [32P]phosphate-labeled cells, demonstrated a dramatic increase in their levels of serine, threonine, and tyrosine phosphorylation after brief treatment with IL-1, we conclude that IL-1 modulates the activity of these extracellular signal-regulated kinase/microtubule-associated protein-2 kinases by altering the level of their phosphorylation.	Tyrosine	169-177	interleukin 1 complex	Mus musculus	244-248
1748476-11	1991	The suppression of KC AP (P less than 0.05) and Ia expression (P less than 0.05) due to haemorrhage was attenuated (P less than 0.05) in anti-TNF Ab-treated mice at 2 and 24 hr and KC IL-1 and TNF synthesis was further (P less than 0.01) increased.	kc ap	19-24	interleukin 1 complex	Mus musculus	184-188
1792067-0	1991	The effect of lipo-prostaglandin E1 on the production of interleukin 1 and platelet-activating factor by hepatic sinusoidal endothelial cells in mice.	lipo-prostaglandin e1	14-35	interleukin 1 complex	Mus musculus	57-70
1792067-2	1991	The incubation of mouse hepatic sinusoidal endothelial cells with lipopolysaccharide (LPS) or calcium-ionophore (CaI) A23187 resulted in a concentration-dependent production of IL1 and PAF.	Calcium	94-101	interleukin 1 complex	Mus musculus	177-180
1792067-2	1991	The incubation of mouse hepatic sinusoidal endothelial cells with lipopolysaccharide (LPS) or calcium-ionophore (CaI) A23187 resulted in a concentration-dependent production of IL1 and PAF.	Calcimycin	118-124	interleukin 1 complex	Mus musculus	177-180
1792067-3	1991	However, Lipo-PGE1 dose-dependently decreased the LPS- or CaI A23187-induced production of IL1 and PAF.	Alprostadil	14-18	interleukin 1 complex	Mus musculus	91-94
1792067-3	1991	However, Lipo-PGE1 dose-dependently decreased the LPS- or CaI A23187-induced production of IL1 and PAF.	Calcimycin	62-68	interleukin 1 complex	Mus musculus	91-94
1792067-4	1991	These results suggested that Lipo-PGE1 acts on hepatic sinusoidal endothelial cells to decrease the production of IL1 and PAF, thereby ameliorating inflammatory reactions in the liver.	Alprostadil	34-38	interleukin 1 complex	Mus musculus	114-117
1935798-5	1991	Both cortisol and IL-1 alpha decreased the incorporation of [3H]proline into collagenase-digestible protein (CDP) and reduced alpha 1(I)procollagen mRNA levels at 72 h. Noncollagen protein (NCP) labeling was increased by IL-1 and decreased by cortisol.	Tritium	61-63	interleukin 1 complex	Mus musculus	18-22
1935798-5	1991	Both cortisol and IL-1 alpha decreased the incorporation of [3H]proline into collagenase-digestible protein (CDP) and reduced alpha 1(I)procollagen mRNA levels at 72 h. Noncollagen protein (NCP) labeling was increased by IL-1 and decreased by cortisol.	Proline	64-71	interleukin 1 complex	Mus musculus	18-22
1793054-6	1991	Indomethacin treatment reduced sIL-1 production, levamisole Ia expression and mIL-1 activity, prinomide all three parameters measured and diclofenac, though clinically effective, none.	Indomethacin	0-12	interleukin 1 complex	Mus musculus	78-83
1833422-2	1991	Murine antisense oligonucleotides inhibited IL-1-stimulated PGE2 synthesis by murine fibroblasts in culture in a time (days) and concentration-dependent (3 microM-30 microM) fashion.	Oligonucleotides	17-33	interleukin 1 complex	Mus musculus	44-48
1833422-2	1991	Murine antisense oligonucleotides inhibited IL-1-stimulated PGE2 synthesis by murine fibroblasts in culture in a time (days) and concentration-dependent (3 microM-30 microM) fashion.	Dinoprostone	60-64	interleukin 1 complex	Mus musculus	44-48
1833422-5	1991	Similarly, antisense oligonucleotides to the human, but not the murine, IL-1 receptor inhibited IL-1-stimulated PGE2 synthesis by cultured human fibroblasts.	Oligonucleotides	21-37	interleukin 1 complex	Mus musculus	96-100
1833422-5	1991	Similarly, antisense oligonucleotides to the human, but not the murine, IL-1 receptor inhibited IL-1-stimulated PGE2 synthesis by cultured human fibroblasts.	Dinoprostone	112-116	interleukin 1 complex	Mus musculus	72-76
1833422-5	1991	Similarly, antisense oligonucleotides to the human, but not the murine, IL-1 receptor inhibited IL-1-stimulated PGE2 synthesis by cultured human fibroblasts.	Dinoprostone	112-116	interleukin 1 complex	Mus musculus	96-100
1833422-6	1991	The attenuation of the cellular response to IL-1 caused by the antisense oligonucleotides correlated with a loss in cell surface receptors for IL-1, without any change in the number of bradykinin receptors on these cells.	Oligonucleotides	73-89	interleukin 1 complex	Mus musculus	44-48
1833422-6	1991	The attenuation of the cellular response to IL-1 caused by the antisense oligonucleotides correlated with a loss in cell surface receptors for IL-1, without any change in the number of bradykinin receptors on these cells.	Oligonucleotides	73-89	interleukin 1 complex	Mus musculus	143-147
1833422-7	1991	When antisense oligonucleotides were encapsulated in liposomes, they blocked completely the appearance of newly synthesized IL-1 receptors and IL-1-stimulated PGE2 synthesis.	Oligonucleotides	15-31	interleukin 1 complex	Mus musculus	124-128
1833422-7	1991	When antisense oligonucleotides were encapsulated in liposomes, they blocked completely the appearance of newly synthesized IL-1 receptors and IL-1-stimulated PGE2 synthesis.	Oligonucleotides	15-31	interleukin 1 complex	Mus musculus	143-147
1833422-7	1991	When antisense oligonucleotides were encapsulated in liposomes, they blocked completely the appearance of newly synthesized IL-1 receptors and IL-1-stimulated PGE2 synthesis.	Dinoprostone	159-163	interleukin 1 complex	Mus musculus	143-147
1833422-8	1991	In mice, subcutaneous injection with an oligonucleotide antisense to the murine IL-1 receptor markedly inhibited the infiltration of neutrophils in response to subsequent injection of IL-1.	Oligonucleotides	40-55	interleukin 1 complex	Mus musculus	80-84
1833422-8	1991	In mice, subcutaneous injection with an oligonucleotide antisense to the murine IL-1 receptor markedly inhibited the infiltration of neutrophils in response to subsequent injection of IL-1.	Oligonucleotides	40-55	interleukin 1 complex	Mus musculus	184-188
1837482-5	1991	IL-1ra at 20 micrograms/mouse completely blocked induction of IL-6 and markedly inhibited hypoglycemia and increase in serum corticosterone induced by 0.1 micrograms of IL-1.	Corticosterone	125-139	interleukin 1 complex	Mus musculus	0-4
1959943-3	1991	High levels of intracellular IL-1 activity were produced which were not released in surrounding media unless silica was added to stimulated cells.	Silicon Dioxide	109-115	interleukin 1 complex	Mus musculus	29-33
1652466-0	1991	[3H]morphine binding is enhanced by IL-1-stimulated thymocyte proliferation.	Tritium	1-3	interleukin 1 complex	Mus musculus	36-40
1949588-4	1991	IL-1 inhibitory activity was induced both by the prototype variants BVDV/NADL cytopathic and BVDV/NY-1 noncytopathic and by BVDV variants isolated from persistently infected cattle.	nadl	73-77	interleukin 1 complex	Mus musculus	0-4
1713511-8	1991	After blocking protein synthesis with cycloheximide, IL-1- or FBS-induced M-CSF expression and IL-1 plus FBS-induced GM-CSF expression still occurred and was increased.	Cycloheximide	38-51	interleukin 1 complex	Mus musculus	53-57
1713511-9	1991	IL-1-induced G-CSF expression was completely prevented in these cells by pretreatment with cycloheximide, illustrating that, for this effect, intermediate protein synthesis was required.	Cycloheximide	91-104	interleukin 1 complex	Mus musculus	0-4
1713511-12	1991	After blocking protein synthesis with cycloheximide, IL-1-or FBS-induced increase in M-CSF transcription rate was also observed.	Cycloheximide	38-51	interleukin 1 complex	Mus musculus	53-57
1868253-0	1991	Role for interleukin-1 (IL-1) in benzene-induced hematotoxicity: inhibition of conversion of pre-IL-1 alpha to mature cytokine in murine macrophages by hydroquinone and prevention of benzene-induced hematotoxicity in mice by IL-1 alpha.	Benzene	33-40	interleukin 1 complex	Mus musculus	9-22
1868253-0	1991	Role for interleukin-1 (IL-1) in benzene-induced hematotoxicity: inhibition of conversion of pre-IL-1 alpha to mature cytokine in murine macrophages by hydroquinone and prevention of benzene-induced hematotoxicity in mice by IL-1 alpha.	Benzene	33-40	interleukin 1 complex	Mus musculus	24-28
1868253-2	1991	The stromal macrophage that produces interleukin-1 (IL-1), a cytokine essential for hematopoiesis, is a target of BZ"s toxicity.	Benzene	114-116	interleukin 1 complex	Mus musculus	37-50
1868253-2	1991	The stromal macrophage that produces interleukin-1 (IL-1), a cytokine essential for hematopoiesis, is a target of BZ"s toxicity.	Benzene	114-116	interleukin 1 complex	Mus musculus	52-56
1868253-4	1991	Hydroquinone (HQ), a toxic bone marrow (BM) metabolite of BZ, causes time- and concentration-dependent inhibition of processing of the 34-Kd pre-interleukin-1 alpha (IL-1 alpha) to the 17-Kd mature cytokine in murine P388D1 macrophages and BM stromal macrophages, as measured by Western immunoblots of cell lysate proteins using a polyclonal rabbit antimurine IL-1 alpha antibody.	hydroquinone	0-12	interleukin 1 complex	Mus musculus	145-158
1868253-4	1991	Hydroquinone (HQ), a toxic bone marrow (BM) metabolite of BZ, causes time- and concentration-dependent inhibition of processing of the 34-Kd pre-interleukin-1 alpha (IL-1 alpha) to the 17-Kd mature cytokine in murine P388D1 macrophages and BM stromal macrophages, as measured by Western immunoblots of cell lysate proteins using a polyclonal rabbit antimurine IL-1 alpha antibody.	Benzene	58-60	interleukin 1 complex	Mus musculus	145-158
1652466-0	1991	[3H]morphine binding is enhanced by IL-1-stimulated thymocyte proliferation.	Morphine	4-12	interleukin 1 complex	Mus musculus	36-40
1652466-1	1991	Mouse thymocytes incubated in vitro with increasing concentrations of interleukin-1 (IL-1) in the presence of phytohemagglutinin (PHA) exhibited a dose-dependent increase in cell proliferation, as measured by [3H]thymidine incorporation.	Tritium	210-212	interleukin 1 complex	Mus musculus	70-83
1652466-1	1991	Mouse thymocytes incubated in vitro with increasing concentrations of interleukin-1 (IL-1) in the presence of phytohemagglutinin (PHA) exhibited a dose-dependent increase in cell proliferation, as measured by [3H]thymidine incorporation.	Tritium	210-212	interleukin 1 complex	Mus musculus	85-89
1652466-1	1991	Mouse thymocytes incubated in vitro with increasing concentrations of interleukin-1 (IL-1) in the presence of phytohemagglutinin (PHA) exhibited a dose-dependent increase in cell proliferation, as measured by [3H]thymidine incorporation.	Thymidine	213-222	interleukin 1 complex	Mus musculus	70-83
1652466-1	1991	Mouse thymocytes incubated in vitro with increasing concentrations of interleukin-1 (IL-1) in the presence of phytohemagglutinin (PHA) exhibited a dose-dependent increase in cell proliferation, as measured by [3H]thymidine incorporation.	Thymidine	213-222	interleukin 1 complex	Mus musculus	85-89
1652466-4	1991	Interleukin-2 was ineffective in promoting either cell proliferation or enhanced opioid binding, but the effects of IL-1 could be mimicked by phorbol myristate acetate (PMA), suggesting the involvement of tyrosine phosphorylation.	Tetradecanoylphorbol Acetate	142-167	interleukin 1 complex	Mus musculus	116-120
1652466-4	1991	Interleukin-2 was ineffective in promoting either cell proliferation or enhanced opioid binding, but the effects of IL-1 could be mimicked by phorbol myristate acetate (PMA), suggesting the involvement of tyrosine phosphorylation.	Tetradecanoylphorbol Acetate	169-172	interleukin 1 complex	Mus musculus	116-120
1652466-4	1991	Interleukin-2 was ineffective in promoting either cell proliferation or enhanced opioid binding, but the effects of IL-1 could be mimicked by phorbol myristate acetate (PMA), suggesting the involvement of tyrosine phosphorylation.	Tyrosine	205-213	interleukin 1 complex	Mus musculus	116-120
1855993-1	1991	The injection of lethal or sublethal doses of bacterial lipopolysaccharide (LPS) into mice results in transient increases in both serum tumor necrosis factor (TNF) and interleukin-1 (IL-1).	bacterial lipopolysaccharide	46-74	interleukin 1 complex	Mus musculus	168-187
1713607-5	1991	IL-1 and agents that elevate intracellular cAMP levels do not, by themselves, induce AP-1 activation, but they synergize with phorbol esters.	Cyclic AMP	43-47	interleukin 1 complex	Mus musculus	0-4
1713607-5	1991	IL-1 and agents that elevate intracellular cAMP levels do not, by themselves, induce AP-1 activation, but they synergize with phorbol esters.	Phorbol Esters	126-140	interleukin 1 complex	Mus musculus	0-4
1713607-6	1991	IL-1 and forskolin may enhance AP-1 function by different mechanisms, because forskolin enhanced gene expression without producing an increase in nuclear AP-1 DNA binding, whereas IL-1 increased AP-1-binding activity and gene expression.	Colforsin	9-18	interleukin 1 complex	Mus musculus	180-184
1713607-6	1991	IL-1 and forskolin may enhance AP-1 function by different mechanisms, because forskolin enhanced gene expression without producing an increase in nuclear AP-1 DNA binding, whereas IL-1 increased AP-1-binding activity and gene expression.	Colforsin	78-87	interleukin 1 complex	Mus musculus	0-4
1713607-9	1991	The effect of protein kinase inhibitor on AP-1 activation in response to IL-1 and tetradecanoyl-phorbol-13-acetate was reversed in the presence of the serine/threonine protein phosphatase inhibitor okadaic acid.	Okadaic Acid	198-210	interleukin 1 complex	Mus musculus	73-77
2066564-1	1991	An agar plating technique was developed for enumeration of IL-1-producing monocytes based on the principle that when IL-1-producing monocytes were cocultured with mouse thymocytes and PHA in semisolid agar medium in a plate, mouse thymocytes proliferated around IL-1-producing monocytes resulting in the clusters or colonies of cells.	Agar	3-7	interleukin 1 complex	Mus musculus	117-121
1830063-5	1991	The stimulatory action of heparan sulfate was mediated, at least in part, by increased production of IL-1, because the increased splenocyte proliferation induced by heparan sulfate was substantially inhibited by anti-murine IL-1 alpha-antibodies.	Heparitin Sulfate	26-41	interleukin 1 complex	Mus musculus	101-105
1830063-5	1991	The stimulatory action of heparan sulfate was mediated, at least in part, by increased production of IL-1, because the increased splenocyte proliferation induced by heparan sulfate was substantially inhibited by anti-murine IL-1 alpha-antibodies.	Heparitin Sulfate	165-180	interleukin 1 complex	Mus musculus	101-105
2066564-1	1991	An agar plating technique was developed for enumeration of IL-1-producing monocytes based on the principle that when IL-1-producing monocytes were cocultured with mouse thymocytes and PHA in semisolid agar medium in a plate, mouse thymocytes proliferated around IL-1-producing monocytes resulting in the clusters or colonies of cells.	Agar	3-7	interleukin 1 complex	Mus musculus	59-63
2060019-8	1991	Indomethacin treatment alone induced the production of IL-1 by macrophages in NM mice.	Indomethacin	0-12	interleukin 1 complex	Mus musculus	55-59
2060019-9	1991	However, 3 days after immunization and the withdrawal of indomethacin in NM mice, IL-1 production was significantly lower than the response of NM mice given antigen alone, suggestive of the induction of a feedback mechanism.	Indomethacin	57-69	interleukin 1 complex	Mus musculus	82-86
2060019-10	1991	Thus indomethacin pretreatment results in a cascade of events in macrophages which produce a decrease in IL-1 production and an increase in inducible Ia expression 3 days after antigen challenge.	Indomethacin	5-17	interleukin 1 complex	Mus musculus	105-109
2066564-1	1991	An agar plating technique was developed for enumeration of IL-1-producing monocytes based on the principle that when IL-1-producing monocytes were cocultured with mouse thymocytes and PHA in semisolid agar medium in a plate, mouse thymocytes proliferated around IL-1-producing monocytes resulting in the clusters or colonies of cells.	Agar	3-7	interleukin 1 complex	Mus musculus	117-121
1651781-2	1991	This study shows the in vitro effect of LiCl on the TNF-induced or interleukin 1 (IL-1)-induced expression of IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-3, IL-2, and the IL-2 receptor-alpha (IL-2R alpha).	Lithium Chloride	40-44	interleukin 1 complex	Mus musculus	67-86
1651781-7	1991	However, LiCl potentiated the IL-1-induced synthesis of IL-6, GM-CSF, IL-3, and IL-2 in PC60 murine T-cell hybridoma cells.	Lithium Chloride	9-13	interleukin 1 complex	Mus musculus	30-34
1908334-0	1991	In vitro cytokine release by activated murine peritoneal macrophages: role of prostaglandins in the differential regulation of tumor necrosis factor alpha, interleukin 1, and interleukin 6.	Prostaglandins	78-92	interleukin 1 complex	Mus musculus	156-169
1651781-10	1991	IL-2R alpha expression was likewise considerably enhanced by IL-1 + LiCl treatment, as compared with treatment with IL-1 alone.	Lithium Chloride	68-72	interleukin 1 complex	Mus musculus	116-120
1651781-11	1991	The effects of LiCl on the TNF-induced and the IL-1-induced gene expression seem to be independent of the protein kinase A and C pathways.	Lithium Chloride	15-19	interleukin 1 complex	Mus musculus	47-51
1651781-12	1991	These results show that LiCl can modulate both TNF-mediated cytotoxicity and TNF-induced and IL-1-induced cytokine expression, suggesting that Li+ acts early in the TNF-signaling pathway, but at a step shared with the IL-1-signaling pathway.	Lithium Chloride	24-28	interleukin 1 complex	Mus musculus	93-97
1651781-12	1991	These results show that LiCl can modulate both TNF-mediated cytotoxicity and TNF-induced and IL-1-induced cytokine expression, suggesting that Li+ acts early in the TNF-signaling pathway, but at a step shared with the IL-1-signaling pathway.	Lithium Chloride	24-28	interleukin 1 complex	Mus musculus	218-222
1873477-3	1991	IL-1 production by murine peritoneal macrophages was induced either by stimulation with lipopolysaccharide (LPS) or by phagocytosis of zymosan.	Zymosan	135-142	interleukin 1 complex	Mus musculus	0-4
1873477-5	1991	Approximately 20 ng/mL of IL-1 was produced by 10(6) macrophages in response to LPS and about half that amount was produced in response to zymosan.	Zymosan	139-146	interleukin 1 complex	Mus musculus	26-30
1873477-9	1991	Because tenidap inhibited IL-1 induction by both zymosan and LPS, it must act subsequently to receptor triggering.	Zymosan	49-56	interleukin 1 complex	Mus musculus	26-30
1709926-5	1991	This biological enhancement by IL-1 was accompanied by a selective increase of alpha-PDGF receptor expression, following the augmentation of alpha receptor autophosphorylation and inositol phosphate hydrolysis induced by PDGF-AA.	Inositol Phosphates	180-198	interleukin 1 complex	Mus musculus	31-35
1902169-8	1991	IL-1 (60 pM) and PTH (2.4 nM) stimulation of PGE2 production showed a similar time course, with a lag phase of 0.75-1.5 h. Cortisol (1-100 nM) reduced basal PGE2 production and calcium release.	Calcium	177-184	interleukin 1 complex	Mus musculus	0-4
2047761-6	1991	When macrophages from mice stressed 8 days or HCC mice were stimulated in vitro with phorbol myristate acetate (PMA) and IL-1 or PMA and IL-2, a changed PG/GAG synthesis was observed only in macrophages from the HCC animals.	Glycosaminoglycans	156-159	interleukin 1 complex	Mus musculus	121-125
1902169-3	1991	We found that both PTH and IL-1 stimulated the release of PGE2 and 6-keto-PGF1 alpha (the stable metabolite of PGI2).	Dinoprostone	58-62	interleukin 1 complex	Mus musculus	27-31
1902169-9	1991	The absolute amounts of PG produced in response to PTH and IL-1 were reduced in the presence of cortisol, but in the presence of AA the relative increases were still from 2.5- to 26-fold compared with levels in cultures treated with cortisol alone.	Prostaglandins	24-26	interleukin 1 complex	Mus musculus	59-63
1902169-3	1991	We found that both PTH and IL-1 stimulated the release of PGE2 and 6-keto-PGF1 alpha (the stable metabolite of PGI2).	6-Ketoprostaglandin F1 alpha	67-84	interleukin 1 complex	Mus musculus	27-31
1902169-5	1991	Thus, IL-1 was 40-fold more potent than PTH in stimulating PG release.	Prostaglandins	59-61	interleukin 1 complex	Mus musculus	6-10
1902169-6	1991	Moreover, IL-1 showed 2- to 3-fold greater efficacy than PTH in stimulating PGE2 release.	Dinoprostone	76-80	interleukin 1 complex	Mus musculus	10-14
1902169-11	1991	AA (10(-5) M) amplified PG production in response to PTH and IL-1, but not 45Ca release.	Prostaglandins	24-26	interleukin 1 complex	Mus musculus	61-65
1902169-8	1991	IL-1 (60 pM) and PTH (2.4 nM) stimulation of PGE2 production showed a similar time course, with a lag phase of 0.75-1.5 h. Cortisol (1-100 nM) reduced basal PGE2 production and calcium release.	Dinoprostone	157-161	interleukin 1 complex	Mus musculus	0-4
1902169-12	1991	In bones labeled with [3H]AA, IL-1 and PTH increased [3H]PGE2 and [3H]6-keto-PGF1 alpha release, as measured by HPLC and TLC.	Tritium	23-25	interleukin 1 complex	Mus musculus	30-34
1902169-12	1991	In bones labeled with [3H]AA, IL-1 and PTH increased [3H]PGE2 and [3H]6-keto-PGF1 alpha release, as measured by HPLC and TLC.	Tritium	54-56	interleukin 1 complex	Mus musculus	30-34
1902169-12	1991	In bones labeled with [3H]AA, IL-1 and PTH increased [3H]PGE2 and [3H]6-keto-PGF1 alpha release, as measured by HPLC and TLC.	Dinoprostone	57-61	interleukin 1 complex	Mus musculus	30-34
1902169-12	1991	In bones labeled with [3H]AA, IL-1 and PTH increased [3H]PGE2 and [3H]6-keto-PGF1 alpha release, as measured by HPLC and TLC.	Tritium	54-56	interleukin 1 complex	Mus musculus	30-34
1902169-12	1991	In bones labeled with [3H]AA, IL-1 and PTH increased [3H]PGE2 and [3H]6-keto-PGF1 alpha release, as measured by HPLC and TLC.	6-keto-pgf1	70-81	interleukin 1 complex	Mus musculus	30-34
1902169-13	1991	IL-1 slightly increased [3H]AA release, but PTH did not.	Tritium	25-27	interleukin 1 complex	Mus musculus	0-4
1902169-16	1991	mRNA was increased by both PTH and IL-1 to a similar extent despite the greater effect of IL-1 on PGE2 production.	Dinoprostone	98-102	interleukin 1 complex	Mus musculus	90-94
1902169-18	1991	We conclude that IL-1 is a more potent stimulator of PG production and bone resorption than PTH.	Prostaglandins	53-55	interleukin 1 complex	Mus musculus	17-21
1902169-19	1991	Stimulation of PG production by both PTH and IL-1 is mediated at least in part by increasing PGH synthase, but IL-1 may have an additional effect on AA release.	Prostaglandins	15-17	interleukin 1 complex	Mus musculus	45-49
2038179-4	1991	Female C57B1/6 mice treated with iv IL-1 24 hr prior to 30 mg/kg LPS ip had improved survival compared to saline-treated controls (P less than 0.01).	Sodium Chloride	106-112	interleukin 1 complex	Mus musculus	36-40
1830617-4	1991	Dexamethasone strongly inhibited the PGE2 and IL-1 production by Y4 LPS-stimulated BALB/c mouse calvaria, as well as Y4 LPS-induced bone resorption.	Dexamethasone	0-13	interleukin 1 complex	Mus musculus	46-50
1830617-5	1991	Dexamethasone inhibited expression of membrane IL-1 on osteoblastic cells stimulated with Y4 LPS, but indomethacin did not.	Dexamethasone	0-13	interleukin 1 complex	Mus musculus	47-51
1830617-6	1991	Furthermore, anti-IL-1 serum partially suppressed the calcium release from Y4 LPS-stimulated BALB/c mouse calvaria.	Calcium	54-61	interleukin 1 complex	Mus musculus	18-22
1826128-11	1991	In addition, IL-1ra and 35F5 significantly blocked the ability of IL-1 to stimulate egress of PMN from bone marrow, to induce a transient neutrophilia, and to elevate serum levels of hepatic acute phase proteins, IL-6, and corticosterone.	Corticosterone	223-237	interleukin 1 complex	Mus musculus	13-17
2059661-5	1991	First, the protein kinase C inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H-7) strongly inhibited PMA-induced activation of NF-kappa B in 70Z/3 cells but had no effect on NF-kappa B activated by IL-1 or LPS.	1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine	85-88	interleukin 1 complex	Mus musculus	206-210
2059661-5	1991	First, the protein kinase C inhibitor 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H-7) strongly inhibited PMA-induced activation of NF-kappa B in 70Z/3 cells but had no effect on NF-kappa B activated by IL-1 or LPS.	Tetradecanoylphorbol Acetate	109-112	interleukin 1 complex	Mus musculus	206-210
1714439-6	1991	On IL1 treatment, actinomycin D caused superinduction of liver ODC, which was at least partly due to increased stability of the ODC enzyme, because actinomycin D doubled the apparent half-life (from 50 to 95 min).	Dactinomycin	18-31	interleukin 1 complex	Mus musculus	3-6
1714439-6	1991	On IL1 treatment, actinomycin D caused superinduction of liver ODC, which was at least partly due to increased stability of the ODC enzyme, because actinomycin D doubled the apparent half-life (from 50 to 95 min).	Dactinomycin	148-161	interleukin 1 complex	Mus musculus	3-6
2025252-1	1991	Interleukin-1 (IL-1) alpha and beta dose-dependently stimulated the release of 45Ca and the formation of prostaglandin E2 (PGE2) and PGI2 in cultured mouse calvarial bones, with IL-1 beta being the most potent agonist.	Dinoprostone	105-121	interleukin 1 complex	Mus musculus	0-13
1857746-0	1991	Inhibitory effect of 8-methoxypsoralen plus ultraviolet-A on interleukin-1 production by murine keratinocytes.	Methoxsalen	21-38	interleukin 1 complex	Mus musculus	61-74
1857746-1	1991	We report the effects of 8-methoxypsoralen (8-MOP) plus ultraviolet-A (UV-A) irradiation on interleukin-1 (IL-1) production by murine epidermal keratinocytes, correlating its effect on IL-1 with cell viability, DNA synthesis, and 8-MOP-DNA photoadduct formation.	Methoxsalen	25-42	interleukin 1 complex	Mus musculus	92-105
1857746-1	1991	We report the effects of 8-methoxypsoralen (8-MOP) plus ultraviolet-A (UV-A) irradiation on interleukin-1 (IL-1) production by murine epidermal keratinocytes, correlating its effect on IL-1 with cell viability, DNA synthesis, and 8-MOP-DNA photoadduct formation.	Methoxsalen	25-42	interleukin 1 complex	Mus musculus	107-111
1857746-1	1991	We report the effects of 8-methoxypsoralen (8-MOP) plus ultraviolet-A (UV-A) irradiation on interleukin-1 (IL-1) production by murine epidermal keratinocytes, correlating its effect on IL-1 with cell viability, DNA synthesis, and 8-MOP-DNA photoadduct formation.	Methoxsalen	25-42	interleukin 1 complex	Mus musculus	185-189
1857746-1	1991	We report the effects of 8-methoxypsoralen (8-MOP) plus ultraviolet-A (UV-A) irradiation on interleukin-1 (IL-1) production by murine epidermal keratinocytes, correlating its effect on IL-1 with cell viability, DNA synthesis, and 8-MOP-DNA photoadduct formation.	morpholinopropane sulfonic acid	46-49	interleukin 1 complex	Mus musculus	92-105
1857746-1	1991	We report the effects of 8-methoxypsoralen (8-MOP) plus ultraviolet-A (UV-A) irradiation on interleukin-1 (IL-1) production by murine epidermal keratinocytes, correlating its effect on IL-1 with cell viability, DNA synthesis, and 8-MOP-DNA photoadduct formation.	morpholinopropane sulfonic acid	46-49	interleukin 1 complex	Mus musculus	107-111
1857746-3	1991	The IL-1/epidermal cell-derived thymocyte-activating factor (ETAF) activity in both supernatant and cell extract was reduced proportionately with increasing doses of 8-MOP/UV-A.	morpholinopropane sulfonic acid	167-171	interleukin 1 complex	Mus musculus	4-8
1857746-4	1991	Interleukin-1 inhibitors induced by 8-MOP plus UV-A were not detected in either supernatant or cell extract.	Methoxsalen	36-41	interleukin 1 complex	Mus musculus	0-13
2025252-1	1991	Interleukin-1 (IL-1) alpha and beta dose-dependently stimulated the release of 45Ca and the formation of prostaglandin E2 (PGE2) and PGI2 in cultured mouse calvarial bones, with IL-1 beta being the most potent agonist.	Dinoprostone	123-127	interleukin 1 complex	Mus musculus	0-13
2025252-1	1991	Interleukin-1 (IL-1) alpha and beta dose-dependently stimulated the release of 45Ca and the formation of prostaglandin E2 (PGE2) and PGI2 in cultured mouse calvarial bones, with IL-1 beta being the most potent agonist.	Epoprostenol	133-137	interleukin 1 complex	Mus musculus	0-13
2001605-8	1991	These results suggest that one mechanism by which levamisole acts to normalize and restore immune responses may be enhancing the signals which enable activated macrophages to secrete IL-1.	Levamisole	50-60	interleukin 1 complex	Mus musculus	183-187
2001605-0	1991	Enhancement of in vitro lipopolysaccharide-stimulated interleukin-1 production by levamisole.	Levamisole	82-92	interleukin 1 complex	Mus musculus	54-67
1999179-5	1991	We investigated the possible roles of changes in serum corticosterone and glucose in the effects of LPS, TNF and IL-1.	Corticosterone	55-69	interleukin 1 complex	Mus musculus	113-117
2001605-2	1991	In vitro IL-1 production by P388D1 cells treated with lipopolysaccharide (LPS) was enhanced by coculture with levamisole (0.1 to 10 microM).	Levamisole	110-120	interleukin 1 complex	Mus musculus	9-13
2001605-3	1991	Oral administration of levamisole (3 mg/kg) to mice also resulted in potentiation of in vitro IL-1 production by thioglycollate-elicited peritoneal macrophages in response to in vitro LPS stimulation.	Levamisole	23-33	interleukin 1 complex	Mus musculus	94-98
2001605-3	1991	Oral administration of levamisole (3 mg/kg) to mice also resulted in potentiation of in vitro IL-1 production by thioglycollate-elicited peritoneal macrophages in response to in vitro LPS stimulation.	Thioglycolates	113-127	interleukin 1 complex	Mus musculus	94-98
1999179-5	1991	We investigated the possible roles of changes in serum corticosterone and glucose in the effects of LPS, TNF and IL-1.	Glucose	74-81	interleukin 1 complex	Mus musculus	113-117
1999179-6	1991	A single injection of LPS, TNF, or IL-1 markedly increased serum corticosterone levels after 2 h. After only 2 days of chronic treatment, mice given LPS or TNF were refractory to induction of serum corticosterone by a subsequent injection of LPS or TNF, but mice given IL-1 for 2 days were still fully responsive to IL-1.	Corticosterone	65-79	interleukin 1 complex	Mus musculus	35-39
1999179-6	1991	A single injection of LPS, TNF, or IL-1 markedly increased serum corticosterone levels after 2 h. After only 2 days of chronic treatment, mice given LPS or TNF were refractory to induction of serum corticosterone by a subsequent injection of LPS or TNF, but mice given IL-1 for 2 days were still fully responsive to IL-1.	Corticosterone	198-212	interleukin 1 complex	Mus musculus	35-39
1992764-15	1991	In contrast, IL-1 levels rose concurrently with corticosterone.	Corticosterone	48-62	interleukin 1 complex	Mus musculus	13-17
1999179-9	1991	This lack of adaptation to the increase of serum corticosterone and hypoglycemia was also observed when IL-1 was given at lower, nonlethal doses (0.25-1.0 microgram) and for a longer period (up to 8 days).	Corticosterone	49-63	interleukin 1 complex	Mus musculus	104-108
1995530-12	1991	An increase in cellular GSH content and synthesis was demonstrated following IL-1 which lasted 24 hr, suggesting a possible mechanism for the radioprotection by IL-1.	Glutathione	24-27	interleukin 1 complex	Mus musculus	77-81
1995530-12	1991	An increase in cellular GSH content and synthesis was demonstrated following IL-1 which lasted 24 hr, suggesting a possible mechanism for the radioprotection by IL-1.	Glutathione	24-27	interleukin 1 complex	Mus musculus	161-165
1650801-6	1991	IL-1 production by M phi from control and infected mice increased after treatment by indomethacin and LPS.	Indomethacin	85-97	interleukin 1 complex	Mus musculus	0-4
1776477-1	1991	Effects of a novel immunopotentiator Polyactin A (PAA), developed in China, on production and responsiveness of murine interleukin 1(IL-1) were investigated.	polyactin A	37-48	interleukin 1 complex	Mus musculus	133-137
1776477-1	1991	Effects of a novel immunopotentiator Polyactin A (PAA), developed in China, on production and responsiveness of murine interleukin 1(IL-1) were investigated.	polyactin A	50-53	interleukin 1 complex	Mus musculus	133-137
1650801-9	1991	These results suggest that the excess activation of cyclo-oxygenase-derived products (prostaglandins) in infected mice might be responsible for the suppression of IL-1 production by M phi, resulting in decreased PMN migration induced by endotoxin.	Prostaglandins	86-100	interleukin 1 complex	Mus musculus	163-167
1671080-4	1991	The antitumor action of IL-1/IL-2 treatment was abolished or markedly reduced in mice treated with antibodies to CD4 or CD8 antigens, whereas antibodies to asialo-GM1 were ineffective.	G(M1) Ganglioside	163-166	interleukin 1 complex	Mus musculus	24-28
1671080-11	1991	IL-1/IL-2 treatments were also highly effective in increasing survival time of mice from which the subcutaneous primary tumors were excised 7 d after FLC injection.	Fluconazole	150-153	interleukin 1 complex	Mus musculus	0-4
1676876-4	1991	These findings suggest that azelastine is not an IL-1 antagonist but inhibits IL-1 synthesis and/or release in leukocytes.	azelastine	28-38	interleukin 1 complex	Mus musculus	78-82
2008002-6	1991	CSF-1 and IL-1 appeared to be products of the GMG cells.	glucose-mannose-glucose	46-49	interleukin 1 complex	Mus musculus	10-14
1847488-7	1991	Electrophysiological studies in cultured primary cortical neurons demonstrated that IL-1 enhanced the GABA-mediated increase in chloride permeability, whereas IL-1 alone produced no alterations in resting conductance.	gamma-Aminobutyric Acid	102-106	interleukin 1 complex	Mus musculus	84-88
1847488-7	1991	Electrophysiological studies in cultured primary cortical neurons demonstrated that IL-1 enhanced the GABA-mediated increase in chloride permeability, whereas IL-1 alone produced no alterations in resting conductance.	Chlorides	128-136	interleukin 1 complex	Mus musculus	84-88
1847488-8	1991	Behavioral studies indicated that IL-1 is similarly active in vivo; mice treated with IL-1 showed a decrease in open-field activity and an increase in the threshold for pentylenetetrazol-induced seizures.	Pentylenetetrazole	169-186	interleukin 1 complex	Mus musculus	34-38
1847488-8	1991	Behavioral studies indicated that IL-1 is similarly active in vivo; mice treated with IL-1 showed a decrease in open-field activity and an increase in the threshold for pentylenetetrazol-induced seizures.	Pentylenetetrazole	169-186	interleukin 1 complex	Mus musculus	86-90
1717027-1	1991	Bestatin (ubenimex), the microbial leucil-aminopeptidase B inhibitor, has been shown previously to stimulate both interleukin-1 (IL-1) and IL-2 production and to enhance T-cell, as well as macrophage mediated immunoreaction when administered in vivo in mice.	ubenimex	0-8	interleukin 1 complex	Mus musculus	114-134
1951475-7	1991	The use of indomethacin resulted in a further increase in IL-1 production.	Indomethacin	11-23	interleukin 1 complex	Mus musculus	58-62
1717027-1	1991	Bestatin (ubenimex), the microbial leucil-aminopeptidase B inhibitor, has been shown previously to stimulate both interleukin-1 (IL-1) and IL-2 production and to enhance T-cell, as well as macrophage mediated immunoreaction when administered in vivo in mice.	ubenimex	10-18	interleukin 1 complex	Mus musculus	114-134
1715770-3	1991	Agents that elevated intracellular cAMP blocked or partially blocked IL-1 induction of IL-2 secretion, whereas agents that activated protein kinase C (PKC) resulted in a synergistic enhancement.	Cyclic AMP	35-39	interleukin 1 complex	Mus musculus	69-73
1684549-7	1991	On the contrary, as is the case for TNF, the LPS-induced production of IL-1 was inhibited by isoproterenol.	Isoproterenol	93-106	interleukin 1 complex	Mus musculus	71-75
1873493-6	1991	Treatment of mice with ibuprofen or with chlorpromazine, both known to counteract some of the toxic effects of IL-1 in vivo, could protect from IL-1 beta induced mortality.	Ibuprofen	23-32	interleukin 1 complex	Mus musculus	111-115
1873493-6	1991	Treatment of mice with ibuprofen or with chlorpromazine, both known to counteract some of the toxic effects of IL-1 in vivo, could protect from IL-1 beta induced mortality.	Chlorpromazine	41-55	interleukin 1 complex	Mus musculus	111-115
1987032-0	1991	Murine macrophage interleukin-1 release by capsularlike serotype-specific polysaccharide antigens of Actinobacillus actinomycetemcomitans.	Polysaccharides	74-88	interleukin 1 complex	Mus musculus	18-31
2019424-2	1991	In the present study, it was found that the cytokines produced by macrophages in response to LPS, interleukin-1 (IL-1, 0.1 microgram/kg or more) and tumour necrosis factor (TNF alpha, 100 micrograms/kg or more), can also induce an increase in liver serotonin and produce hypoglycaemia.	Serotonin	249-258	interleukin 1 complex	Mus musculus	113-117
1761361-2	1991	Intact or cyclophosphamide-treated mice received human rIL-1 beta according to different regimens, and their sera were assayed for CSA at 4, 24 or 48 h. The results indicated that (1) cyclophosphamide alone significantly increased the level of circulating CSA, (2) administration of IL-1 to intact or neutropenic mice resulted in a biphasic pattern of CSA response, an early burst at 4 h being followed at 24-48 h by a significant decrease.	Cyclophosphamide	10-26	interleukin 1 complex	Mus musculus	56-60
1761361-3	1991	In nongranulocytopenic mice, the combined treatment with IL-1 and bacterial cells also resulted in a biphasic pattern of CSA response.	Cyclosporine	121-124	interleukin 1 complex	Mus musculus	57-61
1761361-4	1991	However, when IL-1 was administered in concurrence with the cyclo-oxygenase inhibitor indomethacin, sustained CSA levels could be observed for a prolonged period of time.	Indomethacin	86-98	interleukin 1 complex	Mus musculus	14-18
1761361-4	1991	However, when IL-1 was administered in concurrence with the cyclo-oxygenase inhibitor indomethacin, sustained CSA levels could be observed for a prolonged period of time.	Cyclosporine	110-113	interleukin 1 complex	Mus musculus	14-18
1761361-5	1991	These data expand upon our previous observations on modulation of CSA by IL-1 in granulocytopenic mice, and further support the concept that IL-1 may have both positive and negative effects on the expression of circulating CSA.	Cyclosporine	66-69	interleukin 1 complex	Mus musculus	73-77
1987032-4	1991	Rabbit anti-murine IL-1 serum strongly suppressed the proliferation of C3H/HeJ mouse thymocytes induced with the culture supernatants of Y4 SPA-stimulated P388D1 cells and a submitogenic dose of concanavalin A. Gel filtration of the culture supernatants of Y4 SPA-stimulated macrophages on Sephacryl S-200 showed that an IL-1 peak at a point corresponding to approximately 16.5 kDa was eluted.	sephacryl S 200	290-305	interleukin 1 complex	Mus musculus	19-23
1987032-6	1991	The IL-1-releasing ability of serotype a and c antigens was enhanced by deacetylation of both polysaccharides, suggesting that acetyl groups of these antigens might hinder the interaction between the antigens and macrophages.	Polysaccharides	94-109	interleukin 1 complex	Mus musculus	4-8
1821082-0	1991	[Inhibitory effect of tripterine on activities of IL-1, IL-2 and release of PGE2].	celastrol	22-32	interleukin 1 complex	Mus musculus	50-54
1845804-4	1991	In this cell line IL-1 activates two distinct transmission signal pathways, one leading to increased levels of intracellular cAMP, and the other to the phosphorylation of an 80-kDa substrate of protein kinase C (PKC).	Cyclic AMP	125-129	interleukin 1 complex	Mus musculus	18-22
1881399-1	1991	Supernatants collected from cisplatin-treated macrophages demonstrated enhanced cytotoxicity against actinomycin-D-treated L929 cells and also enhanced the thymocyte proliferation in response to concanavalin A, showing that cisplatin-treated macrophages release interleukin-1 (IL-1) and tumor necrosis factor (TNF) into the culture supernatant.	Cisplatin	28-37	interleukin 1 complex	Mus musculus	262-281
1881399-1	1991	Supernatants collected from cisplatin-treated macrophages demonstrated enhanced cytotoxicity against actinomycin-D-treated L929 cells and also enhanced the thymocyte proliferation in response to concanavalin A, showing that cisplatin-treated macrophages release interleukin-1 (IL-1) and tumor necrosis factor (TNF) into the culture supernatant.	Cisplatin	224-233	interleukin 1 complex	Mus musculus	262-281
1881399-3	1991	The release of TNF and IL-1 was observed to be dependent on the dose and duration of cisplatin treatment.	Cisplatin	85-94	interleukin 1 complex	Mus musculus	23-27
1881399-8	1991	Maximum production and release of IL-1 were observed up to 24 h after cisplatin treatment and then gradually declined.	Cisplatin	70-79	interleukin 1 complex	Mus musculus	34-38
1881399-9	1991	Freeze-thaw lysates of cisplatin-treated macrophages also showed enhanced IL-1 activity.	Cisplatin	23-32	interleukin 1 complex	Mus musculus	74-78
1881399-12	1991	These results suggest that cisplatin treatment of murine macrophages also results in increased expression of membrane-associated IL-1 and TNF activity.	Cisplatin	27-36	interleukin 1 complex	Mus musculus	129-133
1749831-4	1991	In pituitary cell cultures, prolonged treatment with phorbol ester had no effect on IL-1-induced beta-endorphin release, but abolished the potentiating effects of IL-1 on vasopressin-induced beta-endorphin secretion.	Phorbol Esters	53-66	interleukin 1 complex	Mus musculus	163-167
1821082-4	1991	The results showed that tripterine (0.1-1.0 microgram/ml) significantly inhibited IL-1 activity of murine peritoneal macrophages induced by LPS.	celastrol	24-34	interleukin 1 complex	Mus musculus	82-86
1821082-5	1991	Because both intracellular and extracellular IL-1 activities were decreased, so tripterine might be able to reduce the production and release of IL-1.	celastrol	80-90	interleukin 1 complex	Mus musculus	45-49
1821082-5	1991	Because both intracellular and extracellular IL-1 activities were decreased, so tripterine might be able to reduce the production and release of IL-1.	celastrol	80-90	interleukin 1 complex	Mus musculus	145-149
1821082-6	1991	Besides, inhibition of IL-1 production was observed when macrophages were pretreated with the drug for 8 h and 16 h. A good relationship was found between the effect and concentration of tripterine which inhibited IL-2 production from ConA-activated murine splenocytes.	celastrol	187-197	interleukin 1 complex	Mus musculus	23-27
2174104-6	1990	A synthetic oligonucleotide corresponding to this binding site, as well as a similar sequence found in another class III complement C4 gene, conferred IL-1 responsiveness on the minimal factor B promoter.	Oligonucleotides	12-27	interleukin 1 complex	Mus musculus	151-155
2268359-1	1990	Interleukin 1 (IL-1) has been shown to potentiate the release of beta-endorphin induced by secretagogues, including corticotropin releasing factor (CRF) and phorbol ester (TPA), in the mouse AtT-20 pituitary tumor cell line (Fagarasan et al., PNAS, 1989, 86, 2070-2073).	Phorbol Esters	157-170	interleukin 1 complex	Mus musculus	0-13
2268359-1	1990	Interleukin 1 (IL-1) has been shown to potentiate the release of beta-endorphin induced by secretagogues, including corticotropin releasing factor (CRF) and phorbol ester (TPA), in the mouse AtT-20 pituitary tumor cell line (Fagarasan et al., PNAS, 1989, 86, 2070-2073).	Phorbol Esters	157-170	interleukin 1 complex	Mus musculus	15-19
2268359-1	1990	Interleukin 1 (IL-1) has been shown to potentiate the release of beta-endorphin induced by secretagogues, including corticotropin releasing factor (CRF) and phorbol ester (TPA), in the mouse AtT-20 pituitary tumor cell line (Fagarasan et al., PNAS, 1989, 86, 2070-2073).	Tetradecanoylphorbol Acetate	172-175	interleukin 1 complex	Mus musculus	0-13
2268359-1	1990	Interleukin 1 (IL-1) has been shown to potentiate the release of beta-endorphin induced by secretagogues, including corticotropin releasing factor (CRF) and phorbol ester (TPA), in the mouse AtT-20 pituitary tumor cell line (Fagarasan et al., PNAS, 1989, 86, 2070-2073).	Tetradecanoylphorbol Acetate	172-175	interleukin 1 complex	Mus musculus	15-19
2268359-4	1990	However, treatment of AtT-20 cells with IL-1 induced the expression of vasopressin-mediated beta-endorphin release; this effect of IL-1 was reduced after depletion of protein kinase C by prolonged treatment with TPA.	Tetradecanoylphorbol Acetate	212-215	interleukin 1 complex	Mus musculus	40-44
2268359-4	1990	However, treatment of AtT-20 cells with IL-1 induced the expression of vasopressin-mediated beta-endorphin release; this effect of IL-1 was reduced after depletion of protein kinase C by prolonged treatment with TPA.	Tetradecanoylphorbol Acetate	212-215	interleukin 1 complex	Mus musculus	131-135
2268359-5	1990	The enhancement of CRF-stimulated beta-endorphin release by IL-1 was also reduced in AtT-20 cells after depletion of protein kinase C, and after treatment with staurosporine.	Staurosporine	160-173	interleukin 1 complex	Mus musculus	60-64
2124235-10	1990	Protein kinase inhibitors H7 (5-50 microM) and sphingosine (50 microM) inhibited only IL-1-induced CAT activity, whereas H8 (5-50 microM) and HA1004 (50 microM) were ineffective on both parameters.	Sphingosine	47-58	interleukin 1 complex	Mus musculus	86-90
2124235-12	1990	IL-1-stimulated PGE2 release was potentiated by PMA, although this effect was not inhibited by H7.	Dinoprostone	16-20	interleukin 1 complex	Mus musculus	0-4
2174106-3	1990	In the murine thymoma EL4.E1, IL-1 could synergize with the phosphoinositide pathway, because the cells made higher levels of IL-2 in the presence of IL-1 than could be induced by phorbol ester plus calcium ionophore alone.	Phosphatidylinositols	60-76	interleukin 1 complex	Mus musculus	150-154
2174106-3	1990	In the murine thymoma EL4.E1, IL-1 could synergize with the phosphoinositide pathway, because the cells made higher levels of IL-2 in the presence of IL-1 than could be induced by phorbol ester plus calcium ionophore alone.	Phorbol Esters	180-193	interleukin 1 complex	Mus musculus	30-34
2174106-3	1990	In the murine thymoma EL4.E1, IL-1 could synergize with the phosphoinositide pathway, because the cells made higher levels of IL-2 in the presence of IL-1 than could be induced by phorbol ester plus calcium ionophore alone.	Calcium	199-206	interleukin 1 complex	Mus musculus	30-34
2226318-4	1990	In addition, the IL-1-treated mouse thyroid showed an in vitro unresponsiveness to TSH, with an increase of pituitary TSH (2.24-fold by 15 micrograms IL-1).	Thyrotropin	83-86	interleukin 1 complex	Mus musculus	17-21
2242072-5	1990	They also point to the fact that some IL-1 activities may be dependent on intracellular folate pathways.	Folic Acid	88-94	interleukin 1 complex	Mus musculus	38-42
2260089-8	1990	It was observed that the macrophages from aldicarb-treated mice demonstrated a decreased capacity to stimulate conalbumin-specific T helper cell clone, D10.G4, and when activated produced decreased amounts of IL-1 when compared to control macrophages.	Aldicarb	42-50	interleukin 1 complex	Mus musculus	209-213
2085145-3	1990	The present study was undertaken to clarify the effect of bucillamine primarily on the release of interleukin (IL)-1 from monocytes and on the proliferation of T cells.	bucillamine	58-69	interleukin 1 complex	Mus musculus	98-116
2085145-4	1990	Bucillamine significantly inhibited IL-1-induced thymocyte proliferation in a dose-dependent manner.	bucillamine	0-11	interleukin 1 complex	Mus musculus	36-40
2242072-0	1990	Rescue of interleukin-1 activity by leucovorin following inhibition by methotrexate in a murine in vitro system.	Leucovorin	36-46	interleukin 1 complex	Mus musculus	10-23
2242072-0	1990	Rescue of interleukin-1 activity by leucovorin following inhibition by methotrexate in a murine in vitro system.	Methotrexate	71-83	interleukin 1 complex	Mus musculus	10-23
2242072-1	1990	We have recently shown that methotrexate (MTX) inhibits interleukin-1 (IL-1) activity in vitro.	Methotrexate	28-40	interleukin 1 complex	Mus musculus	56-69
2242072-1	1990	We have recently shown that methotrexate (MTX) inhibits interleukin-1 (IL-1) activity in vitro.	Methotrexate	28-40	interleukin 1 complex	Mus musculus	71-75
2242072-1	1990	We have recently shown that methotrexate (MTX) inhibits interleukin-1 (IL-1) activity in vitro.	Methotrexate	42-45	interleukin 1 complex	Mus musculus	56-69
2242072-1	1990	We have recently shown that methotrexate (MTX) inhibits interleukin-1 (IL-1) activity in vitro.	Methotrexate	42-45	interleukin 1 complex	Mus musculus	71-75
2242072-3	1990	In the present study, we showed that the inhibition of IL-1 activity in vitro by MTX is dependent on folate pathways since, after the addition of leucovorin, the inhibitory effect of MTX was abolished.	Methotrexate	81-84	interleukin 1 complex	Mus musculus	55-59
2242072-3	1990	In the present study, we showed that the inhibition of IL-1 activity in vitro by MTX is dependent on folate pathways since, after the addition of leucovorin, the inhibitory effect of MTX was abolished.	Folic Acid	101-107	interleukin 1 complex	Mus musculus	55-59
2242072-3	1990	In the present study, we showed that the inhibition of IL-1 activity in vitro by MTX is dependent on folate pathways since, after the addition of leucovorin, the inhibitory effect of MTX was abolished.	Leucovorin	146-156	interleukin 1 complex	Mus musculus	55-59
2242072-3	1990	In the present study, we showed that the inhibition of IL-1 activity in vitro by MTX is dependent on folate pathways since, after the addition of leucovorin, the inhibitory effect of MTX was abolished.	Methotrexate	183-186	interleukin 1 complex	Mus musculus	55-59
2226318-4	1990	In addition, the IL-1-treated mouse thyroid showed an in vitro unresponsiveness to TSH, with an increase of pituitary TSH (2.24-fold by 15 micrograms IL-1).	Thyrotropin	118-121	interleukin 1 complex	Mus musculus	17-21
2226318-4	1990	In addition, the IL-1-treated mouse thyroid showed an in vitro unresponsiveness to TSH, with an increase of pituitary TSH (2.24-fold by 15 micrograms IL-1).	Thyrotropin	118-121	interleukin 1 complex	Mus musculus	150-154
2226318-7	1990	IL-1 administration induced an increase in the basal thyroidal cAMP level for a prolonged period.	Cyclic AMP	63-67	interleukin 1 complex	Mus musculus	0-4
2400992-0	1990	Evidence that high mannose glycopeptides are able to functionally interact with recombinant tumor necrosis factor and recombinant interleukin 1.	Mannose	19-26	interleukin 1 complex	Mus musculus	130-143
2270781-5	1990	Treatment with IL-1 for 24 h increased medium PGE2 19- to 22-fold, and 10(-10) M T and DHT inhibited this increase by 60 and 70%, respectively.	Dinoprostone	46-50	interleukin 1 complex	Mus musculus	15-19
2121883-3	1990	In this study, ethylenediaminetetraacetic acid (EDTA), a known chelator of divalent cations, was used to evaluate the role of cell attachment vs. spreading in adherence-induced mIL-1 activity on resident C57BL/6 mouse PEC.	Edetic Acid	15-46	interleukin 1 complex	Mus musculus	177-182
2121883-3	1990	In this study, ethylenediaminetetraacetic acid (EDTA), a known chelator of divalent cations, was used to evaluate the role of cell attachment vs. spreading in adherence-induced mIL-1 activity on resident C57BL/6 mouse PEC.	Edetic Acid	48-52	interleukin 1 complex	Mus musculus	177-182
2121883-4	1990	Significant inhibition of PEC spreading on plastic and mIL-1 expression was noted when PEC were cultured in the presence of 10 mM EDTA.	Edetic Acid	130-134	interleukin 1 complex	Mus musculus	55-60
2400992-0	1990	Evidence that high mannose glycopeptides are able to functionally interact with recombinant tumor necrosis factor and recombinant interleukin 1.	Glycopeptides	27-40	interleukin 1 complex	Mus musculus	130-143
2400992-1	1990	Both recombinant tumor necrosis factor (rTNF) and recombinant interleukin 1 (rIL-1) are able to mediate vascular collapse and death in a previously described murine model, using galactosamine to enhance the toxicity of these cytokines.	Galactosamine	178-191	interleukin 1 complex	Mus musculus	62-75
2400992-11	1990	Conversely, castanosperimine, a glucosidase I inhibitor which blocks the synthesis of mature high mannose structures, inhibits the biological activity of IL-1.	castanosperimine	12-28	interleukin 1 complex	Mus musculus	154-158
2144844-2	1990	In normal mice and in mice pretreated with cyclophosphamide, hydrocortisone acetate, or sublethal total body irradiation, the outgrowth of Candida albicans in the kidney was significantly reduced by the administration of a single intraperitoneal dose of 80 ng of IL-1 (P less than 0.05).	Cyclophosphamide	43-59	interleukin 1 complex	Mus musculus	263-267
2144844-3	1990	In mice treated with either cyclophosphamide or irradiation, IL-1 also significantly reduced the outgrowth of C. albicans in the spleen.	Cyclophosphamide	28-44	interleukin 1 complex	Mus musculus	61-65
2144844-4	1990	The protective effect of IL-1 was present when given 24 h before injection of C. albicans but also when IL-1 was given simultaneously with or 6 h after injection of C. albicans in cyclophosphamide-treated mice.	Cyclophosphamide	180-196	interleukin 1 complex	Mus musculus	25-29
2144844-4	1990	The protective effect of IL-1 was present when given 24 h before injection of C. albicans but also when IL-1 was given simultaneously with or 6 h after injection of C. albicans in cyclophosphamide-treated mice.	Cyclophosphamide	180-196	interleukin 1 complex	Mus musculus	104-108
2400992-11	1990	Conversely, castanosperimine, a glucosidase I inhibitor which blocks the synthesis of mature high mannose structures, inhibits the biological activity of IL-1.	Mannose	98-105	interleukin 1 complex	Mus musculus	154-158
1978316-6	1990	Addition to AtT-20 cells of antisense oligonucleotides to Fos and Jun abolished the secretion induced by IL-1.	Oligonucleotides	38-54	interleukin 1 complex	Mus musculus	105-109
1694731-8	1990	However, GPhe also augmented the response of these cells in the presence of exogenous IL-4 (+/- IL-2, +/- IL-1), and exogenous IL-4 added in combination with exogenous IL-2 (+/- IL-1) failed to mimic the GPhe effect, suggesting that another signal was involved in the mechanism of action of GPhe.	gphe	9-13	interleukin 1 complex	Mus musculus	106-110
2400309-3	1990	To better understand the host-foreign body interaction, we quantitated the production of mIL-1 on the surface of two materials commonly used in surgery, expanded polytef (ePTFE) and silicon elastomer (SE).	Polytetrafluoroethylene	162-169	interleukin 1 complex	Mus musculus	89-94
2400309-3	1990	To better understand the host-foreign body interaction, we quantitated the production of mIL-1 on the surface of two materials commonly used in surgery, expanded polytef (ePTFE) and silicon elastomer (SE).	eptfe	171-176	interleukin 1 complex	Mus musculus	89-94
1695235-0	1990	Macrophages from C3H/HeJ mice require an additional step to produce monokines: synergistic effects of silica and poly(I:C) in the release of interleukin 1.	Silicon Dioxide	102-108	interleukin 1 complex	Mus musculus	141-154
2364437-11	1990	The addition of monoclonal anti-IL 1 antibodies (100 neutralizing units) to the supernatants reduced the incorporation of [3H]-thymidine by 90 to 95%, suggesting that the observed activity was due to IL 1.	3h]-thymidine	123-136	interleukin 1 complex	Mus musculus	32-36
1966937-6	1990	Production of interleukin 1 (IL-1) was also stimulated in sera of CY-treated and untreated mice by administration of GLA-60.	Cyclophosphamide	66-68	interleukin 1 complex	Mus musculus	14-33
1966937-6	1990	Production of interleukin 1 (IL-1) was also stimulated in sera of CY-treated and untreated mice by administration of GLA-60.	gamma-Linolenic Acid	117-120	interleukin 1 complex	Mus musculus	14-33
1695235-0	1990	Macrophages from C3H/HeJ mice require an additional step to produce monokines: synergistic effects of silica and poly(I:C) in the release of interleukin 1.	Poly I-C	113-121	interleukin 1 complex	Mus musculus	141-154
1695235-4	1990	In addition, after a two-step activation process, macrophages from BDF1 mice spontaneously released IL-1, whereas silica was required to induce the release of IL-1 from similarly treated C3H/HeJ macrophages.	Silicon Dioxide	114-120	interleukin 1 complex	Mus musculus	159-163
1695235-6	1990	In contrast, poly(I:C) was able to induce the release of FRM by C3H/HeJ macrophages but not that of IL-1; moreover, the addition of silica to poly(I:C)-stimulated cells led to an IL-1 release similar to that obtained with normal mice treated with silica alone.	Poly I-C	13-21	interleukin 1 complex	Mus musculus	179-183
1695235-6	1990	In contrast, poly(I:C) was able to induce the release of FRM by C3H/HeJ macrophages but not that of IL-1; moreover, the addition of silica to poly(I:C)-stimulated cells led to an IL-1 release similar to that obtained with normal mice treated with silica alone.	Silicon Dioxide	132-138	interleukin 1 complex	Mus musculus	179-183
1695235-6	1990	In contrast, poly(I:C) was able to induce the release of FRM by C3H/HeJ macrophages but not that of IL-1; moreover, the addition of silica to poly(I:C)-stimulated cells led to an IL-1 release similar to that obtained with normal mice treated with silica alone.	Poly I-C	13-22	interleukin 1 complex	Mus musculus	179-183
1972922-6	1990	IL-1, which also increases hepatic fatty acid synthesis, produces similar increases in hepatic citrate levels.	hepatic fatty acid	27-45	interleukin 1 complex	Mus musculus	0-4
2382217-10	1990	However, both doses of diltiazem significantly improved peritoneal macrophage antigen presentation, Ia expression, and IL-1 synthesis.	Diltiazem	23-32	interleukin 1 complex	Mus musculus	119-123
1972922-6	1990	IL-1, which also increases hepatic fatty acid synthesis, produces similar increases in hepatic citrate levels.	hepatic citrate	87-102	interleukin 1 complex	Mus musculus	0-4
1972922-11	1990	In contrast, when a low dose of either TNF or IL-1 is combined with a low dose of IFN alpha, there is synergy in stimulating hepatic fatty acid synthesis.	hepatic fatty acid	125-143	interleukin 1 complex	Mus musculus	46-50
1972922-12	1990	A maximal dose of TNF or IL-1 and a high dose of IFN alpha produce a further increase in hepatic fatty acid synthesis.	hepatic fatty acid	89-107	interleukin 1 complex	Mus musculus	25-29
1695006-3	1990	To test our hypothesis that specific in vivo blockade of IL-1"s action might inhibit the catabolic host changes associated with inflammation, mice were passively immunized with a monoclonal antibody directed against the murine IL-1 receptor prior to initiation of a turpentine-induced sterile abscess.	Turpentine	266-276	interleukin 1 complex	Mus musculus	57-61
1698759-2	1990	Both minocycline and tetracycline suppressed the murine thymocyte co-mitogenic bioassay of IL-1 at 2 and 4 mg/l respectively.	Minocycline	5-16	interleukin 1 complex	Mus musculus	91-95
1698759-2	1990	Both minocycline and tetracycline suppressed the murine thymocyte co-mitogenic bioassay of IL-1 at 2 and 4 mg/l respectively.	Tetracycline	21-33	interleukin 1 complex	Mus musculus	91-95
1695006-5	1990	Weight loss following turpentine challenge was prevented by daily injections of anti-IL-1 receptor monoclonal IgG.	Turpentine	22-32	interleukin 1 complex	Mus musculus	85-89
2167003-4	1990	Induction of mIL-1 by LPS was inhibited by PGE2 and dibutyryl cAMP, but higher concentrations were required to inhibit mIL-1 expression compared with sIL-1 release.	Bucladesine	52-66	interleukin 1 complex	Mus musculus	13-18
2200107-2	1990	Since alteration in ion fluxes is crucial for endocrine cell activation and is a denominator of cell death, and since IL-1 was recently shown to increase the total sodium content in a murine pre-B-lymphocyte cell line, we investigated the effect of recombinant human IL-1 beta (rhIL-1 beta) on the cytosolic free sodium concentration (fNa+i) in rat islets.	Sodium	164-170	interleukin 1 complex	Mus musculus	118-122
2167003-3	1990	Low levels of A23187, when combined with OAG (a direct activator of PKC), stimulated mIL-1 expression in the absence of sIL-1 release.	Calcimycin	14-20	interleukin 1 complex	Mus musculus	85-90
2191038-2	1990	IL-1 may influence or be influenced by a number of abnormalities present in psoriasis; including keratinocyte proliferation, eicosanoid production, fibroblast activation, endothelial cell adhesiveness, T cell infiltration and activation, cyclic nucleotide metabolism, and transmembrane signal transduction mechanisms.	Eicosanoids	125-135	interleukin 1 complex	Mus musculus	0-4
2191038-2	1990	IL-1 may influence or be influenced by a number of abnormalities present in psoriasis; including keratinocyte proliferation, eicosanoid production, fibroblast activation, endothelial cell adhesiveness, T cell infiltration and activation, cyclic nucleotide metabolism, and transmembrane signal transduction mechanisms.	Nucleotides, Cyclic	238-255	interleukin 1 complex	Mus musculus	0-4
2386111-7	1990	In other respects, the cyclooxygenase inhibitor indomethacin enhanced the IL-1 like production, but was ineffective on IL-6 like production.	Indomethacin	48-60	interleukin 1 complex	Mus musculus	74-78
2167003-3	1990	Low levels of A23187, when combined with OAG (a direct activator of PKC), stimulated mIL-1 expression in the absence of sIL-1 release.	1-oleoyl-2-acetylglycerol	41-44	interleukin 1 complex	Mus musculus	85-90
2167003-4	1990	Induction of mIL-1 by LPS was inhibited by PGE2 and dibutyryl cAMP, but higher concentrations were required to inhibit mIL-1 expression compared with sIL-1 release.	Dinoprostone	43-47	interleukin 1 complex	Mus musculus	13-18
2168227-2	1990	Among mice receiving paired delivery of cues and IL-1, subsequent re-exposure to cues elicited corticosterone production.	Corticosterone	95-109	interleukin 1 complex	Mus musculus	49-53
2111738-7	1990	Assay of serum colony-stimulating activity (CSA) revealed that (a) cyclophosphamide treatment alone significantly increased the level of circulating CSA, (b) administration of a single dose of IL-1 to neutropenic mice induced an early, further increase in serum CSA, followed by depression, (c) a biphasic pattern of CSA response was also evident in mice repeatedly treated with IL-1.	Cyclosporine	44-47	interleukin 1 complex	Mus musculus	193-197
2111738-7	1990	Assay of serum colony-stimulating activity (CSA) revealed that (a) cyclophosphamide treatment alone significantly increased the level of circulating CSA, (b) administration of a single dose of IL-1 to neutropenic mice induced an early, further increase in serum CSA, followed by depression, (c) a biphasic pattern of CSA response was also evident in mice repeatedly treated with IL-1.	Cyclophosphamide	67-83	interleukin 1 complex	Mus musculus	193-197
2361734-9	1990	Metabolic incorporation of [35S]methionine into mouse SAP occurred in response to both IL-1 and IL-6.	Sulfur-35	28-31	interleukin 1 complex	Mus musculus	87-91
2111738-7	1990	Assay of serum colony-stimulating activity (CSA) revealed that (a) cyclophosphamide treatment alone significantly increased the level of circulating CSA, (b) administration of a single dose of IL-1 to neutropenic mice induced an early, further increase in serum CSA, followed by depression, (c) a biphasic pattern of CSA response was also evident in mice repeatedly treated with IL-1.	Cyclophosphamide	67-83	interleukin 1 complex	Mus musculus	379-383
2111738-7	1990	Assay of serum colony-stimulating activity (CSA) revealed that (a) cyclophosphamide treatment alone significantly increased the level of circulating CSA, (b) administration of a single dose of IL-1 to neutropenic mice induced an early, further increase in serum CSA, followed by depression, (c) a biphasic pattern of CSA response was also evident in mice repeatedly treated with IL-1.	Cyclosporine	149-152	interleukin 1 complex	Mus musculus	193-197
2111738-7	1990	Assay of serum colony-stimulating activity (CSA) revealed that (a) cyclophosphamide treatment alone significantly increased the level of circulating CSA, (b) administration of a single dose of IL-1 to neutropenic mice induced an early, further increase in serum CSA, followed by depression, (c) a biphasic pattern of CSA response was also evident in mice repeatedly treated with IL-1.	Cyclosporine	149-152	interleukin 1 complex	Mus musculus	193-197
2111738-7	1990	Assay of serum colony-stimulating activity (CSA) revealed that (a) cyclophosphamide treatment alone significantly increased the level of circulating CSA, (b) administration of a single dose of IL-1 to neutropenic mice induced an early, further increase in serum CSA, followed by depression, (c) a biphasic pattern of CSA response was also evident in mice repeatedly treated with IL-1.	Cyclosporine	149-152	interleukin 1 complex	Mus musculus	193-197
2165034-0	1990	Possible involvement of adenosine 3":5"-cyclic monophosphate and extracellular calcium ions in histamine stimulation of interleukin-1 release from macrophage-like P388D1 cells.	Cyclic AMP	24-60	interleukin 1 complex	Mus musculus	120-133
2165034-0	1990	Possible involvement of adenosine 3":5"-cyclic monophosphate and extracellular calcium ions in histamine stimulation of interleukin-1 release from macrophage-like P388D1 cells.	Calcium	79-86	interleukin 1 complex	Mus musculus	120-133
2165034-0	1990	Possible involvement of adenosine 3":5"-cyclic monophosphate and extracellular calcium ions in histamine stimulation of interleukin-1 release from macrophage-like P388D1 cells.	Histamine	95-104	interleukin 1 complex	Mus musculus	120-133
2165034-4	1990	An H1-agonist, 2-pyridylethylamine, markedly augmented IL-1 release, reaching a maximum at 10(-4)M. Dimaprit, an H2-agonist, also stimulated IL-1 release, but the effect was far less than that of the H1 agonist.	2-(2-aminoethyl)pyridine	15-34	interleukin 1 complex	Mus musculus	55-59
2165034-4	1990	An H1-agonist, 2-pyridylethylamine, markedly augmented IL-1 release, reaching a maximum at 10(-4)M. Dimaprit, an H2-agonist, also stimulated IL-1 release, but the effect was far less than that of the H1 agonist.	2-(2-aminoethyl)pyridine	15-34	interleukin 1 complex	Mus musculus	141-145
2361734-9	1990	Metabolic incorporation of [35S]methionine into mouse SAP occurred in response to both IL-1 and IL-6.	Methionine	32-42	interleukin 1 complex	Mus musculus	87-91
1691140-5	1990	Aqueous extracts prepared from pulmonary granuloma lesions induced by Bcgs mice by either BCG or dextran beads contained high levels of interleukin-1 (IL-1) activity but not interleukin-2 (IL-2) or interleukin-4 (IL-4) activity.	Dextrans	97-104	interleukin 1 complex	Mus musculus	151-155
1692959-1	1990	Interleukin-1 (IL-1) is known to synergize with phorbol esters in the induction of interleukin-2 (IL-2) expression in T-lymphoid leukemia cells and proliferation of mouse thymocytes.	Phorbol Esters	48-62	interleukin 1 complex	Mus musculus	0-13
1692959-3	1990	Although IL-1 induction of the IL-2 promoter in these cells required costimulus with phorbol myristate acetate, the signal induced by IL-1 was qualitatively different.	Tetradecanoylphorbol Acetate	85-110	interleukin 1 complex	Mus musculus	9-13
1692959-5	1990	That IL-1 and phorbol myristate acetate represent different stimuli was shown by their response to protein kinase C inhibitors, capacity to synergize with increased intracellular free calcium, and requirement for protein synthesis.	Calcium	184-191	interleukin 1 complex	Mus musculus	5-9
1692959-6	1990	In addition we show that pretreatment with IL-1 can prime EL4 cells to subsequent activation by concentrations of phorbol esters not normally sufficient to induce IL-2 expression.	Phorbol Esters	114-128	interleukin 1 complex	Mus musculus	43-47
1691140-6	1990	Very low IL-1 activity was detected in extracts from Bcgr mice injected with BCG and dextran beads.	Dextrans	85-92	interleukin 1 complex	Mus musculus	9-13
2142376-8	1990	Preincubation of cells with IL-1, retinoic acid, transforming growth factor beta (TGF-beta), or phorbol ester caused a reduction in apparent receptor numbers per cell, while preincubation with epidermal growth factor (EGF), dexamethasone, or parathyroid hormone (PTH) increased receptor numbers per cell.	Dexamethasone	224-237	interleukin 1 complex	Mus musculus	28-32
2142376-5	1990	Treatment of surface-bound 125I-IL-1 alpha with a bivalent water-soluble cross-linker identified a membrane peptide of Mr 70,000 cross-linked to IL-1.	Water	59-64	interleukin 1 complex	Mus musculus	32-36
2337505-3	1990	Furthermore, the production of IL-1 by PEC stimulated with LPS in the presence of indomethacin was same in control and tumour-bearing mice.	Indomethacin	82-94	interleukin 1 complex	Mus musculus	31-35
2157407-1	1990	Previously we have reported that human chorionic gonadotropin(hCG)-stimulated testosterone biosynthesis was markedly inhibited by purified natural human interleukin-1 (IL-1).	Testosterone	78-90	interleukin 1 complex	Mus musculus	168-172
2318380-7	1990	Probucol administration did, however, inhibit the fall in serum zinc level induced by intravenous injection of LPS in zymosan-primed mice but had no effect on the LPS-induced increase in serum triglyceride levels, which indirectly confirms that probucol administration inhibits IL 1 but not TNF secretion.	Probucol	0-8	interleukin 1 complex	Mus musculus	278-282
2142376-6	1990	The apparent IL-1 receptor was solubilized from a plasma membrane-enriched fraction using 3-[(3-cholamidopropyldimethylammonio]-1-propanesulfonate (CHAP).	3-[(3-cholamidopropyldimethylammonio]-1-propanesulfonate	90-146	interleukin 1 complex	Mus musculus	13-17
2109011-15	1990	IL-1 activity was first detected in culture supernatants 18 h later, maximal production being in the first 24 h. In accordance with our hybridization results, an increase in IL-1 activity was obtained when eosinophils were stimulated with LPS and treated with indomethacine.	Indomethacin	260-273	interleukin 1 complex	Mus musculus	0-4
2109011-15	1990	IL-1 activity was first detected in culture supernatants 18 h later, maximal production being in the first 24 h. In accordance with our hybridization results, an increase in IL-1 activity was obtained when eosinophils were stimulated with LPS and treated with indomethacine.	Indomethacin	260-273	interleukin 1 complex	Mus musculus	174-178
2317799-9	1990	Enhanced antibacterial resistance by IL-1 and OK432 was also observed in cyclophosphamide- and aminomethylpyrimidinylmethylchloroethylnitrosourea hydrochloride-pretreated (day -5) normal hosts and in cyclophosphamide-treated tumor-bearing hosts.	Cyclophosphamide	73-89	interleukin 1 complex	Mus musculus	37-41
2317799-9	1990	Enhanced antibacterial resistance by IL-1 and OK432 was also observed in cyclophosphamide- and aminomethylpyrimidinylmethylchloroethylnitrosourea hydrochloride-pretreated (day -5) normal hosts and in cyclophosphamide-treated tumor-bearing hosts.	aminomethylpyrimidinylmethylchloroethylnitrosourea hydrochloride	95-159	interleukin 1 complex	Mus musculus	37-41
2317799-9	1990	Enhanced antibacterial resistance by IL-1 and OK432 was also observed in cyclophosphamide- and aminomethylpyrimidinylmethylchloroethylnitrosourea hydrochloride-pretreated (day -5) normal hosts and in cyclophosphamide-treated tumor-bearing hosts.	Cyclophosphamide	200-216	interleukin 1 complex	Mus musculus	37-41
2318380-4	1990	The inhibitory effect of probucol was observed when IL 1 was assayed by the standard bioassay, the thymocyte proliferation assay, or a competitive IL 1 receptor binding assay.	Probucol	25-33	interleukin 1 complex	Mus musculus	52-56
2318380-4	1990	The inhibitory effect of probucol was observed when IL 1 was assayed by the standard bioassay, the thymocyte proliferation assay, or a competitive IL 1 receptor binding assay.	Probucol	25-33	interleukin 1 complex	Mus musculus	147-151
1690213-9	1990	These data are compatible with PHA including activation of phospholipase C and production of inositol phosphates resulting in both release of Ca2+ from internal stores and transmembrane uptake of Ca2+ as well as activation of protein kinase C. However, unlike other growth factor or mitogen-stimulated systems, the changes stimulated by PHA and IL1 in LBRM cells including IL2 secretion are not regulated by a pertussis toxin-sensitive G protein.	Inositol Phosphates	93-112	interleukin 1 complex	Mus musculus	345-348
2157204-2	1990	Desensitization of protein kinase C (PKC) by pretreatment with phorbol ester [phorbol 12-tetradecanoate 13-acetate (TPA)] for 8 hr abolished the secretion induced by TPA as well as the enhancement of TPA-induced beta-endorphin release produced by IL-1.	Phorbol Esters	63-76	interleukin 1 complex	Mus musculus	247-251
2157204-2	1990	Desensitization of protein kinase C (PKC) by pretreatment with phorbol ester [phorbol 12-tetradecanoate 13-acetate (TPA)] for 8 hr abolished the secretion induced by TPA as well as the enhancement of TPA-induced beta-endorphin release produced by IL-1.	Tetradecanoylphorbol Acetate	78-114	interleukin 1 complex	Mus musculus	247-251
2157204-2	1990	Desensitization of protein kinase C (PKC) by pretreatment with phorbol ester [phorbol 12-tetradecanoate 13-acetate (TPA)] for 8 hr abolished the secretion induced by TPA as well as the enhancement of TPA-induced beta-endorphin release produced by IL-1.	Tetradecanoylphorbol Acetate	116-119	interleukin 1 complex	Mus musculus	247-251
2157204-2	1990	Desensitization of protein kinase C (PKC) by pretreatment with phorbol ester [phorbol 12-tetradecanoate 13-acetate (TPA)] for 8 hr abolished the secretion induced by TPA as well as the enhancement of TPA-induced beta-endorphin release produced by IL-1.	Tetradecanoylphorbol Acetate	166-169	interleukin 1 complex	Mus musculus	247-251
2157204-2	1990	Desensitization of protein kinase C (PKC) by pretreatment with phorbol ester [phorbol 12-tetradecanoate 13-acetate (TPA)] for 8 hr abolished the secretion induced by TPA as well as the enhancement of TPA-induced beta-endorphin release produced by IL-1.	Tetradecanoylphorbol Acetate	166-169	interleukin 1 complex	Mus musculus	247-251
2105851-8	1990	The combination of recombinant IL-1 plus ionomycin was found to stimulate [3H]thymidine incorporation by T cell-depleted splenic lymphocytes.	Tritium	75-77	interleukin 1 complex	Mus musculus	31-35
2105851-8	1990	The combination of recombinant IL-1 plus ionomycin was found to stimulate [3H]thymidine incorporation by T cell-depleted splenic lymphocytes.	Thymidine	78-87	interleukin 1 complex	Mus musculus	31-35
2144681-11	1990	The hydrolysis of non-phosphatidyl inositol membrane phospholipids plays an important role in responses to IL-1.	phosphatidyl	22-34	interleukin 1 complex	Mus musculus	107-111
2144681-11	1990	The hydrolysis of non-phosphatidyl inositol membrane phospholipids plays an important role in responses to IL-1.	Phospholipids	53-66	interleukin 1 complex	Mus musculus	107-111
2311646-2	1990	The two IL 1 forms were equally active in vitro in inducing proliferation of murine thymocytes and of the murine T helper clone D10.G4.1, and in triggering release of prostaglandin E2 from human skin fibroblasts.	Dinoprostone	167-183	interleukin 1 complex	Mus musculus	8-12
2154471-8	1990	Experiments in which the concentration of [35S]GTP gamma S was varied revealed that IL1 increased the affinity of the binding sites for [35S]GTP gamma S and not their number.	Sulfur-35	43-46	interleukin 1 complex	Mus musculus	84-87
2154471-8	1990	Experiments in which the concentration of [35S]GTP gamma S was varied revealed that IL1 increased the affinity of the binding sites for [35S]GTP gamma S and not their number.	Guanosine Triphosphate	47-50	interleukin 1 complex	Mus musculus	84-87
2154471-8	1990	Experiments in which the concentration of [35S]GTP gamma S was varied revealed that IL1 increased the affinity of the binding sites for [35S]GTP gamma S and not their number.	Sulfur-35	137-140	interleukin 1 complex	Mus musculus	84-87
2154471-8	1990	Experiments in which the concentration of [35S]GTP gamma S was varied revealed that IL1 increased the affinity of the binding sites for [35S]GTP gamma S and not their number.	Guanosine Triphosphate	141-144	interleukin 1 complex	Mus musculus	84-87
2154471-10	1990	Half-maximal enhancement of [35S]GTP gamma S binding by IL1 alpha, measured after 4 min, occurred at 5% IL1 receptor occupancy.	Sulfur-35	29-32	interleukin 1 complex	Mus musculus	56-59
2154471-10	1990	Half-maximal enhancement of [35S]GTP gamma S binding by IL1 alpha, measured after 4 min, occurred at 5% IL1 receptor occupancy.	Guanosine Triphosphate	33-36	interleukin 1 complex	Mus musculus	56-59
2154471-12	1990	Experiments with pertussis and cholera toxins revealed that pretreating membranes with pertussis toxin (100 ng/ml) inhibited by 50% the IL1-induced [35S]GTP gamma S binding and [gamma-32P]GTP hydrolysis.	Sulfur-35	149-152	interleukin 1 complex	Mus musculus	136-139
2154471-12	1990	Experiments with pertussis and cholera toxins revealed that pretreating membranes with pertussis toxin (100 ng/ml) inhibited by 50% the IL1-induced [35S]GTP gamma S binding and [gamma-32P]GTP hydrolysis.	Guanosine Triphosphate	153-156	interleukin 1 complex	Mus musculus	136-139
2154471-12	1990	Experiments with pertussis and cholera toxins revealed that pretreating membranes with pertussis toxin (100 ng/ml) inhibited by 50% the IL1-induced [35S]GTP gamma S binding and [gamma-32P]GTP hydrolysis.	Guanosine Triphosphate	188-191	interleukin 1 complex	Mus musculus	136-139
2300594-7	1990	In contrast, the amounts of IL-2 and interleukin 1 (IL-1) produced by lymphocytes and macrophages, respectively, removed from Se-deficient or Se-supplemented animals did not differ significantly from the amounts of IL-2 and IL-1 produced by cells removed from animals maintained on the control diet.	Selenium	126-128	interleukin 1 complex	Mus musculus	52-56
2317653-5	1990	IL-1 production was assayed by the murine thymocyte 3H-thymidine incorporation assay.	Tritium	52-54	interleukin 1 complex	Mus musculus	0-4
2317653-5	1990	IL-1 production was assayed by the murine thymocyte 3H-thymidine incorporation assay.	Thymidine	55-64	interleukin 1 complex	Mus musculus	0-4
2329998-7	1990	The effects of IL-1 were mimicked by the tumor promoter phorbol 12-myristate 13-acetate (PMA) at 1-100 nM, which inhibited CDP and reduced procollagen alpha 1(I) mRNA levels to a similar extent.	Tetradecanoylphorbol Acetate	56-87	interleukin 1 complex	Mus musculus	15-19
2329998-7	1990	The effects of IL-1 were mimicked by the tumor promoter phorbol 12-myristate 13-acetate (PMA) at 1-100 nM, which inhibited CDP and reduced procollagen alpha 1(I) mRNA levels to a similar extent.	Tetradecanoylphorbol Acetate	89-92	interleukin 1 complex	Mus musculus	15-19
2183563-4	1990	Supernatants from normal spleen cells treated in vitro either with the polysaccharide or the intact endotoxin showed immunoenhancing helper activity for both normal and FLV infected spleen cells and this enhancing activity was due to IL-1 induced by either bacterial product.	Polysaccharides	71-85	interleukin 1 complex	Mus musculus	234-238
2183563-5	1990	Thus the immunoenhancing soluble mediator, i.e., IL-1, is induced equally by PS or LPS and has immunorestorative activity for FLV infected animals.	Phosphorus	77-79	interleukin 1 complex	Mus musculus	49-53
2312155-5	1990	Addition of exogenous histamine accentuated the IL-1 production by macrophages as a function of its dose.	Histamine	22-31	interleukin 1 complex	Mus musculus	48-52
2224057-3	1990	IL-1 and IL-6 are also known to enhance GM colony formation.	gm	40-42	interleukin 1 complex	Mus musculus	0-4
2177620-0	1990	Cyclic AMP modulates interleukin-1 action in a cytotoxic T-cell hybridoma.	Cyclic AMP	0-10	interleukin 1 complex	Mus musculus	21-34
2177620-4	1990	Stimulators of the adenylate cyclase, such as forskolin and cholera toxin, induced a similar enhancement of the BLT-esterase response to IL-1.	Colforsin	46-55	interleukin 1 complex	Mus musculus	137-141
2177620-6	1990	When the two stimuli were added sequentially a second effect for cAMP emerged: preincubation with dibutyryl cAMP or activators of the adenylate cyclase for 4 h or longer completely blocked the action of subsequently added IL-1.	Cyclic AMP	65-69	interleukin 1 complex	Mus musculus	222-226
2177620-6	1990	When the two stimuli were added sequentially a second effect for cAMP emerged: preincubation with dibutyryl cAMP or activators of the adenylate cyclase for 4 h or longer completely blocked the action of subsequently added IL-1.	Cyclic AMP	108-112	interleukin 1 complex	Mus musculus	222-226
2177620-7	1990	Taken together, the data demonstrate a dual modulatory role for cAMP in T-lymphocytes activated by IL-1.	Cyclic AMP	64-68	interleukin 1 complex	Mus musculus	99-103
2312155-6	1990	These results suggest that IL-1 production by mouse peritoneal macrophages is regulated by histamine synthesized in the system per se and that the effect of histamine is dependent on both H1 and H2 histamine receptors located on the surface of the cells.	Histamine	91-100	interleukin 1 complex	Mus musculus	27-31
2307488-1	1990	The peritoneal cells of mice injected with aclacinomycin (ACM), an oncostatic drug of the anthracyclin family, were found to secrete more interleukin (IL-1), after two successive 24-h periods of in vitro LPS stimulation than those of control mice.	aclacinomycins	43-56	interleukin 1 complex	Mus musculus	151-155
1688572-8	1990	The proliferative response induced in D10.G4 cells by IL-1 + ionomycin but not that induced by IL-1 + PMA was sensitive to inhibition by FK-506 and CsA.	Ionomycin	61-70	interleukin 1 complex	Mus musculus	54-58
2307488-4	1990	In contrast, macrophages from ACM-injected mice only increased their IL-1 production after the first 24-h incubation with PMA, and not after the second 24-h incubation.	Tetradecanoylphorbol Acetate	122-125	interleukin 1 complex	Mus musculus	69-73
2307488-6	1990	We have also compared the IL-1 production by macrophages from mice injected with other anthracyclins, at doses equimolar to that of 4 mg/kg ACM and we have observed that adriamycin, 4"-epiadriamycin and aclacinomycin had similar activity, while THP-adriamycin an daunorubicine were slightly more active.	anthracyclins	87-100	interleukin 1 complex	Mus musculus	26-30
2307488-6	1990	We have also compared the IL-1 production by macrophages from mice injected with other anthracyclins, at doses equimolar to that of 4 mg/kg ACM and we have observed that adriamycin, 4"-epiadriamycin and aclacinomycin had similar activity, while THP-adriamycin an daunorubicine were slightly more active.	Doxorubicin	170-180	interleukin 1 complex	Mus musculus	26-30
2312155-3	1990	Alpha-fluoromethylhistidine, a suicide inhibitor of HDC, attenuated, in a dose-dependent manner, both spontaneous and LPS-stimulated IL-1 synthesis by macrophages.	alpha-fluoromethylhistidine	0-27	interleukin 1 complex	Mus musculus	133-137
2312155-4	1990	IL-1 production was significantly blocked by either an H1 anti-histamine, diphenhydramine, or H2 anti-histamine ranitidine, in the absence of any exogenous histamine.	Histamine	63-72	interleukin 1 complex	Mus musculus	0-4
2312155-4	1990	IL-1 production was significantly blocked by either an H1 anti-histamine, diphenhydramine, or H2 anti-histamine ranitidine, in the absence of any exogenous histamine.	Diphenhydramine	74-89	interleukin 1 complex	Mus musculus	0-4
2312155-4	1990	IL-1 production was significantly blocked by either an H1 anti-histamine, diphenhydramine, or H2 anti-histamine ranitidine, in the absence of any exogenous histamine.	histamine ranitidine	102-122	interleukin 1 complex	Mus musculus	0-4
2312155-4	1990	IL-1 production was significantly blocked by either an H1 anti-histamine, diphenhydramine, or H2 anti-histamine ranitidine, in the absence of any exogenous histamine.	Histamine	102-111	interleukin 1 complex	Mus musculus	0-4
2180256-5	1990	Furthermore, pretreatment of the M phi with dexamethasone, in order to reduce the release of IL1 and TNF, hardly reduces the effect on granulocyte activation.	Dexamethasone	44-57	interleukin 1 complex	Mus musculus	93-96
2104887-1	1990	Enhancement of IL-1 secretion and processing by calcium ionophores.	Calcium	48-55	interleukin 1 complex	Mus musculus	15-19
2104887-8	1990	The rapid release of IL-1 in response to a change in the intracellular level of calcium does not appear to be caused by release of a membrane-bound form of the protein, nor is there evidence that IL-1 is packaged and released from cytoskeletal associated secretory granules.	Calcium	80-87	interleukin 1 complex	Mus musculus	21-25
1688572-8	1990	The proliferative response induced in D10.G4 cells by IL-1 + ionomycin but not that induced by IL-1 + PMA was sensitive to inhibition by FK-506 and CsA.	Tacrolimus	137-143	interleukin 1 complex	Mus musculus	54-58
29566712-6	2018	IL1ss and IL6 had a subtle but significant negative effect on cell viability and testosterone concentrations, with a marked significant decrease in progesterone concentration at all concentrations investigated.	Testosterone	81-93	interleukin 1 complex	Mus musculus	0-3
2134298-4	1990	LPSs from A. actinomycetemcomitans ATCC 29522 and 29523 exhibited the same inducing activity for IL-1 production as did A-LPS.	lpss	0-4	interleukin 1 complex	Mus musculus	97-101
2134298-5	1990	The IL-1 production with A-LPS was inhibited drastically when the LPS was pretreated with polymyxin B. A-LPS-induced IL-1 production was augmented significantly by treatment of the cells with a inhibitor, indomethacin, but not with a lipooxygenase inhibitor, nordihydroguariatic acid.	Indomethacin	205-217	interleukin 1 complex	Mus musculus	4-8
2134298-5	1990	The IL-1 production with A-LPS was inhibited drastically when the LPS was pretreated with polymyxin B. A-LPS-induced IL-1 production was augmented significantly by treatment of the cells with a inhibitor, indomethacin, but not with a lipooxygenase inhibitor, nordihydroguariatic acid.	Indomethacin	205-217	interleukin 1 complex	Mus musculus	117-121
2134298-5	1990	The IL-1 production with A-LPS was inhibited drastically when the LPS was pretreated with polymyxin B. A-LPS-induced IL-1 production was augmented significantly by treatment of the cells with a inhibitor, indomethacin, but not with a lipooxygenase inhibitor, nordihydroguariatic acid.	nordihydroguariatic acid	259-283	interleukin 1 complex	Mus musculus	4-8
2134298-5	1990	The IL-1 production with A-LPS was inhibited drastically when the LPS was pretreated with polymyxin B. A-LPS-induced IL-1 production was augmented significantly by treatment of the cells with a inhibitor, indomethacin, but not with a lipooxygenase inhibitor, nordihydroguariatic acid.	nordihydroguariatic acid	259-283	interleukin 1 complex	Mus musculus	117-121
2134298-7	1990	In light of recent studies showing that IL-1 plays a regulatory role in bone remodeling systems, the present result suggest the possibility that A-LPS-induced IL-1 may play a significant role in mechanism(s) of alveolar bone resorption in juvenile periodontitis and also that its production may be regulated by prostaglandins.	Prostaglandins	311-325	interleukin 1 complex	Mus musculus	159-163
33773150-8	2021	The ELISA results displayed that 100 muM PFOA exposure induced macrophage activation and enhanced cytokines secretion, including TNF-alpha, IL-1, IL-6, and IL-12.	perfluorooctanoic acid	41-45	interleukin 1 complex	Mus musculus	140-144
2133288-8	1990	Thus, the enhancing effect of PAF on IL-1 release appears to be due to the production of lipoxygenase metabolites, leading to superoxide production and alterations of cAMP levels.	Superoxides	126-136	interleukin 1 complex	Mus musculus	37-41
2133288-8	1990	Thus, the enhancing effect of PAF on IL-1 release appears to be due to the production of lipoxygenase metabolites, leading to superoxide production and alterations of cAMP levels.	Cyclic AMP	167-171	interleukin 1 complex	Mus musculus	37-41
33812254-1	2021	BACKGROUND: Isoniazid (INH) is well known as a first-line anti-tuberculosis, while some studies demonstrate that it has anti-inflammatory activity via a different mechanism such as inhibitionthe production of IL-1, ROS, activation of PPARgamma expression, inhibition of the transcriptional regulatory activity of NF-kappaB and AP-1.	Isoniazid	12-21	interleukin 1 complex	Mus musculus	209-213
29566712-6	2018	IL1ss and IL6 had a subtle but significant negative effect on cell viability and testosterone concentrations, with a marked significant decrease in progesterone concentration at all concentrations investigated.	Progesterone	148-160	interleukin 1 complex	Mus musculus	0-3
34724970-15	2021	Moreover, L-carnitine reduced the serum levels of IL-1 and IL-6, factors known to induce cancer cachexia.	Carnitine	10-21	interleukin 1 complex	Mus musculus	50-54
8070358-0	1994	Regulation of the two prostaglandin G/H synthases by parathyroid hormone, interleukin-1, cortisol, and prostaglandin E2 in cultured neonatal mouse calvariae.	Prostaglandins	22-35	interleukin 1 complex	Mus musculus	74-87
8070358-6	1994	However, with IL-1, PGE2 production was increased more than PGHS-2 mRNA levels (treated/control ratio, 3.4 and 1.5, respectively), whereas with PTH there was a closer correspondence (2.0 and 2.1).	Dinoprostone	20-24	interleukin 1 complex	Mus musculus	14-18
8070358-8	1994	In the presence of exogenous arachidonic acid, changes in PGHS-2 mRNA levels with IL-1, PTH, and cortisol correlated closely with changes in PGE2 production.	Arachidonic Acid	29-45	interleukin 1 complex	Mus musculus	82-86
8070358-8	1994	In the presence of exogenous arachidonic acid, changes in PGHS-2 mRNA levels with IL-1, PTH, and cortisol correlated closely with changes in PGE2 production.	Dinoprostone	141-145	interleukin 1 complex	Mus musculus	82-86
8070358-11	1994	We conclude that regulation of PGE2 production is predominantly through PGHS-2, rather than PGHS-1; that IL-1 and cortisol may also regulate arachidonic acid release; and that PGE2 may amplify its own production through stimulation of PGHS-2.	Arachidonic Acid	141-157	interleukin 1 complex	Mus musculus	105-109
34757891-10	2021	Compared to OP mice, AU-treated mice exhibited decreased serum concentrations of TRAP5b (19.6% to 28.4%), IL-1 (12.2% to 12.6%), IL-6 (12.1%) and ROS (5.9% to 10.7%) and increased serum concentrations of SOD (14.6% to 19.4%) and CAT (17.2% to 27.4%).	aucubin	21-23	interleukin 1 complex	Mus musculus	106-110
34806822-9	2022	In lipopolysaccharide (LPS) treated cell model, emodin treatment markedly decreased LPS-induced release of IL-1, IL-6, and tumor necrosis factor (TNF)-alpha, inhibited LPS-induced cell apoptosis and suppressed protein levels of P-P65/P65 and HMGB1.	Emodin	48-54	interleukin 1 complex	Mus musculus	107-111
34832320-5	2021	Here, we show that ADL reduced lipopolysaccharide (LPS)-induced macrophage polarization of the pro-inflammatory (M1) phenotype, indicated by attenuated Interleukin 1 (IL1), Interleukine 6 (IL6)and cyclooxygenase 2 (COX2) expression.	ADL	19-22	interleukin 1 complex	Mus musculus	152-165
34832320-5	2021	Here, we show that ADL reduced lipopolysaccharide (LPS)-induced macrophage polarization of the pro-inflammatory (M1) phenotype, indicated by attenuated Interleukin 1 (IL1), Interleukine 6 (IL6)and cyclooxygenase 2 (COX2) expression.	ADL	19-22	interleukin 1 complex	Mus musculus	167-170
34502316-6	2021	Proinflammatory cytokines (e.g., IL-6, TNF-alpha, and IL-1) have been identified as a driver of the pathological mechanisms underlying involuntary weight loss and impaired physical function, i.e., cachexia, during cancer; in the present study, we showed that farrerol attenuates TNF-alpha-induced lipolysis and increases adipogenic differentiation in 3T3-L1 cells.	farrerol	259-267	interleukin 1 complex	Mus musculus	54-58
34385100-7	2021	Significantly, dCPP could inhibit the proliferation of IL-4-induced M2-like TAMs, and significantly increase the mRNA expression levels of IL-1, IL-6, iNOS and TNF-a, thereby promoting the repolarization of M2-like TAMs to M1-like TAMs.	4,4-dicarboxy-5-pyridoxylproline	15-19	interleukin 1 complex	Mus musculus	139-143
34385100-7	2021	Significantly, dCPP could inhibit the proliferation of IL-4-induced M2-like TAMs, and significantly increase the mRNA expression levels of IL-1, IL-6, iNOS and TNF-a, thereby promoting the repolarization of M2-like TAMs to M1-like TAMs.	tams	215-219	interleukin 1 complex	Mus musculus	139-143
34575874-7	2021	LPS/IL-1-mediated inhibition of RXR Function, TWEAK signaling, and Toll-like receptor signaling were the most activated canonical pathways targeted by melatonin.	Melatonin	151-160	interleukin 1 complex	Mus musculus	4-8
34202859-8	2021	The anti-inflammatory activity of SSZ-loaded MPs was studied by quantifying interleukins IL-1, IL-6 and TNF-alpha in macrophages.	Sulfasalazine	34-37	interleukin 1 complex	Mus musculus	89-93
34421682-8	2021	GUO also mitigated the OBX-induced hippocampal neuroinflammation (IL-1, IL-6, TNF-alpha, INF-gamma, and IL-10).	Guanosine	0-3	interleukin 1 complex	Mus musculus	66-70
34202859-10	2021	Gene expression of IL-1, IL-6 and TNF-alpha was decreased by SSZ-loaded MPs.	Sulfasalazine	61-64	interleukin 1 complex	Mus musculus	19-23
34345387-11	2021	The results showed that betulinic acid could increase insulin and C-peptide, and decrease fasting blood sugar, kidney lesions and TNF-alpha, IFN-gamma, IL-1 in the treated groups.	betulinic acid	24-38	interleukin 1 complex	Mus musculus	152-156
35336732-5	2022	AR281 significantly decreased the critical osteoclast activator, the ratio of the receptor activator for nuclear factor kappa B (NF-kappaB) ligand (RANKL) to osteoprotegerin, and pro-inflammatory osteoclastogenic mediators, such as IL-1, IL-6, and IL-17, which can increase the RANKL expression.	ar281	0-5	interleukin 1 complex	Mus musculus	232-236
35628698-12	2022	In addition, LH-AuNPs inhibited IPA-induced pro-inflammatory cytokines production, including interleukin-1 (IL-1), interleukin-17 (IL-17), and tumor necrosis factor-alpha (TNF-alpha), and reduced oxidative stress in lung.	lh-aunps	13-21	interleukin 1 complex	Mus musculus	93-106
35628698-12	2022	In addition, LH-AuNPs inhibited IPA-induced pro-inflammatory cytokines production, including interleukin-1 (IL-1), interleukin-17 (IL-17), and tumor necrosis factor-alpha (TNF-alpha), and reduced oxidative stress in lung.	lh-aunps	13-21	interleukin 1 complex	Mus musculus	108-112
35455979-5	2022	Our results are supported by literature data, particularly the DMBA generated ROS-induced inflammatory and proliferative signal transducers, such as TNF, IL1, IL6, and NF-kappaB; as well as oncogenes, namely RAS and MYC.	9,10-Dimethyl-1,2-benzanthracene	63-67	interleukin 1 complex	Mus musculus	154-157
35455979-5	2022	Our results are supported by literature data, particularly the DMBA generated ROS-induced inflammatory and proliferative signal transducers, such as TNF, IL1, IL6, and NF-kappaB; as well as oncogenes, namely RAS and MYC.	ros	78-81	interleukin 1 complex	Mus musculus	154-157
35332327-6	2022	Thus, the IL-1 pathway plays a key role in triggering RNA vaccine-associated innate signaling, an effect that was unexpectedly amplified by certain lipids used in vaccine formulations incorporating N1-methyl-pseudouridine-modified RNA to reduce activation of Toll-like receptor signaling.	1-methylpseudouridine	198-221	interleukin 1 complex	Mus musculus	10-14
35432562-10	2022	Mechanistic evaluation revealed that GPS treatment reduced intestinal permeability and serum levels of inflammatory factors: IL-1, IL-6, and TNF-alpha, while increasing serum levels of the anti-inflammatory factor IL-10, suggesting that GPS"s mechanism in UC is related to reducing intestinal permeability and inhibiting the inflammatory response, with intestinal permeability implicated as the initiating mechanism.	(9R,10R)-9-(S-GLUTATHIONYL)-10-HYDROXY-9,10-DIHYDROPHENANTHRENE	37-40	interleukin 1 complex	Mus musculus	125-129
35355075-10	2022	C1CH and C1CHCE also attenuated IL-10 upregulation and upregulated IL-1, IFN-gamma, TNF-alpha and prostaglandin E2 levels, as well as myeloperoxidase, N-acetyl-beta-d-glucosaminidase and cyclooxygenase 2 activity compared with untreated psoriatic animals.	c1ch	0-4	interleukin 1 complex	Mus musculus	67-71
35355075-10	2022	C1CH and C1CHCE also attenuated IL-10 upregulation and upregulated IL-1, IFN-gamma, TNF-alpha and prostaglandin E2 levels, as well as myeloperoxidase, N-acetyl-beta-d-glucosaminidase and cyclooxygenase 2 activity compared with untreated psoriatic animals.	c1chce	9-15	interleukin 1 complex	Mus musculus	67-71
35209110-5	2022	Consistently, in primary murine macrophages, both flavonoids decreased the inflammatory response by lowering LPS-induced IL1 and IL6 expression.	Flavonoids	50-60	interleukin 1 complex	Mus musculus	121-124
2556473-8	1989	The IL-1-induced rise in pHi is both sodium dependent and amiloride sensitive, indicative of activation of the Na+/H+ antiport.	Sodium	37-43	interleukin 1 complex	Mus musculus	4-8
2556473-8	1989	The IL-1-induced rise in pHi is both sodium dependent and amiloride sensitive, indicative of activation of the Na+/H+ antiport.	Amiloride	58-67	interleukin 1 complex	Mus musculus	4-8
2592770-12	1989	Blockade of PG synthesis by using the cyclo-oxygenase inhibitor indomethacin abrogates the myelopoietic suppressive effects associated with IL-1 administration and optimizes its myelopoietic stimulatory capacity.	Prostaglandins	12-14	interleukin 1 complex	Mus musculus	140-144
2592770-5	1989	Treatment of mice with indomethacin, a PG synthesis inhibitor, completely blocked the generation of IL-1-alpha-induced myelopoietic suppressor cells, and significantly enhanced femoral and splenic CFU-GM proliferation after a single injection of 0.4 microgram/mouse IL-1.	Indomethacin	23-35	interleukin 1 complex	Mus musculus	100-104
2592770-5	1989	Treatment of mice with indomethacin, a PG synthesis inhibitor, completely blocked the generation of IL-1-alpha-induced myelopoietic suppressor cells, and significantly enhanced femoral and splenic CFU-GM proliferation after a single injection of 0.4 microgram/mouse IL-1.	Prostaglandins	39-41	interleukin 1 complex	Mus musculus	100-104
2592770-12	1989	Blockade of PG synthesis by using the cyclo-oxygenase inhibitor indomethacin abrogates the myelopoietic suppressive effects associated with IL-1 administration and optimizes its myelopoietic stimulatory capacity.	Indomethacin	64-76	interleukin 1 complex	Mus musculus	140-144
2592770-6	1989	The peripheral blood neutrophilia observed within 6 h after IL-1 injection was delayed to 18 to 24 h postinjection in indomethacin-pretreated mice.	Indomethacin	118-130	interleukin 1 complex	Mus musculus	60-64
2592770-9	1989	In IL-1 plus indomethacin-treated mice, sustained peripheral neutrophilia was observed although to a lesser degree than with IL-1 alone.	Indomethacin	13-25	interleukin 1 complex	Mus musculus	125-129
2574679-5	1989	Similarly to plastic-adsorbed antibodies, phorbol myristic acetate (PMA) or a combination of PMA and the calcium ionophore Ionomycin also induces secretion of growth factors without inducing proliferation, but in this case addition of IL 1 is ineffective in inducing AK-8 proliferation.	Tetradecanoylphorbol Acetate	68-71	interleukin 1 complex	Mus musculus	235-239
2806435-1	1989	Previous reports have shown that interleukin 1 (IL-1) has radioprotective effects when given to mice 20 h before a lethal dose of irradiation and enhances granulocyte recovery in mice treated with cyclophosphamide.	Cyclophosphamide	197-213	interleukin 1 complex	Mus musculus	33-52
2692568-2	1989	We have tested the effect of dexamethasone (DEX) and chlorpromazine (CPZ) on the lethal effect of IL-1, TNF and endotoxin.	Dexamethasone	29-42	interleukin 1 complex	Mus musculus	98-121
2692568-2	1989	We have tested the effect of dexamethasone (DEX) and chlorpromazine (CPZ) on the lethal effect of IL-1, TNF and endotoxin.	Dexamethasone	44-47	interleukin 1 complex	Mus musculus	98-121
2692568-2	1989	We have tested the effect of dexamethasone (DEX) and chlorpromazine (CPZ) on the lethal effect of IL-1, TNF and endotoxin.	Chlorpromazine	53-67	interleukin 1 complex	Mus musculus	98-121
2692568-2	1989	We have tested the effect of dexamethasone (DEX) and chlorpromazine (CPZ) on the lethal effect of IL-1, TNF and endotoxin.	Chlorpromazine	69-72	interleukin 1 complex	Mus musculus	98-121
2692568-3	1989	Two different experimental models were used to sensitize mice to the lethal effect of IL-1: adrenalectomy and pretreatment with actinomycin D.	Dactinomycin	128-141	interleukin 1 complex	Mus musculus	86-90
2692568-4	1989	CPZ (4 mg/kg) was found to protect mice against IL-1 and endotoxin toxicity in all cases, while DEX had a protective effect only in adrenalectomized mice.	Chlorpromazine	0-3	interleukin 1 complex	Mus musculus	48-52
2481587-5	1989	This is in agreement with our previous finding that IL1 and TNF productions can be selectively triggered by synthetic analogs of lipid A substructures (Lasfargues and Chaby, Cell.	Lipid A	129-136	interleukin 1 complex	Mus musculus	52-55
2530274-6	1989	Phosphorylation increases as the concentration of IL-1 increases from 10(-13) to 10(-8) M. Potassium hydroxide hydrolysis of the phosphorylated IL-1R shows that more than 90% of the phosphate is incorporated into serine or threonine.	potassium hydroxide	91-110	interleukin 1 complex	Mus musculus	50-54
2530274-6	1989	Phosphorylation increases as the concentration of IL-1 increases from 10(-13) to 10(-8) M. Potassium hydroxide hydrolysis of the phosphorylated IL-1R shows that more than 90% of the phosphate is incorporated into serine or threonine.	Phosphates	182-191	interleukin 1 complex	Mus musculus	50-54
2530274-6	1989	Phosphorylation increases as the concentration of IL-1 increases from 10(-13) to 10(-8) M. Potassium hydroxide hydrolysis of the phosphorylated IL-1R shows that more than 90% of the phosphate is incorporated into serine or threonine.	Serine	213-219	interleukin 1 complex	Mus musculus	50-54
2530274-6	1989	Phosphorylation increases as the concentration of IL-1 increases from 10(-13) to 10(-8) M. Potassium hydroxide hydrolysis of the phosphorylated IL-1R shows that more than 90% of the phosphate is incorporated into serine or threonine.	Threonine	223-232	interleukin 1 complex	Mus musculus	50-54
2574679-5	1989	Similarly to plastic-adsorbed antibodies, phorbol myristic acetate (PMA) or a combination of PMA and the calcium ionophore Ionomycin also induces secretion of growth factors without inducing proliferation, but in this case addition of IL 1 is ineffective in inducing AK-8 proliferation.	Ionomycin	123-132	interleukin 1 complex	Mus musculus	235-239
2558326-3	1989	Rats chronically cannulated in the right jugular veins showed a time-related increase in plasma corticosterone concentrations in response to intraperitoneal administration of IL-1 that lasted up to 4 h. In the same rats, plasma epinephrine (E) and norepinephrine (NE) concentrations were only slightly elevated (2-fold increase) at 30 min and at 1 h after IL-1 administration.	Corticosterone	96-110	interleukin 1 complex	Mus musculus	175-179
2558326-3	1989	Rats chronically cannulated in the right jugular veins showed a time-related increase in plasma corticosterone concentrations in response to intraperitoneal administration of IL-1 that lasted up to 4 h. In the same rats, plasma epinephrine (E) and norepinephrine (NE) concentrations were only slightly elevated (2-fold increase) at 30 min and at 1 h after IL-1 administration.	Epinephrine	228-239	interleukin 1 complex	Mus musculus	175-179
2558326-3	1989	Rats chronically cannulated in the right jugular veins showed a time-related increase in plasma corticosterone concentrations in response to intraperitoneal administration of IL-1 that lasted up to 4 h. In the same rats, plasma epinephrine (E) and norepinephrine (NE) concentrations were only slightly elevated (2-fold increase) at 30 min and at 1 h after IL-1 administration.	Norepinephrine	248-262	interleukin 1 complex	Mus musculus	175-179
2789251-6	1989	Salmon calcitonin strongly suppressed the calcium release from mouse calvaria in the presence of membrane IL-1.	Calcium	42-49	interleukin 1 complex	Mus musculus	106-110
2528328-2	1989	After solubilization of the receptor from intact cells with the zwitterionic detergent 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate, the IL-1 binding activity was purified greater than 23,000-fold.	3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate	87-144	interleukin 1 complex	Mus musculus	150-154
2528328-3	1989	Analysis of the purified protein by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, immunoblot, and ligand blot demonstrated that a single protein of molecular mass of approximately 80 kDa is the IL-1 binding polypeptide.	Sodium Dodecyl Sulfate	36-58	interleukin 1 complex	Mus musculus	207-211
2528328-3	1989	Analysis of the purified protein by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, immunoblot, and ligand blot demonstrated that a single protein of molecular mass of approximately 80 kDa is the IL-1 binding polypeptide.	polyacrylamide	59-73	interleukin 1 complex	Mus musculus	207-211
2813453-0	1989	Protection of 3"-azido-3"-deoxythymidine induced toxicity to murine hematopoietic progenitors (CFU-GM, BFU-E and CFU-MEG) with interleukin-1.	Zidovudine	14-40	interleukin 1 complex	Mus musculus	127-140
2813453-7	1989	IL-1 inhibited AZT induced toxicity.	Zidovudine	15-18	interleukin 1 complex	Mus musculus	0-4
2813453-8	1989	The maximum IL-1 dose effect was observed for CFU-GM and CFU-Meg at 300 units, 0.3 micrograms protein; however BFU-E required a dose of 600 units, 0.6 micrograms/ml protein to reverse the effects of AZT.	Zidovudine	199-202	interleukin 1 complex	Mus musculus	12-16
2813453-9	1989	These results demonstrate marrow progenitors respond differently to AZT and identifies the potential efficacy of IL-1 to minimize the hematopoietic toxicity associated with AZT treatment.	Zidovudine	173-176	interleukin 1 complex	Mus musculus	113-117
2691218-4	1989	However, glucose-stimulated insulin release was significantly impaired after 3 days of in vivo administration of IL-1, either 3 micrograms/animal/day or 0.3 micrograms/animal/day.	Glucose	9-16	interleukin 1 complex	Mus musculus	113-117
2691218-5	1989	The administration of IL-1 inhibited an acute phase of glucose-induced insulin release, whereas neither basal insulin secretion nor insulin release from 10-30 min of perifusion with glucose was impaired.	Glucose	55-62	interleukin 1 complex	Mus musculus	22-26
2691218-6	1989	There was an only partial (27%) and non-significant restoration of the insulin secretory response to glucose stimulation 4 days after discontinuation of IL-1 treatment.	Glucose	101-108	interleukin 1 complex	Mus musculus	153-157
2691218-7	1989	We conclude that IL-1 administered in vivo is capable of adversely affecting pancreatic islet response to glucose stimulation.	Glucose	106-113	interleukin 1 complex	Mus musculus	17-21
2789251-7	1989	Indomethacin partially inhibited the bone resorption induced by membrane IL-1 on P388D1 cells.	Indomethacin	0-12	interleukin 1 complex	Mus musculus	73-77
2788075-3	1989	Increased bone resorption inside the calvariae and elevated plasma calcium concentrations were present 24 h after the last IL-1 injection.	Calcium	67-74	interleukin 1 complex	Mus musculus	123-127
2681261-5	1989	Exogenous administration of either IL-1 or TNF could induce increases in serum corticosterone in sham-operated mice.	Corticosterone	79-93	interleukin 1 complex	Mus musculus	35-39
2681261-6	1989	Finally, treatment of adrenalectomized mice with corticosterone or dexamethasone could inhibit the induction of serum IL-1 and TNF and modified the pattern of these cytokine-induced deaths.	Corticosterone	49-63	interleukin 1 complex	Mus musculus	118-122
2681261-6	1989	Finally, treatment of adrenalectomized mice with corticosterone or dexamethasone could inhibit the induction of serum IL-1 and TNF and modified the pattern of these cytokine-induced deaths.	Dexamethasone	67-80	interleukin 1 complex	Mus musculus	118-122
2530580-6	1989	Activation of phospholipid/Ca2+-dependent protein kinase, protein kinase C, by phorbol 12-myristate 13-acetate (PMA) greatly reduced the number of IL-1 binding sites on 70Z/3.	Tetradecanoylphorbol Acetate	79-110	interleukin 1 complex	Mus musculus	147-151
2530580-6	1989	Activation of phospholipid/Ca2+-dependent protein kinase, protein kinase C, by phorbol 12-myristate 13-acetate (PMA) greatly reduced the number of IL-1 binding sites on 70Z/3.	Tetradecanoylphorbol Acetate	112-115	interleukin 1 complex	Mus musculus	147-151
2788075-8	1989	These findings indicate that IL-1 stimulates bone turnover systemically, independent of prostaglandin production, and that it has profound long term local effects on bone turnover that are mediated through prostaglandins.	Prostaglandins	206-220	interleukin 1 complex	Mus musculus	29-33
2787357-4	1989	The dissociated IL-1 was detected as both a biological activity and, by immunoprecipitation and SDS-PAGE, as a 33 kDa IL-1 alpha precursor.	Sodium Dodecyl Sulfate	96-99	interleukin 1 complex	Mus musculus	16-20
2788206-0	1989	Dexamethasone modulation of in vivo effects of endotoxin, tumor necrosis factor, and interleukin-1 on liver cytochrome P-450, plasma fibrinogen, and serum iron.	Dexamethasone	0-13	interleukin 1 complex	Mus musculus	85-98
2788206-0	1989	Dexamethasone modulation of in vivo effects of endotoxin, tumor necrosis factor, and interleukin-1 on liver cytochrome P-450, plasma fibrinogen, and serum iron.	Iron	155-159	interleukin 1 complex	Mus musculus	85-98
2789044-4	1989	Pretreatment of the animals with indomethacin, a cyclooxygenase inhibitor, provided partial protection against TNF lethality in IL1-sensitized but not in galactosamine-sensitized mice.	Indomethacin	33-45	interleukin 1 complex	Mus musculus	128-131
2788206-4	1989	This factor was inhibited by anti-IL-1 antiserum, and its synthesis, like that of IL-1, was inhibited by dexamethasone (DEX).	Dexamethasone	105-118	interleukin 1 complex	Mus musculus	82-86
2788206-4	1989	This factor was inhibited by anti-IL-1 antiserum, and its synthesis, like that of IL-1, was inhibited by dexamethasone (DEX).	Dexamethasone	120-123	interleukin 1 complex	Mus musculus	34-38
2788206-4	1989	This factor was inhibited by anti-IL-1 antiserum, and its synthesis, like that of IL-1, was inhibited by dexamethasone (DEX).	Dexamethasone	120-123	interleukin 1 complex	Mus musculus	82-86
2788206-5	1989	Pretreatment of mice with DEX protected against the depression of liver cytochrome P-450 by LPS or TNF but not by IL-1, suggesting that IL-1 directly depresses cytochrome P-450 and that DEX acts by inhibiting IL-1 synthesis in vivo induced by LPS or TNF.	Dexamethasone	26-29	interleukin 1 complex	Mus musculus	136-140
2788206-5	1989	Pretreatment of mice with DEX protected against the depression of liver cytochrome P-450 by LPS or TNF but not by IL-1, suggesting that IL-1 directly depresses cytochrome P-450 and that DEX acts by inhibiting IL-1 synthesis in vivo induced by LPS or TNF.	Dexamethasone	26-29	interleukin 1 complex	Mus musculus	136-140
2787357-5	1989	Treatment of macrophages with D-mannose before fixation depleted detectable IL-1 biological activity associated with the membrane.	Mannose	30-39	interleukin 1 complex	Mus musculus	76-80
2787357-6	1989	Pro-IL-1 alpha was glycosylated in these cells, as shown by incorporation of D-[14C]mannose; thus it is likely that a cell surface lectin binds pro-IL-1 via these carbohydrate residues.	d-[14c]mannose	77-91	interleukin 1 complex	Mus musculus	4-8
2787357-6	1989	Pro-IL-1 alpha was glycosylated in these cells, as shown by incorporation of D-[14C]mannose; thus it is likely that a cell surface lectin binds pro-IL-1 via these carbohydrate residues.	d-[14c]mannose	77-91	interleukin 1 complex	Mus musculus	148-152
2787357-6	1989	Pro-IL-1 alpha was glycosylated in these cells, as shown by incorporation of D-[14C]mannose; thus it is likely that a cell surface lectin binds pro-IL-1 via these carbohydrate residues.	Carbohydrates	163-175	interleukin 1 complex	Mus musculus	4-8
2787357-6	1989	Pro-IL-1 alpha was glycosylated in these cells, as shown by incorporation of D-[14C]mannose; thus it is likely that a cell surface lectin binds pro-IL-1 via these carbohydrate residues.	Carbohydrates	163-175	interleukin 1 complex	Mus musculus	148-152
2787874-7	1989	In conditioned media from LPS-PMA-stimulated macrophages, IL-1 levels were significantly greater than in media from unstimulated macrophages and peaked on Postsurgical Day 3.	Tetradecanoylphorbol Acetate	30-33	interleukin 1 complex	Mus musculus	58-62
2589897-3	1989	GMDP induced marked production of TNF (54 per cent cytotoxic index) and IL-1 (stimulation index 8).	glucosaminylmuramyl-2-alanine-D-isoglutamine	0-4	interleukin 1 complex	Mus musculus	72-76
2666587-5	1989	Because one of the responses to IL-1 is increased prostaglandin (PG) production and with the known activity of PGs on hematopoiesis, additional studies incorporated the cyclooxygenase inhibitor indomethacin (IM) (10 mg/kg body weight).	Prostaglandins	65-67	interleukin 1 complex	Mus musculus	32-36
2666587-12	1989	Erythroid progenitors were increased following low IL-1 concentrations and reduced in animals receiving IM, thus indicating a role for prostaglandins in the mechanism of IL-1 for influencing hematopoiesis.	Prostaglandins	135-149	interleukin 1 complex	Mus musculus	170-174
2668949-5	1989	Furthermore, IL-1 markedly reduced the levels of triglycerides in blood of streptozotocin-induced diabetic mice at later stages of the disease.	Triglycerides	49-62	interleukin 1 complex	Mus musculus	13-17
2668949-5	1989	Furthermore, IL-1 markedly reduced the levels of triglycerides in blood of streptozotocin-induced diabetic mice at later stages of the disease.	Streptozocin	75-89	interleukin 1 complex	Mus musculus	13-17
2787029-4	1989	However, the viable bacteria required about 1 log lower concentrations than the formalin-killed bacteria to induce the same level of IL-1 activity measured in the thymocyte proliferation assay.	Formaldehyde	80-88	interleukin 1 complex	Mus musculus	133-137
2786594-4	1989	Human recombinant IL-1 beta, human natural IL-1, and partially purified murine IL-1-rich supernatant also stimulated eicosanoid production by macrophages, although IL-1 alpha appeared to be the most effective.	Eicosanoids	117-127	interleukin 1 complex	Mus musculus	43-47
2667373-7	1989	Culture supernatants of dextran induced granulomas contained high levels of interleukin-1 (IL-1) activity but not interleukin-2 (IL-2) or interleukin-4 (IL-4) activity.	Dextrans	24-31	interleukin 1 complex	Mus musculus	91-95
2529741-1	1989	CI-949 (5-methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H -indole- 2-carboxamide, L-arginine salt), an antiallergy compound, was found to be a weak inhibitor of IL-1 release from LPS-stimulated murine peritoneal exudate cells and human peripheral blood leukocytes, with IC50S of 186.2 and 267.9 microM, respectively.	CI 949	0-6	interleukin 1 complex	Mus musculus	171-175
2529741-1	1989	CI-949 (5-methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H -indole- 2-carboxamide, L-arginine salt), an antiallergy compound, was found to be a weak inhibitor of IL-1 release from LPS-stimulated murine peritoneal exudate cells and human peripheral blood leukocytes, with IC50S of 186.2 and 267.9 microM, respectively.	5-methoxy-3-(1-methylethoxy)-1-phenyl-n-1h-tetrazol-5-yl-1h -indole	8-75	interleukin 1 complex	Mus musculus	171-175
2529741-1	1989	CI-949 (5-methoxy-3-(1-methylethoxy)-1-phenyl-N-1H-tetrazol-5-yl-1H -indole- 2-carboxamide, L-arginine salt), an antiallergy compound, was found to be a weak inhibitor of IL-1 release from LPS-stimulated murine peritoneal exudate cells and human peripheral blood leukocytes, with IC50S of 186.2 and 267.9 microM, respectively.	2-carboxamide	77-90	interleukin 1 complex	Mus musculus	171-175
2801312-2	1989	Membrane IL-1 activity was measured on paraformaldehyde fixed peritoneal macrophages using EL4 6.1 lymphocyte cell line.	paraform	39-55	interleukin 1 complex	Mus musculus	9-13
2801312-5	1989	Dexamethasone reduced mIL-1 activity induced in vivo by C. parvum and also that induced by adherence in vitro.	Dexamethasone	0-13	interleukin 1 complex	Mus musculus	22-27
2785869-5	1989	Lipopolysaccharide (LPS)-triggered release of IL-1 and TNF was determined in culture supernatants of splenic MPs from phorbol ester-sensitive (SENCAR) and resistant (B6C3F1) mice following topical application of 8 micrograms of TPA twice in one week.	Phorbol Esters	118-131	interleukin 1 complex	Mus musculus	46-58
2785869-5	1989	Lipopolysaccharide (LPS)-triggered release of IL-1 and TNF was determined in culture supernatants of splenic MPs from phorbol ester-sensitive (SENCAR) and resistant (B6C3F1) mice following topical application of 8 micrograms of TPA twice in one week.	Tetradecanoylphorbol Acetate	228-231	interleukin 1 complex	Mus musculus	46-58
2675486-4	1989	All the GMD compounds except GMD-323 showed potent inducing activities for IL-1 and tumoricidal macrophages, especially GMD-324 and -326, which exhibited much higher activity than GLA-60.	gamma-Linolenic Acid	180-183	interleukin 1 complex	Mus musculus	75-79
2675486-6	1989	IL-1-inducing activity of the mixture of MDP derivative (GMD-267) and GLA-60 was higher than that of the conjugates (GMD-324) or that of GLA-60 and GMD-267 alone.	gamma-Linolenic Acid	70-73	interleukin 1 complex	Mus musculus	0-4
2651135-10	1989	Poly I:C treatment caused an increase in both IL-1 and IL-2 production in control and Bu-pretreated mice and in the ability of the treated mice to reject transplanted lymphoma cells.	Poly I-C	0-8	interleukin 1 complex	Mus musculus	46-50
2540858-7	1989	However, a mixture of hrIL-1 alpha and hrIL-1 beta reproduced the ability of mIL-1 to inhibit the oxidative response to suboptimal doses of phorbol myristate acetate (PMA).	Tetradecanoylphorbol Acetate	140-165	interleukin 1 complex	Mus musculus	77-82
2540858-7	1989	However, a mixture of hrIL-1 alpha and hrIL-1 beta reproduced the ability of mIL-1 to inhibit the oxidative response to suboptimal doses of phorbol myristate acetate (PMA).	Tetradecanoylphorbol Acetate	167-170	interleukin 1 complex	Mus musculus	77-82
2651135-10	1989	Poly I:C treatment caused an increase in both IL-1 and IL-2 production in control and Bu-pretreated mice and in the ability of the treated mice to reject transplanted lymphoma cells.	Busulfan	86-88	interleukin 1 complex	Mus musculus	46-50
2651547-2	1989	Treatment of lipopolysaccharide (LPS)-stimulated adjuvant-elicited murine macrophages with 5 x 10(-7) M PGE2 caused a 70% reduction in cell-associated TNF but had no suppressive effect on cell-associated interleukin-1 (IL-1) activity.	Dinoprostone	104-108	interleukin 1 complex	Mus musculus	188-223
2523425-8	1989	Furthermore, T cells from spleens of mice treated with IL-1 provided significantly more help in both carrier (SRBC)- and hapten (TNP)- specific PFC.	srbc	110-114	interleukin 1 complex	Mus musculus	55-59
2565932-3	1989	Although the latter cells strongly proliferate in response to phorbol myristate acetate (PMA) + ionomycin, DETC, when exposed to interleukin-1 (IL-1), interleukin-3 (IL-3), concanavalin A (ConA), PMA, and ionomycin used either alone or in combination, do not exhibit significant mitotic activity.	Tetradecanoylphorbol Acetate	89-92	interleukin 1 complex	Mus musculus	144-148
2787652-0	1989	Interleukin-1 induces a pertussis toxin-sensitive increase in diacylglycerol accumulation in mouse thymoma cells.	Diglycerides	62-76	interleukin 1 complex	Mus musculus	0-13
2565932-3	1989	Although the latter cells strongly proliferate in response to phorbol myristate acetate (PMA) + ionomycin, DETC, when exposed to interleukin-1 (IL-1), interleukin-3 (IL-3), concanavalin A (ConA), PMA, and ionomycin used either alone or in combination, do not exhibit significant mitotic activity.	DETC	107-111	interleukin 1 complex	Mus musculus	144-148
2565932-4	1989	Recombinant interleukin 2 (rIL-2), albeit ineffective by itself, leads to vigorous proliferation of DETC when used with either ConA or PMA + ionomycin + IL-1.	DETC	100-104	interleukin 1 complex	Mus musculus	153-157
2787652-3	1989	Interleukin-1 caused a rapid increase in diacylglycerol production (approx.	Diglycerides	41-55	interleukin 1 complex	Mus musculus	0-13
2787652-6	1989	Interestingly, a similar IL-1 induced increase in diacylglycerol was observed when the cells were preincubated with [3H]-myristic acid.	Diglycerides	50-64	interleukin 1 complex	Mus musculus	25-29
2787652-6	1989	Interestingly, a similar IL-1 induced increase in diacylglycerol was observed when the cells were preincubated with [3H]-myristic acid.	[3h]-myristic acid	116-134	interleukin 1 complex	Mus musculus	25-29
2787652-7	1989	These results appear to suggest a novel mode of action of interleukin-1 which involves a G-protein mediated breakdown of a membrane lipid resulting in the production of diacylglycerol.	Diglycerides	169-183	interleukin 1 complex	Mus musculus	58-71
2784964-0	1989	The effects of methotrexate on the production and activity of interleukin-1.	Methotrexate	15-27	interleukin 1 complex	Mus musculus	62-75
2784963-6	1989	These results suggest that the syntheses of histamine and putrescine are regulated by IL-1 and/or TNF alpha in inflammatory or immune responses.	Histamine	44-53	interleukin 1 complex	Mus musculus	86-90
2784963-6	1989	These results suggest that the syntheses of histamine and putrescine are regulated by IL-1 and/or TNF alpha in inflammatory or immune responses.	Putrescine	58-68	interleukin 1 complex	Mus musculus	86-90
2784964-1	1989	To explore the possibility that the mechanism of action of methotrexate (MTX) in rheumatoid arthritis (RA) is related to modulation of interleukin-1 (IL-1), the effects of MTX on IL-1 production and activity were evaluated.	Methotrexate	59-71	interleukin 1 complex	Mus musculus	135-148
2784964-1	1989	To explore the possibility that the mechanism of action of methotrexate (MTX) in rheumatoid arthritis (RA) is related to modulation of interleukin-1 (IL-1), the effects of MTX on IL-1 production and activity were evaluated.	Methotrexate	59-71	interleukin 1 complex	Mus musculus	150-154
2784964-1	1989	To explore the possibility that the mechanism of action of methotrexate (MTX) in rheumatoid arthritis (RA) is related to modulation of interleukin-1 (IL-1), the effects of MTX on IL-1 production and activity were evaluated.	Methotrexate	59-71	interleukin 1 complex	Mus musculus	179-183
2784964-1	1989	To explore the possibility that the mechanism of action of methotrexate (MTX) in rheumatoid arthritis (RA) is related to modulation of interleukin-1 (IL-1), the effects of MTX on IL-1 production and activity were evaluated.	Methotrexate	73-76	interleukin 1 complex	Mus musculus	135-148
2784964-1	1989	To explore the possibility that the mechanism of action of methotrexate (MTX) in rheumatoid arthritis (RA) is related to modulation of interleukin-1 (IL-1), the effects of MTX on IL-1 production and activity were evaluated.	Methotrexate	73-76	interleukin 1 complex	Mus musculus	150-154
2784964-1	1989	To explore the possibility that the mechanism of action of methotrexate (MTX) in rheumatoid arthritis (RA) is related to modulation of interleukin-1 (IL-1), the effects of MTX on IL-1 production and activity were evaluated.	Methotrexate	73-76	interleukin 1 complex	Mus musculus	179-183
2784964-4	1989	We did show, however, that MTX had an inhibitory effect on IL-1 activity in 2 assays that demonstrate 2 different functions of IL-1.	Methotrexate	27-30	interleukin 1 complex	Mus musculus	59-63
2784964-4	1989	We did show, however, that MTX had an inhibitory effect on IL-1 activity in 2 assays that demonstrate 2 different functions of IL-1.	Methotrexate	27-30	interleukin 1 complex	Mus musculus	127-131
2784964-5	1989	In a 2-step assay using LBRM-33-1A5 (1A5) and CTLD cells, MTX inhibited the secretion of IL-2 by 1A5 lymphoma cells in response to phytohemagglutinin and IL-1.	Methotrexate	58-61	interleukin 1 complex	Mus musculus	154-158
2784964-6	1989	In an assay using D10.G4.1 (D10) cells, MTX inhibited IL-1-induced proliferation of the D10 T cell clone.	Methotrexate	40-43	interleukin 1 complex	Mus musculus	54-58
2784964-8	1989	The results demonstrate that MTX is capable of inhibiting some IL-1 activities without affecting IL-1 production or secretion.	Methotrexate	29-32	interleukin 1 complex	Mus musculus	63-67
2784964-9	1989	We propose that the inhibition of IL-1 activity or IL-1-dependent events may be one of the mechanisms of action of MTX in RA.	Methotrexate	115-118	interleukin 1 complex	Mus musculus	34-38
2784964-9	1989	We propose that the inhibition of IL-1 activity or IL-1-dependent events may be one of the mechanisms of action of MTX in RA.	Methotrexate	115-118	interleukin 1 complex	Mus musculus	51-55
2789244-0	1989	IL-1 and PGE2 productions by the regional lymph node cells from DNFB-sensitized mice.	Dinitrofluorobenzene	64-68	interleukin 1 complex	Mus musculus	0-4
2467751-6	1989	In addition, TE-71-conditioned medium exhibited IL-1-like activity which could be neutralized with anti-IL-1 antibodies.	te-71	13-18	interleukin 1 complex	Mus musculus	48-52
2467751-6	1989	In addition, TE-71-conditioned medium exhibited IL-1-like activity which could be neutralized with anti-IL-1 antibodies.	te-71	13-18	interleukin 1 complex	Mus musculus	104-108
2495247-10	1989	These findings are contrary to those suggested for the regulation by prostanoids of IL-1 production by murine macrophages.	Prostaglandins	69-80	interleukin 1 complex	Mus musculus	84-88
2784143-1	1989	Based on recently published data, IL-1 has been shown to provide radioprotective effects when given to mice 20 h before a lethal dose of irradiation and to enhance granulocyte recovery in mice treated with cyclophosphamide.	Cyclophosphamide	206-222	interleukin 1 complex	Mus musculus	34-38
2542770-3	1989	In the present study, we found that these effects of IL-1 are mimicked by cyclic AMP (cAMP) analogs and cAMP-elevating drugs.	Cyclic AMP	74-84	interleukin 1 complex	Mus musculus	53-57
2542770-3	1989	In the present study, we found that these effects of IL-1 are mimicked by cyclic AMP (cAMP) analogs and cAMP-elevating drugs.	Cyclic AMP	86-90	interleukin 1 complex	Mus musculus	53-57
2542770-3	1989	In the present study, we found that these effects of IL-1 are mimicked by cyclic AMP (cAMP) analogs and cAMP-elevating drugs.	Cyclic AMP	104-108	interleukin 1 complex	Mus musculus	53-57
2542770-4	1989	The induction of kappa immunoglobulin light-chain gene expression by IL-1 was associated with an increase in intracellular cAMP levels.	Cyclic AMP	123-127	interleukin 1 complex	Mus musculus	69-73
2537258-0	1989	Dissociation of cell-associated interleukin-1 (IL-1) and IL-1 release induced by lipopolysaccharide and lipid A.	Lipid A	104-111	interleukin 1 complex	Mus musculus	16-51
2537258-1	1989	The capacities of lipopolysaccharide (LPS) and lipid A to trigger mouse BALB/c peritoneal macrophages and to induce the production of cell-associated interleukin-1 (IL-1) and membrane-associated IL-1 and IL-1 release have been compared.	Lipid A	47-54	interleukin 1 complex	Mus musculus	134-170
2537258-1	1989	The capacities of lipopolysaccharide (LPS) and lipid A to trigger mouse BALB/c peritoneal macrophages and to induce the production of cell-associated interleukin-1 (IL-1) and membrane-associated IL-1 and IL-1 release have been compared.	Lipid A	47-54	interleukin 1 complex	Mus musculus	165-169
2537258-1	1989	The capacities of lipopolysaccharide (LPS) and lipid A to trigger mouse BALB/c peritoneal macrophages and to induce the production of cell-associated interleukin-1 (IL-1) and membrane-associated IL-1 and IL-1 release have been compared.	Lipid A	47-54	interleukin 1 complex	Mus musculus	195-199
2537258-3	1989	When resident macrophages were studied, lipid A, at high concentrations (greater than 2 micrograms/ml), induced significant levels of cell-associated IL-1 but little or no IL-1 release.	Lipid A	40-47	interleukin 1 complex	Mus musculus	150-154
2537258-3	1989	When resident macrophages were studied, lipid A, at high concentrations (greater than 2 micrograms/ml), induced significant levels of cell-associated IL-1 but little or no IL-1 release.	Lipid A	40-47	interleukin 1 complex	Mus musculus	172-176
2537258-4	1989	With synthetic lipid A built up with the Escherichia coli lipid A structure (compound 506), IL-1 activity was present in the supernatants of elicited peritoneal macrophages and to a lesser extent in those of resident macrophages.	Lipid A	15-22	interleukin 1 complex	Mus musculus	92-96
2537258-6	1989	Membrane-associated IL-1 could be induced on BALB/c macrophages with LPS and natural or synthetic lipid A, the LPS being the most active.	Lipid A	98-105	interleukin 1 complex	Mus musculus	20-24
2542770-8	1989	These results suggest that cAMP may play an important role as a second messenger for IL-1 in the induction of kappa immunoglobulin light-chain synthesis in pre-B cells via the activation of a DNA-binding protein that is similar or identical to NF-kappa B.	Cyclic AMP	27-31	interleukin 1 complex	Mus musculus	85-89
2536771-4	1989	If macrophages are first treated with cholera toxin or dibutyryl cAMP 15 min before stimulation with LPS, the accumulation of mRNA encoding both JE and TNF is strongly suppressed whereas mRNA levels for KC and IL-1 are unaffected.	Cyclic AMP	65-69	interleukin 1 complex	Mus musculus	210-214
2538829-6	1989	IL-1 did not affect forskolin-induced cAMP generation but enhanced the effect of forskolin on beta-endorphin secretion.	Colforsin	81-90	interleukin 1 complex	Mus musculus	0-4
2538829-8	1989	IL-1 enhanced phorbol ester-induced beta-endorphin secretion.	Phorbol Esters	14-27	interleukin 1 complex	Mus musculus	0-4
2538829-9	1989	After prolonged treatment with phorbol ester (an activator of protein kinase C), the secretion induced by phorbol ester was abolished as well as the enhancement induced by IL-1.	Phorbol Esters	31-44	interleukin 1 complex	Mus musculus	172-176
2522880-4	1989	In the presence of the tumor promoter phorbol 12-myristate 13-acetate IL 1 augments IL 2 secretion and IL 2R expression of EL4 5D3 but not of EL4 D6/76 cells.	Tetradecanoylphorbol Acetate	38-69	interleukin 1 complex	Mus musculus	70-74
2783705-1	1989	As previously reported, LPS and 8-derivatized guanosine (both generators of IL-1 release), as well as IL-1 itself interfere with the in vivo induction of tolerance to DHGG in A/J mice.	Guanosine	46-55	interleukin 1 complex	Mus musculus	76-80
2783705-1	1989	As previously reported, LPS and 8-derivatized guanosine (both generators of IL-1 release), as well as IL-1 itself interfere with the in vivo induction of tolerance to DHGG in A/J mice.	dhgg	167-171	interleukin 1 complex	Mus musculus	76-80
2783705-1	1989	As previously reported, LPS and 8-derivatized guanosine (both generators of IL-1 release), as well as IL-1 itself interfere with the in vivo induction of tolerance to DHGG in A/J mice.	dhgg	167-171	interleukin 1 complex	Mus musculus	102-106
2784766-8	1989	In contrast with the transient increase in TNF, serum IL 1 was maximal 4 h post LPS injection and remained elevated at 24 h. In vitro studies with primary cultures of human peripheral blood monocytes and human umbilical cord vein endothelial cells demonstrated that LPS-induced monocyte IL 1 levels were reduced approximately 5-fold by 10(-7) M dexamethasone while dexamethasone had only minimal effects on endothelial cell IL 1.	Dexamethasone	345-358	interleukin 1 complex	Mus musculus	54-58
2784766-8	1989	In contrast with the transient increase in TNF, serum IL 1 was maximal 4 h post LPS injection and remained elevated at 24 h. In vitro studies with primary cultures of human peripheral blood monocytes and human umbilical cord vein endothelial cells demonstrated that LPS-induced monocyte IL 1 levels were reduced approximately 5-fold by 10(-7) M dexamethasone while dexamethasone had only minimal effects on endothelial cell IL 1.	Dexamethasone	365-378	interleukin 1 complex	Mus musculus	54-58
2783307-5	1989	Although food intake was decreased by 65% in IL-1-treated mice (1 microgram/day) compared with that in fed control mice, type I iodothyronine 5"-deiodinating activity in liver was significantly increased compared with that in fed control mice.	iodothyronine	128-141	interleukin 1 complex	Mus musculus	45-49
2643663-7	1989	IL-1 effects were observed in mice treated with a wide dose range (50 to 300 mg/kg) of cyclophosphamide, with optimal effects occurring at a dose of 200 mg/kg.	Cyclophosphamide	87-103	interleukin 1 complex	Mus musculus	0-4
2484306-7	1989	IL-1 administered alone or in combination with other colony stimulating factors to spontaneous breast tumor bearing mice following 5-FU therapy resulted in a rapid recovery of neutrophils, improved survival, and markedly reduced the tumor mass.	Fluorouracil	131-135	interleukin 1 complex	Mus musculus	0-4
2468413-8	1989	IL-1 was released by asialo-GM1-positive cells and IL-2 by Thy-1-positive cells.	asialo GM1 ganglioside	21-31	interleukin 1 complex	Mus musculus	0-4
2783307-6	1989	Furthermore, the T3 and T4 responses to TSH were greatly diminished in IL-1-treated mice.	Thyrotropin	40-43	interleukin 1 complex	Mus musculus	71-75
2783307-7	1989	These findings suggest that IL-1 directly inhibited the effect of TSH on the thyroid gland and decreased the serum concentrations of T4 and T3, and that an increase in type I iodothyronine 5"-deiodinating activity in livers of IL-1-treated mice may account for the greater T3/T4 ratio and lower serum rT3 concentration than those in PFC mice.	iodothyronine	175-188	interleukin 1 complex	Mus musculus	28-32
2783307-7	1989	These findings suggest that IL-1 directly inhibited the effect of TSH on the thyroid gland and decreased the serum concentrations of T4 and T3, and that an increase in type I iodothyronine 5"-deiodinating activity in livers of IL-1-treated mice may account for the greater T3/T4 ratio and lower serum rT3 concentration than those in PFC mice.	iodothyronine	175-188	interleukin 1 complex	Mus musculus	227-231
2783314-6	1989	Both neutrophilia and augmented resistance to infection were eliminated by a second dose of cyclophosphamide administered during the IL-1 treatments.	Cyclophosphamide	92-108	interleukin 1 complex	Mus musculus	133-137
2517780-7	1989	IL-1-stimulated bone resorption and PGE2 production in murine calvarial cultures were inhibited with IC50 values of 3 x 10(-7) and 2 x 10(-8) mol/l, respectively.	Dinoprostone	36-40	interleukin 1 complex	Mus musculus	0-4
2534682-0	1989	Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages.	Clarithromycin	47-61	interleukin 1 complex	Mus musculus	77-90
2535139-3	1989	However, over a wide range of concentrations (10(-6)-10(-14) M) beta-endorphin potentiated lipopolysaccharide (LPS)- or silica-induced production of intracellular and extracellular IL-1.	Silicon Dioxide	120-126	interleukin 1 complex	Mus musculus	181-185
2535139-5	1989	Naloxone, a competitive inhibitor of beta-endorphin opioid receptor interactions, abrogated the enhancing effects of beta-endorphin on LPS-induced IL-1 production.	Naloxone	0-8	interleukin 1 complex	Mus musculus	147-151
2535139-6	1989	Furthermore, LPS-induced IL-1 production by macrophages (in the absence of added beta-endorphin) was also partially inhibited following treatment with naloxone, suggesting that opioids derived from activated macrophages may also modulate IL-1 generation and secretion.	Naloxone	151-159	interleukin 1 complex	Mus musculus	25-29
2535139-6	1989	Furthermore, LPS-induced IL-1 production by macrophages (in the absence of added beta-endorphin) was also partially inhibited following treatment with naloxone, suggesting that opioids derived from activated macrophages may also modulate IL-1 generation and secretion.	Naloxone	151-159	interleukin 1 complex	Mus musculus	238-242
2786120-4	1989	Peritoneal macrophages of THP-ADM-treated mice have an in vitro cytostatic activity towards P815 tumor cells higher than normal cells and when stimulated with LPS they secrete more IL-1, an important effector of the immune response.	pirarubicin	26-33	interleukin 1 complex	Mus musculus	181-185
2785952-6	1989	Furthermore, IL-1 seems to adjust the "set point" for glucose regulation to a lower level.	Glucose	54-61	interleukin 1 complex	Mus musculus	13-17
2668476-3	1989	Okadaic acid added directly to mouse thymocytes showed a peak response in IL-1 synthesis at 0.01 microgram OA/ml, while significant inhibition was shown for concentrations of OA greater than 0.1 microgram OA/ml.	Okadaic Acid	0-12	interleukin 1 complex	Mus musculus	74-78
2671565-3	1989	Serum from IL-1 injected mice showed marked granulocyte/macrophage CSA (GM-CSA), but little megakaryocyte CSA (Meg-CSA).	Cyclosporine	67-70	interleukin 1 complex	Mus musculus	11-15
2671565-3	1989	Serum from IL-1 injected mice showed marked granulocyte/macrophage CSA (GM-CSA), but little megakaryocyte CSA (Meg-CSA).	gm-csa	72-78	interleukin 1 complex	Mus musculus	11-15
2671565-3	1989	Serum from IL-1 injected mice showed marked granulocyte/macrophage CSA (GM-CSA), but little megakaryocyte CSA (Meg-CSA).	Cyclosporine	75-78	interleukin 1 complex	Mus musculus	11-15
2671565-3	1989	Serum from IL-1 injected mice showed marked granulocyte/macrophage CSA (GM-CSA), but little megakaryocyte CSA (Meg-CSA).	meg-csa	111-118	interleukin 1 complex	Mus musculus	11-15
2489680-4	1989	IL-1-like cytokine activity was measured by incorporation of [3H] thymidine into C3H/HeJ thymocytes treated with lipopolysaccharide (LPS) from Haemophilus actinomycetemcomitans, a bacterium found in juvenile periodontopathy.	3h] thymidine	62-75	interleukin 1 complex	Mus musculus	0-4
2489680-6	1989	The maximum production of IL-1-like cytokine was observed at 24 hours with the LPS in serum-free alpha-MEM.	alpha minimal essential medium	97-106	interleukin 1 complex	Mus musculus	26-30
2525802-8	1989	Both strains were, however, able to recover from the infection without functional T-helper lympho-cytes and/or the IL-1 IL-2 which had been inhibited by treatment with CsA.	Cyclosporine	168-171	interleukin 1 complex	Mus musculus	115-124
2461986-4	1988	However, when the cells were cultured with IL-1 plus substance P or IL-1 plus BK, the ensuing proliferative responses, as measured by [3H]TdR incorporation, were consistently magnified greater than or equal to twofold above the anticipated additive response caused by IL-1 in combination with either of those neuropeptides.	Tritium	135-137	interleukin 1 complex	Mus musculus	43-47
2788795-2	1989	Allo A stimulated [3H]thymidine uptake of mouse thymocytes in the presence of IL-1.	allo a	0-6	interleukin 1 complex	Mus musculus	78-82
2788795-2	1989	Allo A stimulated [3H]thymidine uptake of mouse thymocytes in the presence of IL-1.	Tritium	19-21	interleukin 1 complex	Mus musculus	78-82
2788795-2	1989	Allo A stimulated [3H]thymidine uptake of mouse thymocytes in the presence of IL-1.	Thymidine	22-31	interleukin 1 complex	Mus musculus	78-82
2461986-4	1988	However, when the cells were cultured with IL-1 plus substance P or IL-1 plus BK, the ensuing proliferative responses, as measured by [3H]TdR incorporation, were consistently magnified greater than or equal to twofold above the anticipated additive response caused by IL-1 in combination with either of those neuropeptides.	Tritium	135-137	interleukin 1 complex	Mus musculus	68-72
3265384-5	1988	By contrast, injection of endotoxin, interleukin-1 (IL-1) or tumor necrosis factor (TNF) caused not only a depression in liver ED but also a marked increase in serum triglycerides.	Triglycerides	166-179	interleukin 1 complex	Mus musculus	37-50
3265384-5	1988	By contrast, injection of endotoxin, interleukin-1 (IL-1) or tumor necrosis factor (TNF) caused not only a depression in liver ED but also a marked increase in serum triglycerides.	Triglycerides	166-179	interleukin 1 complex	Mus musculus	52-56
2461986-4	1988	However, when the cells were cultured with IL-1 plus substance P or IL-1 plus BK, the ensuing proliferative responses, as measured by [3H]TdR incorporation, were consistently magnified greater than or equal to twofold above the anticipated additive response caused by IL-1 in combination with either of those neuropeptides.	Tritium	135-137	interleukin 1 complex	Mus musculus	68-72
3266614-1	1988	Studies were carried out to determine whether inhibition of gangliosides on lymphoproliferation was related to interleukin (IL)-1.	Gangliosides	60-72	interleukin 1 complex	Mus musculus	111-129
3264289-2	1988	With single intraperitoneal injections of IL-1 the plasma iron concentrations decreased significantly in mice with either normal neutrophil counts or neutropenia.	Iron	58-62	interleukin 1 complex	Mus musculus	42-46
3264289-5	1988	4-d continuous infusions of IL-1 also led to reductions in serum iron concentrations, but transferrin concentrations doubled.	Iron	65-69	interleukin 1 complex	Mus musculus	28-32
3264289-7	1988	In mice not given cyclophosphamide, chronic IL-1 infusion was associated with a reduction in mean hemoglobin concentrations from 14.7 to 13.5 g/dl, consistent with restricted availability of iron for erythropoiesis associated with low saturation of transferrin.	Iron	191-195	interleukin 1 complex	Mus musculus	44-48
3264289-8	1988	We conclude that IL-1 can decrease the serum iron despite profound peripheral neutropenia and that transferrin in a positive acute phase reactant in the mouse.	Iron	45-49	interleukin 1 complex	Mus musculus	17-21
2977423-2	1988	Although 12-O-tetradecanoylphorbol-13-acetate (TPA) was capable of replacing IL-1 as an activating stimulus under certain conditions, biologic studies indicated that TPA failed to synergize with Ti-CD3-dependent stimuli under conditions in which IL-1 was clearly active.	Tetradecanoylphorbol Acetate	47-50	interleukin 1 complex	Mus musculus	77-81
3263703-6	1988	These effects of TNF-alpha and IL-1 on target cells may contribute to their reported protective activity against radiation as well as their ability to induce resistance to cell killing induced by the combination of TNF-alpha and cycloheximide.	Cycloheximide	229-242	interleukin 1 complex	Mus musculus	31-35
3264009-5	1988	In response to mitogen stimulation, however, splenocytes from athymic mice produced a factor (not IL-1), which, upon injection, increased corticosterone levels and suppressed inflammation.	Corticosterone	138-152	interleukin 1 complex	Mus musculus	98-102
2847154-0	1988	Cyclic AMP--an intracellular second messenger for interleukin 1.	Cyclic AMP	0-10	interleukin 1 complex	Mus musculus	50-63
3265597-7	1988	However, 500 micrograms/ml of HME inhibited (P less than .05) IL-2 production (63.0% of controls) in the IL-1 utilization assay.	elliptinium	30-33	interleukin 1 complex	Mus musculus	105-109
3262418-6	1988	In RIF-1 tumors, the extracell water volume at 12 h after IL-1 (395 microI/g) was nearly twice that in untreated controls (215 microI/g).	Water	31-36	interleukin 1 complex	Mus musculus	58-62
2847154-1	1988	We demonstrated that interleukin 1 (IL-1), a potent peptide mediator in immune and inflammatory responses, stimulates the synthesis of cAMP in a variety of IL-1-responsive cell targets.	Cyclic AMP	135-139	interleukin 1 complex	Mus musculus	21-34
2847154-1	1988	We demonstrated that interleukin 1 (IL-1), a potent peptide mediator in immune and inflammatory responses, stimulates the synthesis of cAMP in a variety of IL-1-responsive cell targets.	Cyclic AMP	135-139	interleukin 1 complex	Mus musculus	36-40
2847154-1	1988	We demonstrated that interleukin 1 (IL-1), a potent peptide mediator in immune and inflammatory responses, stimulates the synthesis of cAMP in a variety of IL-1-responsive cell targets.	Cyclic AMP	135-139	interleukin 1 complex	Mus musculus	156-160
2847154-3	1988	By use of IL-1 and the cAMP-inducer, forskolin, a direct correlation between the induced level of cAMP and the degree of lymphocyte interleukin 2 receptor expression or thymocyte proliferation was established.	Cyclic AMP	98-102	interleukin 1 complex	Mus musculus	10-14
2847154-4	1988	Our results indicate that cAMP may be an important intracellular second messenger for IL-1.	Cyclic AMP	26-30	interleukin 1 complex	Mus musculus	86-90
3263922-0	1988	Studies on the release of cell-associated interleukin 1 by paraformaldehyde-treated murine macrophages.	paraform	59-75	interleukin 1 complex	Mus musculus	42-55
3263128-3	1988	We show that preparations of heat-separated epidermis possess abundant IL1/ETAF activity as indicated by PGE/collagenase induction in cultured synovial cells and proliferation of mouse thymocytes.	Prostaglandins E	105-108	interleukin 1 complex	Mus musculus	71-74
2971724-9	1988	In contrast, putrescine, like IL-1, exhibited some co-mitogenic activity on D10.G4.1 cells.	Putrescine	13-23	interleukin 1 complex	Mus musculus	30-34
3263922-1	1988	Experiments are presented demonstrating the release of interleukin 1 (IL1) by lipopolysaccharide-stimulated murine macrophages (M phi) after treatment of the cells with paraformaldehyde (PFA).	paraform	169-185	interleukin 1 complex	Mus musculus	55-68
3263922-1	1988	Experiments are presented demonstrating the release of interleukin 1 (IL1) by lipopolysaccharide-stimulated murine macrophages (M phi) after treatment of the cells with paraformaldehyde (PFA).	paraform	169-185	interleukin 1 complex	Mus musculus	70-73
3263922-1	1988	Experiments are presented demonstrating the release of interleukin 1 (IL1) by lipopolysaccharide-stimulated murine macrophages (M phi) after treatment of the cells with paraformaldehyde (PFA).	paraform	187-190	interleukin 1 complex	Mus musculus	55-68
3263922-1	1988	Experiments are presented demonstrating the release of interleukin 1 (IL1) by lipopolysaccharide-stimulated murine macrophages (M phi) after treatment of the cells with paraformaldehyde (PFA).	paraform	187-190	interleukin 1 complex	Mus musculus	70-73
3263922-5	1988	Addition of leupeptin to PFA-treated M phi also reduced the amount of released IL1 activity, suggesting that proteolytic modification of the IL1 alpha precursor is involved in the generation of biological active IL1 alpha.	leupeptin	12-21	interleukin 1 complex	Mus musculus	79-82
3263922-5	1988	Addition of leupeptin to PFA-treated M phi also reduced the amount of released IL1 activity, suggesting that proteolytic modification of the IL1 alpha precursor is involved in the generation of biological active IL1 alpha.	paraform	25-28	interleukin 1 complex	Mus musculus	79-82
2969895-2	1988	Functional receptors (IL1-R) for the proinflammatory cytokine interleukin 1 (IL1) were solubilized from plasma membranes of the NOB-1 subclone of murine EL4 6.1 thymoma cells using the zwitterionic detergent 3[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS).	3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate	266-271	interleukin 1 complex	Mus musculus	77-80
3263552-3	1988	Using a recently developed Radiant Heat technology for safely producing 41-42 degrees C Whole Body Hyperthermia in mice, we have investigated the effect of 1 hour of 41 +/- 0.5 degrees C WBH on the production of cutaneous IL-1.	wbh	187-190	interleukin 1 complex	Mus musculus	222-226
2969895-6	1988	IL1-R was purified to apparent homogeneity from solubilized NOB-1 membranes by affinity chromatography on wheat germ agglutinin-Sepharose and IL1 alpha-Sepharose.	Sepharose	128-137	interleukin 1 complex	Mus musculus	0-3
2969895-6	1988	IL1-R was purified to apparent homogeneity from solubilized NOB-1 membranes by affinity chromatography on wheat germ agglutinin-Sepharose and IL1 alpha-Sepharose.	alpha-sepharose	146-161	interleukin 1 complex	Mus musculus	0-3
2969895-2	1988	Functional receptors (IL1-R) for the proinflammatory cytokine interleukin 1 (IL1) were solubilized from plasma membranes of the NOB-1 subclone of murine EL4 6.1 thymoma cells using the zwitterionic detergent 3[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS).	[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate	209-264	interleukin 1 complex	Mus musculus	62-75
2969895-2	1988	Functional receptors (IL1-R) for the proinflammatory cytokine interleukin 1 (IL1) were solubilized from plasma membranes of the NOB-1 subclone of murine EL4 6.1 thymoma cells using the zwitterionic detergent 3[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS).	[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate	209-264	interleukin 1 complex	Mus musculus	77-80
2969895-2	1988	Functional receptors (IL1-R) for the proinflammatory cytokine interleukin 1 (IL1) were solubilized from plasma membranes of the NOB-1 subclone of murine EL4 6.1 thymoma cells using the zwitterionic detergent 3[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS).	3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate	266-271	interleukin 1 complex	Mus musculus	62-75
3260741-4	1988	Inhibition of IL-1 secretion by probucol may contribute to the therapeutic effect of probucol in atherosclerosis since as little as 1 unit of recombinant IL-1 beta was found to induce proliferation of aortic smooth muscle cells.	Probucol	85-93	interleukin 1 complex	Mus musculus	14-18
3135943-0	1988	Endotoxin-induced tumor necrosis factor (TNF): selective triggering of TNF and interleukin-1 production by distinct glucosamine-derived lipids.	glucosamine-derived lipids	116-142	interleukin 1 complex	Mus musculus	79-92
3135943-6	1988	Synthetic monosaccharides, chemically closely related to substructures recognized to be present in isolated lipid A preparations, could induce either TNF or interleukin-1 (IL-1) production, but not both simultaneously: the monosaccharides M4 and M6 were active TNF inducers, but did not initiate IL-1 production, while the monosaccharides M9 and lipid X efficiently elicited IL-1 production, but did not trigger TNF secretion.	Monosaccharides	10-25	interleukin 1 complex	Mus musculus	157-170
3135943-6	1988	Synthetic monosaccharides, chemically closely related to substructures recognized to be present in isolated lipid A preparations, could induce either TNF or interleukin-1 (IL-1) production, but not both simultaneously: the monosaccharides M4 and M6 were active TNF inducers, but did not initiate IL-1 production, while the monosaccharides M9 and lipid X efficiently elicited IL-1 production, but did not trigger TNF secretion.	Monosaccharides	10-25	interleukin 1 complex	Mus musculus	172-176
3135943-6	1988	Synthetic monosaccharides, chemically closely related to substructures recognized to be present in isolated lipid A preparations, could induce either TNF or interleukin-1 (IL-1) production, but not both simultaneously: the monosaccharides M4 and M6 were active TNF inducers, but did not initiate IL-1 production, while the monosaccharides M9 and lipid X efficiently elicited IL-1 production, but did not trigger TNF secretion.	Monosaccharides	10-25	interleukin 1 complex	Mus musculus	296-300
3135943-6	1988	Synthetic monosaccharides, chemically closely related to substructures recognized to be present in isolated lipid A preparations, could induce either TNF or interleukin-1 (IL-1) production, but not both simultaneously: the monosaccharides M4 and M6 were active TNF inducers, but did not initiate IL-1 production, while the monosaccharides M9 and lipid X efficiently elicited IL-1 production, but did not trigger TNF secretion.	Monosaccharides	10-25	interleukin 1 complex	Mus musculus	296-300
3135943-6	1988	Synthetic monosaccharides, chemically closely related to substructures recognized to be present in isolated lipid A preparations, could induce either TNF or interleukin-1 (IL-1) production, but not both simultaneously: the monosaccharides M4 and M6 were active TNF inducers, but did not initiate IL-1 production, while the monosaccharides M9 and lipid X efficiently elicited IL-1 production, but did not trigger TNF secretion.	Lipid A	108-115	interleukin 1 complex	Mus musculus	157-170
3135943-6	1988	Synthetic monosaccharides, chemically closely related to substructures recognized to be present in isolated lipid A preparations, could induce either TNF or interleukin-1 (IL-1) production, but not both simultaneously: the monosaccharides M4 and M6 were active TNF inducers, but did not initiate IL-1 production, while the monosaccharides M9 and lipid X efficiently elicited IL-1 production, but did not trigger TNF secretion.	Lipid A	108-115	interleukin 1 complex	Mus musculus	172-176
3135943-6	1988	Synthetic monosaccharides, chemically closely related to substructures recognized to be present in isolated lipid A preparations, could induce either TNF or interleukin-1 (IL-1) production, but not both simultaneously: the monosaccharides M4 and M6 were active TNF inducers, but did not initiate IL-1 production, while the monosaccharides M9 and lipid X efficiently elicited IL-1 production, but did not trigger TNF secretion.	Lipid A	108-115	interleukin 1 complex	Mus musculus	296-300
3135943-6	1988	Synthetic monosaccharides, chemically closely related to substructures recognized to be present in isolated lipid A preparations, could induce either TNF or interleukin-1 (IL-1) production, but not both simultaneously: the monosaccharides M4 and M6 were active TNF inducers, but did not initiate IL-1 production, while the monosaccharides M9 and lipid X efficiently elicited IL-1 production, but did not trigger TNF secretion.	Lipid A	108-115	interleukin 1 complex	Mus musculus	296-300
3135943-6	1988	Synthetic monosaccharides, chemically closely related to substructures recognized to be present in isolated lipid A preparations, could induce either TNF or interleukin-1 (IL-1) production, but not both simultaneously: the monosaccharides M4 and M6 were active TNF inducers, but did not initiate IL-1 production, while the monosaccharides M9 and lipid X efficiently elicited IL-1 production, but did not trigger TNF secretion.	Monosaccharides	223-238	interleukin 1 complex	Mus musculus	296-300
3135943-6	1988	Synthetic monosaccharides, chemically closely related to substructures recognized to be present in isolated lipid A preparations, could induce either TNF or interleukin-1 (IL-1) production, but not both simultaneously: the monosaccharides M4 and M6 were active TNF inducers, but did not initiate IL-1 production, while the monosaccharides M9 and lipid X efficiently elicited IL-1 production, but did not trigger TNF secretion.	Monosaccharides	223-238	interleukin 1 complex	Mus musculus	296-300
3135943-6	1988	Synthetic monosaccharides, chemically closely related to substructures recognized to be present in isolated lipid A preparations, could induce either TNF or interleukin-1 (IL-1) production, but not both simultaneously: the monosaccharides M4 and M6 were active TNF inducers, but did not initiate IL-1 production, while the monosaccharides M9 and lipid X efficiently elicited IL-1 production, but did not trigger TNF secretion.	Monosaccharides	223-238	interleukin 1 complex	Mus musculus	296-300
3135943-6	1988	Synthetic monosaccharides, chemically closely related to substructures recognized to be present in isolated lipid A preparations, could induce either TNF or interleukin-1 (IL-1) production, but not both simultaneously: the monosaccharides M4 and M6 were active TNF inducers, but did not initiate IL-1 production, while the monosaccharides M9 and lipid X efficiently elicited IL-1 production, but did not trigger TNF secretion.	Monosaccharides	223-238	interleukin 1 complex	Mus musculus	296-300
3260256-9	1988	CM from mycophenolic acid- treated adherent layers exposed for 24 h to 50 U/ml of IL-1 was added at volume concentrations of 5, 10, and 25% to MBMC at the time of transfer to lymphoid bone marrow culture conditions and at each feeding thereafter.	Mycophenolic Acid	8-25	interleukin 1 complex	Mus musculus	82-86
2968844-1	1988	The role of prostaglandins in the regulation of lipopolysaccharide (LPS)-induced interleukin-1 (IL-1) production by murine C3H/HeN resident peritoneal macrophages was studied.	Prostaglandins	12-26	interleukin 1 complex	Mus musculus	81-94
2968844-1	1988	The role of prostaglandins in the regulation of lipopolysaccharide (LPS)-induced interleukin-1 (IL-1) production by murine C3H/HeN resident peritoneal macrophages was studied.	Prostaglandins	12-26	interleukin 1 complex	Mus musculus	96-100
2968844-2	1988	IL-1 production was initially studied in the presence of piroxicam and indomethacin, both inhibitors of prostaglandin biosynthesis.	Piroxicam	57-66	interleukin 1 complex	Mus musculus	0-4
2968844-2	1988	IL-1 production was initially studied in the presence of piroxicam and indomethacin, both inhibitors of prostaglandin biosynthesis.	Indomethacin	71-83	interleukin 1 complex	Mus musculus	0-4
2968844-2	1988	IL-1 production was initially studied in the presence of piroxicam and indomethacin, both inhibitors of prostaglandin biosynthesis.	Prostaglandins	104-117	interleukin 1 complex	Mus musculus	0-4
2968844-5	1988	IL-1-containing supernatants from drug-treated macrophages at dilutions of up to 1:32 resulted in enhanced thymocyte proliferation compared to control, non-drug-treated cultures and contained less than 2 ng/ml of PGE2.	Dinoprostone	213-217	interleukin 1 complex	Mus musculus	0-4
2968844-9	1988	Exogenous PGE2, in the concentration range produced in macrophage supernatants (10-20 ng/ml), directly inhibited IL-1-stimulated thymocyte proliferation.	Dinoprostone	10-14	interleukin 1 complex	Mus musculus	113-117
2968844-10	1988	Finally, when macrophages were stimulated with LPS for 24 hr in the presence of added PGE2, thymocyte proliferation was inhibited at the lowest supernatant dilutions, but as the IL-1-containing supernatants were diluted out, the assay curves were indistinguishable from non-PGE2-treated control.	Dinoprostone	86-90	interleukin 1 complex	Mus musculus	178-182
2968844-12	1988	Nonsteroidal anti-inflammatory drugs are not stimulating IL-1 production but are, in fact, relieving inhibition of the thymocyte IL-1 assay caused by the presence of prostaglandins.	Prostaglandins	166-180	interleukin 1 complex	Mus musculus	129-133
3262467-2	1988	When stimulated with suboptimal concentrations of ionomycin and phorbol myristate acetate (PMA), the immature subpopulation of Lyt2-,L3T4- (2-4-) thymocytes responded to exogenous, purified IL-1 in a dose-dependent manner.	Ionomycin	50-59	interleukin 1 complex	Mus musculus	190-194
3262467-2	1988	When stimulated with suboptimal concentrations of ionomycin and phorbol myristate acetate (PMA), the immature subpopulation of Lyt2-,L3T4- (2-4-) thymocytes responded to exogenous, purified IL-1 in a dose-dependent manner.	Tetradecanoylphorbol Acetate	64-89	interleukin 1 complex	Mus musculus	190-194
3262467-2	1988	When stimulated with suboptimal concentrations of ionomycin and phorbol myristate acetate (PMA), the immature subpopulation of Lyt2-,L3T4- (2-4-) thymocytes responded to exogenous, purified IL-1 in a dose-dependent manner.	Tetradecanoylphorbol Acetate	91-94	interleukin 1 complex	Mus musculus	190-194
3261749-0	1988	In vivo administration of IL-1 induces thymic hypoplasia and increased levels of serum corticosterone.	Corticosterone	87-101	interleukin 1 complex	Mus musculus	26-30
3261749-10	1988	injection of IL-1 caused a three-fold increase in serum corticosterone levels, which peaked approximately 3 h after IL-1 administration.	Corticosterone	56-70	interleukin 1 complex	Mus musculus	13-17
3261749-10	1988	injection of IL-1 caused a three-fold increase in serum corticosterone levels, which peaked approximately 3 h after IL-1 administration.	Corticosterone	56-70	interleukin 1 complex	Mus musculus	116-120
3261749-11	1988	Thus, an IL-1-dependent increase in serum corticosterone levels may be responsible for the observed thymic hypoplasia.	Corticosterone	42-56	interleukin 1 complex	Mus musculus	9-13
3261759-1	1988	Prostaglandin- and leukotriene-independent induction of infiltration by IL-1 and tumor necrosis factor.	Prostaglandins	0-13	interleukin 1 complex	Mus musculus	72-76
3261759-1	1988	Prostaglandin- and leukotriene-independent induction of infiltration by IL-1 and tumor necrosis factor.	Leukotrienes	19-30	interleukin 1 complex	Mus musculus	72-76
3260741-1	1988	Intravenous injection of 1.5 mg of acetylated low-density lipoprotein (LDL) or 100 micrograms of lipopolysaccharide (LPS) to zymosan-primed mice induced a decrease in serum zinc levels measured 6 hours after injection, suggesting the release of interleukin 1 (IL-1).	Zymosan	125-132	interleukin 1 complex	Mus musculus	245-264
3260741-2	1988	Oral administration of probucol, 100 mg/kg once daily for 14 days, inhibited the LPS-induced fall in serum zinc levels, suggesting inhibition of IL-1 release.	Probucol	23-31	interleukin 1 complex	Mus musculus	145-149
3260741-3	1988	Direct evidence for inhibition of IL-1 release by probucol was obtained with an ex vivo system in which, compared with controls, peritoneal macrophages from probucol-treated mice (100 mg/kg orally X 3, or 0.25% in the diet for 3 weeks) secreted 80 to 90% less IL-1 upon LPS stimulation, measured by the C3H/HeJ thymocyte proliferation assay.	Probucol	50-58	interleukin 1 complex	Mus musculus	34-38
3260741-4	1988	Inhibition of IL-1 secretion by probucol may contribute to the therapeutic effect of probucol in atherosclerosis since as little as 1 unit of recombinant IL-1 beta was found to induce proliferation of aortic smooth muscle cells.	Probucol	32-40	interleukin 1 complex	Mus musculus	14-18
3260077-6	1988	Recombinant IL 1 (mol wt 17,500) reproduced changes in AMG and aspartate uptake seen with macrophage supernatants.	Aspartic Acid	63-72	interleukin 1 complex	Mus musculus	12-16
3261378-0	1988	Dexamethasone modulation of LPS, IL-1, and TNF stimulated serum amyloid A synthesis in mice.	Dexamethasone	0-13	interleukin 1 complex	Mus musculus	33-37
3261378-4	1988	Dexamethasone (DEX), a potent inhibitor of macrophage IL-1, TNF and IL-6 synthesis, was utilized to analyze the endogenous mediators of SAA synthesis in mice injected with lipopolysaccharide (LPS).	Dexamethasone	0-13	interleukin 1 complex	Mus musculus	54-58
3261378-4	1988	Dexamethasone (DEX), a potent inhibitor of macrophage IL-1, TNF and IL-6 synthesis, was utilized to analyze the endogenous mediators of SAA synthesis in mice injected with lipopolysaccharide (LPS).	Dexamethasone	15-18	interleukin 1 complex	Mus musculus	54-58
2856206-6	1988	Second, we demonstrated that MHV 3 induced a dose-dependent interleukin 1 (IL-1) activity in the supernatants of infected Kupffer cells of both strains.	mhv	29-32	interleukin 1 complex	Mus musculus	60-79
3275131-8	1988	The indirect stimulatory effect of IL 1 on PP B cells could not be reproduced when PP B cells were cultured with recombinant preparations of interleukins 2 and 4.	pp b	43-47	interleukin 1 complex	Mus musculus	35-39
3260077-9	1988	These data indicate that macrophages, via IL 1 secretion, are capable of modulation of sodium-linked solute transport in proximal tubular epithelium.	Sodium	87-93	interleukin 1 complex	Mus musculus	42-46
3260101-0	1988	Aminobisphosphonate inhibition of interleukin-1-induced bone resorption in mouse calvariae.	aminobisphosphonate	0-19	interleukin 1 complex	Mus musculus	34-47
3140533-5	1988	In vitro analysis showed that B-LPS was a potent activator of both neutrophils and macrophages in luminol-dependent response and IL-1 secretion from macrophages and was mitogenic to the spleen cells not only from BALB/c mice but also from LPS-non-responder C3H/HeJ mice.	b-lps	30-35	interleukin 1 complex	Mus musculus	129-133
3168320-6	1988	Although taurine did not have any activity on the proliferation of thymocytes nor stimulate IL-2 production, taurine did induce IL-1 production by macrophages.	Taurine	109-116	interleukin 1 complex	Mus musculus	128-132
3168320-7	1988	It was considered that taurine-induced IL-1 would play an essential role in the proliferation and differentiation of B cells.	Taurine	23-30	interleukin 1 complex	Mus musculus	39-43
3260101-4	1988	The resorptive action of IL-1 was not entirely dependent on prostaglandin mediation, since its effect was evident when prostaglandin synthesis was inhibited in the cultures by indomethacin.	Prostaglandins	60-73	interleukin 1 complex	Mus musculus	25-29
3260101-4	1988	The resorptive action of IL-1 was not entirely dependent on prostaglandin mediation, since its effect was evident when prostaglandin synthesis was inhibited in the cultures by indomethacin.	Prostaglandins	119-132	interleukin 1 complex	Mus musculus	25-29
3260101-4	1988	The resorptive action of IL-1 was not entirely dependent on prostaglandin mediation, since its effect was evident when prostaglandin synthesis was inhibited in the cultures by indomethacin.	Indomethacin	176-188	interleukin 1 complex	Mus musculus	25-29
3260101-5	1988	IL-1-induced resorption has been shown to be inhibited by 10(-5) M 3-amino-1-hydroxypropylidene-1-1-bisphosphonate (APD).	Pamidronate	67-114	interleukin 1 complex	Mus musculus	0-4
2839894-2	1988	The data reported here show that although the levels of secreted IL-1 were equally high after in vitro stimulation with an optimal dose of LPS or silica, there were two clear differences: (i) the levels of membrane-associated IL-1 (as detected by the comitogenic effect of paraformaldehyde (PFA)-fixed cells or purified membrane fragments on murine thymocytes) were ca.	Silicon Dioxide	146-152	interleukin 1 complex	Mus musculus	65-69
3135104-0	1988	Recombinant interleukin-1 stimulates prostaglandin E2 production by osteoblastic cells: synergy with parathyroid hormone.	Dinoprostone	37-53	interleukin 1 complex	Mus musculus	12-25
3135104-1	1988	Recombinant mouse IL-1 (Interleukin-1) has been shown to be capable of stimulating prostaglandin E2 (PGE2) production by isolated rat osteoblastic cells in a dose-dependent manner.	Dinoprostone	83-99	interleukin 1 complex	Mus musculus	18-22
3135104-1	1988	Recombinant mouse IL-1 (Interleukin-1) has been shown to be capable of stimulating prostaglandin E2 (PGE2) production by isolated rat osteoblastic cells in a dose-dependent manner.	Dinoprostone	83-99	interleukin 1 complex	Mus musculus	24-37
3135104-1	1988	Recombinant mouse IL-1 (Interleukin-1) has been shown to be capable of stimulating prostaglandin E2 (PGE2) production by isolated rat osteoblastic cells in a dose-dependent manner.	Dinoprostone	101-105	interleukin 1 complex	Mus musculus	18-22
3135104-1	1988	Recombinant mouse IL-1 (Interleukin-1) has been shown to be capable of stimulating prostaglandin E2 (PGE2) production by isolated rat osteoblastic cells in a dose-dependent manner.	Dinoprostone	101-105	interleukin 1 complex	Mus musculus	24-37
3135104-2	1988	The rapidity of the effect (1 hour) and the potency of IL-1 (5 x 10(-12) M) in producing this effect suggest that IL-1 may exert some of its effects on bone via PGE2.	Dinoprostone	161-165	interleukin 1 complex	Mus musculus	55-59
3135104-2	1988	The rapidity of the effect (1 hour) and the potency of IL-1 (5 x 10(-12) M) in producing this effect suggest that IL-1 may exert some of its effects on bone via PGE2.	Dinoprostone	161-165	interleukin 1 complex	Mus musculus	114-118
2839894-2	1988	The data reported here show that although the levels of secreted IL-1 were equally high after in vitro stimulation with an optimal dose of LPS or silica, there were two clear differences: (i) the levels of membrane-associated IL-1 (as detected by the comitogenic effect of paraformaldehyde (PFA)-fixed cells or purified membrane fragments on murine thymocytes) were ca.	paraform	273-289	interleukin 1 complex	Mus musculus	226-230
2839894-2	1988	The data reported here show that although the levels of secreted IL-1 were equally high after in vitro stimulation with an optimal dose of LPS or silica, there were two clear differences: (i) the levels of membrane-associated IL-1 (as detected by the comitogenic effect of paraformaldehyde (PFA)-fixed cells or purified membrane fragments on murine thymocytes) were ca.	paraform	291-294	interleukin 1 complex	Mus musculus	226-230
3258210-2	1988	Zine not only enhances the responses of cells suboptimally activated by PHA but can also prime the cells to respond to IL-1 in the absence of activation by PHA.	zine	0-4	interleukin 1 complex	Mus musculus	119-123
2839894-6	1988	Moreover, the finding that after silica stimulation the amount of membrane-associated IL-1 (which was recently shown to be of the IL-1 alpha type) was low, while IL-1 alpha in the culture fluid was clearly elevated, suggests that the IL-1 alpha not attached to the cell membrane (or released from it) significantly contributes to the secreted IL-1 pool.	Silicon Dioxide	33-39	interleukin 1 complex	Mus musculus	86-90
3259257-3	1988	The lethality of endotoxin, TNF, or IL-1 was totally prevented by pretreatment with dexamethasone (minimal effective dose, 0.3 mg/Kg) but not by ibuprofen (10 mg/Kg).	Dexamethasone	84-97	interleukin 1 complex	Mus musculus	36-40
3283241-0	1988	Exacerbation of arthritis by IL-1 in rat joints previously injured by peptidoglycan-polysaccharide.	peptidoglycan-polysaccharide	70-98	interleukin 1 complex	Mus musculus	29-33
3280472-4	1988	Addition of IL-1 to the culture of normal B-cells and sheep red blood cells (SRBC) induced a dose-dependent anti-SRBC IgM response, with maximal response at 100 U/ml, whereas the response induced by TRF/IL-5 was less than that induced by IL-1 and did not reach the maximum even at 100 U/ml.	srbc	77-81	interleukin 1 complex	Mus musculus	12-16
2832480-1	1988	A method for separating IL-1 from plasma inhibitors by silica extraction has been developed and coupled to a highly sensitive bioassay using the LBRM TG6 cell line and the I1-2 dependent HT2A cell line.	Silicon Dioxide	55-61	interleukin 1 complex	Mus musculus	24-28
3281726-8	1988	Growth of mixed erythroid colonies from 5-FU-treated marrow is thus stimulated by adherent marrow cell-derived factors that appear distinct not only from the known CSFs including IL 3, but also from IL 1.	Fluorouracil	40-44	interleukin 1 complex	Mus musculus	199-203
3258127-5	1988	Aqueous extracts prepared from pulmonary granuloma lesions induced in mice by Sephadex G-50 beads contained high levels of interleukin-1 (IL-1) activity but not interleukin-2 (IL-2) activity.	sephadex	78-91	interleukin 1 complex	Mus musculus	138-142
3258127-7	1988	In a subsequent step, large granulomas were induced by the intratracheal injection of Sepharose 4B beads coupled to fractions of the extracts containing IL-1 activity (ie, granuloma-derived IL-1) prepared from Sephadex G-50-induced granulomatous lungs.	sephadex	210-223	interleukin 1 complex	Mus musculus	190-194
3258127-8	1988	In addition, large granulomas were induced by the intratracheal injection of recombinant IL-1-coated Sepharose 4B beads.	Sepharose	101-113	interleukin 1 complex	Mus musculus	89-93
3133308-8	1988	Membrane-bound IL-1, thought to be important in the presentation of particulate antigens, was detected on glutaraldehyde-fixed resident AM and was significantly elevated in BCG-activated macrophages.	Glutaral	106-120	interleukin 1 complex	Mus musculus	15-19
3259542-3	1988	The production was not affected, but 1,25(OH)2D3 (greater than 10(-11) M) and a synthetic derivative MC 903 (greater than = 10(-10) M) inhibited the proliferation of mouse thymocytes to IL-1.	Calcitriol	37-48	interleukin 1 complex	Mus musculus	186-190
3280472-4	1988	Addition of IL-1 to the culture of normal B-cells and sheep red blood cells (SRBC) induced a dose-dependent anti-SRBC IgM response, with maximal response at 100 U/ml, whereas the response induced by TRF/IL-5 was less than that induced by IL-1 and did not reach the maximum even at 100 U/ml.	srbc	77-81	interleukin 1 complex	Mus musculus	238-242
3280472-4	1988	Addition of IL-1 to the culture of normal B-cells and sheep red blood cells (SRBC) induced a dose-dependent anti-SRBC IgM response, with maximal response at 100 U/ml, whereas the response induced by TRF/IL-5 was less than that induced by IL-1 and did not reach the maximum even at 100 U/ml.	srbc	113-117	interleukin 1 complex	Mus musculus	12-16
3280472-5	1988	Addition of anti-IL-1 antibody, but not anti-TRF/IL-5 antibody or anti-IL-2 receptor antibody, inhibited IL-1-induced anti-SRBC responses.	srbc	123-127	interleukin 1 complex	Mus musculus	17-21
3267107-4	1988	These IL-1-like antibodies were affinity purified either on an anti-IL-1-enriched Ig-Sepharose 4B column from an early bleed or sequentially on anti-Ig and Protein A immunoadsorbent columns.	Sepharose	85-97	interleukin 1 complex	Mus musculus	6-10
3280472-5	1988	Addition of anti-IL-1 antibody, but not anti-TRF/IL-5 antibody or anti-IL-2 receptor antibody, inhibited IL-1-induced anti-SRBC responses.	srbc	123-127	interleukin 1 complex	Mus musculus	105-109
3280472-8	1988	Of great interest is that suboptimal doses of IL-1 (10 U/ml) could synergize with TRF in the primary anti-SRBC PFC responses.	srbc	106-110	interleukin 1 complex	Mus musculus	46-50
2826594-3	1988	cAMP inhibits B cell proliferation facilitated by BSF-1 and enhances the B cell response facilitated by IL-1.	Cyclic AMP	0-4	interleukin 1 complex	Mus musculus	104-108
3258842-5	1988	IC-SACs additionally cultured without poly I:C for 24 h lost their suppressive activity; however, when they were cultured in the presence of indomethacin, they could retain their activity, and interleukin 1 (IL 1) activity in culture supernatant was greater in the group cultured with indomethacin than without it.	Indomethacin	141-153	interleukin 1 complex	Mus musculus	193-212
2826594-6	1988	This suggests that IL-1 determines whether cAMP, which has elsewhere been shown to cause nuclear translocation of protein kinase C in resting B cells, inhibits or enhances B cell responses.	Cyclic AMP	43-47	interleukin 1 complex	Mus musculus	19-23
3258857-6	1988	The cyclic adenosine monophosphate (cAMP)-elevating agents prostaglandin E2, dibutyryl cAMP, and theophylline inhibited IL-2 production during the early, IL-1-dependent programming stage.	Cyclic AMP	87-91	interleukin 1 complex	Mus musculus	154-158
3258857-6	1988	The cyclic adenosine monophosphate (cAMP)-elevating agents prostaglandin E2, dibutyryl cAMP, and theophylline inhibited IL-2 production during the early, IL-1-dependent programming stage.	Cyclic AMP	4-34	interleukin 1 complex	Mus musculus	154-158
2462440-6	1988	Heparin, in combination with 0.1 mu/ml IL1, stimulated significant calcium release compared to heparin but not to IL1 tested alone.	Calcium	67-74	interleukin 1 complex	Mus musculus	39-42
2462440-6	1988	Heparin, in combination with 0.1 mu/ml IL1, stimulated significant calcium release compared to heparin but not to IL1 tested alone.	Heparin	95-102	interleukin 1 complex	Mus musculus	39-42
2462440-8	1988	Two of the heparin fragments combined with 0.1 U/ml IL1 significantly inhibited calcium release compared to IL1 alone.	Heparin	11-18	interleukin 1 complex	Mus musculus	108-111
2462440-8	1988	Two of the heparin fragments combined with 0.1 U/ml IL1 significantly inhibited calcium release compared to IL1 alone.	Calcium	80-87	interleukin 1 complex	Mus musculus	52-55
2462440-8	1988	Two of the heparin fragments combined with 0.1 U/ml IL1 significantly inhibited calcium release compared to IL1 alone.	Calcium	80-87	interleukin 1 complex	Mus musculus	108-111
2462440-9	1988	In combination with 1.0 U/ml of IL1, heparin and hyaluronic acid inhibited calcium release compared to IL1 alone but this inhibition was not significant.	Heparin	37-44	interleukin 1 complex	Mus musculus	103-106
2462440-9	1988	In combination with 1.0 U/ml of IL1, heparin and hyaluronic acid inhibited calcium release compared to IL1 alone but this inhibition was not significant.	Hyaluronic Acid	49-64	interleukin 1 complex	Mus musculus	103-106
2462440-9	1988	In combination with 1.0 U/ml of IL1, heparin and hyaluronic acid inhibited calcium release compared to IL1 alone but this inhibition was not significant.	Calcium	75-82	interleukin 1 complex	Mus musculus	32-35
3258857-6	1988	The cyclic adenosine monophosphate (cAMP)-elevating agents prostaglandin E2, dibutyryl cAMP, and theophylline inhibited IL-2 production during the early, IL-1-dependent programming stage.	Cyclic AMP	36-40	interleukin 1 complex	Mus musculus	154-158
3258857-6	1988	The cyclic adenosine monophosphate (cAMP)-elevating agents prostaglandin E2, dibutyryl cAMP, and theophylline inhibited IL-2 production during the early, IL-1-dependent programming stage.	Dinoprostone	59-75	interleukin 1 complex	Mus musculus	154-158
3258857-6	1988	The cyclic adenosine monophosphate (cAMP)-elevating agents prostaglandin E2, dibutyryl cAMP, and theophylline inhibited IL-2 production during the early, IL-1-dependent programming stage.	Theophylline	97-109	interleukin 1 complex	Mus musculus	154-158
3263337-5	1988	Experiments on the regulation of the N-CWS-augmented IL-1 production showed that prostaglandin E2 inhibited the augmentation, and indomethacin (cyclo-oxygenase inhibitor) further augmented it.	Dinoprostone	81-97	interleukin 1 complex	Mus musculus	53-57
2848778-4	1988	An assay for the measurement of interleukin-1 (IL-1), based on its ability to induce interleukin-2 (IL-2) production by the EL-4 mouse thymoma line in the presence of the calcium ionophore A23187, was examined.	Calcium	171-178	interleukin 1 complex	Mus musculus	32-51
2848778-4	1988	An assay for the measurement of interleukin-1 (IL-1), based on its ability to induce interleukin-2 (IL-2) production by the EL-4 mouse thymoma line in the presence of the calcium ionophore A23187, was examined.	Calcimycin	189-195	interleukin 1 complex	Mus musculus	32-51
3263339-1	1988	Production of an IL-1-like activity in cultures of irradiated splenic adherent cells can be elicited by the C8-substituted guanine ribonucleosides 8-bromoguanosine (8BrGuo) and 8-mercaptoguanosine (8MGuo).	c8-substituted guanine ribonucleosides 8-bromoguanosine	108-163	interleukin 1 complex	Mus musculus	17-21
3263339-1	1988	Production of an IL-1-like activity in cultures of irradiated splenic adherent cells can be elicited by the C8-substituted guanine ribonucleosides 8-bromoguanosine (8BrGuo) and 8-mercaptoguanosine (8MGuo).	8-bromoguanosine	165-171	interleukin 1 complex	Mus musculus	17-21
3263339-1	1988	Production of an IL-1-like activity in cultures of irradiated splenic adherent cells can be elicited by the C8-substituted guanine ribonucleosides 8-bromoguanosine (8BrGuo) and 8-mercaptoguanosine (8MGuo).	8-thioguanosine	177-196	interleukin 1 complex	Mus musculus	17-21
3263339-7	1988	Anti-IL-1 antibodies that neutralize the biologic activity of an IL-1 standard also eliminate the IL-1-like activity induced by 8BrGuo.	8-bromoguanosine	128-134	interleukin 1 complex	Mus musculus	5-9
3263339-7	1988	Anti-IL-1 antibodies that neutralize the biologic activity of an IL-1 standard also eliminate the IL-1-like activity induced by 8BrGuo.	8-bromoguanosine	128-134	interleukin 1 complex	Mus musculus	65-69
3263339-7	1988	Anti-IL-1 antibodies that neutralize the biologic activity of an IL-1 standard also eliminate the IL-1-like activity induced by 8BrGuo.	8-bromoguanosine	128-134	interleukin 1 complex	Mus musculus	65-69
3263339-9	1988	These data indicate that C8-substituted guanosines, known intracellular stimuli for B-lymphocytes, can also induce non-lymphocytic cells (including a macrophage-like cell line) to elaborate an active principle which exhibits IL-1-like activity.	Guanosine	40-50	interleukin 1 complex	Mus musculus	225-229
3260987-0	1988	Systemic interleukin-1 administration stimulates hypothalamic norepinephrine metabolism parallelling the increased plasma corticosterone.	Norepinephrine	62-76	interleukin 1 complex	Mus musculus	9-22
3257232-7	1988	IL-1 which synergistically interacts with various CSF species to confer a clonogenic response by primitive stem cells present in 5-fluorouracil-treated marrow also failed to stimulate eosinophil production.	Fluorouracil	129-143	interleukin 1 complex	Mus musculus	0-4
3257232-9	1988	Furthermore, pre-culture of 5-fluorouracil-treated marrow cells with a combination of IL-1 and IL-3 resulted in a more than 260-fold increase of CFU-eo over input numbers.	Fluorouracil	28-42	interleukin 1 complex	Mus musculus	86-90
3260987-0	1988	Systemic interleukin-1 administration stimulates hypothalamic norepinephrine metabolism parallelling the increased plasma corticosterone.	Corticosterone	122-136	interleukin 1 complex	Mus musculus	9-22
3260987-1	1988	Intraperitoneal injection of purified recombinant interleukin-1 (IL-1) into mice increased the cerebral concentration of the norepinephrine (NE) catabolite, 3-methoxy,4-hydroxyphenylethyleneglycol (MHPG), probably reflecting increased activity of noradrenergic neurons.	Norepinephrine	125-139	interleukin 1 complex	Mus musculus	50-63
3260987-1	1988	Intraperitoneal injection of purified recombinant interleukin-1 (IL-1) into mice increased the cerebral concentration of the norepinephrine (NE) catabolite, 3-methoxy,4-hydroxyphenylethyleneglycol (MHPG), probably reflecting increased activity of noradrenergic neurons.	Norepinephrine	125-139	interleukin 1 complex	Mus musculus	65-69
3260987-1	1988	Intraperitoneal injection of purified recombinant interleukin-1 (IL-1) into mice increased the cerebral concentration of the norepinephrine (NE) catabolite, 3-methoxy,4-hydroxyphenylethyleneglycol (MHPG), probably reflecting increased activity of noradrenergic neurons.	(ne) catabolite	140-155	interleukin 1 complex	Mus musculus	50-63
3260987-1	1988	Intraperitoneal injection of purified recombinant interleukin-1 (IL-1) into mice increased the cerebral concentration of the norepinephrine (NE) catabolite, 3-methoxy,4-hydroxyphenylethyleneglycol (MHPG), probably reflecting increased activity of noradrenergic neurons.	(ne) catabolite	140-155	interleukin 1 complex	Mus musculus	65-69
3260987-1	1988	Intraperitoneal injection of purified recombinant interleukin-1 (IL-1) into mice increased the cerebral concentration of the norepinephrine (NE) catabolite, 3-methoxy,4-hydroxyphenylethyleneglycol (MHPG), probably reflecting increased activity of noradrenergic neurons.	Methoxyhydroxyphenylglycol	157-196	interleukin 1 complex	Mus musculus	50-63
3260987-1	1988	Intraperitoneal injection of purified recombinant interleukin-1 (IL-1) into mice increased the cerebral concentration of the norepinephrine (NE) catabolite, 3-methoxy,4-hydroxyphenylethyleneglycol (MHPG), probably reflecting increased activity of noradrenergic neurons.	Methoxyhydroxyphenylglycol	157-196	interleukin 1 complex	Mus musculus	65-69
3260987-1	1988	Intraperitoneal injection of purified recombinant interleukin-1 (IL-1) into mice increased the cerebral concentration of the norepinephrine (NE) catabolite, 3-methoxy,4-hydroxyphenylethyleneglycol (MHPG), probably reflecting increased activity of noradrenergic neurons.	Methoxyhydroxyphenylglycol	198-202	interleukin 1 complex	Mus musculus	50-63
3260987-1	1988	Intraperitoneal injection of purified recombinant interleukin-1 (IL-1) into mice increased the cerebral concentration of the norepinephrine (NE) catabolite, 3-methoxy,4-hydroxyphenylethyleneglycol (MHPG), probably reflecting increased activity of noradrenergic neurons.	Methoxyhydroxyphenylglycol	198-202	interleukin 1 complex	Mus musculus	65-69
3260987-4	1988	The increase of MHPG peaked around 4 hours after IL-1 administration, parallelling the increase of plasma corticosterone.	Methoxyhydroxyphenylglycol	16-20	interleukin 1 complex	Mus musculus	49-53
3500955-2	1987	This report examines the effects of IL-1 on the induction by dexamethasone of alkaline phosphatase in LEII murine endothelial cells.	Dexamethasone	61-74	interleukin 1 complex	Mus musculus	36-40
2453616-6	1987	We then showed that ABPP induced significant serum levels of IFN and IL-1, but not IL-2.	Bropirimine	20-24	interleukin 1 complex	Mus musculus	69-73
2453616-7	1987	The induction of IL-1 by ABPP in vivo was further verified by demonstration of increased serum levels of the acute phase protein serum amyloid P in ABPP-treated mice.	Bropirimine	25-29	interleukin 1 complex	Mus musculus	17-21
2453616-7	1987	The induction of IL-1 by ABPP in vivo was further verified by demonstration of increased serum levels of the acute phase protein serum amyloid P in ABPP-treated mice.	Bropirimine	148-152	interleukin 1 complex	Mus musculus	17-21
2453616-10	1987	These results suggest a role for IFN and IL-1 in the augmentation of NK activity in vivo by ABPP, but no evidence for a role for IL-2 was found.	Bropirimine	92-96	interleukin 1 complex	Mus musculus	41-45
2961613-2	1987	In contrast, similar doses of each type of IL1 stimulated increased lactate production by Balb/C 3T3 fibroblasts.	Lactic Acid	68-75	interleukin 1 complex	Mus musculus	43-46
3500955-4	1987	This IL-1-mediated antagonism of dexamethasone activity is not due to a down-regulation of glucocorticoid receptors in the cell line used, because the number of receptors and their affinity for dexamethasone is unchanged in IL-1-treated cells.	Dexamethasone	33-46	interleukin 1 complex	Mus musculus	5-9
3500955-4	1987	This IL-1-mediated antagonism of dexamethasone activity is not due to a down-regulation of glucocorticoid receptors in the cell line used, because the number of receptors and their affinity for dexamethasone is unchanged in IL-1-treated cells.	Dexamethasone	194-207	interleukin 1 complex	Mus musculus	5-9
3501158-4	1987	On the other hand, cells from animals treated with glucan-plastic beads produced less thymocyte-stimulatory activity--presumably corresponding to interleukin 1 (IL-1)--than cells from control animals treated with commercial latex beads.	Glucans	51-57	interleukin 1 complex	Mus musculus	146-165
3501508-6	1987	Injection of 10 micrograms bacterial lipopolysaccharide (LPS), an inducer of IL-1 synthesis, exhibited a pattern of tissue responsiveness which was distinct from the responses elicited by rIL-1 beta, most notably a marked 5-fold induction of ODC in spleen.	bacterial lipopolysaccharide	27-55	interleukin 1 complex	Mus musculus	77-81
3318508-6	1987	A moderate hypoglycemia, paralleled by increased glucagon and corticosterone blood levels, was also observed in IL 1-injected rats, but no increase in insulin levels was detected.	Glucagon	49-57	interleukin 1 complex	Mus musculus	112-116
3318508-6	1987	A moderate hypoglycemia, paralleled by increased glucagon and corticosterone blood levels, was also observed in IL 1-injected rats, but no increase in insulin levels was detected.	Corticosterone	62-76	interleukin 1 complex	Mus musculus	112-116
2958556-6	1987	MD10 cells show the maximal IL-1 effect at 72 hr where the response exceeds the base line by 100-fold (approximately 3,000----300,000 cpm of [3H]thymidine).	Tritium	142-144	interleukin 1 complex	Mus musculus	28-32
2958556-6	1987	MD10 cells show the maximal IL-1 effect at 72 hr where the response exceeds the base line by 100-fold (approximately 3,000----300,000 cpm of [3H]thymidine).	Thymidine	145-154	interleukin 1 complex	Mus musculus	28-32
2958556-13	1987	These data suggest that, in respect to this particular T cell line, IL-1 is directly growth-promoting or, alternatively, induces the production of undetectable, intermediate growth factor(s) resistant to inhibition by cyclosporine A.	Cyclosporine	218-232	interleukin 1 complex	Mus musculus	68-72
3116092-5	1987	A23187 induced IL-1 production by C3H/He macrophages, but it did not induce IL-1 production by C3H/HeJ macrophages and neither did LPS.	Calcimycin	0-6	interleukin 1 complex	Mus musculus	15-19
3116092-7	1987	In contrast, PMA was able to induce IL-1 production by both C3H/He and C3H/HeJ macrophages without increasing intracellular Ca2+.	Tetradecanoylphorbol Acetate	13-16	interleukin 1 complex	Mus musculus	36-40
3116092-9	1987	A calmodulin antagonist W-7 effectively inhibited A23187-induced IL-1 production by C3H/He macrophages.	W 7	24-27	interleukin 1 complex	Mus musculus	65-69
3116092-9	1987	A calmodulin antagonist W-7 effectively inhibited A23187-induced IL-1 production by C3H/He macrophages.	Calcimycin	50-56	interleukin 1 complex	Mus musculus	65-69
3116092-9	1987	A calmodulin antagonist W-7 effectively inhibited A23187-induced IL-1 production by C3H/He macrophages.	Helium	88-90	interleukin 1 complex	Mus musculus	65-69
2961488-7	1987	Interleukin 1 (IL-1) activity of supernatants of ADH was assayed on C3H/HeJ mouse thymocytes.	adh	49-52	interleukin 1 complex	Mus musculus	0-13
2961488-7	1987	Interleukin 1 (IL-1) activity of supernatants of ADH was assayed on C3H/HeJ mouse thymocytes.	adh	49-52	interleukin 1 complex	Mus musculus	15-19
3323504-3	1987	Recombinant murine IL-1 was also a potent dose dependent activator of chondrocyte arachidonate metabolism and protease secretion.	Arachidonic Acid	82-94	interleukin 1 complex	Mus musculus	19-23
2956325-7	1987	Recombinant human and murine IL 1 alpha were equally effective in inhibiting the binding of 125I-labeled human and murine IL 1, based on both micrograms of protein and units of IL 1 activity.	Iodine-125	92-96	interleukin 1 complex	Mus musculus	29-33
2956325-7	1987	Recombinant human and murine IL 1 alpha were equally effective in inhibiting the binding of 125I-labeled human and murine IL 1, based on both micrograms of protein and units of IL 1 activity.	Iodine-125	92-96	interleukin 1 complex	Mus musculus	122-126
2956124-3	1987	The putative IL-1 receptor is a membrane-associated glycopeptide of Mr = 82,000 containing probably two or three N-linked glycan units as indicated by its conversion into a Mr = 60,000 polypeptide upon deglycosylation with endo-beta-N-glycosidase F.	n-linked glycan	113-128	interleukin 1 complex	Mus musculus	13-17
3497573-4	1987	IL-1 preparations from severely and moderately iron-deficient rats enhanced mouse thymocyte proliferation in vitro less than half as much as IL-1 preparations from control rats.	Iron	47-51	interleukin 1 complex	Mus musculus	0-4
3497573-5	1987	In a rabbit bioassay, injection of IL-1 prepared with PEC from either group of iron-deficient rats had little effect on body temperature or plasma minerals, while IL-1 from iron-adequate source PEC produced a febrile response and markedly lowered plasma iron and zinc in recipient rabbits.	Iron	173-177	interleukin 1 complex	Mus musculus	163-167
3297891-3	1987	Inhibition of glucose-induced insulin secretion was observed after a 15-h treatment of islets with either purified IL-1, murine recombinant IL-1 (rIL-1), or human rIL-1, rIL-1 inhibition of glucose-induced insulin secretion was dose dependent with half-maximal inhibition observed at 25 pM human rIL-1.	Glucose	14-21	interleukin 1 complex	Mus musculus	115-119
3297891-3	1987	Inhibition of glucose-induced insulin secretion was observed after a 15-h treatment of islets with either purified IL-1, murine recombinant IL-1 (rIL-1), or human rIL-1, rIL-1 inhibition of glucose-induced insulin secretion was dose dependent with half-maximal inhibition observed at 25 pM human rIL-1.	Glucose	14-21	interleukin 1 complex	Mus musculus	140-144
3112227-3	1987	The findings that i) PFA-fixed Mo did not produce or release IL 1, ii) the accessory function of PFA-fixed Mo could be inhibited with pretreatment with anti-IL 1 antibody, iii) PFA-fixed Mo had a comitogenic effect in the murine thymocyte assay, and iv) there was a temporal difference between the capacities to function in the comitogenic assay and to produce soluble IL 1, suggest that human Mo can express membrane-associated IL 1 and that it is functionally relevant.	paraform	97-100	interleukin 1 complex	Mus musculus	157-161
3112227-3	1987	The findings that i) PFA-fixed Mo did not produce or release IL 1, ii) the accessory function of PFA-fixed Mo could be inhibited with pretreatment with anti-IL 1 antibody, iii) PFA-fixed Mo had a comitogenic effect in the murine thymocyte assay, and iv) there was a temporal difference between the capacities to function in the comitogenic assay and to produce soluble IL 1, suggest that human Mo can express membrane-associated IL 1 and that it is functionally relevant.	paraform	97-100	interleukin 1 complex	Mus musculus	157-161
3112227-3	1987	The findings that i) PFA-fixed Mo did not produce or release IL 1, ii) the accessory function of PFA-fixed Mo could be inhibited with pretreatment with anti-IL 1 antibody, iii) PFA-fixed Mo had a comitogenic effect in the murine thymocyte assay, and iv) there was a temporal difference between the capacities to function in the comitogenic assay and to produce soluble IL 1, suggest that human Mo can express membrane-associated IL 1 and that it is functionally relevant.	paraform	97-100	interleukin 1 complex	Mus musculus	157-161
3112227-3	1987	The findings that i) PFA-fixed Mo did not produce or release IL 1, ii) the accessory function of PFA-fixed Mo could be inhibited with pretreatment with anti-IL 1 antibody, iii) PFA-fixed Mo had a comitogenic effect in the murine thymocyte assay, and iv) there was a temporal difference between the capacities to function in the comitogenic assay and to produce soluble IL 1, suggest that human Mo can express membrane-associated IL 1 and that it is functionally relevant.	paraform	97-100	interleukin 1 complex	Mus musculus	157-161
3497573-5	1987	In a rabbit bioassay, injection of IL-1 prepared with PEC from either group of iron-deficient rats had little effect on body temperature or plasma minerals, while IL-1 from iron-adequate source PEC produced a febrile response and markedly lowered plasma iron and zinc in recipient rabbits.	Iron	173-177	interleukin 1 complex	Mus musculus	163-167
3496381-3	1987	Both isolated regions of this LPS (PS and Lipid A) were able to induce IL 1 synthesis by monocytes and macrophages.	Polysaccharides	31-33	interleukin 1 complex	Mus musculus	71-75
3496381-4	1987	Among the synthetic glycolipids employed, propyl-2-deoxy-2-[(3R)-3-hydroxytetrade-canamido]-4-O-pho sph ono-6-O-tetradecanoyl-beta-D-glucopyranoside (glycolipid M9) induced IL 1 secretion more efficiently than Lipid A and LPS, whereas the amounts of intracellular IL 1 produced upon induction by these three substances were comparable.	ono-6-o-tetradecanoyl-beta-d-glucopyranoside	104-148	interleukin 1 complex	Mus musculus	264-268
3496381-3	1987	Both isolated regions of this LPS (PS and Lipid A) were able to induce IL 1 synthesis by monocytes and macrophages.	Lipid A	42-49	interleukin 1 complex	Mus musculus	71-75
3496381-4	1987	Among the synthetic glycolipids employed, propyl-2-deoxy-2-[(3R)-3-hydroxytetrade-canamido]-4-O-pho sph ono-6-O-tetradecanoyl-beta-D-glucopyranoside (glycolipid M9) induced IL 1 secretion more efficiently than Lipid A and LPS, whereas the amounts of intracellular IL 1 produced upon induction by these three substances were comparable.	Glycolipids	20-31	interleukin 1 complex	Mus musculus	173-177
3496381-5	1987	Macrophages from C3H/HeJ mice were unresponsive to Lipid A and to glycolipid M9, but produced IL 1 when incubated with PS or with a hydrophilic fragment isolated after methanolysis of the endotoxin.	Polysaccharides	119-121	interleukin 1 complex	Mus musculus	94-98
3496381-4	1987	Among the synthetic glycolipids employed, propyl-2-deoxy-2-[(3R)-3-hydroxytetrade-canamido]-4-O-pho sph ono-6-O-tetradecanoyl-beta-D-glucopyranoside (glycolipid M9) induced IL 1 secretion more efficiently than Lipid A and LPS, whereas the amounts of intracellular IL 1 produced upon induction by these three substances were comparable.	Glycolipids	20-31	interleukin 1 complex	Mus musculus	264-268
3496381-4	1987	Among the synthetic glycolipids employed, propyl-2-deoxy-2-[(3R)-3-hydroxytetrade-canamido]-4-O-pho sph ono-6-O-tetradecanoyl-beta-D-glucopyranoside (glycolipid M9) induced IL 1 secretion more efficiently than Lipid A and LPS, whereas the amounts of intracellular IL 1 produced upon induction by these three substances were comparable.	propyl-2-deoxy-2-[(3r)-3-hydroxytetrade-canamido]-4-o-pho	42-99	interleukin 1 complex	Mus musculus	173-177
3496381-4	1987	Among the synthetic glycolipids employed, propyl-2-deoxy-2-[(3R)-3-hydroxytetrade-canamido]-4-O-pho sph ono-6-O-tetradecanoyl-beta-D-glucopyranoside (glycolipid M9) induced IL 1 secretion more efficiently than Lipid A and LPS, whereas the amounts of intracellular IL 1 produced upon induction by these three substances were comparable.	propyl-2-deoxy-2-[(3r)-3-hydroxytetrade-canamido]-4-o-pho	42-99	interleukin 1 complex	Mus musculus	264-268
3496381-4	1987	Among the synthetic glycolipids employed, propyl-2-deoxy-2-[(3R)-3-hydroxytetrade-canamido]-4-O-pho sph ono-6-O-tetradecanoyl-beta-D-glucopyranoside (glycolipid M9) induced IL 1 secretion more efficiently than Lipid A and LPS, whereas the amounts of intracellular IL 1 produced upon induction by these three substances were comparable.	Sphingosine	100-103	interleukin 1 complex	Mus musculus	173-177
3496381-4	1987	Among the synthetic glycolipids employed, propyl-2-deoxy-2-[(3R)-3-hydroxytetrade-canamido]-4-O-pho sph ono-6-O-tetradecanoyl-beta-D-glucopyranoside (glycolipid M9) induced IL 1 secretion more efficiently than Lipid A and LPS, whereas the amounts of intracellular IL 1 produced upon induction by these three substances were comparable.	Sphingosine	100-103	interleukin 1 complex	Mus musculus	264-268
3496381-4	1987	Among the synthetic glycolipids employed, propyl-2-deoxy-2-[(3R)-3-hydroxytetrade-canamido]-4-O-pho sph ono-6-O-tetradecanoyl-beta-D-glucopyranoside (glycolipid M9) induced IL 1 secretion more efficiently than Lipid A and LPS, whereas the amounts of intracellular IL 1 produced upon induction by these three substances were comparable.	ono-6-o-tetradecanoyl-beta-d-glucopyranoside	104-148	interleukin 1 complex	Mus musculus	173-177
3495584-1	1987	IL 1 activity, as assayed by the proliferation of responsive mouse thymocytes and a human astrocytoma cell line, was detected on the membrane of 1% paraformaldehyde-fixed activated human monocytes.	paraform	148-164	interleukin 1 complex	Mus musculus	0-4
3496165-2	1987	The synthetic immunostimulant muramyl dipeptide (MDP) is known to induce secretion of IL-1 and its adjuvant effect was found to be mediated through enhancement of T-helper cells.	Acetylmuramyl-Alanyl-Isoglutamine	30-47	interleukin 1 complex	Mus musculus	86-90
3496165-2	1987	The synthetic immunostimulant muramyl dipeptide (MDP) is known to induce secretion of IL-1 and its adjuvant effect was found to be mediated through enhancement of T-helper cells.	Acetylmuramyl-Alanyl-Isoglutamine	49-52	interleukin 1 complex	Mus musculus	86-90
2955042-3	1987	We have developed a binding assay for 125I-labeled recombinant murine IL 1 and show it to be highly specific.	Iodine-125	38-42	interleukin 1 complex	Mus musculus	70-74
3495587-1	1987	Peritoneal macrophages from mice bearing a transplantable methylcholanthrene-induced sarcoma produced progressively less IL 1 as tumor burden increased.	Methylcholanthrene	58-76	interleukin 1 complex	Mus musculus	121-125
2883234-6	1987	RNA from mesangial cells and P388D macrophages hybridized in dot blots with a 32P-probe nick-translated from the murine IL 1 cDNA.	Phosphorus-32	78-81	interleukin 1 complex	Mus musculus	120-124
3115645-1	1987	The aim of this study was to examine the effect in vitro of gold sodium thiomalate (GST) on interleukin 1 (IL-1), and interleukin 2 (IL-2) production and IL-2 receptor expression in thymocytes of mice and in human peripheral blood mononuclear cells (PBMC).	Gold Sodium Thiomalate	60-82	interleukin 1 complex	Mus musculus	107-111
3115645-1	1987	The aim of this study was to examine the effect in vitro of gold sodium thiomalate (GST) on interleukin 1 (IL-1), and interleukin 2 (IL-2) production and IL-2 receptor expression in thymocytes of mice and in human peripheral blood mononuclear cells (PBMC).	Gold Sodium Thiomalate	84-87	interleukin 1 complex	Mus musculus	107-111
3309816-7	1987	So, we investigated whether quinolones could act on interleukin 1 (IL 1) production by macrophages.	Quinolones	28-38	interleukin 1 complex	Mus musculus	52-71
3309816-8	1987	Our results showed that pefloxacin and ofloxacin, used at low concentrations, enhanced LPS induced IL 1 production by macrophages.	Pefloxacin	24-34	interleukin 1 complex	Mus musculus	99-103
3309816-8	1987	Our results showed that pefloxacin and ofloxacin, used at low concentrations, enhanced LPS induced IL 1 production by macrophages.	Ofloxacin	39-48	interleukin 1 complex	Mus musculus	99-103
3553325-9	1987	After (NH4)2SO4 precipitation and hydrophobic phenyl-Sepharose chromatography, the measurable level of IL 1-like activity could be increased significantly.	Ammonium Sulfate	6-15	interleukin 1 complex	Mus musculus	103-107
3553325-9	1987	After (NH4)2SO4 precipitation and hydrophobic phenyl-Sepharose chromatography, the measurable level of IL 1-like activity could be increased significantly.	phenyl-sepharose	46-62	interleukin 1 complex	Mus musculus	103-107
3553325-17	1987	of these IL 1-like activities were 14,000, 14,500, 17,000, 18,000, and 21,000 in CBA AF fractions, and 15,000, 19,000, and 21,000 in NZB AF fractions according to SDS-polyacrylamide gel electrophoresis.	Sodium Dodecyl Sulfate	163-166	interleukin 1 complex	Mus musculus	9-13
3553325-17	1987	of these IL 1-like activities were 14,000, 14,500, 17,000, 18,000, and 21,000 in CBA AF fractions, and 15,000, 19,000, and 21,000 in NZB AF fractions according to SDS-polyacrylamide gel electrophoresis.	polyacrylamide	167-181	interleukin 1 complex	Mus musculus	9-13
3294578-4	1987	A similar increase of the in vitro responsiveness of male F1 hybrid spleen cells to TNP-PAA antigen was provoked by the addition of supernatants from P 388-D1 cells stimulated by muramyl-dipeptide (MDP) mainly containing interleukin-1 (IL-1) or supernatants from phorbol 12-myristate 13-acetate (PMA)-stimulated EL-4 cells that contained T-cell factors.	Acetylmuramyl-Alanyl-Isoglutamine	179-196	interleukin 1 complex	Mus musculus	221-234
3294578-4	1987	A similar increase of the in vitro responsiveness of male F1 hybrid spleen cells to TNP-PAA antigen was provoked by the addition of supernatants from P 388-D1 cells stimulated by muramyl-dipeptide (MDP) mainly containing interleukin-1 (IL-1) or supernatants from phorbol 12-myristate 13-acetate (PMA)-stimulated EL-4 cells that contained T-cell factors.	Acetylmuramyl-Alanyl-Isoglutamine	179-196	interleukin 1 complex	Mus musculus	236-240
3104480-6	1987	Similarly, indomethacin was also capable of abrogating the ability of IL-1 to depress CH responses of adoptive recipients of primed CH-effector cells.	Indomethacin	11-23	interleukin 1 complex	Mus musculus	70-74
3294578-8	1987	Moreover, in a specific proliferation test measuring IL-1 activity, when macrophage supernatants from female F1 produced a 13-fold increase of thymidine incorporation, supernatants from male F1 only produced a three-fold increase.	Thymidine	143-152	interleukin 1 complex	Mus musculus	53-57
2951435-2	1987	Binding of IL 1 to the solubilized receptor was detected by a polyethylene glycol (PEG) precipitation procedure.	Polyethylene Glycols	62-81	interleukin 1 complex	Mus musculus	11-15
2951435-2	1987	Binding of IL 1 to the solubilized receptor was detected by a polyethylene glycol (PEG) precipitation procedure.	Polyethylene Glycols	83-86	interleukin 1 complex	Mus musculus	11-15
3497875-4	1987	The results showed that the mitogenesis induced by Con A, natural killer cell (NK) cytotoxicity, production of IL-1 and IL-2 as well as the reactivity to IL-1 were all suppressed in ALN mice but stimulated in ARN mice compared to sham-operated controls.	Aluminum	182-185	interleukin 1 complex	Mus musculus	111-115
3497875-4	1987	The results showed that the mitogenesis induced by Con A, natural killer cell (NK) cytotoxicity, production of IL-1 and IL-2 as well as the reactivity to IL-1 were all suppressed in ALN mice but stimulated in ARN mice compared to sham-operated controls.	Aluminum	182-185	interleukin 1 complex	Mus musculus	154-158
3104480-0	1987	In vivo administration of interleukin 1 to normal mice depresses their capacity to elicit contact hypersensitivity responses: prostaglandins are involved in this modification of immune function.	Prostaglandins	126-140	interleukin 1 complex	Mus musculus	26-39
3104480-7	1987	Our results indicate that the capacity of IL-1 to depress CH responses in normal mice is due to an indomethacin-sensitive process, presumably mediated through the IL-1-induced generation and action of prostaglandins.	Indomethacin	99-111	interleukin 1 complex	Mus musculus	42-46
3104480-1	1987	The administration of pyrogenic doses of interleukin 1 (IL-1) to normal mice before contact sensitization with dinitrofluorobenzene (DNFB) resulted in a significant reduction in the intensity of the elicited contact hypersensitivity (CH) responses.	Dinitrofluorobenzene	133-137	interleukin 1 complex	Mus musculus	41-60
3104480-7	1987	Our results indicate that the capacity of IL-1 to depress CH responses in normal mice is due to an indomethacin-sensitive process, presumably mediated through the IL-1-induced generation and action of prostaglandins.	Indomethacin	99-111	interleukin 1 complex	Mus musculus	163-167
3104480-5	1987	Treatment of mice with indomethacin, a potent inhibitor of prostaglandin production, abrogated the capacity of IL-1 to depress CH responses following skin sensitization with DNFB.	Indomethacin	23-35	interleukin 1 complex	Mus musculus	111-115
3104480-5	1987	Treatment of mice with indomethacin, a potent inhibitor of prostaglandin production, abrogated the capacity of IL-1 to depress CH responses following skin sensitization with DNFB.	Prostaglandins	59-72	interleukin 1 complex	Mus musculus	111-115
3104480-5	1987	Treatment of mice with indomethacin, a potent inhibitor of prostaglandin production, abrogated the capacity of IL-1 to depress CH responses following skin sensitization with DNFB.	Dinitrofluorobenzene	174-178	interleukin 1 complex	Mus musculus	111-115
3104480-7	1987	Our results indicate that the capacity of IL-1 to depress CH responses in normal mice is due to an indomethacin-sensitive process, presumably mediated through the IL-1-induced generation and action of prostaglandins.	Prostaglandins	201-215	interleukin 1 complex	Mus musculus	42-46
3104480-7	1987	Our results indicate that the capacity of IL-1 to depress CH responses in normal mice is due to an indomethacin-sensitive process, presumably mediated through the IL-1-induced generation and action of prostaglandins.	Prostaglandins	201-215	interleukin 1 complex	Mus musculus	163-167
3494719-1	1987	The effect of ubenimex on the release of interleukin 1 (IL-1) and interleukin 2 (IL-2) from immuno-competent cells was studied.	ubenimex	14-22	interleukin 1 complex	Mus musculus	56-60
3493084-4	1987	Gel chromatography of IC IL-1 and extracellular (EC) IL-1 from TAM induced to secrete IL-1 by stimulation with lipopolysaccharide indicated a single peak of activity of similar molecular size.	tam	63-66	interleukin 1 complex	Mus musculus	53-57
3493084-4	1987	Gel chromatography of IC IL-1 and extracellular (EC) IL-1 from TAM induced to secrete IL-1 by stimulation with lipopolysaccharide indicated a single peak of activity of similar molecular size.	tam	63-66	interleukin 1 complex	Mus musculus	53-57
3493084-7	1987	Filtrates (less than 10 kDa) obtained on concentration of the IC and EC IL-1 samples prior to fractionation were shown to contain an activity (3-5 kDa) that inhibited the uptake of [3H]TdR by thymocytes in the mitogenic and comitogenic assays.	Tritium	182-184	interleukin 1 complex	Mus musculus	72-76
3494719-2	1987	Ubenimex enhanced release of IL-1 from mouse peritoneal macrophages at 1.0 and 100 micrograms/ml in vitro and the release at 1.0 microgram/ml was larger.	ubenimex	0-8	interleukin 1 complex	Mus musculus	29-33
3494719-3	1987	When ubenimex was administered to mice IL-1-releasing activity of the peritoneal macrophages was enhanced 3 and 5 days after the administration but not enhanced 1 day after the administration.	ubenimex	5-13	interleukin 1 complex	Mus musculus	39-43
3031000-4	1987	IL-1 administration induced significant (P less than 0.01) granulocytopenia compared with saline-injected controls and at 3 h induced significant increases in both mean alveolar septal wall granulocytes per high power field (HPF) (P less than 0.001) and mean myeloperoxidase (MPO) activity per gram lung tissue (P less than 0.001).	Sodium Chloride	90-96	interleukin 1 complex	Mus musculus	0-4
2950198-5	1987	However, when IL-1 was added at the onset of culture, the response to limiting doses of dendritic cells was increased 3- to 10-fold in several systems: the syngeneic and allogeneic MLR, Con A- and periodate-induced polyclonal mitogenesis, and T-dependent antibody formation against foreign red cells.	metaperiodate	197-206	interleukin 1 complex	Mus musculus	14-18
2965941-4	1987	In contrast, in the presence of silica only IL 1 is produced.	Silicon Dioxide	32-38	interleukin 1 complex	Mus musculus	44-48
2965941-7	1987	In every strain of mice studied, including nude mice, we observed a spontaneous release of MRF and a silica-induced shift to the secretion of IL 1, except in lipopolysaccharide (LPS)-hyporesponsive C3H/HeJ mice.	Silicon Dioxide	101-107	interleukin 1 complex	Mus musculus	142-146
3113689-1	1987	Conditioned medium from P388 D1 cell line containing interleukin 1 (IL-1) and granulocyte macrophage colony stimulating factor (GM-CSF) can stimulate prostaglandin E2 (PGE2) production by murine bone marrow cells.	Dinoprostone	150-166	interleukin 1 complex	Mus musculus	53-72
3113689-1	1987	Conditioned medium from P388 D1 cell line containing interleukin 1 (IL-1) and granulocyte macrophage colony stimulating factor (GM-CSF) can stimulate prostaglandin E2 (PGE2) production by murine bone marrow cells.	Dinoprostone	168-172	interleukin 1 complex	Mus musculus	53-72
3113689-4	1987	However, the simultaneous addition of IL-1 and GM-CSF markedly increases PGE2 production.	Dinoprostone	73-77	interleukin 1 complex	Mus musculus	38-42
3113689-5	1987	Thus, the ability of P388 D1 CM to stimulate PGE2 synthesis by bone marrow cells appears to result from a synergistic action between GM-CSF and IL-1.	Dinoprostone	45-49	interleukin 1 complex	Mus musculus	144-148
3497063-6	1987	Also, the actual ratio between neutrophilic and monocyte/macrophage colonies was reduced when compared to cultures stimulated in the presence of CSA, indicating that IL-1 increased myeloid differentiation.	Cyclosporine	145-148	interleukin 1 complex	Mus musculus	166-170
3497063-7	1987	In the presence of indomethacin, an effective inhibitor of prostaglandin synthesis (1 microgram/ml), greater numbers of CFU-GM were present with IL-1 and/or CSA than without indomethacin.	Indomethacin	19-31	interleukin 1 complex	Mus musculus	145-149
3497063-7	1987	In the presence of indomethacin, an effective inhibitor of prostaglandin synthesis (1 microgram/ml), greater numbers of CFU-GM were present with IL-1 and/or CSA than without indomethacin.	Prostaglandins	59-72	interleukin 1 complex	Mus musculus	145-149
3497063-8	1987	Cultures with anti-CSA demonstrated a reduced number of CFU-GM when plated in the presence of CSA but not with IL-1, demonstrating the specificity of IL-1 to stimulate CFU-GM in the presence of anti-CSA antibody.	Cyclosporine	19-22	interleukin 1 complex	Mus musculus	150-154
3497063-8	1987	Cultures with anti-CSA demonstrated a reduced number of CFU-GM when plated in the presence of CSA but not with IL-1, demonstrating the specificity of IL-1 to stimulate CFU-GM in the presence of anti-CSA antibody.	Cyclosporine	94-97	interleukin 1 complex	Mus musculus	150-154
3497063-8	1987	Cultures with anti-CSA demonstrated a reduced number of CFU-GM when plated in the presence of CSA but not with IL-1, demonstrating the specificity of IL-1 to stimulate CFU-GM in the presence of anti-CSA antibody.	Cyclosporine	94-97	interleukin 1 complex	Mus musculus	150-154
3497889-8	1987	This finding indicates that IL-1 could partially reverse or antagonize the suppressive effect of PGE2 on IL-2 production.	Dinoprostone	97-101	interleukin 1 complex	Mus musculus	28-32
3497889-10	1987	The addition of IL-1 to these cultured T cells neither altered the response of the culture T cells to IL-2 nor altered the sensitivity of these cells to PGE2.	Dinoprostone	153-157	interleukin 1 complex	Mus musculus	16-20
3502482-2	1987	IL-1 activity was evaluated by incorporation of [3H]-thymidine in mouse thymocytes in samples of 1:3 dilution.	Tritium	49-51	interleukin 1 complex	Mus musculus	0-4
3502482-2	1987	IL-1 activity was evaluated by incorporation of [3H]-thymidine in mouse thymocytes in samples of 1:3 dilution.	Thymidine	53-62	interleukin 1 complex	Mus musculus	0-4
3029093-3	1987	The activation signals provided by PHA and IL1 were replaced by the Ca2+ ionophore, ionomycin, and the phorbol ester, 12-O-tetradecanoylphorbol 13-acetate (TPA), respectively.	Tetradecanoylphorbol Acetate	156-159	interleukin 1 complex	Mus musculus	43-46
3029093-6	1987	Both signal 1-type mediators, PHA and ionomycin, exerted pleiotropic effects at the concentrations required for synergy with signal 2-type mediators (IL1, TPA).	Ionomycin	38-47	interleukin 1 complex	Mus musculus	150-153
3492923-2	1987	We studied the role of granulocytes and lactoferrin (LF) in endotoxin and murine interleukin 1 (IL-1)-induced depression of serum Fe and Zn concentrations in both rabbits and rats.	Iron	130-132	interleukin 1 complex	Mus musculus	81-100
3492923-2	1987	We studied the role of granulocytes and lactoferrin (LF) in endotoxin and murine interleukin 1 (IL-1)-induced depression of serum Fe and Zn concentrations in both rabbits and rats.	Zinc	137-139	interleukin 1 complex	Mus musculus	81-100
3497117-0	1987	Increased release of interleukin-1 from mouse peritoneal macrophages in vitro after cisplatin treatment.	Cisplatin	84-93	interleukin 1 complex	Mus musculus	21-34
3497117-2	1987	The supernatants collected from the untreated macrophage monolayers show a gradual ten fold increase in the interleukin-1 (IL-1) activity during 30 min to 48 h incubation at 37 degrees C. Supernatants collected from macrophage monolayers treated with 2 micrograms/ml of cis-platin show only a marginal increase in IL-1 activity as compared to untreated monolayers.	Cisplatin	270-280	interleukin 1 complex	Mus musculus	108-127
3497117-2	1987	The supernatants collected from the untreated macrophage monolayers show a gradual ten fold increase in the interleukin-1 (IL-1) activity during 30 min to 48 h incubation at 37 degrees C. Supernatants collected from macrophage monolayers treated with 2 micrograms/ml of cis-platin show only a marginal increase in IL-1 activity as compared to untreated monolayers.	Cisplatin	270-280	interleukin 1 complex	Mus musculus	123-127
3497117-3	1987	However, compared to controls, 30 to 40 fold increases in IL-1 activity were measured in supernatants collected from the macrophage monolayers incubated with 5, 10 and 20 micrograms/ml cis-platin at 37 degrees C. The IL-1 activity in supernatants collected from macrophage monolayers treated with cis platin and LPS are also compared.	Cisplatin	297-307	interleukin 1 complex	Mus musculus	58-62
3497889-5	1987	PGE2 at concentrations ranging from 0.1 to 5.0 ng/ml effectively inhibited or antagonized this enhancing effect of IL-1, with the majority of this IL-1 augmentation abrogated by 5.0 ng/ml PGE2.	Dinoprostone	0-4	interleukin 1 complex	Mus musculus	115-119
3497889-5	1987	PGE2 at concentrations ranging from 0.1 to 5.0 ng/ml effectively inhibited or antagonized this enhancing effect of IL-1, with the majority of this IL-1 augmentation abrogated by 5.0 ng/ml PGE2.	Dinoprostone	0-4	interleukin 1 complex	Mus musculus	147-151
3497889-5	1987	PGE2 at concentrations ranging from 0.1 to 5.0 ng/ml effectively inhibited or antagonized this enhancing effect of IL-1, with the majority of this IL-1 augmentation abrogated by 5.0 ng/ml PGE2.	Dinoprostone	188-192	interleukin 1 complex	Mus musculus	115-119
3497889-5	1987	PGE2 at concentrations ranging from 0.1 to 5.0 ng/ml effectively inhibited or antagonized this enhancing effect of IL-1, with the majority of this IL-1 augmentation abrogated by 5.0 ng/ml PGE2.	Dinoprostone	188-192	interleukin 1 complex	Mus musculus	147-151
3497889-7	1987	PGE2 was also found to markedly suppress the enhanced production of IL-2 resulting from the addition of IL-1 to Con A stimulated lymphocytes, however, the amount of IL-2 produced in the cultures containing both IL-1 and PGE2 was always greater than that produced in the cultures which contained only PGE2.	Dinoprostone	0-4	interleukin 1 complex	Mus musculus	104-108
3497889-7	1987	PGE2 was also found to markedly suppress the enhanced production of IL-2 resulting from the addition of IL-1 to Con A stimulated lymphocytes, however, the amount of IL-2 produced in the cultures containing both IL-1 and PGE2 was always greater than that produced in the cultures which contained only PGE2.	Dinoprostone	0-4	interleukin 1 complex	Mus musculus	211-215
3491626-4	1986	When the effect of Il-1 on the major metabolic pathways of the adipocyte was investigated, lipolysis as measured by glycerol release from the cells was markedly enhanced after a 17 h incubation with the hormone, while no effect was observed on de novo fatty acid synthesis.	Glycerol	116-124	interleukin 1 complex	Mus musculus	19-23
2824799-4	1987	In extending our studies to rats, we showed that increased ACTH and blood corticosterone levels are also induced by IL-1 in this species.	Corticosterone	74-88	interleukin 1 complex	Mus musculus	116-120
2824799-5	1987	Another in vivo activity of IL-1 relates to its capacity to induce a reduction in blood glucose levels.	Glucose	88-95	interleukin 1 complex	Mus musculus	28-32
2824799-12	1987	After 2 hr and for at least another 6 hr, glucose levels of alloxan-treated mice injected with IL-1 remained within the normal range.	Glucose	42-49	interleukin 1 complex	Mus musculus	95-99
3491626-4	1986	When the effect of Il-1 on the major metabolic pathways of the adipocyte was investigated, lipolysis as measured by glycerol release from the cells was markedly enhanced after a 17 h incubation with the hormone, while no effect was observed on de novo fatty acid synthesis.	Fatty Acids	252-262	interleukin 1 complex	Mus musculus	19-23
3100060-6	1986	Il-1 required the simultaneous presence of ionomycin and TPA to have any demonstrable effect on T lymphocytes from spleen and on thymocytes.	Ionomycin	43-52	interleukin 1 complex	Mus musculus	0-4
3100060-6	1986	Il-1 required the simultaneous presence of ionomycin and TPA to have any demonstrable effect on T lymphocytes from spleen and on thymocytes.	Tetradecanoylphorbol Acetate	57-60	interleukin 1 complex	Mus musculus	0-4
3100060-7	1986	However, on EL4 cells which were also partially responsive to TPA alone, Il-1 showed strong synergy with TPA to induce Il-2 secretion and Il-2 receptor expression.	Tetradecanoylphorbol Acetate	62-65	interleukin 1 complex	Mus musculus	73-77
3100060-8	1986	The effect of Il-1 on EL4 cells was dose dependent where increasingly higher concentrations of Il-1 in the presence of a fixed concentration of TPA caused higher percentage of EL4 cells to become Il-2 receptor positive.	Tetradecanoylphorbol Acetate	144-147	interleukin 1 complex	Mus musculus	14-18
3100060-8	1986	The effect of Il-1 on EL4 cells was dose dependent where increasingly higher concentrations of Il-1 in the presence of a fixed concentration of TPA caused higher percentage of EL4 cells to become Il-2 receptor positive.	Tetradecanoylphorbol Acetate	144-147	interleukin 1 complex	Mus musculus	95-99
3025091-3	1986	The administration of ACTH or glucocorticosteroids lacked most of these direct IL-1 inhibitory properties.	glucocorticosteroids	30-50	interleukin 1 complex	Mus musculus	79-83
2946770-7	1986	In the first, T cells, whose protein synthesizing capacity was completely eliminated by pretreatment with the irreversible protein synthesis inhibitor emetine, induced levels of mIL 1 expression indistinguishable from controls.	Emetine	151-158	interleukin 1 complex	Mus musculus	178-183
2946770-8	1986	In the second, T cells stimulated by paraformaldehyde-fixed macrophages in the presence of concanavalin A or antigen secreted a soluble factor that induced macrophage mIL 1 expression.	paraform	37-53	interleukin 1 complex	Mus musculus	167-172
3492202-5	1986	These results suggest that bone resorption induced by IL-1s is at least in part mediated by PGE2 produced by osteoblasts, and that M-CSA produced by osteoblasts may synergistically potentiate bone resorption by recruiting osteoclast precursors.	Dinoprostone	92-96	interleukin 1 complex	Mus musculus	54-58
3097240-1	1986	Exposure of mouse resident and thioglycollate-elicited peritoneal macrophages to IFN-gamma leads to a marked increase in the TNF-alpha (tumor necrosis factor/cachectin), IL-1 and u-PA (urokinase-type plasminogen activator) mRNA levels.	Thioglycolates	31-45	interleukin 1 complex	Mus musculus	170-174
3489761-3	1986	IL 1-induced production of prostaglandin E (PGE) by fibroblasts was also inhibited by alpha MSH with a biphasic dose response.	Prostaglandins E	27-42	interleukin 1 complex	Mus musculus	0-4
3492438-5	1986	Upon stimulation with bacterial lipopolysaccharides or silica, TAM showed a limited capacity to produce and release IL-1 activity compared to peritoneal macrophages.	tam	63-66	interleukin 1 complex	Mus musculus	116-120
3490433-7	1986	These results suggest that the synergistic effect of Con A and LPS or Bu-WSA on the proliferative response of HC-treated thymic cells is mainly due to the enhanced production of IL-2 and its action to increase cell growth, and there are two pathways by which the enhancement of IL-2 production by Con A and LPS or Bu-WSA can occur: an IL-1-dependent pathway, or an IL-1-independent one.	wsa	73-76	interleukin 1 complex	Mus musculus	335-339
3490433-7	1986	These results suggest that the synergistic effect of Con A and LPS or Bu-WSA on the proliferative response of HC-treated thymic cells is mainly due to the enhanced production of IL-2 and its action to increase cell growth, and there are two pathways by which the enhancement of IL-2 production by Con A and LPS or Bu-WSA can occur: an IL-1-dependent pathway, or an IL-1-independent one.	wsa	73-76	interleukin 1 complex	Mus musculus	365-369
3489761-3	1986	IL 1-induced production of prostaglandin E (PGE) by fibroblasts was also inhibited by alpha MSH with a biphasic dose response.	Prostaglandins E	44-47	interleukin 1 complex	Mus musculus	0-4
3091558-3	1986	The KHF which is present in PPD-CFS devoid of the activities of IL-1 or IL-2 was required in conjunction with IL-2 for generation of CTL in PNA+ thymocytes.	khf	4-7	interleukin 1 complex	Mus musculus	64-68
3023761-0	1986	Catecholamine-induced suppression of interleukin-1 production.	Catecholamines	0-13	interleukin 1 complex	Mus musculus	37-50
3023761-5	1986	Norepinephrine and epinephrine inhibited the capacity of gamma interferon and lipopolysaccharide to stimulate IL-1 production from mouse peritoneal macrophages.	Norepinephrine	0-14	interleukin 1 complex	Mus musculus	110-114
3023761-5	1986	Norepinephrine and epinephrine inhibited the capacity of gamma interferon and lipopolysaccharide to stimulate IL-1 production from mouse peritoneal macrophages.	Epinephrine	3-14	interleukin 1 complex	Mus musculus	110-114
3023761-6	1986	Moreover, when intracellular and extracellular levels of IL-1 were quantitated, the studies demonstrated a catecholamine-mediated block in IL-1 synthesis without effect on its release.	Catecholamines	107-120	interleukin 1 complex	Mus musculus	57-61
3023761-6	1986	Moreover, when intracellular and extracellular levels of IL-1 were quantitated, the studies demonstrated a catecholamine-mediated block in IL-1 synthesis without effect on its release.	Catecholamines	107-120	interleukin 1 complex	Mus musculus	139-143
3023761-7	1986	We also observed that exogenous cyclic AMP (cAMP) administered to mouse macrophages suppressed IL-1 production.	Cyclic AMP	32-42	interleukin 1 complex	Mus musculus	95-99
3023761-7	1986	We also observed that exogenous cyclic AMP (cAMP) administered to mouse macrophages suppressed IL-1 production.	Cyclic AMP	44-48	interleukin 1 complex	Mus musculus	95-99
3023761-8	1986	This, coupled with the capacity of norepinephrine and epinephrine to enhance intracellular cAMP levels in macrophages, strongly suggested that the catecholamine-induced suppression of IL-1 production may be mediated by elevated intracellular cAMP levels.	Norepinephrine	35-49	interleukin 1 complex	Mus musculus	184-188
3023761-8	1986	This, coupled with the capacity of norepinephrine and epinephrine to enhance intracellular cAMP levels in macrophages, strongly suggested that the catecholamine-induced suppression of IL-1 production may be mediated by elevated intracellular cAMP levels.	Epinephrine	38-49	interleukin 1 complex	Mus musculus	184-188
3023761-8	1986	This, coupled with the capacity of norepinephrine and epinephrine to enhance intracellular cAMP levels in macrophages, strongly suggested that the catecholamine-induced suppression of IL-1 production may be mediated by elevated intracellular cAMP levels.	Cyclic AMP	91-95	interleukin 1 complex	Mus musculus	184-188
3023761-8	1986	This, coupled with the capacity of norepinephrine and epinephrine to enhance intracellular cAMP levels in macrophages, strongly suggested that the catecholamine-induced suppression of IL-1 production may be mediated by elevated intracellular cAMP levels.	Catecholamines	147-160	interleukin 1 complex	Mus musculus	184-188
3023761-8	1986	This, coupled with the capacity of norepinephrine and epinephrine to enhance intracellular cAMP levels in macrophages, strongly suggested that the catecholamine-induced suppression of IL-1 production may be mediated by elevated intracellular cAMP levels.	Cyclic AMP	242-246	interleukin 1 complex	Mus musculus	184-188
3489286-7	1986	Supernatants obtained from the spleen cell cultures or the mixed cell cultures with T lymphocytes and M phi in the presence of Con A and Bu-WSA contained greater amounts of IL-1 and IL-2 than those from cultures containing Con A or Bu-WSA alone.	bu-wsa	137-143	interleukin 1 complex	Mus musculus	173-177
3487590-6	1986	In adrenalectomized mice, IL 1 (5 PU) treatment produced similar results in steroid binding (66% of control) and plasma glucose (71% of control).	Steroids	76-83	interleukin 1 complex	Mus musculus	26-30
3487590-6	1986	In adrenalectomized mice, IL 1 (5 PU) treatment produced similar results in steroid binding (66% of control) and plasma glucose (71% of control).	Glucose	120-127	interleukin 1 complex	Mus musculus	26-30
3487590-9	1986	IL 1 treatment inhibited the induction of PEPCK in fasted animals (13.4 +/- 2.0 U/mg) and caused a significant decrease in steroid binding (78% of fasted control) and plasma glucose (82% of fasted control).	Steroids	123-130	interleukin 1 complex	Mus musculus	0-4
3487590-9	1986	IL 1 treatment inhibited the induction of PEPCK in fasted animals (13.4 +/- 2.0 U/mg) and caused a significant decrease in steroid binding (78% of fasted control) and plasma glucose (82% of fasted control).	Glucose	174-181	interleukin 1 complex	Mus musculus	0-4
3487590-11	1986	These data indicate that IL 1 decreases intracellular steroid receptors, resulting in decreased induction of PEPCK and subsequent reduced gluconeogenesis and plasma glucose.	Glucose	165-172	interleukin 1 complex	Mus musculus	25-29
3487617-3	1986	When added to astroglia grown in culture, microglial IL-1 increased the cell number of five- to sevenfold, and increased astroglial incorporation of [3H]thymidine by three- to fivefold.	3h]thymidine	150-162	interleukin 1 complex	Mus musculus	53-57
2424900-3	1986	IL 1 production was inhibited by PGE2, the adenosine 3":5"-monophosphate analog dibutyryl cAMP, the cAMP agonist isoproterenol, and the phosphodiesterase inhibitor isobutylmethylxanthine.	Dinoprostone	33-37	interleukin 1 complex	Mus musculus	0-4
2424900-3	1986	IL 1 production was inhibited by PGE2, the adenosine 3":5"-monophosphate analog dibutyryl cAMP, the cAMP agonist isoproterenol, and the phosphodiesterase inhibitor isobutylmethylxanthine.	Cyclic AMP	43-72	interleukin 1 complex	Mus musculus	0-4
2424900-3	1986	IL 1 production was inhibited by PGE2, the adenosine 3":5"-monophosphate analog dibutyryl cAMP, the cAMP agonist isoproterenol, and the phosphodiesterase inhibitor isobutylmethylxanthine.	dibutyryl	80-89	interleukin 1 complex	Mus musculus	0-4
2424900-3	1986	IL 1 production was inhibited by PGE2, the adenosine 3":5"-monophosphate analog dibutyryl cAMP, the cAMP agonist isoproterenol, and the phosphodiesterase inhibitor isobutylmethylxanthine.	Cyclic AMP	90-94	interleukin 1 complex	Mus musculus	0-4
2424900-3	1986	IL 1 production was inhibited by PGE2, the adenosine 3":5"-monophosphate analog dibutyryl cAMP, the cAMP agonist isoproterenol, and the phosphodiesterase inhibitor isobutylmethylxanthine.	Cyclic AMP	100-104	interleukin 1 complex	Mus musculus	0-4
2424900-3	1986	IL 1 production was inhibited by PGE2, the adenosine 3":5"-monophosphate analog dibutyryl cAMP, the cAMP agonist isoproterenol, and the phosphodiesterase inhibitor isobutylmethylxanthine.	Isoproterenol	113-126	interleukin 1 complex	Mus musculus	0-4
2424900-3	1986	IL 1 production was inhibited by PGE2, the adenosine 3":5"-monophosphate analog dibutyryl cAMP, the cAMP agonist isoproterenol, and the phosphodiesterase inhibitor isobutylmethylxanthine.	1-Methyl-3-isobutylxanthine	164-186	interleukin 1 complex	Mus musculus	0-4
2424900-5	1986	Production of both the intracellular and extracellular forms of IL 1 was blocked by PGE2 and cAMP.	Dinoprostone	84-88	interleukin 1 complex	Mus musculus	64-68
2424900-5	1986	Production of both the intracellular and extracellular forms of IL 1 was blocked by PGE2 and cAMP.	Cyclic AMP	93-97	interleukin 1 complex	Mus musculus	64-68
2424900-6	1986	Suppression of LPS-induced IL 1 production by PGE2 was prevented by leukocyte alpha-interferon.	Dinoprostone	46-50	interleukin 1 complex	Mus musculus	27-31
2424900-9	1986	The lipoxygenase inhibitor eicosa-5,8,11,14-tetraynoic acid suppressed, whereas 3-amino-1-(3-trifluoromethylphenyl)-2-pyrazoline augmented, LPS-induced IL 1 production.	ETYA	27-59	interleukin 1 complex	Mus musculus	152-156
2944949-8	1986	The addition of IL 1 to cultures of DNBS-tolerant cells and glutaraldehyde fixed DNP-SC restored the ability of the Ts to release the synthesized factor.	2,4-dinitrofluorobenzene sulfonic acid	36-40	interleukin 1 complex	Mus musculus	16-20
3090144-5	1986	In the presence of either suboptimal levels of phorbol ester (PMA) or Ionomycin, the addition of IL 1 resulted in up to an 80-fold enhancement in the amount of IL 2 secreted.	Phorbol Esters	47-60	interleukin 1 complex	Mus musculus	97-101
3090144-5	1986	In the presence of either suboptimal levels of phorbol ester (PMA) or Ionomycin, the addition of IL 1 resulted in up to an 80-fold enhancement in the amount of IL 2 secreted.	Tetradecanoylphorbol Acetate	62-65	interleukin 1 complex	Mus musculus	97-101
3090144-5	1986	In the presence of either suboptimal levels of phorbol ester (PMA) or Ionomycin, the addition of IL 1 resulted in up to an 80-fold enhancement in the amount of IL 2 secreted.	Ionomycin	70-79	interleukin 1 complex	Mus musculus	97-101
2426952-13	1986	In contrast, bleomycin treatment caused a reduction in alveolar macrophage interleukin-1 (IL-1) production, and NDGA treatment did not alter this reduction, which suggests that MDGF is separate from IL-1 in this case, and that MDGF played a more dominant role, at least in this model of pulmonary fibrosis.	Bleomycin	13-22	interleukin 1 complex	Mus musculus	90-94
2424900-9	1986	The lipoxygenase inhibitor eicosa-5,8,11,14-tetraynoic acid suppressed, whereas 3-amino-1-(3-trifluoromethylphenyl)-2-pyrazoline augmented, LPS-induced IL 1 production.	4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine	80-128	interleukin 1 complex	Mus musculus	152-156
2424900-13	1986	Thus, net IL 1 production by macrophages may be regulated by a balance between the effects of PGE2, cAMP, alpha-interferon, and gamma-interferon, but not LTB4.	Dinoprostone	94-98	interleukin 1 complex	Mus musculus	10-14
2424900-13	1986	Thus, net IL 1 production by macrophages may be regulated by a balance between the effects of PGE2, cAMP, alpha-interferon, and gamma-interferon, but not LTB4.	Cyclic AMP	100-104	interleukin 1 complex	Mus musculus	10-14
3485687-2	1986	The purified IL 1 stimulated the proliferative response of the D10.G4.1 cell line, a mouse IL 1 indicator T cell; caused the release of prostaglandin E2 and prostacyclin from cultured human foreskin fibroblasts and from primary human umbilical vein endothelial cells; and elicited characteristic endogenous pyrogen fever in rabbits.	Dinoprostone	136-152	interleukin 1 complex	Mus musculus	13-17
3486936-2	1986	On a weight basis (1 microgram/kg) rTNF alpha and rIL-1 produce the same amount of fever and induce comparable levels of PGE2 in rabbit hypothalamic cells in vitro; like IL-1, TNF fever is blocked by drugs that inhibit cyclooxygenase.	Dinoprostone	121-125	interleukin 1 complex	Mus musculus	51-55
3486936-12	1986	These studies show that TNF (cachectin) is another endogenous pyrogen which, like IL-1 and IFN-alpha, directly stimulate hypothalamic PGE2 synthesis.	Dinoprostone	134-138	interleukin 1 complex	Mus musculus	82-86
3084639-5	1986	This study shows that normal human PMN can be stimulated by particulate agents such as zymosan and soluble agents such as phorbol myristic acetate to produce a factor(s) which induces proliferation of mouse thymocytes, i.e., PMN IL 1.	phorbol myristic acetate	122-146	interleukin 1 complex	Mus musculus	229-233
3084468-0	1986	Effect of interleukin-1 on intracellular concentration of sodium, calcium, and potassium in 70Z/3 cells.	Sodium	58-64	interleukin 1 complex	Mus musculus	10-23
3084468-0	1986	Effect of interleukin-1 on intracellular concentration of sodium, calcium, and potassium in 70Z/3 cells.	Potassium	79-88	interleukin 1 complex	Mus musculus	10-23
3084468-2	1986	An early intracellular event caused by exposure to IL-1 is an amiloride-sensitive progressive rise in the total concentration of intracellular sodium ([Na]i), caused by influx of Na+ from outside, and a transient fall in total intracellular calcium.	Amiloride	62-71	interleukin 1 complex	Mus musculus	51-55
3084468-2	1986	An early intracellular event caused by exposure to IL-1 is an amiloride-sensitive progressive rise in the total concentration of intracellular sodium ([Na]i), caused by influx of Na+ from outside, and a transient fall in total intracellular calcium.	Sodium	143-149	interleukin 1 complex	Mus musculus	51-55
3084468-2	1986	An early intracellular event caused by exposure to IL-1 is an amiloride-sensitive progressive rise in the total concentration of intracellular sodium ([Na]i), caused by influx of Na+ from outside, and a transient fall in total intracellular calcium.	Calcium	241-248	interleukin 1 complex	Mus musculus	51-55
3084468-4	1986	IL-1-induced differentiation is also blocked by amiloride suggesting that stimulation of Na+/H+ exchange may play a role in IL-1-induced differentiation.	Amiloride	48-57	interleukin 1 complex	Mus musculus	0-4
3084468-4	1986	IL-1-induced differentiation is also blocked by amiloride suggesting that stimulation of Na+/H+ exchange may play a role in IL-1-induced differentiation.	Amiloride	48-57	interleukin 1 complex	Mus musculus	124-128
3485687-2	1986	The purified IL 1 stimulated the proliferative response of the D10.G4.1 cell line, a mouse IL 1 indicator T cell; caused the release of prostaglandin E2 and prostacyclin from cultured human foreskin fibroblasts and from primary human umbilical vein endothelial cells; and elicited characteristic endogenous pyrogen fever in rabbits.	Epoprostenol	157-169	interleukin 1 complex	Mus musculus	13-17
3934287-1	1985	A simple and reliable biological assay for interleukin-1 (IL-1) was developed, based on the production of interleukin-2 (IL-2) from the EL-4 murine T-cell lymphoma cell line, in the presence of 2-5 X 10(-7) M calcium ionophore A23187.	Calcium	209-216	interleukin 1 complex	Mus musculus	43-62
3083809-1	1986	Both lipopolysaccharide (LPS) and phorbol-12,13-dibutyrate (PDBu), a protein kinase C-activating phorbol ester, induced interleukin-1 (IL-1) production in mouse peritoneal macrophages.	Phorbol 12,13-Dibutyrate	34-58	interleukin 1 complex	Mus musculus	120-133
3083809-1	1986	Both lipopolysaccharide (LPS) and phorbol-12,13-dibutyrate (PDBu), a protein kinase C-activating phorbol ester, induced interleukin-1 (IL-1) production in mouse peritoneal macrophages.	Phorbol 12,13-Dibutyrate	34-58	interleukin 1 complex	Mus musculus	135-139
3083809-1	1986	Both lipopolysaccharide (LPS) and phorbol-12,13-dibutyrate (PDBu), a protein kinase C-activating phorbol ester, induced interleukin-1 (IL-1) production in mouse peritoneal macrophages.	Phorbol 12,13-Dibutyrate	60-64	interleukin 1 complex	Mus musculus	120-133
3083809-1	1986	Both lipopolysaccharide (LPS) and phorbol-12,13-dibutyrate (PDBu), a protein kinase C-activating phorbol ester, induced interleukin-1 (IL-1) production in mouse peritoneal macrophages.	Phorbol 12,13-Dibutyrate	60-64	interleukin 1 complex	Mus musculus	135-139
3083809-1	1986	Both lipopolysaccharide (LPS) and phorbol-12,13-dibutyrate (PDBu), a protein kinase C-activating phorbol ester, induced interleukin-1 (IL-1) production in mouse peritoneal macrophages.	Phorbol Esters	97-110	interleukin 1 complex	Mus musculus	120-133
3083809-1	1986	Both lipopolysaccharide (LPS) and phorbol-12,13-dibutyrate (PDBu), a protein kinase C-activating phorbol ester, induced interleukin-1 (IL-1) production in mouse peritoneal macrophages.	Phorbol Esters	97-110	interleukin 1 complex	Mus musculus	135-139
3079793-0	1986	Activation of IL 1-dependent and IL 1-independent T cell lines by calcium ionophore and phorbol ester.	Calcium	66-73	interleukin 1 complex	Mus musculus	14-18
3079793-0	1986	Activation of IL 1-dependent and IL 1-independent T cell lines by calcium ionophore and phorbol ester.	Calcium	66-73	interleukin 1 complex	Mus musculus	33-37
3079793-0	1986	Activation of IL 1-dependent and IL 1-independent T cell lines by calcium ionophore and phorbol ester.	Phorbol Esters	88-101	interleukin 1 complex	Mus musculus	14-18
3079793-0	1986	Activation of IL 1-dependent and IL 1-independent T cell lines by calcium ionophore and phorbol ester.	Phorbol Esters	88-101	interleukin 1 complex	Mus musculus	33-37
3079793-6	1986	In the case of the IL 1-dependent line LBRM33-1A5.47, there was a strong response when both A23187 and PMA were used simultaneously.	Calcimycin	92-98	interleukin 1 complex	Mus musculus	19-23
3079793-8	1986	These observations suggest that the signal(s) provided by PHA and IL 1 involve at least in part a calcium flux, and activation of protein kinase C. Parallel experiments with the use of the IL 1-independent T cell lines showed a strong response to both agents when used simultaneously.	Calcium	98-105	interleukin 1 complex	Mus musculus	66-70
3079793-8	1986	These observations suggest that the signal(s) provided by PHA and IL 1 involve at least in part a calcium flux, and activation of protein kinase C. Parallel experiments with the use of the IL 1-independent T cell lines showed a strong response to both agents when used simultaneously.	Calcium	98-105	interleukin 1 complex	Mus musculus	189-193
3079793-12	1986	We suggest that the activating signals provided by A23187 and PMA are at least part of the sequence of events that lead to production of IL 2 in either IL 1-dependent or IL 1-independent T cell lines.	Calcimycin	51-57	interleukin 1 complex	Mus musculus	152-156
3079793-12	1986	We suggest that the activating signals provided by A23187 and PMA are at least part of the sequence of events that lead to production of IL 2 in either IL 1-dependent or IL 1-independent T cell lines.	Calcimycin	51-57	interleukin 1 complex	Mus musculus	170-174
3488279-0	1986	Modulation of interleukin-1 production by macrophages following benzo(a)pyrene exposure.	Benzo(a)pyrene	64-78	interleukin 1 complex	Mus musculus	14-27
3488279-1	1986	The effects of benzo(a)pyrene (BaP), a highly prevalent environmental carcinogen, on the ability of peritoneal exudate macrophages to produce the secretory immunomodulatory molecule interleukin-1 (IL-1) in vitro was examined.	Benzo(a)pyrene	15-29	interleukin 1 complex	Mus musculus	182-201
3488279-1	1986	The effects of benzo(a)pyrene (BaP), a highly prevalent environmental carcinogen, on the ability of peritoneal exudate macrophages to produce the secretory immunomodulatory molecule interleukin-1 (IL-1) in vitro was examined.	Benzo(a)pyrene	31-34	interleukin 1 complex	Mus musculus	182-201
3488279-2	1986	A dose-dependent increase in lipopolysaccharide stimulated IL-1 production concomitant with decreased cell viabilities was noted in macrophages cultured in the presence of BaP.	Benzo(a)pyrene	172-175	interleukin 1 complex	Mus musculus	59-63
3488279-3	1986	Antibody responses which are suppressed in BaP dosed mice can be reconstituted in vitro by the addition of exogenous interleukin-1.	Benzo(a)pyrene	43-46	interleukin 1 complex	Mus musculus	117-130
3488279-5	1986	Furthermore, BaP induced suppression of antibody responsiveness may be a result of alterations in production of IL-1.	Benzo(a)pyrene	13-16	interleukin 1 complex	Mus musculus	112-116
3002965-1	1985	We investigated the effect of vitamin D3 metabolites on the release of the three interleukins (IL) IL 1, IL 2 and IL 3 by mononuclear cells.	Cholecalciferol	30-40	interleukin 1 complex	Mus musculus	99-103
3002965-3	1985	IL 1 production was significantly increased with 1 alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3) at 10(-10)M and above.	1 alpha,25-dihydroxyvitamin d3 (1,25(oh)2d3	49-92	interleukin 1 complex	Mus musculus	0-4
3002965-7	1985	The minimal effective dose varied between experiments and ranged from 10(-11) to 10(-8) M. Moreover, proliferation (3H-TdR incorporation) of mouse thymocytes treated with phytohemagglutinin and IL 1 was decreased in a dose-dependent fashion by 1,25(OH)2D3 starting at 10-11) M. This effect might be secondary to a decrease of endogenous IL 2 production.	Tritium	116-118	interleukin 1 complex	Mus musculus	194-198
3002965-7	1985	The minimal effective dose varied between experiments and ranged from 10(-11) to 10(-8) M. Moreover, proliferation (3H-TdR incorporation) of mouse thymocytes treated with phytohemagglutinin and IL 1 was decreased in a dose-dependent fashion by 1,25(OH)2D3 starting at 10-11) M. This effect might be secondary to a decrease of endogenous IL 2 production.	25(oh)2d3	246-255	interleukin 1 complex	Mus musculus	194-198
3878827-1	1985	4 beta-phorbol 12-myristate 13-acetate (PMA), a potent tumor promoter, was found to have a dual effect on interleukin 1-(IL 1) stimulated murine thymocyte cultures.	Tetradecanoylphorbol Acetate	0-38	interleukin 1 complex	Mus musculus	121-125
3878827-1	1985	4 beta-phorbol 12-myristate 13-acetate (PMA), a potent tumor promoter, was found to have a dual effect on interleukin 1-(IL 1) stimulated murine thymocyte cultures.	Tetradecanoylphorbol Acetate	40-43	interleukin 1 complex	Mus musculus	121-125
3878827-6	1985	On the other hand, the stimulatory effect of PMA on cultures activated with IL 1 in the presence of 2-ME took place mainly during the last 24 h of the 72-h culture period.	Mercaptoethanol	100-104	interleukin 1 complex	Mus musculus	76-80
2936823-10	1986	The finding that IL 1 enhanced T cell responses to PFA-treated or UV-irradiated TD-DC in the absence and in the presence of excess IL 2 indicates that loss of stimulatory activity of TD-DC may be due in part to loss or inactivation of IL 1.	paraform	51-54	interleukin 1 complex	Mus musculus	17-21
3484685-0	1986	Stimulation of fibroblast proliferation and prostaglandin production by purified recombinant murine interleukin 1.	Prostaglandins	44-57	interleukin 1 complex	Mus musculus	100-113
3484685-2	1986	The purified recombinant IL-1 exhibited a pI of approximately 5.2 and a sp act of 6 X 10(6) units/mg.	TFF2 protein, human	72-74	interleukin 1 complex	Mus musculus	25-29
3484685-5	1986	In addition, IL-1 stimulated fibroblast PGE2 5- to 30-fold over a 24-hr period.	Dinoprostone	40-44	interleukin 1 complex	Mus musculus	13-17
3485562-3	1986	Macrophages in cefodizime-treated mice showed enhanced activity (chemiluminescence, IL-1-synthesis, IFN-synthesis).	cefodizime	15-25	interleukin 1 complex	Mus musculus	84-88
3001212-0	1986	Release of interleukin-1 (IL-1) and IL-1-like factors from rabbit macrophages with silica.	Silicon Dioxide	83-89	interleukin 1 complex	Mus musculus	26-30
3001212-0	1986	Release of interleukin-1 (IL-1) and IL-1-like factors from rabbit macrophages with silica.	Silicon Dioxide	83-89	interleukin 1 complex	Mus musculus	36-40
3001212-1	1986	Oil-elicited rabbit macrophages stimulated by endotoxin were found to release increased amounts of interleukin 1 (IL-1) when incubated with silica.	Oils	0-3	interleukin 1 complex	Mus musculus	114-118
3001212-1	1986	Oil-elicited rabbit macrophages stimulated by endotoxin were found to release increased amounts of interleukin 1 (IL-1) when incubated with silica.	Silicon Dioxide	140-146	interleukin 1 complex	Mus musculus	114-118
3001212-2	1986	The assays used to determine the amount of IL-1 released were uptake of thymidine by mouse thymocytes, fever in rabbits, and neutrophilia in rats.	Thymidine	72-81	interleukin 1 complex	Mus musculus	43-47
3001212-3	1986	All three assays showed that endotoxin-stimulated macrophages released five to 10 times more IL-1 when incubated with silica.	Silicon Dioxide	118-124	interleukin 1 complex	Mus musculus	93-97
3079606-0	1986	Prostaglandins as endogenous mediators of interleukin 1 production.	Prostaglandins	0-14	interleukin 1 complex	Mus musculus	42-55
3079606-1	1986	We examined the role of cyclooxygenase (CO)-derived metabolites of arachidonic acid (AA) in the regulation of interleukin 1 (IL 1) production by lipopolysaccharide (LPS)-stimulated murine resident peritoneal macrophages.	Arachidonic Acid	67-83	interleukin 1 complex	Mus musculus	110-129
3079606-4	1986	The addition of exogenous PGE2 or PGI2 resulted in a dose-dependent suppression of macrophage IL 1 production.	Dinoprostone	26-30	interleukin 1 complex	Mus musculus	94-98
3079606-4	1986	The addition of exogenous PGE2 or PGI2 resulted in a dose-dependent suppression of macrophage IL 1 production.	Epoprostenol	34-38	interleukin 1 complex	Mus musculus	94-98
3079606-5	1986	Inhibitors of the CO pathway (indomethacin, piroxicam, and ibuprofen) caused a dose-dependent augmentation in the LPS-induced IL 1 response.	Indomethacin	30-42	interleukin 1 complex	Mus musculus	126-130
3079606-5	1986	Inhibitors of the CO pathway (indomethacin, piroxicam, and ibuprofen) caused a dose-dependent augmentation in the LPS-induced IL 1 response.	Piroxicam	44-53	interleukin 1 complex	Mus musculus	126-130
3079606-5	1986	Inhibitors of the CO pathway (indomethacin, piroxicam, and ibuprofen) caused a dose-dependent augmentation in the LPS-induced IL 1 response.	Ibuprofen	59-68	interleukin 1 complex	Mus musculus	126-130
3079606-8	1986	The addition of exogenous IL 1 to macrophage cultures caused an increase in the levels of PGE2, over a narrow dose range (0.05 to 0.6 IL 1 units).	Dinoprostone	90-94	interleukin 1 complex	Mus musculus	26-30
3079606-8	1986	The addition of exogenous IL 1 to macrophage cultures caused an increase in the levels of PGE2, over a narrow dose range (0.05 to 0.6 IL 1 units).	Dinoprostone	90-94	interleukin 1 complex	Mus musculus	134-138
3079606-10	1986	In addition, our data support the concept that IL 1, as with classical hormones, can regulate its own production through a self-induced inhibitor, PGE2.	Dinoprostone	147-151	interleukin 1 complex	Mus musculus	47-51
3879808-2	1985	Physiological concentrations of 1,25(OH)2D3 inhibited thymocyte proliferation induced by IL-1 and IL-2 in similar fashion suggesting an inhibition of the response to IL-2 by this hormone.	Calcitriol	32-43	interleukin 1 complex	Mus musculus	89-93
3879808-3	1985	In addition, cortisone-resistant thymocytes (including a majority of medullary thymocytes), which proliferate more vigorously in response to IL-1 than do untreated thymocytes, were more sensitive to 1,25(OH)2D3 inhibition.	Cortisone	13-22	interleukin 1 complex	Mus musculus	141-145
3930604-1	1985	Recombinant murine IL 1 stimulated arachidonic acid metabolism by rat liver cells (the C-9 cell line) and squirrel monkey smooth muscle cells, and in the presence of tumor promoters this stimulation was synergistic.	Arachidonic Acid	35-51	interleukin 1 complex	Mus musculus	19-23
3930604-2	1985	In the rat liver cells that had been prelabeled with [3H]arachidonic acid, the release of 6-keto-PGF1 alpha and arachidonic acid also was stimulated by the IL 1, and this release was synergistic in the presence of TPA.	[3h]arachidonic acid	53-73	interleukin 1 complex	Mus musculus	156-160
3930604-2	1985	In the rat liver cells that had been prelabeled with [3H]arachidonic acid, the release of 6-keto-PGF1 alpha and arachidonic acid also was stimulated by the IL 1, and this release was synergistic in the presence of TPA.	6-Ketoprostaglandin F1 alpha	90-107	interleukin 1 complex	Mus musculus	156-160
3930604-2	1985	In the rat liver cells that had been prelabeled with [3H]arachidonic acid, the release of 6-keto-PGF1 alpha and arachidonic acid also was stimulated by the IL 1, and this release was synergistic in the presence of TPA.	Arachidonic Acid	57-73	interleukin 1 complex	Mus musculus	156-160
3930604-2	1985	In the rat liver cells that had been prelabeled with [3H]arachidonic acid, the release of 6-keto-PGF1 alpha and arachidonic acid also was stimulated by the IL 1, and this release was synergistic in the presence of TPA.	Tetradecanoylphorbol Acetate	214-217	interleukin 1 complex	Mus musculus	156-160
3930604-3	1985	1-Oleoyl-2-acetyl-glycerol (OAG) stimulated prostaglandin production, and IL 1 synergized the prostaglandin production in the presence of OAG.	Prostaglandins	94-107	interleukin 1 complex	Mus musculus	74-78
3930604-3	1985	1-Oleoyl-2-acetyl-glycerol (OAG) stimulated prostaglandin production, and IL 1 synergized the prostaglandin production in the presence of OAG.	1-oleoyl-2-acetylglycerol	138-141	interleukin 1 complex	Mus musculus	74-78
3930604-4	1985	OAG and TPA mimic the endogenous activator of protein kinase C, 1,2-diacylglycerol, and therefore IL 1 may amplify arachidonic acid metabolism during signal transmission processes.	1-oleoyl-2-acetylglycerol	0-3	interleukin 1 complex	Mus musculus	98-102
3930604-4	1985	OAG and TPA mimic the endogenous activator of protein kinase C, 1,2-diacylglycerol, and therefore IL 1 may amplify arachidonic acid metabolism during signal transmission processes.	Arachidonic Acid	115-131	interleukin 1 complex	Mus musculus	98-102
3934287-1	1985	A simple and reliable biological assay for interleukin-1 (IL-1) was developed, based on the production of interleukin-2 (IL-2) from the EL-4 murine T-cell lymphoma cell line, in the presence of 2-5 X 10(-7) M calcium ionophore A23187.	Calcimycin	227-233	interleukin 1 complex	Mus musculus	43-62
3160805-7	1985	Treatment of surface-bound 125I-IL-1 with bivalent water-soluble crosslinkers identified a membrane polypeptide of Mr 79,500 to which IL-1 is crosslinked.	Water	51-56	interleukin 1 complex	Mus musculus	32-36
3876285-5	1985	However, the IL-1 production induced by B-LPS (10 micrograms/ml) in C3H/HeN macrophages was four times lower compared with that induced by Escherichia coli O111 B4 LPS.	b-lps	40-45	interleukin 1 complex	Mus musculus	13-17
3876285-7	1985	That B-LPS-induced IL-1 exhibits some molecular weight heterogeneity was indicated from Sephadex G-75 gel filtration profiles.	sephadex	88-101	interleukin 1 complex	Mus musculus	19-23
3931632-5	1985	Retinoic acid stimulated IL 1 release by P388D1 cells in a dose-related fashion, starting at 10(-9) M and maximally at 10(-8)-10(-6) M. With peripheral blood mononuclear cells a maximal stimulation of IL 1 release was observed with 10(-7) M-retinoic acid.	Tretinoin	0-13	interleukin 1 complex	Mus musculus	25-29
3931632-5	1985	Retinoic acid stimulated IL 1 release by P388D1 cells in a dose-related fashion, starting at 10(-9) M and maximally at 10(-8)-10(-6) M. With peripheral blood mononuclear cells a maximal stimulation of IL 1 release was observed with 10(-7) M-retinoic acid.	Tretinoin	0-13	interleukin 1 complex	Mus musculus	201-205
3931632-5	1985	Retinoic acid stimulated IL 1 release by P388D1 cells in a dose-related fashion, starting at 10(-9) M and maximally at 10(-8)-10(-6) M. With peripheral blood mononuclear cells a maximal stimulation of IL 1 release was observed with 10(-7) M-retinoic acid.	Tretinoin	241-254	interleukin 1 complex	Mus musculus	25-29
3931632-8	1985	These results show that retinoic acid, in physiological concentrations, exerts selective effects on interleukin production in vitro, and this stimulation of IL 1 and IL 3 release may explain some of the immunostimulatory effects of retinoids in vivo.	Tretinoin	24-37	interleukin 1 complex	Mus musculus	157-178
3931632-8	1985	These results show that retinoic acid, in physiological concentrations, exerts selective effects on interleukin production in vitro, and this stimulation of IL 1 and IL 3 release may explain some of the immunostimulatory effects of retinoids in vivo.	Retinoids	232-241	interleukin 1 complex	Mus musculus	157-178
3931632-9	1985	Moreover, since IL 1 is known to influence connective tissues and bone, an increase in IL 1 might also explain some of the changes observed in these tissues in vitamin A poisoning and with high-dose retinoid therapy.	Vitamin A	160-169	interleukin 1 complex	Mus musculus	16-20
3931632-9	1985	Moreover, since IL 1 is known to influence connective tissues and bone, an increase in IL 1 might also explain some of the changes observed in these tissues in vitamin A poisoning and with high-dose retinoid therapy.	Vitamin A	160-169	interleukin 1 complex	Mus musculus	87-91
3931632-9	1985	Moreover, since IL 1 is known to influence connective tissues and bone, an increase in IL 1 might also explain some of the changes observed in these tissues in vitamin A poisoning and with high-dose retinoid therapy.	Retinoids	199-207	interleukin 1 complex	Mus musculus	87-91
3932286-3	1985	C3H/HeN mice were inoculated intradermally with viable syngeneic X5563 tumor cells, followed by five consecutive subcutaneous or intraperitoneal inoculations of IL 1-containing CFS.	thallium sulfate	177-180	interleukin 1 complex	Mus musculus	161-165
2989361-0	1985	Sodium periodate-induced T cell mitogenesis: an analysis of the requirement for Ia and IL 1.	metaperiodate	0-16	interleukin 1 complex	Mus musculus	87-91
2989361-8	1985	Exogenous IL 1 alone was able to trigger periodate-treated T cells, suggesting that Ia was required for the induction of IL 1 synthesis by the accessory cells.	metaperiodate	41-50	interleukin 1 complex	Mus musculus	10-14
2989361-10	1985	These data suggest that periodate-treated T cells can proliferate with IL 1 alone and that Ia+ accessory cells in periodate-mediated T cell mitogenicity may function in the release of IL 1 and the induction of IL 2 synthesis by the T cells.	metaperiodate	24-33	interleukin 1 complex	Mus musculus	71-75
2989361-10	1985	These data suggest that periodate-treated T cells can proliferate with IL 1 alone and that Ia+ accessory cells in periodate-mediated T cell mitogenicity may function in the release of IL 1 and the induction of IL 2 synthesis by the T cells.	metaperiodate	24-33	interleukin 1 complex	Mus musculus	184-188
2989361-10	1985	These data suggest that periodate-treated T cells can proliferate with IL 1 alone and that Ia+ accessory cells in periodate-mediated T cell mitogenicity may function in the release of IL 1 and the induction of IL 2 synthesis by the T cells.	metaperiodate	114-123	interleukin 1 complex	Mus musculus	184-188
3913786-6	1985	Recent advances in immunological studies have demonstrated that silica stimulates macrophages to release monokines such as interleukin 1 (IL-1) and that IL-1 has chemical properties identical to the fibrogenic factor, which enhances the level of collagen production by modulating the proliferation of fibroblasts.	Silicon Dioxide	64-70	interleukin 1 complex	Mus musculus	123-142
3913786-6	1985	Recent advances in immunological studies have demonstrated that silica stimulates macrophages to release monokines such as interleukin 1 (IL-1) and that IL-1 has chemical properties identical to the fibrogenic factor, which enhances the level of collagen production by modulating the proliferation of fibroblasts.	Silicon Dioxide	64-70	interleukin 1 complex	Mus musculus	138-142
3160805-7	1985	Treatment of surface-bound 125I-IL-1 with bivalent water-soluble crosslinkers identified a membrane polypeptide of Mr 79,500 to which IL-1 is crosslinked.	Water	51-56	interleukin 1 complex	Mus musculus	134-138
3911147-9	1985	Effects of cefoxitin and cefotaxime on IL-1 production and--as shown in previous studies--on prostaglandin E2 (PGE2) production and sensitivity of immunocompetent cells to PGE2 may be important factors in the mechanism of immunological side effects which result in a modulation of the course of experimental infection.	Cefotaxime	25-35	interleukin 1 complex	Mus musculus	39-43
3874817-6	1985	The results revealed that (i) IL-1 production by cells of old BALB/c and C57BL/6 mice is reduced to about 40% and 30% that of young mice, respectively; (ii) indomethacin enhances IL-1 production by cells of both young and old mice to the same extent; and (iii) reduction in the IL-1 producing capacity by cells of old mice results from altered activities of both the IL-1 producing peritoneal macrophages and the augmenting T cells.	Indomethacin	157-169	interleukin 1 complex	Mus musculus	30-34
3874817-6	1985	The results revealed that (i) IL-1 production by cells of old BALB/c and C57BL/6 mice is reduced to about 40% and 30% that of young mice, respectively; (ii) indomethacin enhances IL-1 production by cells of both young and old mice to the same extent; and (iii) reduction in the IL-1 producing capacity by cells of old mice results from altered activities of both the IL-1 producing peritoneal macrophages and the augmenting T cells.	Indomethacin	157-169	interleukin 1 complex	Mus musculus	179-183
3874817-6	1985	The results revealed that (i) IL-1 production by cells of old BALB/c and C57BL/6 mice is reduced to about 40% and 30% that of young mice, respectively; (ii) indomethacin enhances IL-1 production by cells of both young and old mice to the same extent; and (iii) reduction in the IL-1 producing capacity by cells of old mice results from altered activities of both the IL-1 producing peritoneal macrophages and the augmenting T cells.	Indomethacin	157-169	interleukin 1 complex	Mus musculus	179-183
3874817-6	1985	The results revealed that (i) IL-1 production by cells of old BALB/c and C57BL/6 mice is reduced to about 40% and 30% that of young mice, respectively; (ii) indomethacin enhances IL-1 production by cells of both young and old mice to the same extent; and (iii) reduction in the IL-1 producing capacity by cells of old mice results from altered activities of both the IL-1 producing peritoneal macrophages and the augmenting T cells.	Indomethacin	157-169	interleukin 1 complex	Mus musculus	179-183
3911147-1	1985	Influence of cefoxitin and cefotaxime on interleukin-1 production (IL-1) by mice peritoneal resident macrophages activated by opsonized zymosan was investigated.	Zymosan	136-143	interleukin 1 complex	Mus musculus	67-71
3911147-6	1985	Cefoxitin in a concentration of 300 micrograms/ml induced a threefold increase in IL-1 production.	Cefoxitin	0-9	interleukin 1 complex	Mus musculus	82-86
3873733-7	1985	The possibility that CsA actually affects interleukin-1 (IL-1) production by macrophages by inhibiting uninvolved T cells could be ruled out.	Cyclosporine	21-24	interleukin 1 complex	Mus musculus	42-55
3911147-7	1985	IL-1 production was increased tenfold and eightfold respectively by 150 and 300 micrograms/ml cefotaxime.	Cefotaxime	94-104	interleukin 1 complex	Mus musculus	0-4
3873733-7	1985	The possibility that CsA actually affects interleukin-1 (IL-1) production by macrophages by inhibiting uninvolved T cells could be ruled out.	Cyclosporine	21-24	interleukin 1 complex	Mus musculus	57-61
3875934-3	1985	We suspected that the low apparent temperature optimum for IL-1 action was due to inadequate pH control by the bicarbonate-buffered medium.	Bicarbonates	111-122	interleukin 1 complex	Mus musculus	59-63
3926280-1	1985	The effect of parathormone (PTH), lipopolysaccharide (LPS), or interleukin-1 (IL-1) on calcium release and collagen degradation in bone was examined in vitro using labeled neonatal calvaria of normal mice and also of osteopetrotic microphthalmic (mi/mi) mice that have defective osteoclasts.	Calcium	87-94	interleukin 1 complex	Mus musculus	63-82
3926280-1	1985	The effect of parathormone (PTH), lipopolysaccharide (LPS), or interleukin-1 (IL-1) on calcium release and collagen degradation in bone was examined in vitro using labeled neonatal calvaria of normal mice and also of osteopetrotic microphthalmic (mi/mi) mice that have defective osteoclasts.	2-methyl-4-isothiazolin-3-one	143-145	interleukin 1 complex	Mus musculus	63-82
3006732-2	1985	Since interleukin 1 (IL-1)-like activity has been shown to stimulate bone resorption in vitro, we have studied whether bisphosphonates inhibit either the production of IL-1-like activity or its effect on one type of connective tissue cell, chondrocytes.	Diphosphonates	119-134	interleukin 1 complex	Mus musculus	168-172
3871468-1	1985	The ability of steroids to modulate the appearance of Interleukin-1(IL-1) in vivo was evaluated in a model of endotoxin shock.	Steroids	15-23	interleukin 1 complex	Mus musculus	68-72
3871468-6	1985	1</protein-id>) The reduced activity was not due to the presence of proliferation inhibitors since mixing the serum from dexamethasone-treated mice with purified IL-1 or adding the equivalent amount of steroid directly to thymocyte cultures did not reduce the degree of proliferation.	Dexamethasone	121-134	interleukin 1 complex	Mus musculus	162-166
3006732-4	1985	Production of IL-1-like activity was unaffected by bisphosphonates, whereas the effect of IL-1-like activity on collagenase and prostaglandin E2 secretion by rabbit chondrocytes was increased rather than inhibited by bisphosphonates.	Dinoprostone	128-144	interleukin 1 complex	Mus musculus	90-94
3006732-4	1985	Production of IL-1-like activity was unaffected by bisphosphonates, whereas the effect of IL-1-like activity on collagenase and prostaglandin E2 secretion by rabbit chondrocytes was increased rather than inhibited by bisphosphonates.	Diphosphonates	217-232	interleukin 1 complex	Mus musculus	90-94
3006732-5	1985	Finally, bisphosphonates increased DNA and cell number in chondrocyte cultures, but this effect was blocked when IL-1-like activity was added to the cultures.	Diphosphonates	9-24	interleukin 1 complex	Mus musculus	113-117
3874175-5	1985	OK-432-induced IL-1 was consisted of three molecular weight species (two major peaks: 85 K and 15 K daltons and one minor peak: 67 K daltons) on Sephadex G-100 chromatography.	sephadex	145-159	interleukin 1 complex	Mus musculus	15-19
3876299-4	1985	The resistance to CsA of the mitogenic activity of IL-1 was unexpected since this response is assumed to be mediated by newly formed IL-2 and CsA inhibits IL-2 production.	Cyclosporine	18-21	interleukin 1 complex	Mus musculus	51-55
3876299-4	1985	The resistance to CsA of the mitogenic activity of IL-1 was unexpected since this response is assumed to be mediated by newly formed IL-2 and CsA inhibits IL-2 production.	Cyclosporine	142-145	interleukin 1 complex	Mus musculus	51-55
3876299-10	1985	Yet, this partial protection by IL-1 was achieved only at CsA concentrations about 100 fold lower than those resisted by thymocytes directly stimulated by IL-1.	Cyclosporine	58-61	interleukin 1 complex	Mus musculus	32-36
6334740-3	1984	In a macrophage model, colchicine stimulated baseline production of IL-1 (SAA inducer and lymphocyte activating factor activities) and augmented lipopolysaccharide (LPS) induced IL-1 production.	Colchicine	23-33	interleukin 1 complex	Mus musculus	68-72
3871106-0	1985	Strain dependence of muramyl dipeptide-induced LAF(IL 1) release by murine-adherent peritoneal cells.	Dipeptides	29-38	interleukin 1 complex	Mus musculus	47-55
6334740-0	1984	Colchicine in acute inflammation: stimulation of production of interleukin-1 and modulation of the acute phase serum amyloid A protein response.	Colchicine	0-10	interleukin 1 complex	Mus musculus	63-76
6334740-3	1984	In a macrophage model, colchicine stimulated baseline production of IL-1 (SAA inducer and lymphocyte activating factor activities) and augmented lipopolysaccharide (LPS) induced IL-1 production.	Colchicine	23-33	interleukin 1 complex	Mus musculus	178-182
6370464-0	1984	Correlation between strong adjuvanticity of Klebsiella O3 lipopolysaccharide and its ability to induce interleukin-1 secretion.	Klebsiella O3 lipopolysaccharide	44-76	interleukin 1 complex	Mus musculus	103-116
6205079-6	1984	In cultures of normal B cells activated with anti-IgM and dextran sulfate together, BGDF/IL 1 induced a proliferative response comparable with the sum of the responses to the factor and either stimulus alone.	Dextran Sulfate	58-73	interleukin 1 complex	Mus musculus	89-93
6205079-7	1984	These results suggest that anti-IgM and dextran sulfate activate distinct and independent B cell subpopulations, both of which are responsive to BGDF/IL 1.	Dextran Sulfate	40-55	interleukin 1 complex	Mus musculus	150-154
6378771-4	1984	The activity of these supernatants was associated with interleukin-1 (IL-1) and partially purified IL-1 prepared from P388D1 cells also enhanced the primary in vitro response to DAGG-Ficoll.	dagg	178-182	interleukin 1 complex	Mus musculus	99-103
6432347-3	1984	The optimal effective concentration of A23187 was found to be 2.5 X 10(-7) M, and the costimulating effect of IL-1 was dose-dependent.	Calcimycin	39-45	interleukin 1 complex	Mus musculus	110-114
6432347-6	1984	In addition, the calcium ionophore also augmented release of IL-1 from the P388D1 murine macrophage cell line.	Calcium	17-24	interleukin 1 complex	Mus musculus	61-65
6611372-9	1984	This UV-induced activity was cycloheximide-sensitive, suggesting that de novo protein synthesis rather than release from cells was responsible for the increased IL 1 activity.	Cycloheximide	29-42	interleukin 1 complex	Mus musculus	161-165
6332323-7	1984	Levels of IL-1 activity in culture supernatants of adherent splenocytes from indomethacin treated old mice were higher than those of the untreated age-mates.	Indomethacin	77-89	interleukin 1 complex	Mus musculus	10-14
6332323-8	1984	Conversely, in the young, in vivo treatment with indomethacin led to reduced IL-1 levels.	Indomethacin	49-61	interleukin 1 complex	Mus musculus	77-81
6329770-5	1984	Our findings suggest that the factor which induced collagenase and PGE2 secretion by rabbit chondrocytes was an IL 1-like factor.	Dinoprostone	67-71	interleukin 1 complex	Mus musculus	112-116
6199415-3	1984	DEAE-cellulose chromatography separated CHF activity from the majority of interleukin 1 (IL 1), interleukin 2 (IL 2), granulocyte-macrophage colony-stimulating factor (CSF), and interferon (IFN).	DEAE-Cellulose	0-14	interleukin 1 complex	Mus musculus	89-93
6352805-6	1983	Six major species of IL 1 were resolved by using tris-glycinate discontinuous polyacrylamide gels.	tris-glycinate	49-63	interleukin 1 complex	Mus musculus	21-25
6327542-7	1984	A major effect of indomethacin in vivo and of PGE2 in vitro however, was on the production and expression of IL1 and IL2.	Indomethacin	18-30	interleukin 1 complex	Mus musculus	109-112
6327542-7	1984	A major effect of indomethacin in vivo and of PGE2 in vitro however, was on the production and expression of IL1 and IL2.	Dinoprostone	46-50	interleukin 1 complex	Mus musculus	109-112
6327542-8	1984	Secretion of IL1 by macrophages in vitro was greatly enhanced in indomethacin treated mice and was suppressed in vitro by PGE2.	Indomethacin	65-77	interleukin 1 complex	Mus musculus	13-16
6327542-8	1984	Secretion of IL1 by macrophages in vitro was greatly enhanced in indomethacin treated mice and was suppressed in vitro by PGE2.	Dinoprostone	122-126	interleukin 1 complex	Mus musculus	13-16
6228602-2	1984	IL 1 also protects helper T cells and myeloid precursors from glucosteroid suppression.	glucosteroid	62-74	interleukin 1 complex	Mus musculus	0-4
6327542-9	1984	Prostaglandin E2 also inhibited IL1 dependent T-lymphocyte differentiation.	Dinoprostone	0-16	interleukin 1 complex	Mus musculus	32-35
6335509-5	1984	IL-1 is reduced when IL-1-containing supernatants are concentrated by ammonium sulfate precipitation subsequent to hollow-fiber filtration.	Ammonium Sulfate	70-86	interleukin 1 complex	Mus musculus	0-4
6335509-5	1984	IL-1 is reduced when IL-1-containing supernatants are concentrated by ammonium sulfate precipitation subsequent to hollow-fiber filtration.	Ammonium Sulfate	70-86	interleukin 1 complex	Mus musculus	21-25
6352805-6	1983	Six major species of IL 1 were resolved by using tris-glycinate discontinuous polyacrylamide gels.	polyacrylamide	78-92	interleukin 1 complex	Mus musculus	21-25
6602200-4	1983	Such cultures show an absolute dependence on exogenously added IL-1 when 2-mercaptoethanol is omitted from the medium.	Mercaptoethanol	73-90	interleukin 1 complex	Mus musculus	63-67
6604093-4	1983	The WEHI-3-derived material responsible for BGDF/IL 1 activity, however, exhibited different behavior on DEAE chromatography (elution at 175 mM NaCl) to that reported for IL 1 from the P388D1 cell line (elution at 50 mM NaCl).	2-diethylaminoethanol	105-109	interleukin 1 complex	Mus musculus	44-53
6604093-4	1983	The WEHI-3-derived material responsible for BGDF/IL 1 activity, however, exhibited different behavior on DEAE chromatography (elution at 175 mM NaCl) to that reported for IL 1 from the P388D1 cell line (elution at 50 mM NaCl).	Sodium Chloride	144-148	interleukin 1 complex	Mus musculus	44-53
6604093-4	1983	The WEHI-3-derived material responsible for BGDF/IL 1 activity, however, exhibited different behavior on DEAE chromatography (elution at 175 mM NaCl) to that reported for IL 1 from the P388D1 cell line (elution at 50 mM NaCl).	Sodium Chloride	144-148	interleukin 1 complex	Mus musculus	49-53
6604093-4	1983	The WEHI-3-derived material responsible for BGDF/IL 1 activity, however, exhibited different behavior on DEAE chromatography (elution at 175 mM NaCl) to that reported for IL 1 from the P388D1 cell line (elution at 50 mM NaCl).	Sodium Chloride	220-224	interleukin 1 complex	Mus musculus	44-53
6602721-5	1983	Biochemical studies showed that murine and human ETAF, like interleukin 1 (IL 1), had a molecular weight between 12,000 and 20,000, interacted with hydrophobic phenyl-Sepharose, and was eluted from anion but not cation exchangers.	phenyl-sepharose	160-176	interleukin 1 complex	Mus musculus	75-79
6602218-7	1983	There was an inverse correlation between IL1 production and PGE production after stimulation with C3-zymosan or lipopolysaccharide (LPS).	Prostaglandins E	60-63	interleukin 1 complex	Mus musculus	41-44
6602218-7	1983	There was an inverse correlation between IL1 production and PGE production after stimulation with C3-zymosan or lipopolysaccharide (LPS).	c3-zymosan	98-108	interleukin 1 complex	Mus musculus	41-44
34025642-6	2021	Meanwhile we proved that hyperforin suppressed infiltration of CD3+ T cells and downregulated expression of Il1, Il6, Il23, Il17a, Il22, antimicrobial peptides (AMPs) in the skin lesion.	hyperforin	25-35	interleukin 1 complex	Mus musculus	108-111
6801116-0	1982	Prevention of the in vitro myelosuppressive effects of glucocorticosteroids by interleukin 1 (IL 1).	glucocorticosteroids	55-75	interleukin 1 complex	Mus musculus	79-98
6307493-3	1983	In contrast, addition of silica enhances the release of IL1.	Silicon Dioxide	25-31	interleukin 1 complex	Mus musculus	56-59
6307493-9	1983	The same effect has been observed with Rats: IL1 is released instead of FRM when silica is added to peritoneal macrophages.	Silicon Dioxide	81-87	interleukin 1 complex	Mus musculus	45-48
33966129-9	2021	Adding the corticosteroid dexamethasone significantly reduced the response to IL1-ss stimulation.	Dexamethasone	26-39	interleukin 1 complex	Mus musculus	78-81
33200254-5	2021	We also observed elevated levels of inflammatory cytokines such as TNFalpha, IL-6 and IL-1 in jaw bone at the extraction site relative to other sites in zoledronate-treated mice.	Zoledronic Acid	153-164	interleukin 1 complex	Mus musculus	86-90
33893687-8	2021	In animal study, PA-treated mice showed reduced intravesical IL-1, IL-6 levels, and lactate dehydrogenase content, downregulated TNF-alpha and upregulated TP53 proteins in bladder samples.	pachymic acid	17-19	interleukin 1 complex	Mus musculus	61-65
33654394-9	2021	Also, IL-1-Exo reversed the LPS-induced effect on calcium signaling.	Calcium	50-57	interleukin 1 complex	Mus musculus	6-10
33874887-11	2021	RESULTS: The pancreatic pathological changes, plasma amylase and lipase activity, and the increase of plasma IL-1 and IL-6 levels in AP mice were significantly improved by the hydrogen-rich gases pretreatment, Meanwhile, the pancreatic GSH content increased and the pancreatic MDA content decreased.	Hydrogen	176-184	interleukin 1 complex	Mus musculus	109-113
33152425-11	2021	Carvacrol inhibited the expression of inflammation-associated cytokines including IFN-gamma, IL-2, IL-4, IL-5, IL-12 and TNF-alpha, IL-1, IL-10, IL-6.	carvacrol	0-9	interleukin 1 complex	Mus musculus	111-115
33729573-6	2021	RESULTS: The in vitro results showed that TAK-242 blocked the overproduction of IL-1, IL-6, TNF-alpha and RANKL in HGEC treated with LPS.	ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate	42-49	interleukin 1 complex	Mus musculus	80-84
33750416-9	2021	However, gm9795 in NASH cell models significantly promoted the expression of TNF [Formula: see text], IL-6, IL-1[Formula: see text], the important inflammatory mediators in NASH.	gm9795	9-15	interleukin 1 complex	Mus musculus	108-112
33465362-4	2021	The polysaccharides stimulated RAW264.7 cells to produce considerable amounts of NO and up-regulate the expression of TNF-alpha, IL-1 and COX-2 genes.	Polysaccharides	4-19	interleukin 1 complex	Mus musculus	129-133
33495836-8	2021	CFA also robustly suppressed apoptosis induced by H2O2 in murine chondrocytes and reduced the expression of matrix metalloproteinase (MMP)1, MMP3, interleukin (IL)-1 and IL-6 in vivo.	coniferaldehyde	0-3	interleukin 1 complex	Mus musculus	147-165
33285301-8	2021	This observation was consistent with our finding that glucose-stimulated insulin secretion was reduced in islets isolated from IL-1alphaPdx1-/- mice.	Glucose	54-61	interleukin 1 complex	Mus musculus	127-140
33550610-0	2021	Nitric oxide inhibits IL-1 mediated protection against Escherichia coli K1-induced sepsis and meningitis in neonatal murine model.	Nitric Oxide	0-12	interleukin 1 complex	Mus musculus	22-26
33550610-8	2021	Neonates are known to have increased nitric oxide (NO) levels compared to adults, and we found NO inhibited the secretion of IL-1 by macrophages in response to NMEC.	Nitric Oxide	37-49	interleukin 1 complex	Mus musculus	125-129
33562323-8	2021	The addition of IL-1 did not affect developed cells in MCS compared to control, but in combination with testosterone, it significantly increased the percentages of VASA-positive cells and BOULE-positive cells compared to IL-1 or testosterone.	Testosterone	104-116	interleukin 1 complex	Mus musculus	221-225
33371810-4	2021	In this study, baicalin displayed a suppressing role on IL-1[Formula: see text], TNF[Formula: see text] and IL-6 in both cell and mice models.	baicalin	15-23	interleukin 1 complex	Mus musculus	56-60
32547156-6	2020	Moreover, IL-1, IL-6, and TNF-alpha knocked-out mice have delayed parturition and lower levels of PGs compared to the wild types.	Prostaglandins	98-101	interleukin 1 complex	Mus musculus	10-14
33103493-7	2020	A significant decrease in the levels of IL-1betaand TNF-alpha was observed in the 0.05% and 0.01% SIN-treated groups.	sinomenine	98-101	interleukin 1 complex	Mus musculus	40-44
33269624-9	2020	RESULTS: Baicalin remarkably inhibited the production of IL-1, IL-18, mitochondria ROS, total ROS, ICAM-1, and VCAM-1.	baicalin	9-17	interleukin 1 complex	Mus musculus	57-61
32768191-5	2020	Different concentrations of Rk1 (10 and 20 mg/kg) and Flu significantly decreased the levels of tumor necrosis factor (TNF)-alpha and interleukin (IL)-1 in serum, while Rk1 (5, 10, and 20 mg/kg) and Flu reduced the concentrations of IL-6 in a dose-dependent manner.	Fluoxetine	54-57	interleukin 1 complex	Mus musculus	134-152
31659629-0	2020	IL-1 promotes alpha-epithelial Sodium Channel (alpha-ENaC) expression in murine lung epithelial cells: involvement of NF-kappaB.	Sodium	31-37	interleukin 1 complex	Mus musculus	0-4
31659629-8	2020	IL-1-dependent increases in alpha-ENaC protein were mitigated by IL-1ra and cycloheximide.	Cycloheximide	76-89	interleukin 1 complex	Mus musculus	0-4
31659629-12	2020	In contrast, IL-1-induced alpha-ENaC protein levels were unaffected by a c-Jun N-terminal kinase (JNK) inhibitor.	Nitrogen	33-34	interleukin 1 complex	Mus musculus	13-17
32222637-6	2020	Isovitexin inhibited CP-induced inflammation by inhibiting TNF-alpha, IL-1ss and IL-6 production in kidney tissues.	isovitexin	0-10	interleukin 1 complex	Mus musculus	70-74
33051350-5	2020	for four consecutive days (LPSx4) consistently elicit a reactive spinal cord microglia response marked by dramatic morphological changes, increased production of IL-1, and enhanced proliferation without triggering leukocyte recruitment or overt neuropathology.	lpsx4	27-32	interleukin 1 complex	Mus musculus	162-166
32608990-11	2020	In addition, miR-874-3p was found to target and downregulate CXCL12, thus reducing TNF-alpha, IL-1, IL-6, and IL-8 levels, but enhancing IL-10 level.	mir-874-3p	13-23	interleukin 1 complex	Mus musculus	94-98
32351320-7	2020	Furthermore, MitoQ inhibited the LPS-induced intestinal oxidative stress and inflammatory response, evidenced by increased levels of intestinal superoxide dismutase and glutathione, and decreased levels of intestinal IL-1, IL-6, TNF-alpha, and nitric oxide levels.	mitoquinone	13-18	interleukin 1 complex	Mus musculus	217-221
32342686-3	2020	High intake of L-carnitine also induced liver injury, which was proved by the increases in the serum AST and ALT activities, production of inflammatory liver cytokines (IL-1, IL-6, TNF-alpha and TNF-beta), lipid metabolism (TC, TG, HDL and LDL) disorder, and the decline in antioxidant ability (SOD, GSH-Px, MDA and RAHFR).	Carnitine	15-26	interleukin 1 complex	Mus musculus	169-173
32433977-0	2020	beta-Glucan Induces Protective Trained Immunity against Mycobacterium tuberculosis Infection: A Key Role for IL-1.	beta-Glucans	0-11	interleukin 1 complex	Mus musculus	109-113
32433977-5	2020	The protective signature of beta-glucan is mediated via IL-1 signaling, as beta-glucan shows no protection in mice lacking a functional IL-1 receptor (IL1R-/-).	beta-Glucans	28-39	interleukin 1 complex	Mus musculus	56-60
31770101-7	2020	Treatment with butyrate restores the homeostatic levels of NOX4 and IL-1 .	Butyrates	15-23	interleukin 1 complex	Mus musculus	68-72
31758701-8	2020	Thus, similar to clinical KD, the LCWE-induced KD vasculitis mouse model also exhibits electrophysiological abnormalities and cardiac neuronal remodeling, and these changes can be prevented by blocking IL-1 signaling.	lcwe	34-38	interleukin 1 complex	Mus musculus	202-206
31854009-2	2020	Excessive alcohol use results in neuroinflammation characterized by activation of the inflammasome, a multiprotein complex, and IL-1 increase in the brain.	Ethanol	10-17	interleukin 1 complex	Mus musculus	128-132
31854009-10	2020	Inhibition of NLRP3 inflammasome activation and the inflammasome-IL-1 cascade opens novel insights into the development of new therapies to address alcohol use disorder in an era of targeted and precision medicine.	Ethanol	148-155	interleukin 1 complex	Mus musculus	65-69
31530996-17	2019	Compared with the PM2.5 treatment group, the curcumin intervention group can reduce the amount of ALB, LDH, and ALP in BALF; reduce the levels of MDA, IL-1, and TNF-alpha in the lung tissue; and improve GSH-PX, T-AOC, and CAT levels, but there is no statistical difference (P &gt; 0.05).	Curcumin	45-53	interleukin 1 complex	Mus musculus	151-155
31228609-11	2019	RNA sequencing of IL-1 stimulated endothelial cells revealed increased expression of genes involved in the production and processing of hyaluronic acid (HA), suggesting HA as a candidate of IMAF.	Hyaluronic Acid	136-151	interleukin 1 complex	Mus musculus	18-22
31228609-11	2019	RNA sequencing of IL-1 stimulated endothelial cells revealed increased expression of genes involved in the production and processing of hyaluronic acid (HA), suggesting HA as a candidate of IMAF.	Hyaluronic Acid	153-155	interleukin 1 complex	Mus musculus	18-22
31392398-8	2019	Multiple genes related to chemotaxis, IL-1, chemokines, regulation of inflammation, and extracellular signal-regulated kinases (ERK) were upregulated in lungs of mice treated with bleomycin and MIA-602.	Bleomycin	180-189	interleukin 1 complex	Mus musculus	38-42
31835366-10	2019	PEG-GNPs inhibited the production of pro-inflammatory cytokines (IL-1, IL-6, IL-8, TNF-alpha) and Th1-related cytokines (IFN-Upsilon and IL-12p70), and increased the production of Th2 cytokines (IL-4 and IL-5).	poly(ethylene glycol)-poly(caprolactone)-poly(ethylene glycol)	0-3	interleukin 1 complex	Mus musculus	65-69
31671940-4	2019	Meanwhile, DISO resulted in strong inhibition against the elevation of hepatic injury marker (AST, ALT, and ALP) activities and dyslipidemia (TC, TG, LDL-C, and HDL-C), as well as liver inflammatory cytokine (IL-1, IL-6, TNF-alpha, and TNF-beta) release in l-carnitine-fed mice (p < 0.05).	diso	11-15	interleukin 1 complex	Mus musculus	209-213
31707400-9	2019	RESULTS AB23A improved the survival rate and ameliorated myocardial injury, decreased inflammatory infiltration and the level of IL-6, IL-1ss, and TNF-alpha in the LPS-stimulated mouse model.	alisol B 23-acetate	8-13	interleukin 1 complex	Mus musculus	135-139
30001646-2	2019	Interleukin-1 (IL-1) contributes to experimental adult diffuse and contusion TBI models, and IL-1 antagonists have entered clinical trials for severe TBI in adults; however, no such data exist for adolescent TBI.	Thioacetazone	77-80	interleukin 1 complex	Mus musculus	0-13
30001646-2	2019	Interleukin-1 (IL-1) contributes to experimental adult diffuse and contusion TBI models, and IL-1 antagonists have entered clinical trials for severe TBI in adults; however, no such data exist for adolescent TBI.	Thioacetazone	77-80	interleukin 1 complex	Mus musculus	15-19
30001646-2	2019	Interleukin-1 (IL-1) contributes to experimental adult diffuse and contusion TBI models, and IL-1 antagonists have entered clinical trials for severe TBI in adults; however, no such data exist for adolescent TBI.	Thioacetazone	150-153	interleukin 1 complex	Mus musculus	93-97
30001646-2	2019	Interleukin-1 (IL-1) contributes to experimental adult diffuse and contusion TBI models, and IL-1 antagonists have entered clinical trials for severe TBI in adults; however, no such data exist for adolescent TBI.	Thioacetazone	150-153	interleukin 1 complex	Mus musculus	93-97
31513213-5	2019	Concentrations of hepatic TNF-alpha, IL-1 and IL-6 were decreased after OSO treatment when compared with alcohol-treated mice, respectively (p < 0.05).	oso	72-75	interleukin 1 complex	Mus musculus	37-41
31325186-0	2019	Interleukin-1 and histamine are essential for inducing nickel allergy in mice.	Nickel	55-61	interleukin 1 complex	Mus musculus	0-13
31046128-7	2019	RESULTS: IL-1 mRNA expression was significantly higher in the EDTA + BC group than in the Empty and BC groups at the 7th and 14th days of evaluation (P &lt; 0.05).	Edetic Acid	62-66	interleukin 1 complex	Mus musculus	9-13
31119787-7	2019	Moreover, Plin3 knockdown increased cellular sensitivity to alcohol-induced apoptosis, endoplasmic reticulum (ER) stress, and inflammatory cytokines release, including TNF-alpha, IL-1, and IL-6beta.	Alcohols	60-67	interleukin 1 complex	Mus musculus	179-183
31035087-7	2019	The levels of TNF-alpha and IL-1ss were increased by DSS and dose-dependently inhibited by Saikosaponin A.	Dextran Sulfate	53-56	interleukin 1 complex	Mus musculus	28-32
31035087-7	2019	The levels of TNF-alpha and IL-1ss were increased by DSS and dose-dependently inhibited by Saikosaponin A.	saikosaponin D	91-105	interleukin 1 complex	Mus musculus	28-32
30996002-7	2019	Critically, although mice deficient in IL-1 signaling have extensive acute inflammation following C. albicans water-soluble complex challenge, they do not develop coronary vasculitis.	Water	110-115	interleukin 1 complex	Mus musculus	39-43
30872170-12	2019	CAM negated the Paracetamol-induced damage by inhibiting expression of pro-inflammatory cytokines (MCP 1, IL 1, TNF beta), and increasing the expression of the anti-inflammatory cytokine (IL 10) profoundly.	cafestol palmitate	0-3	interleukin 1 complex	Mus musculus	106-110
30872170-12	2019	CAM negated the Paracetamol-induced damage by inhibiting expression of pro-inflammatory cytokines (MCP 1, IL 1, TNF beta), and increasing the expression of the anti-inflammatory cytokine (IL 10) profoundly.	Acetaminophen	16-27	interleukin 1 complex	Mus musculus	106-110
30988731-9	2019	Results demonstrated that the expression levels of IL-1, -4, -8 and TNF-alpha were significantly downregulated in the sera of mice with fibrillation and thromboembolism following treatment with edoxaban (P&lt;0.01).	edoxaban	194-202	interleukin 1 complex	Mus musculus	51-63
31223429-4	2019	Results showed that DMA remarkably inhibited the mRNA and protein expression of receptor for AGEs (RAGE), thereby inhibiting the production of ROS and proinflammatory cytokines, including tumor necrosis factor- (TNF-) alpha, interleukin (IL) 1, IL 6, and monocyte chemoattractant protein- (MCP-) 1 in RAW 264.7 cells.	dma	20-23	interleukin 1 complex	Mus musculus	225-243
30664361-13	2019	CONCLUSIONS: This study indicates that the three CsA formulations effectively modulated TLR4, TGFbeta1, IL1, and IL6 pathways to reduce corneal epithelium lesions in a mouse model of severe dry eye.	Cyclosporine	49-52	interleukin 1 complex	Mus musculus	104-107
30578561-11	2019	Knockout of IL-1 receptors prevented the development of acute pain induced by paclitaxel in mice.	Paclitaxel	78-88	interleukin 1 complex	Mus musculus	12-16
30890189-6	2019	IL-1 pathway modulation in mouse models was accomplished by administration of IL-1RA, stable overexpression of IL-1alpha in SQ20B cells, administration of rIL-1alpha, and administration of a polyanhydride nanoparticle formulation of IL-1alpha.	Polyanhydrides	191-204	interleukin 1 complex	Mus musculus	0-4
29923862-7	2018	The expressions of F4/80 and neutrophil elastase-positive inflammatory cells and IL-1 and TNF-alpha cytokine levels were significantly reduced in the 8-oxo-dG group compared with the PBS group (each P &lt; 0.01).	8-ohdg	150-158	interleukin 1 complex	Mus musculus	81-85
30298517-10	2019	Pro-inflammatory cytokines including MCP-1, TNF-alpha, IL-1 and IL-6 were detected through RT-PCR and ELISA in experiment and GME can significantly inhibit the expression of TNF-alpha, IL-1 and IL-6 but have no effect on MCP-1.	gme	126-129	interleukin 1 complex	Mus musculus	55-59
30298517-10	2019	Pro-inflammatory cytokines including MCP-1, TNF-alpha, IL-1 and IL-6 were detected through RT-PCR and ELISA in experiment and GME can significantly inhibit the expression of TNF-alpha, IL-1 and IL-6 but have no effect on MCP-1.	gme	126-129	interleukin 1 complex	Mus musculus	185-189
30500420-8	2019	Allicin stimulated the immune response by causing Zn2+ release from proteins and increasing the Zn2+-dependent IL-1-triggered production of IL-2 in murine EL-4 T-cells.	allicin	0-7	interleukin 1 complex	Mus musculus	111-115
30500420-8	2019	Allicin stimulated the immune response by causing Zn2+ release from proteins and increasing the Zn2+-dependent IL-1-triggered production of IL-2 in murine EL-4 T-cells.	Zinc	96-100	interleukin 1 complex	Mus musculus	111-115
30361689-3	2018	Here, we newly established a mouse model in which IL-1 signaling is conditionally activated in adult mice (hIL-1 cTg) and observed phenotypes similar to those seen in auto-inflammatory syndrome patients.	ctg	113-116	interleukin 1 complex	Mus musculus	50-54
29852215-6	2018	Molecular biology analyses suggested that both TLR2/MyD88/NF-kappaB pathway and NLRP3 inflammasome participated in the CdTe QD-induced IL-1ss secretion.	cadmium telluride	119-123	interleukin 1 complex	Mus musculus	135-139
30221762-6	2018	LP-CQPC06 also reduced the serum levels of interleukin 8 (IL-8), IL-1, tumor necrosis factor alpha, and macrophage inflammatory protein-1 alpha, as well as reducing levels of myeloperoxidase (MPO) and nitric oxide (NO) in the colon tissues of mice with DSS-induced colitis.	lp-cqpc06	0-9	interleukin 1 complex	Mus musculus	65-98
29852215-8	2018	The results, taken together, demonstrated that MPA-modified CdTe QDs exposure with a high concentration was capable of activating microglial cells and promoting IL-1ss secretion, which was highly correlated with the activations of both TLR2/MyD88/NF-kappaB pathway and ROS-induced NLRP3 inflammasome.	cadmium telluride	60-64	interleukin 1 complex	Mus musculus	161-165
29666981-4	2018	In fact, this low-dose DSS priming apparently decreased the acute inflammation, as colitis scores along with IFNgamma, IL-1ss, and IL-4 were significantly decreased with the same tendency for IL-5, TNFalpha, and IL-2 on day 3 post-induction compared to control mice.	Dextran Sulfate	23-26	interleukin 1 complex	Mus musculus	119-123
29901822-9	2018	Taken together, these data support the hypothesis that Malt1-/- macrophages contribute to increased susceptibility of Malt1-/- mice to DSS-induced colitis, which is dependent on IL-1 signaling.	dss	135-138	interleukin 1 complex	Mus musculus	178-182
29684419-6	2018	Interruption of ERbeta/c-MET or ERbeta/IL-1/c-MET signaling via ERbeta-shRNA, IL-1 antagonist, or the c-MET inhibitor, SU11274, could partially reverse the T cell-enhanced BCa cell invasion and proliferation.	((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide)	119-126	interleukin 1 complex	Mus musculus	39-43
30198495-5	2018	The levels of inflammatory factors, including interleukin-1 (IL1), IL6, IL8, and tumor necrosis factor-alpha (TNF-alpha), in lycopene-treated cells were also reduced by lycopene treatment.	Lycopene	125-133	interleukin 1 complex	Mus musculus	46-59
30198495-5	2018	The levels of inflammatory factors, including interleukin-1 (IL1), IL6, IL8, and tumor necrosis factor-alpha (TNF-alpha), in lycopene-treated cells were also reduced by lycopene treatment.	Lycopene	125-133	interleukin 1 complex	Mus musculus	61-64
30198495-5	2018	The levels of inflammatory factors, including interleukin-1 (IL1), IL6, IL8, and tumor necrosis factor-alpha (TNF-alpha), in lycopene-treated cells were also reduced by lycopene treatment.	Lycopene	169-177	interleukin 1 complex	Mus musculus	46-59
30198495-5	2018	The levels of inflammatory factors, including interleukin-1 (IL1), IL6, IL8, and tumor necrosis factor-alpha (TNF-alpha), in lycopene-treated cells were also reduced by lycopene treatment.	Lycopene	169-177	interleukin 1 complex	Mus musculus	61-64
29921037-6	2018	Meanwhile, H2 inhibited the overexpression of MCP-1, E-selectin, P-selectin and ICAM-1 in oxidant-induced endothelia and reduced inflammatory cells infiltration and proinflammatory cytokines (TNF-alpha, IL-1, IL-6 and IL-8) production in the wound.	Hydrogen	11-13	interleukin 1 complex	Mus musculus	203-207
30230981-7	2018	We observed that metformin prevented the stimulating effect of LPS on these chemokines as well as IL-1 and IL-6.	Metformin	17-26	interleukin 1 complex	Mus musculus	98-102
30070336-8	2018	In the pravastatin group, the expression of TREM-1 in the aorta atherosclerotic plaque of mice was decreased, the expressions of TREM-1 and DAP12 genes and proteins in vascular tissue cells declined, and the expressions of the downstream inflammatory factors, TNF-alpha, IL-1 were reduced.	Pravastatin	7-18	interleukin 1 complex	Mus musculus	271-275
29742950-0	2018	Inflammation in the pleural cavity following injection of multi-walled carbon nanotubes is dependent on their characteristics and the presence of IL-1 genes.	Carbon	71-77	interleukin 1 complex	Mus musculus	146-150
28866071-2	2017	The neuroinflammatory response is characterized by the upregulation of the pro-inflammatory cytokine, interleukin-1 (IL-1), which mediates the expression of other neurotoxic cytokines induced after GD exposure.	Gadolinium	198-200	interleukin 1 complex	Mus musculus	102-115
29701676-5	2018	Baicalein at concentrations up to 100 &amp;mu;M significantly inhibited the production of NO, IL-1&amp;alpha;, IL-6, G-CSF, GM-CSF, VEGF, MCP-1, IP-10, LIX, and RANTES as well as calcium release in RAW 264.7 cells induced by poly I:C (50 &amp;micro;g/mL) (all p &lt; 0.05).	baicalein	0-9	interleukin 1 complex	Mus musculus	94-98
29207167-12	2018	The results of the present study identified that prazosin decreased the expression levels of inflammatory factors, interleukin (IL)-6, tumor necrosis factor (TNF)-alpha, IL-10 and IL-1 in the serum of mice exhibiting hypoxia/reoxygenation injury.	Prazosin	49-57	interleukin 1 complex	Mus musculus	170-174
28866071-2	2017	The neuroinflammatory response is characterized by the upregulation of the pro-inflammatory cytokine, interleukin-1 (IL-1), which mediates the expression of other neurotoxic cytokines induced after GD exposure.	Gadolinium	198-200	interleukin 1 complex	Mus musculus	117-121
28866071-11	2017	Therefore, the IL-1 signaling pathway affects neurodegeneration and behavior after GD-induced convulsions.	Gadolinium	83-85	interleukin 1 complex	Mus musculus	15-19
29075987-7	2017	Anthocyanins also maintained the stability of the redox system (GSH-PX, T-SOD and MDA) in plasma and liver structures (p &lt; 0.001) and reduced the levels of inflammatory factors (IL-1, IL-6 and TNF-alpha) in the liver (p &lt; 0.05).	Anthocyanins	0-12	interleukin 1 complex	Mus musculus	181-185
27273552-2	2017	Here, we examined the role of interleukin 1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha) in regulation of voluntary alcohol consumption, alcohol reward and stress-induced drinking.	Alcohols	122-129	interleukin 1 complex	Mus musculus	30-49
29123474-0	2017	Brain Interleukin-1 Facilitates Learning of a Water Maze Spatial Memory Task in Young Mice.	Water	46-51	interleukin 1 complex	Mus musculus	6-19
28363651-6	2017	Alcalase assistant alginate stimulated RAW264.7 cells to release nitric oxide and inflammatory cytokines TNF-alpha, IL-1, IL-6, IL-10 and IL-12.	Alginates	19-27	interleukin 1 complex	Mus musculus	116-120
28716092-11	2017	Third, BzATP-induced release of IL1 family cytokines including IL1alpha, IL1beta, and IL18 was blocked in P2X7-/- microglia or by A-804598 in pro-inflammatory microglia, while the release of other cytokines/chemokines was independent of P2X7 activation.	3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate	7-12	interleukin 1 complex	Mus musculus	32-35
28678919-6	2017	As a result, cell viability was significantly decreased, as well as apoptosis and the expression of IL-1 and TNF-alpha were remarkably increased after 50 and 100 mug/mL of bleomycin administration.	Bleomycin	172-181	interleukin 1 complex	Mus musculus	100-104
28345165-6	2017	CONCLUSION: Our novel findings suggest that IL-1 drives sustained liver inflammation and impaired hepatocyte regeneration even after cessation of ethanol exposure.	Ethanol	146-153	interleukin 1 complex	Mus musculus	44-48
28067111-4	2017	Furthermore, air toluene induced the expression of Hsp72 and enhanced IL-1, IL-6, and TNF-alpha in blood plasma, which is indicative of a pro-inflammatory response.	Toluene	17-24	interleukin 1 complex	Mus musculus	70-74
28286228-6	2017	IL-1 and TNF-alpha levels in the serum were markedly decreased in birinapant pretreatment mice compared with control mice (P&lt;0.05).The cellular inhibitor of apoptosis protein 1 (cIAP1) expression in liver resident macrophage (Kupffer cells, KCs) was significantly decreased in the Birinapant group compared to the Vehicle group (P&lt;0.05).	birinapant	66-76	interleukin 1 complex	Mus musculus	0-4
28104981-7	2017	Endotoxin-associated genes such as TLR4 and Myd88, pro-inflammation genes such as MCP-1, TNF-alpha, IL-1, IL-2, IL-6 and IFN-gamma in liver or epididymal fat were obviously downregulated after NaB intervention.	nab	193-196	interleukin 1 complex	Mus musculus	100-104
27444347-9	2016	Furthermore, the administration of SBE prevented significantly the increase of MPO activity, the NOx content, and the levels of IL-1, IL-6, TNF-alpha, INF-gamma and CRP and was able to increase the IL-10 levels after the inflammation induced by carrageenan in mice.	SBE	35-38	interleukin 1 complex	Mus musculus	128-132
29456573-7	2017	The results also showed that CRME can reduce the levels of IL-1, IL-6, TNF-alpha, and PGE2 and inhibit the expression of NF-kappaB p65.	crme	29-33	interleukin 1 complex	Mus musculus	59-63
27863396-8	2016	Furthermore, P2rx4-deficient bone marrow derived DCs (BMDCs) showed a reduced IL-1ss production in response to ATP accompanied by a decreased P2rx7 expression and attenuated Th2 priming capacity compared to wild type (WT) BMDCs in vitro.	Adenosine Triphosphate	111-114	interleukin 1 complex	Mus musculus	78-82
27916090-8	2016	Gallic acid could reduce the elevated expression levels of TNF-alpha, IL-1 and IL-6 induced by LPS.	Gallic Acid	0-11	interleukin 1 complex	Mus musculus	70-74
27775054-8	2016	Administration of SQ29548 inhibited microglia/macrophages activation and enrichment, including both M1 and M2 phenotypes, and attenuated ischemia-induced IL-1ss, IL-6, and TNF-alpha up-regulation and iNOS release.	SQ 29548	18-25	interleukin 1 complex	Mus musculus	154-158
27313060-6	2016	Moreover, during irritant-induced sterile inflammation in mice leading to induction of the acute-phase response, which is dependent on IL-1, expression of ORMDL proteins in the liver was strongly downregulated and accompanied by increased ceramide levels in the liver and accumulation in the blood.	Ceramides	239-247	interleukin 1 complex	Mus musculus	135-139
26643538-9	2016	The results showed that, in an activity-dependent and paracrine/autocrine manner, endogenous IL-1 produced by neurons and astrocytes facilitates glucose uptake by these cells.	Glucose	145-152	interleukin 1 complex	Mus musculus	93-97
26911702-10	2016	In mouse mammary tissue, BPA exposure in utero significantly decreased the expression of members of the chemokine CXC family (Cxcl2, Cxcl4, Cxcl14, and Ccl20), interleukin 1 (Il1) gene family (Il1beta and Il1rn), interleukin 2 gene family (Il7 receptor), and interferon gene family (interferon regulatory factor 9 (Irf9), as well as immune response gene 1 (Irg1).	bisphenol A	25-28	interleukin 1 complex	Mus musculus	160-178
27507205-13	2016	In addition, EPSAH enhanced phagocytic activity and the generation of pro-inflammatory cytokines IL-1 and IL-12 in macrophages.	epsah	13-18	interleukin 1 complex	Mus musculus	97-101
27180984-10	2016	Network target analysis and experimental validation in SY5Y and CT26 cells showed that the anti-tumor effect of nuciferine was mediated through inhibiting the PI3K-AKT signaling pathway and IL-1 levels in SY5Y and CT26 cells.	nuciferine	112-122	interleukin 1 complex	Mus musculus	190-194
27180984-11	2016	CONCLUSION: By using a TCM network pharmacology method, nuciferine is identified as an anti-tumor agent against human neuroblastoma and mouse colorectal cancer in vitro and in vivo, through inhibiting the PI3K-AKT signaling pathways and IL-1 levels.	nuciferine	56-66	interleukin 1 complex	Mus musculus	237-241
27148737-0	2016	Estradiol Enhances CD4+ T-Cell Anti-Viral Immunity by Priming Vaginal DCs to Induce Th17 Responses via an IL-1-Dependent Pathway.	Estradiol	0-9	interleukin 1 complex	Mus musculus	106-110
27222857-2	2016	(2016) [2] that ArtinM induces the IL-17 production through interaction with CD4(+) T cells and stimulation of IL-23 and IL-1.	artinm	16-22	interleukin 1 complex	Mus musculus	35-39
27302110-13	2016	The results showed that curcumin treatment led to less macrophage infiltration and less local inflammatory responses as demonstrated by decreasing TNF-alpha, IL-1, and IL-6 levels.	Curcumin	24-32	interleukin 1 complex	Mus musculus	158-162
27100888-0	2016	IL-1 Contributes to the Anti-Cancer Efficacy of Ingenol Mebutate.	3-ingenyl angelate	48-64	interleukin 1 complex	Mus musculus	0-4
27100888-6	2016	These studies suggest IL-1, via its action on neutrophils, promotes the anti-cancer efficacy of ingenol mebutate, with ingenol mebutate treatment causing both IL-1beta induction and IL-1alpha released from keratinocytes.	3-ingenyl angelate	96-112	interleukin 1 complex	Mus musculus	22-26
26961674-5	2016	ISO also remarkably ameliorated HF-induced hepatic oxidative injury and inflammation by decreasing ALT, AST, and ALP levels; enhancing antioxidant enzyme activities; and inhibiting inflammatory cytokine (TNF-alpha, IL-1, IL-6) release.	Hafnium	32-34	interleukin 1 complex	Mus musculus	215-219
26961674-5	2016	ISO also remarkably ameliorated HF-induced hepatic oxidative injury and inflammation by decreasing ALT, AST, and ALP levels; enhancing antioxidant enzyme activities; and inhibiting inflammatory cytokine (TNF-alpha, IL-1, IL-6) release.	homoorientin	0-3	interleukin 1 complex	Mus musculus	215-219
27430908-3	2016	Here, we found that [Formula: see text]-(1,3)-glucan predominantly induced the tumor necrosis factor (TNF)-[Formula: see text], interleukin (IL)-1[Formula: see text], IL-6, IL-12p70, and nitric oxide, which was dependent on mitogen-activated protein kinases (MAPK) and nuclear factor (NF)-[Formula: see text]B signaling.	(1,3)-glucan	40-52	interleukin 1 complex	Mus musculus	128-146
26901413-14	2016	In conclusion, ArtinM stimulates the production of IL-17 by CD4+ T cells in two major ways: (I) through the induction of IL-23 and IL-1 by APCs and (II) through the direct interaction with CD3 on the CD4+ T cells.	artinm	15-21	interleukin 1 complex	Mus musculus	51-55
26712462-4	2016	Here we report that IL-1 receptor (IL-1R1) deficiency or blockade limits blood pressure elevation in this model by mitigating sodium reabsorption via the NKCC2 co-transporter in the nephron.	Sodium	126-132	interleukin 1 complex	Mus musculus	20-24
27041460-11	2016	Furthermore, hyperoside decreased LPS-stimulated production of TNF-alpha, IL-6, IL-1 and MMP-9 in the cells.	hyperoside	13-23	interleukin 1 complex	Mus musculus	80-84
26901413-0	2016	IL-17 Induction by ArtinM is Due to Stimulation of IL-23 and IL-1 Release and/or Interaction with CD3 in CD4+ T Cells.	artinm	19-25	interleukin 1 complex	Mus musculus	0-4
26901413-6	2016	Furthermore, we showed that ArtinM directly induced the IL-23 mRNA expression and the IL-1 production by macrophages.	artinm	28-34	interleukin 1 complex	Mus musculus	86-90
25852553-0	2015	IL-1 interacts with ethanol effects on GABAergic transmission in the mouse central amygdala.	Ethanol	20-27	interleukin 1 complex	Mus musculus	0-4
26220217-0	2015	Target Inhibition of IL-1 Receptor Prevents Ifosfamide Induced Hemorrhagic Cystitis in Mice.	Ifosfamide	44-54	interleukin 1 complex	Mus musculus	21-25
26611836-5	2015	Treatment of hyperoxia-exposed mice with either IL1 receptor antagonist to block IL1beta or glyburide to block the Nlrp3 inflammasome results in decreased inflammation and increased alveolarization.	Glyburide	92-101	interleukin 1 complex	Mus musculus	48-51
26599867-3	2015	Taking advantage of our masticatory behavior (Restrained/Gnawing) model, we herein show that IL-1alpha/1beta-double-knockout (IL-1-KO) mice exhibit compromised masseter muscle (MM) activity which is at least partially attributable to abnormalities of glucose handling (rapid glycogen depletion along with impaired glucose uptake) and dysfunction of IL-6 upregulation in working MMs.	Glycogen	275-283	interleukin 1 complex	Mus musculus	93-97
26599867-6	2015	Thus, our findings confirm that the locally-increased IL-1 elicited by masticatory behavior, although present small in amounts, contributes to supporting MM activity by maintaining normal glucose homeostasis in these muscles.	Glucose	188-195	interleukin 1 complex	Mus musculus	54-58
26527454-4	2015	A synergistic reaction between aging and ZnO NP exposure occurred regarding serum interleukin 1 (IL-1) and interleukin 6 (IL-6).	Zinc Oxide	41-44	interleukin 1 complex	Mus musculus	82-102
25616105-9	2015	Finally, airway epithelial NF-kB activation induced allergic sensitization in CAIKKbeta mice on Dox that required IL-4 and IL-1 signalling in vivo.	Doxorubicin	96-99	interleukin 1 complex	Mus musculus	123-127
25887886-4	2015	Tumors from mice treated with combined therapy of paclitaxel and the IL1 receptor antagonist anakinra exhibit increased number of M2 macrophages and vessel leakiness when compared with paclitaxel monotherapy-treated mice, indicating a prometastatic role of M2 macrophages in the IL1beta-deprived microenvironment.	Paclitaxel	185-195	interleukin 1 complex	Mus musculus	69-72
25843059-6	2015	Using qRT-PCR as a follow up to the array, we demonstrated that didox suppresses LPS-induced mRNA levels of iNOS, IL-6, IL-1, TNF-alpha, NF-kappabeta (p65), and p38-alpha, after 24h of treatment.	3,4-dihydroxybenzohydroxamic acid	64-69	interleukin 1 complex	Mus musculus	120-124
25175163-2	2015	HMF suppressed the osteoclast formation and PGE2 production induced by IL-1.	Dinoprostone	44-48	interleukin 1 complex	Mus musculus	71-75
25449670-10	2015	Collectively, our data demonstrate that acidified saline injection increases intramuscular IL-1 and IL-6, but not TNF; that intramuscular pre-treatment with an NF-kappaB inhibitor blocks mechanical hypersensitivity; and that genetic manipulation of the IL-1 and IL-6, but not TNF systems, prevents mechanical hypersensitivity following musculoskeletal sensitization.	Sodium Chloride	50-56	interleukin 1 complex	Mus musculus	91-95
25449670-10	2015	Collectively, our data demonstrate that acidified saline injection increases intramuscular IL-1 and IL-6, but not TNF; that intramuscular pre-treatment with an NF-kappaB inhibitor blocks mechanical hypersensitivity; and that genetic manipulation of the IL-1 and IL-6, but not TNF systems, prevents mechanical hypersensitivity following musculoskeletal sensitization.	Sodium Chloride	50-56	interleukin 1 complex	Mus musculus	253-257
26417317-5	2014	However, in case of IL-1ss, with the same dose (40 mg/Kg), jasmonic acid (11) exhibited significant reduction with 54.2 % followed by crocin (14) (50.2 %) and crocetin (4) (39.8 %) while L-mimosine (12) was found to reduce only 16.3 %.	jasmonic acid	59-72	interleukin 1 complex	Mus musculus	20-24
24945082-10	2014	MiR497, IL-6, and IL-1ss were upregulated after CCI but not affected by anesthetics.	CCI	48-51	interleukin 1 complex	Mus musculus	18-22
24718703-0	2014	Liver tumor promotion by 2,3,7,8-tetrachlorodibenzo-p-dioxin is dependent on the aryl hydrocarbon receptor and TNF/IL-1 receptors.	Polychlorinated Dibenzodioxins	25-60	interleukin 1 complex	Mus musculus	115-119
25104388-1	2014	25-Hydroxycholesterol suppresses interleukin-1-driven inflammation downstream of type I interferon.	25-hydroxycholesterol	0-21	interleukin 1 complex	Mus musculus	33-46
24685903-3	2014	Interleukin-1 (IL-1) family members IL-1alpha,beta are released from LPS-primed macrophages exposed to NPs, including silica NPs (SNPs), via activation of nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 inflammasomes.	Silicon Dioxide	118-124	interleukin 1 complex	Mus musculus	0-13
24685903-3	2014	Interleukin-1 (IL-1) family members IL-1alpha,beta are released from LPS-primed macrophages exposed to NPs, including silica NPs (SNPs), via activation of nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 inflammasomes.	Silicon Dioxide	118-124	interleukin 1 complex	Mus musculus	15-19
24718703-4	2014	The importance of this question arose from our earlier observation that aspects of the acute hepatocellular toxicity of dioxin are dependent upon IL1-like cytokine signaling.	Dioxins	120-126	interleukin 1 complex	Mus musculus	146-149
24718703-7	2014	Collectively, these data support the idea that the mechanism of dioxin acute hepatotoxicity and its activity as a promoter in a mouse two stage liver cancer model may be similar, i.e., tumor promotion by dioxin, like acute hepatotoxicity, are mediated by the linked action of two receptor systems, the AHR and the receptors for the "IL-1-like" cytokines.	Dioxins	64-70	interleukin 1 complex	Mus musculus	333-337
24558360-3	2014	IL-1RaKO arthritis models were injected intraperitoneally with EGCG three times per week after the first immunization.	epigallocatechin gallate	63-67	interleukin 1 complex	Mus musculus	0-4
24952384-8	2014	Pre-treatment with glimepiride significantly reduced TNF, IL-1 and IL-6 secretion from RAW 264 and microglial cells incubated with LPS, Abeta42, alphaSN and PrP82-146.	glimepiride	19-30	interleukin 1 complex	Mus musculus	58-62
24754510-7	2014	Tea saponin with OVA increased the expression of interleukin (IL)-1, IL-2, IL-12, interferon-gamma and tumor necrosis factor (TNF)-alpha and decreased the expression level of IL-10 and IL-8 in T-lymphocytes.	Saponins	4-11	interleukin 1 complex	Mus musculus	49-67
24590763-4	2014	Mechanistically, development of SPs was associated with a local decrease in epithelial barrier function, bacterial invasion, production of antimicrobials, and increased expression of several inflammatory factors such as IL-17, Cxcl2, Tnf-alpha, and IL-1.	Sodium phenolsulfonate	32-35	interleukin 1 complex	Mus musculus	220-224
24349275-8	2013	The macrophages differentiated from BMC of orlistat-administered mice showed characteristic features of M1 macrophage phenotype confirmed by expression of CD11c, TLR-2, generation of reactive oxygen species, phagocytosis, tumor cell cytotoxicity, production of IL-1,TNF-alpha and nitric oxide.	Orlistat	43-51	interleukin 1 complex	Mus musculus	261-265
24985584-4	2014	We hypothesized that heparin might inhibit burn-induced apoptosis in the spleen via suppression of the IL-1 pathway.	Heparin	21-28	interleukin 1 complex	Mus musculus	103-107
24985584-13	2014	CONCLUSION: Heparin inhibits burn-induced apoptosis of the spleen cells by suppressing IL-1 expression in mice.	Heparin	12-19	interleukin 1 complex	Mus musculus	87-91
24692850-11	2014	Blocking the function of IL-1 signal pathway could suppress the level of IL-17A, which played the major role in modulating silica-induced Th responses in vitro.	Silicon Dioxide	123-129	interleukin 1 complex	Mus musculus	25-29
23586622-12	2013	CONCLUSION: IL-1Ra regulates IL-1 activity and appears to reduce the levels of other inflammatory cytokines, including TNF-alpha and IL-6, while it also reduces expression of the EP4 receptor related to prostanoid sensitivity and osteoclast formation.	Prostaglandins	203-213	interleukin 1 complex	Mus musculus	12-16
24013028-5	2013	Therefore, we hypothesized that hypothalamic IL-1 gene expression is regulated by glucose and glucose-induced feeding suppression is mediated via hypothalamic IL-1 signaling.	Glucose	82-89	interleukin 1 complex	Mus musculus	45-49
24013028-5	2013	Therefore, we hypothesized that hypothalamic IL-1 gene expression is regulated by glucose and glucose-induced feeding suppression is mediated via hypothalamic IL-1 signaling.	Glucose	94-101	interleukin 1 complex	Mus musculus	45-49
24013028-5	2013	Therefore, we hypothesized that hypothalamic IL-1 gene expression is regulated by glucose and glucose-induced feeding suppression is mediated via hypothalamic IL-1 signaling.	Glucose	94-101	interleukin 1 complex	Mus musculus	159-163
24013028-11	2013	These findings support the role for hypothalamic IL-1 signaling in the mediation of the anorectic effect of glucose.	Glucose	108-115	interleukin 1 complex	Mus musculus	49-53
24076200-8	2013	Together, these findings revealed that RMP treatment effectively attenuated STZ-induced cytotoxicity in renal tissue, in which RMP-exerted renoprotection was associated with intrarenally debilitating inflammation reaction through blocking the IL-1/NF-kappaB pathway, thereby maintaining the renal homeostasis.	Streptozocin	76-79	interleukin 1 complex	Mus musculus	243-247
24351180-8	2013	These data also suggest that local delivery of IL-1Ra genes or recombinant proteins (anakinra) or other IL-1 antagonists such as antibodies or soluble IL-1 receptors would suppress sensor-induced tissue reactions and likely enhance glucose sensor function by inhibiting inflammation and wound healing at sensor implantation sites.	Glucose	232-239	interleukin 1 complex	Mus musculus	47-51
24351180-8	2013	These data also suggest that local delivery of IL-1Ra genes or recombinant proteins (anakinra) or other IL-1 antagonists such as antibodies or soluble IL-1 receptors would suppress sensor-induced tissue reactions and likely enhance glucose sensor function by inhibiting inflammation and wound healing at sensor implantation sites.	Glucose	232-239	interleukin 1 complex	Mus musculus	104-108
24351180-0	2013	Role of interleukin-1/interleukin-1 receptor antagonist family of cytokines in long-term continuous glucose monitoring in vivo.	Glucose	100-107	interleukin 1 complex	Mus musculus	8-21
23851196-0	2013	(-)-Epigallocatechin gallate amplifies interleukin-1-stimulated interleukin-6 synthesis in osteoblast-like MC3T3-E1 cells.	epigallocatechin gallate	0-28	interleukin 1 complex	Mus musculus	39-52
24351180-0	2013	Role of interleukin-1/interleukin-1 receptor antagonist family of cytokines in long-term continuous glucose monitoring in vivo.	Glucose	100-107	interleukin 1 complex	Mus musculus	22-35
24205219-3	2013	IL-1 plays a key role in inflammation-induced sickness behaviour, resulting in depressed locomotor activity, decreased exploration, reduced food and water intake and acute cognitive deficits.	Water	149-154	interleukin 1 complex	Mus musculus	0-4
23851196-4	2013	In the present study, we investigated the effect of EGCG on the IL-1 stimulated IL-6 synthesis in osteoblast-like MC3T3-E1 cells.	epigallocatechin gallate	52-56	interleukin 1 complex	Mus musculus	64-68
23851196-5	2013	EGCG significantly enhanced the IL-1-stimulated IL-6 synthesis in a dose-dependent manner in the range between 50 and 100 muM.	epigallocatechin gallate	0-4	interleukin 1 complex	Mus musculus	32-36
23851196-6	2013	EGCG increased the mRNA levels of IL-6 stimulated by IL-1.	epigallocatechin gallate	0-4	interleukin 1 complex	Mus musculus	53-57
23851196-7	2013	IL-1-induced phosphorylation of IkappaB and NF-kappaB were suppressed by EGCG.	epigallocatechin gallate	73-77	interleukin 1 complex	Mus musculus	0-4
23851196-9	2013	These results strongly suggest that EGCG enhances IL-1-stimulated IL-6 synthesis through inhibiting the AMPK-IkappaB/NF-kappaB pathway at the point between AMPK and IkappaB/NF-kappaB in osteoblasts.	epigallocatechin gallate	36-40	interleukin 1 complex	Mus musculus	50-54
24103259-9	2013	However, geniposide down-regulated the expression of TNF-alpha, IL-1, and IL-6, and also inhibited the expression of TLR4 and the activity of NF-kappaB.	geniposide	9-19	interleukin 1 complex	Mus musculus	64-68
23582173-4	2013	Accordingly diarrhoea and DSS-induced colon inflammation were impaired in ST2(-/-) BALB/c mice and exacerbated in wild-type mice by treatment with exogenous recombinant IL-33, associated respectively with reduced and enhanced expression of chemokines (CXCL9 and CXCL10), and inflammatory (IL-4, IL-13, IL-1, IL-6, IL-17) and angiogenic (vascular endothelial growth factor) cytokines in vivo.	dss	26-29	interleukin 1 complex	Mus musculus	295-299
23076999-0	2013	Reducing scar formation by regulation of IL-1 and MMP-9 expression by using sustained release of prednisolone-loaded PDLL microspheres in a murine wound model.	Prednisolone	97-109	interleukin 1 complex	Mus musculus	41-45
23455655-7	2013	DTPP-based PDT cell lysate vaccination had a significant inhibitory effect on tumor growth based on increased CD4(+)/CD8(+) ratios, NK cell percentages, elevated serum IFN-gamma and IL-1 levels, and lymphocyte aggregation at the edge of tumors.	DTPP	0-4	interleukin 1 complex	Mus musculus	182-186
23557965-8	2013	RESULTS: Metformin attenuated both arthritis scores and bone destruction in CAIA mice, decreased the serum levels of the pro-inflammatory cytokines, TNF-alpha and IL-1, and reduced the number of RORgammat+CD4+ T cells in the ALNs.	Metformin	9-18	interleukin 1 complex	Mus musculus	163-167
23317771-1	2013	Solution and surface chemical behavior of two phosphonium based ionic liquids triisobutyl (methyl) phosphonium tosylate (IL-1) and trihexyl (tetradecyl) phosphonium bis 2,4,4-(trimethylpentyl)phosphinate (IL-2) have been studied.	Phosphoranes	46-57	interleukin 1 complex	Mus musculus	121-125
23317771-6	2013	IL-1 can replace water in forming microemulsions with the oil isopropylmyristate (IPM), stabilized by IL-2 (surfactant)+isopropanol (IP as a co-surfactant) like the IL-1/IPM/(IL-2+IP) system.	isopropyl myristate	62-80	interleukin 1 complex	Mus musculus	0-4
23317771-6	2013	IL-1 can replace water in forming microemulsions with the oil isopropylmyristate (IPM), stabilized by IL-2 (surfactant)+isopropanol (IP as a co-surfactant) like the IL-1/IPM/(IL-2+IP) system.	isopropyl myristate	62-80	interleukin 1 complex	Mus musculus	165-169
23317771-6	2013	IL-1 can replace water in forming microemulsions with the oil isopropylmyristate (IPM), stabilized by IL-2 (surfactant)+isopropanol (IP as a co-surfactant) like the IL-1/IPM/(IL-2+IP) system.	isopropyl myristate	82-85	interleukin 1 complex	Mus musculus	0-4
23317771-6	2013	IL-1 can replace water in forming microemulsions with the oil isopropylmyristate (IPM), stabilized by IL-2 (surfactant)+isopropanol (IP as a co-surfactant) like the IL-1/IPM/(IL-2+IP) system.	isopropyl myristate	82-85	interleukin 1 complex	Mus musculus	165-169
23317771-6	2013	IL-1 can replace water in forming microemulsions with the oil isopropylmyristate (IPM), stabilized by IL-2 (surfactant)+isopropanol (IP as a co-surfactant) like the IL-1/IPM/(IL-2+IP) system.	2-Propanol	120-131	interleukin 1 complex	Mus musculus	0-4
23317771-6	2013	IL-1 can replace water in forming microemulsions with the oil isopropylmyristate (IPM), stabilized by IL-2 (surfactant)+isopropanol (IP as a co-surfactant) like the IL-1/IPM/(IL-2+IP) system.	2-Propanol	120-131	interleukin 1 complex	Mus musculus	165-169
23460134-2	2013	Here, we elucidate the striking anti-catabolic and anti-inflammatory effects of bovine lactoferricin (LfcinB) in the intervertebral disc (IVD) via antagonism of both IL-1 and LPS-mediated catabolic activity using in vitro and ex vivo analyses.	LFcinB	102-108	interleukin 1 complex	Mus musculus	166-170
24524041-10	2012	RESULTS: alphaTP-suc inhibits osteoclast formation in cocultures stimulated by IL-1 and decreased the level of expression of RANKL mRNA in osteoblasts.	alpha-Tocopherol	9-20	interleukin 1 complex	Mus musculus	79-83
23426399-5	2013	IL-1, IL-3, IL-6, TNF-alpha, TGF-beta, PDGF, MCP-1 and MIP-1 expression were higher in rapamycin-treated mice compared to the control group, however, IGF-1 expression was lower.	Sirolimus	87-96	interleukin 1 complex	Mus musculus	0-4
23943454-2	2013	We have shown that the Th2-inducing adjuvant aluminum hydroxide or exposure of the airways to house dust mite leads to the release of DAMPs: uric acid, ATP, and IL-1.	Aluminum Hydroxide	45-63	interleukin 1 complex	Mus musculus	161-165
23468973-2	2013	BCP crystals induce in vitro catabolic responses with the production of metalloproteases and inflammatory cytokines such as interleukin-1 (IL-1).	bcp	0-3	interleukin 1 complex	Mus musculus	139-143
23468973-3	2013	In vivo, IL-1 production induced by BCP crystals is both dependant and independent of NLRP3 inflammasome.	bcp	36-39	interleukin 1 complex	Mus musculus	9-13
23468973-4	2013	We aimed to clarify 1/ the role of BCP crystals in cartilage destruction and 2/ the role of IL-1 and NLRP3 inflammasome in cartilage degradation related to BCP crystals.	bcp	156-159	interleukin 1 complex	Mus musculus	92-96
24524041-11	2012	In addition, administered intraperitoneal injections of alphaTP-suc prevented IL-1-mediated osteoclast formation and bone loss in vivo.	alpha-Tocopherol	56-67	interleukin 1 complex	Mus musculus	78-82
23241108-5	2012	Substance P is capable to induce VEGF from mast cells, and IL-33, the newest pro-inflammatory member of the IL-1 cytokine family, augments the effect of SP in VEGF transcription and translation protein.	TFF2 protein, human	153-155	interleukin 1 complex	Mus musculus	108-112
22949675-9	2012	Silencing of the IL-1 receptor signaling in the central nervous system by brain-specific overexpression of the human IL-1 receptor antagonist (hIL1ra(Ast)(+/+) mice) leads to very low skeletal VAChT expression and ACh levels.	Acetylcholine	194-197	interleukin 1 complex	Mus musculus	17-21
25780643-13	2012	The ZnO NP HPPS, however, significantly activated NF-kappa B and up-regulated its dependent genes such as TNF-alpha, IL-1, and MCP-1.	Zinc Oxide	4-7	interleukin 1 complex	Mus musculus	117-121
22387558-0	2012	Cutting edge: nitrogen bisphosphonate-induced inflammation is dependent upon mast cells and IL-1.	nitrogen bisphosphonate	14-37	interleukin 1 complex	Mus musculus	92-96
24832046-5	2012	The role of IL-1 mediated inflammatory events in controlling tribbles expression was also addressed by inducing experimental atherosclerosis in ApoE-/-IL1R1-/- (double knockout) mice.	tribbles	61-69	interleukin 1 complex	Mus musculus	12-16
22560875-4	2012	IL-1 induced phosphorylation of AMPK-alpha (Thr-172), which regulates AMPK activities, and acetyl-CoA carboxylase, a direct substrate of AMPK.	Threonine	44-47	interleukin 1 complex	Mus musculus	0-4
22560875-8	2012	Wedelolactone, an inhibitor of IkappaB kinase, which reduced the phosphorylation both of IkappaB and NF-kappaB, significantly enhanced the IL-1-stimulated IL-6 synthesis.	wedelolactone	0-13	interleukin 1 complex	Mus musculus	139-143
24750630-2	2012	Treatment with MT-alpha-glucan (300 or 100 mg kg(-1)) could decrease the levels of fasting plasma glucose, triglycerides, cholesterol, free fatty acid, the proliferative response of macrophages and IL-1, NO production by macrophages significantly.	mt-alpha-glucan	15-30	interleukin 1 complex	Mus musculus	198-202
22453828-5	2012	Finally, an increase in cytosolic cathepsins, NLRP3-inflammasome activation, and IL-1 production is seen in dendritic cells from annexin A2-null mice, following exposure to polyethylene particles.	Polyethylene	173-185	interleukin 1 complex	Mus musculus	81-85
22307082-4	2012	With the help of a novel O-GlcNAc site-specific antibody, we demonstrate that O-GlcNAcylation of TAB1 is induced by IL-1 and osmotic stress, known inducers of the TAK1 signalling cascade.	o-glcnac	25-33	interleukin 1 complex	Mus musculus	116-120
22293356-2	2012	Involvement of inflammatory cytokines, particularly interleukin-1 (IL-1), in alterations of HMGR and Cyp7a1 gene expression during development of lead nitrate (LN)-induced hypercholesterolemia was examined in IL-1alpha/beta-knockout (IL-1-KO) and wild-type (WT) mice.	lead nitrate	146-158	interleukin 1 complex	Mus musculus	67-71
22293356-0	2012	Involvement of interleukin-1 in lead nitrate-induced hypercholesterolemia in mice.	Nitrates	37-44	interleukin 1 complex	Mus musculus	15-28
22293356-2	2012	Involvement of inflammatory cytokines, particularly interleukin-1 (IL-1), in alterations of HMGR and Cyp7a1 gene expression during development of lead nitrate (LN)-induced hypercholesterolemia was examined in IL-1alpha/beta-knockout (IL-1-KO) and wild-type (WT) mice.	lead nitrate	160-162	interleukin 1 complex	Mus musculus	52-65
22293356-2	2012	Involvement of inflammatory cytokines, particularly interleukin-1 (IL-1), in alterations of HMGR and Cyp7a1 gene expression during development of lead nitrate (LN)-induced hypercholesterolemia was examined in IL-1alpha/beta-knockout (IL-1-KO) and wild-type (WT) mice.	lead nitrate	160-162	interleukin 1 complex	Mus musculus	67-71
22293356-2	2012	Involvement of inflammatory cytokines, particularly interleukin-1 (IL-1), in alterations of HMGR and Cyp7a1 gene expression during development of lead nitrate (LN)-induced hypercholesterolemia was examined in IL-1alpha/beta-knockout (IL-1-KO) and wild-type (WT) mice.	lead nitrate	160-162	interleukin 1 complex	Mus musculus	209-213
22293356-3	2012	Lead nitrate treatment of WT mice led to not only a marked downregulation of the Cyp7a1 gene at 6-12 h, but also a significant upregulation of the HMGR gene at 12 h. However, such changes were not observed at significant levels in IL-1-KO mice, although a slight, transient downregulation of the Cyp7a1 gene and a minimal upregulation of the HMGR gene occurred at 6 h and 24 h, respectively.	lead nitrate	0-12	interleukin 1 complex	Mus musculus	231-235
23038000-8	2012	The activation of MPO and increase in IL-1, IL-6, TNF-alpha and IFN-gamma levels induced by CdCl(2) were also reduced by oxime.	Cadmium Chloride	92-99	interleukin 1 complex	Mus musculus	38-42
23038000-8	2012	The activation of MPO and increase in IL-1, IL-6, TNF-alpha and IFN-gamma levels induced by CdCl(2) were also reduced by oxime.	Oximes	121-126	interleukin 1 complex	Mus musculus	38-42
22606244-13	2012	For agents that inhibit translation through mechanisms that do not involve loss of potassium, high extracellular potassium suppresses IL-1ss processing through a mechanism that remains undefined.	Potassium	113-122	interleukin 1 complex	Mus musculus	134-138
23056330-6	2012	rVSV-induced pathology was reduced in mice deficient in the IL-1 receptor Type I, but the IL-1R-/- mice were fully protected from lethal rechallenge with a high dose of VSV.	rvsv	0-4	interleukin 1 complex	Mus musculus	60-64
22000485-2	2011	After we found the high expression of interleukin-1 receptor I (IL-1RI) gene in mice cardiac tissues with DOX-induced cardiotoxicity, we assumed interleukin-1 (IL-1) signaling might mediate acute DOX-induced cardiotoxicity.	Doxorubicin	106-109	interleukin 1 complex	Mus musculus	64-68
22000485-2	2011	After we found the high expression of interleukin-1 receptor I (IL-1RI) gene in mice cardiac tissues with DOX-induced cardiotoxicity, we assumed interleukin-1 (IL-1) signaling might mediate acute DOX-induced cardiotoxicity.	Doxorubicin	196-199	interleukin 1 complex	Mus musculus	38-51
22000485-2	2011	After we found the high expression of interleukin-1 receptor I (IL-1RI) gene in mice cardiac tissues with DOX-induced cardiotoxicity, we assumed interleukin-1 (IL-1) signaling might mediate acute DOX-induced cardiotoxicity.	Doxorubicin	196-199	interleukin 1 complex	Mus musculus	145-158
22000485-2	2011	After we found the high expression of interleukin-1 receptor I (IL-1RI) gene in mice cardiac tissues with DOX-induced cardiotoxicity, we assumed interleukin-1 (IL-1) signaling might mediate acute DOX-induced cardiotoxicity.	Doxorubicin	196-199	interleukin 1 complex	Mus musculus	64-68
22000485-5	2011	Furthermore, IL-1 signaling was found to express higher with the increased dosage of DOX treatment.	Doxorubicin	85-88	interleukin 1 complex	Mus musculus	13-17
22027773-4	2011	RESULTS: Polyethylene wear particles-stimulated inflammatory responses (increased cellular infiltration and IL-1 and TNF production) were markedly reduced by IL-4 treatment either alone or combined with OPG (P&lt;0.05).	Polyethylene	9-21	interleukin 1 complex	Mus musculus	108-120
22000485-0	2011	Interleukin-1 signaling mediates acute doxorubicin-induced cardiotoxicity.	Doxorubicin	39-50	interleukin 1 complex	Mus musculus	0-13
22000485-2	2011	After we found the high expression of interleukin-1 receptor I (IL-1RI) gene in mice cardiac tissues with DOX-induced cardiotoxicity, we assumed interleukin-1 (IL-1) signaling might mediate acute DOX-induced cardiotoxicity.	Doxorubicin	106-109	interleukin 1 complex	Mus musculus	38-51
22000485-2	2011	After we found the high expression of interleukin-1 receptor I (IL-1RI) gene in mice cardiac tissues with DOX-induced cardiotoxicity, we assumed interleukin-1 (IL-1) signaling might mediate acute DOX-induced cardiotoxicity.	Doxorubicin	106-109	interleukin 1 complex	Mus musculus	145-158
20936359-12	2011	RT-PCR demonstrated that both IL-1 and IL-10 expression were up-regulated in DSS-induced colitis while heparin lessened the up-regulation extent.	Dextran Sulfate	77-80	interleukin 1 complex	Mus musculus	30-34
21690387-3	2011	In mice, intraperitoneal NBP administration causes a rapid influx of neutrophils and monocytes that is dependent on the myeloid differentiation primary response gene 88 (MyD88) mediator of Toll-like receptor (TLR) and IL-1 signaling.	nbp	25-28	interleukin 1 complex	Mus musculus	218-222
21464611-7	2011	Studies with IL-1R-deficient mice demonstrate that IL-1 signaling plays a role in doxorubicin-induced increases in IL-6 and GCSF.	Doxorubicin	82-93	interleukin 1 complex	Mus musculus	13-17
21458563-4	2011	After L-165041 treatment, serum TNFalpha, IL-6 and IL-1 levels were significantly decreased in STZ mice.	4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid	6-14	interleukin 1 complex	Mus musculus	51-55
21458563-4	2011	After L-165041 treatment, serum TNFalpha, IL-6 and IL-1 levels were significantly decreased in STZ mice.	Streptozocin	95-98	interleukin 1 complex	Mus musculus	51-55
21952987-3	2011	Splenocytes of infected mice (C3H/HeN) responded to Tc-antigenic stimulus by more than a two-fold increase in NADPH oxidase (NOX) activity, ROS generation, cytokine production (IFN-gamma &gt; IL-4 &gt; TNFalpha &gt; IL1-beta  IL6), and predominant expansion of CD4(+) and CD8(+) T cells.	Technetium	52-54	interleukin 1 complex	Mus musculus	216-219
21760510-8	2011	There are some intriguing results and hypotheses about the link between isoprenoid metabolism and the IL-1 pathway through geranylgeranylation that deserve to be further examined.	Terpenes	72-82	interleukin 1 complex	Mus musculus	102-106
21605706-9	2011	Specifically, down-regulation of P-gp by Venlafaxine (VLX) inhibits the differentiation of DC and cytokine production, such as IL-1, IL-10, and IL-12 during DC maturation.	Venlafaxine Hydrochloride	41-52	interleukin 1 complex	Mus musculus	127-131
21605706-9	2011	Specifically, down-regulation of P-gp by Venlafaxine (VLX) inhibits the differentiation of DC and cytokine production, such as IL-1, IL-10, and IL-12 during DC maturation.	Venlafaxine Hydrochloride	54-57	interleukin 1 complex	Mus musculus	127-131
21593451-8	2011	In Teff, A2aR activation (CGS21680) potently inhibited the release of IL-1, IL-2, IL-3, IL-4, IL-12, IL-13, IFN-gamma, TNF-alpha, granulocyte-macrophage colony-stimulating factor (GM-CSF), CCL3, and CCL4.	2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine	26-34	interleukin 1 complex	Mus musculus	70-74
21258168-3	2011	In vitro, nobiletin suppressed osteoclast formation and bone resorption induced by interleukin (IL)-1.	nobiletin	10-19	interleukin 1 complex	Mus musculus	83-101
21279999-0	2011	Octacalcium phosphate crystals induce inflammation in vivo through interleukin-1 but independent of the NLRP3 inflammasome in mice.	octacalcium phosphate	0-21	interleukin 1 complex	Mus musculus	67-80
21279999-13	2011	Additionally, OCP crystals induce IL-1-dependent peritoneal inflammation without requiring the NLRP3 inflammasome.	octacalcium phosphate	14-17	interleukin 1 complex	Mus musculus	34-38
21731759-7	2011	Interestingly, leptin upregulatory effects on cell proliferation/migration and pro-angiogenic factors Notch, IL-1 and VEGF/VEGFR-2 were abrogated by a gamma-secretase inhibitor, DAPT, as well as siRNA against CSL.	dapt	178-182	interleukin 1 complex	Mus musculus	79-113
24278534-6	2010	When mice were intraperitoneally injected with carbon fullerene, serum cytokine levels of IL-1 and IL-6 were increased with the increased expression of inflammatory genes in peritoneal macrophage and T cell distribution in blood lymphocytes.The results suggested inflammatory responses were induced by carbon fullerene.	carbon fullerene	47-63	interleukin 1 complex	Mus musculus	90-94
24278534-6	2010	When mice were intraperitoneally injected with carbon fullerene, serum cytokine levels of IL-1 and IL-6 were increased with the increased expression of inflammatory genes in peritoneal macrophage and T cell distribution in blood lymphocytes.The results suggested inflammatory responses were induced by carbon fullerene.	carbon fullerene	302-318	interleukin 1 complex	Mus musculus	90-94
21036709-3	2010	MATERIALS AND METHODS: The capacity of IL-1 Ra anakinra to reduce IL-1-induced production of IL-6 in order to improve the efficacy of a subsequent booster vaccination with survivin-derived peptides and soluble beta-glucan as adjuvant was tested in colon-26 adenocarcinoma-bearing Balb/c-mice.	beta-Glucans	210-221	interleukin 1 complex	Mus musculus	39-43
20601188-7	2010	In addition, diosgenin inhibits production of reactive oxygen species (ROS), interleukin-1 (IL-1), and IL-6, but not that of tumor necrosis factor-alpha (TNF-alpha).	Diosgenin	13-22	interleukin 1 complex	Mus musculus	77-96
20609517-9	2010	Similarly, IL-1beta-induced hyperalgesia in LysM-GRK2(f/+) mice is attenuated by intrathecal administration of anti-CX3CR1 to abrogate fractalkine signaling, the p38 inhibitor SB239063 and the IL-1 antagonist IL-1ra.	SB 239063	176-184	interleukin 1 complex	Mus musculus	11-15
20637853-11	2010	In the BCG/LPS model, increase of the levels of important pro-inflammatory mediators TNF-alpha and IL-1 was significantly (P&lt;0.01) suppressed by AEAA pretreatment.	aeaa	148-152	interleukin 1 complex	Mus musculus	99-103
20100194-3	2010	Treatment of the mouse ear with LXA(4) exhibited the inhibitory effects on oedema, neutrophil infiltration, vascular permeability, expressions of interleukin (IL)-1, IL-6 and IL-8 mRNA, DNA-binding activity of nuclear factor-kappaB (NF-kappaB), and on dermal hyperplasia.	N-(1H-benzimidazol-2-ylmethyl)-2-methoxyacetamide	32-35	interleukin 1 complex	Mus musculus	146-164
20846471-8	2010	IL-33 is the newest inflammatory member of the IL-1 cytokine family and we show here that SP can induce VEGF secretion from mast cells and IL-33 augments the effect of SP in VEGF transcription and translation protein.	TFF2 protein, human	90-92	interleukin 1 complex	Mus musculus	47-51
20659336-12	2010	Co-cultures of ova-specific CD4+ T cells from naive mice and CD11c+ pulmonary cells from NO2-exposed mice produced IL-1, IL-12p70, and IL-6 in vitro and augmented antigen-induced IL-5 production.	Nitrogen Dioxide	89-92	interleukin 1 complex	Mus musculus	115-119
20846471-8	2010	IL-33 is the newest inflammatory member of the IL-1 cytokine family and we show here that SP can induce VEGF secretion from mast cells and IL-33 augments the effect of SP in VEGF transcription and translation protein.	TFF2 protein, human	168-170	interleukin 1 complex	Mus musculus	47-51
19766171-8	2009	In contrast, IL-1 significantly increased glutamate uptake by Muller cells and the number of surviving RGCs in the wild-type and EAAC1-deficient mice.	Glutamic Acid	42-51	interleukin 1 complex	Mus musculus	13-17
20428172-7	2010	Similarly, when injected intraperitoneally, cholesterol crystals induce acute inflammation, which is impaired in mice deficient in components of the NLRP3 inflammasome, cathepsin B, cathepsin L or IL-1 molecules.	Cholesterol	44-55	interleukin 1 complex	Mus musculus	197-201
19766171-5	2009	IL-1 promoted increased glutamate uptake in Muller cells by suppressing intracellular Na(+) accumulation, which is necessary to counteract Na(+)-glutamate cotransport.	Glutamic Acid	24-33	interleukin 1 complex	Mus musculus	0-4
19843943-9	2009	These findings represent a novel mechanism by which thalidomide exerts its pharmacological activity and suggest that inhibition of the activity of IL-1 might represent a novel strategy to substitute thalidomide.	Thalidomide	52-63	interleukin 1 complex	Mus musculus	147-151
19843943-9	2009	These findings represent a novel mechanism by which thalidomide exerts its pharmacological activity and suggest that inhibition of the activity of IL-1 might represent a novel strategy to substitute thalidomide.	Thalidomide	199-210	interleukin 1 complex	Mus musculus	147-151
19572781-7	2009	A single intraperitoneal injection of dexamethasone (10 mg/kg body weight) 1 hour after melphalan exposure significantly reduced interleukin (IL)-1 and IL-6 in bronchoalveolar lavage fluid (BALF) and diminished the acute airway inflammation.	Dexamethasone	38-51	interleukin 1 complex	Mus musculus	129-147
19572781-7	2009	A single intraperitoneal injection of dexamethasone (10 mg/kg body weight) 1 hour after melphalan exposure significantly reduced interleukin (IL)-1 and IL-6 in bronchoalveolar lavage fluid (BALF) and diminished the acute airway inflammation.	Melphalan	88-97	interleukin 1 complex	Mus musculus	129-147
19703244-3	2009	However, when the mice were pretreated with cyclophosphamide, bacteremia-induced mortality was significantly greater in the IL-1-deficient mice than in the WT mice (P &lt; 0.01).	Cyclophosphamide	44-60	interleukin 1 complex	Mus musculus	124-128
19342666-1	2009	Using IL-1/IL-1Ra knockout BALB/c mice, we showed that 3-methylcholatrene (3-MCA)-induced carcinogenesis is dependent on IL-1beta-induced inflammatory responses.	3-methylcholatrene	55-73	interleukin 1 complex	Mus musculus	6-10
19059888-6	2009	Compared with bleomycin-treated mice, dmPGE(2) co-treated mice exhibited a reduced degree of body weight loss and mortality rate as well as of lung damage and inflammation, as shown by the significant reduction of: (1) lung infiltration by leukocytes; (2) myeloperoxidase activity; (3) IL-1, TNF-alpha, and nitrotyrosine immunostaining; (4) lung edema; and (5) histologic evidence of lung injury and collagen deposition.	dmpge	38-43	interleukin 1 complex	Mus musculus	286-290
19342666-1	2009	Using IL-1/IL-1Ra knockout BALB/c mice, we showed that 3-methylcholatrene (3-MCA)-induced carcinogenesis is dependent on IL-1beta-induced inflammatory responses.	Methylcholanthrene	75-80	interleukin 1 complex	Mus musculus	6-10
19338766-0	2009	Hyaluronan inhibits bone resorption by suppressing prostaglandin E synthesis in osteoblasts treated with interleukin-1.	Hyaluronic Acid	0-10	interleukin 1 complex	Mus musculus	105-118
19338766-0	2009	Hyaluronan inhibits bone resorption by suppressing prostaglandin E synthesis in osteoblasts treated with interleukin-1.	Prostaglandins E	51-66	interleukin 1 complex	Mus musculus	105-118
19338766-3	2009	Bone resorption associated with inflammation is closely related to prostaglandin E (PGE) synthesis by osteoblasts induced by cytokines such as interleukin-1 (IL-1).	Prostaglandins E	67-82	interleukin 1 complex	Mus musculus	143-156
19338766-3	2009	Bone resorption associated with inflammation is closely related to prostaglandin E (PGE) synthesis by osteoblasts induced by cytokines such as interleukin-1 (IL-1).	Prostaglandins E	67-82	interleukin 1 complex	Mus musculus	158-162
19338766-3	2009	Bone resorption associated with inflammation is closely related to prostaglandin E (PGE) synthesis by osteoblasts induced by cytokines such as interleukin-1 (IL-1).	Prostaglandins E	84-87	interleukin 1 complex	Mus musculus	143-156
19338766-3	2009	Bone resorption associated with inflammation is closely related to prostaglandin E (PGE) synthesis by osteoblasts induced by cytokines such as interleukin-1 (IL-1).	Prostaglandins E	84-87	interleukin 1 complex	Mus musculus	158-162
19338766-4	2009	In mouse calvarial cultures, HA inhibited osteoclastic bone resorption and PGE production induced by IL-1.	Prostaglandins E	75-78	interleukin 1 complex	Mus musculus	101-105
19338766-5	2009	In mouse osteoblasts, HA suppressed IL-1-induced expression of cyclooxygenase(COX)-2 and membrane-bound PGE synthase (mPGES)-1 mRNAs, and PGE2 production.	Dinoprostone	138-142	interleukin 1 complex	Mus musculus	36-40
19236331-2	2009	There is a peripheral component in the hypoglycemia that the cytokine induces resulting from an increased glucose uptake, an effect that can be exerted in a paracrine fashion at the site where IL-1 is locally produced.	Glucose	106-113	interleukin 1 complex	Mus musculus	193-197
19236331-5	2009	Here we report that administration of IL-1 or long-lasting insulin results in different changes in food intake and in neuroendocrine mechanisms 8 h following induction of the same degree of hypoglycemia (40-45% decrease in glucose blood levels).	Glucose	223-230	interleukin 1 complex	Mus musculus	38-42
18442781-3	2008	Diacerhein has antiinflammatory properties, inhibiting IL-1.	diacerein	0-10	interleukin 1 complex	Mus musculus	55-59
19101514-0	2009	IL-1 regulates the Cyp7a1 gene and serum total cholesterol level at steady state in mice.	Cholesterol	47-58	interleukin 1 complex	Mus musculus	0-4
18617512-5	2008	Consistently, TAK1 mutant with alanine substitution of these two residues severely inhibits IL-1-induced NFkappaB and AP-1 activities, whereas TAK1 mutant with replacement of these two sites with acidic residues slightly enhances IL-1-induced NFkappaB and AP-1 activities compared with the TAK1 wild-type.	Alanine	31-38	interleukin 1 complex	Mus musculus	92-96
18617512-6	2008	IL-1 induces the phosphorylation of endogenous TAK1 at Thr-178 and Thr-184.	Threonine	55-58	interleukin 1 complex	Mus musculus	0-4
18617512-6	2008	IL-1 induces the phosphorylation of endogenous TAK1 at Thr-178 and Thr-184.	Threonine	67-70	interleukin 1 complex	Mus musculus	0-4
17700577-6	2008	The blunting of the adrenocortical activation in IL-1rKO mice may play a causal role in their resistance to depression, because removal of endogenous glucocorticoids by adrenalectomy also abolished the depressive-like effects of CMS, whereas chronic administration of corticosterone for 4 weeks produced depressive symptoms and reduced neurogenesis in both WT and IL-1rKO mice.	Corticosterone	268-282	interleukin 1 complex	Mus musculus	49-53
18325987-7	2008	IL-1- or IL-6-mediated acute-phase response was inhibited by fenofibrate treatment in liver-specific PPARalpha-expressing mice but not in PPARalpha-deficient mice.	Fenofibrate	61-72	interleukin 1 complex	Mus musculus	0-5
18068099-5	2008	A time-dependent enhancement showed that the production of IL-1, NO and IL-12 were significantly increased within 6 h. Superoxide anion (O(2)(-)) production by macrophages from GP-treated mice was higher than that of cells from untreated mice.	Superoxides	119-135	interleukin 1 complex	Mus musculus	59-63
18508495-2	2008	Recent studies show that reduced calorie intake and supplementation of diet with n-3 FA delays the onset of autoimmune renal disease, primarily, due to increased antioxidant enzyme activities, decreased NF-kappaB activation and decreased IL-1, IL-6 and TNF-alpha mRNA expression in the kidney tissue.	Fatty Acids, Omega-3	81-87	interleukin 1 complex	Mus musculus	238-242
17960567-10	2008	Cells in alginate treated with BMP-2 resulted in increased synthesis of proteoglycan which was released into the conditioned media on IL-1 stimulation.	Alginates	9-17	interleukin 1 complex	Mus musculus	134-138
17618512-3	2008	Titanium is a commonly utilized metal in joint arthroplasty and titanium debris induces the production of the pro-inflammatory cytokine IL-1.	Titanium	0-8	interleukin 1 complex	Mus musculus	136-140
17618512-3	2008	Titanium is a commonly utilized metal in joint arthroplasty and titanium debris induces the production of the pro-inflammatory cytokine IL-1.	Titanium	64-72	interleukin 1 complex	Mus musculus	136-140
18068099-5	2008	A time-dependent enhancement showed that the production of IL-1, NO and IL-12 were significantly increased within 6 h. Superoxide anion (O(2)(-)) production by macrophages from GP-treated mice was higher than that of cells from untreated mice.	Superoxides	137-141	interleukin 1 complex	Mus musculus	59-63
18160842-2	2007	Here, we investigated whether celastrol, which has been used as a potent anti-inflammatory and anti-oxidative agent in Chinese medicine, attenuates excessive production of NO and proinflammatory cytokines such as TNF-alpha and IL-1betal in LPS-stimulated BV-2 cells, a mouse microglial cell line.	celastrol	30-39	interleukin 1 complex	Mus musculus	227-231
17992263-6	2007	Exogenous rIL-1beta recapitulated a high degree of bleomycin-induced lung pathology, and specific blockade of IL-1R1 by IL-1 receptor antagonist dramatically reduced bleomycin-induced inflammation.	Bleomycin	51-60	interleukin 1 complex	Mus musculus	11-15
17992263-8	2007	In conclusion, bleomycin-induced lung pathology required the inflammasome and IL-1R1/MyD88 signaling, and IL-1 represented a critical effector of pathology and therapeutic target of chronic lung inflammation and fibrosis.	Bleomycin	15-24	interleukin 1 complex	Mus musculus	78-82
18338607-6	2007	RESULT: Polysaccharide ATPS-2 from A. tabescens (25, 50, 100 mg x kg(-1)) could obviously reduce the high level of ALT, AST, NO and TNF-alpha, IL-1 on serum, inhibit the high level of MDA, increase the low activity of SOD in liver homogenate and enhance T-and B-lymphocyte proliferation, elevate the spleen, thymic index and decrease liver index of the mice to different extent.	Polysaccharides	8-22	interleukin 1 complex	Mus musculus	143-147
18338607-6	2007	RESULT: Polysaccharide ATPS-2 from A. tabescens (25, 50, 100 mg x kg(-1)) could obviously reduce the high level of ALT, AST, NO and TNF-alpha, IL-1 on serum, inhibit the high level of MDA, increase the low activity of SOD in liver homogenate and enhance T-and B-lymphocyte proliferation, elevate the spleen, thymic index and decrease liver index of the mice to different extent.	atps-2	23-29	interleukin 1 complex	Mus musculus	143-147
18231633-3	2008	IL-1 also stimulates PGE(2) synthesis in osteoblasts by regulation of cyclooxygenase (COX)-2 and regulates osteoclastic bone resorption in various diseases such as RA and osteoporosis.	Prostaglandins E	21-24	interleukin 1 complex	Mus musculus	0-4
18097146-5	2008	pGlcNAc treatment activates mitogen-activated protein kinase and increases Ets1, vascular endothelial growth factor (VEGF) and interleukin 1 (IL-1) expression.	poly-N-acetyl glucosamine	0-7	interleukin 1 complex	Mus musculus	127-146
17592750-6	2007	MPTP-induced microgliosis in striatum and olfactory bulb was reduced in IL-1alpha/beta knockout mice, indicating that IL-1 affects microglia activation.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	0-4	interleukin 1 complex	Mus musculus	72-76
17967442-1	2007	It is known that peripherally administered IL-1 and TNFalpha induce fever through mechanisms involving prostaglandin (PG)E2.	Dinoprostone	103-123	interleukin 1 complex	Mus musculus	43-47
18087241-14	2007	Tollip and IL-1 expressions were increased in some groups after BTX-B injection regardless of the treatment type.	btx-b	64-69	interleukin 1 complex	Mus musculus	11-15
17592750-7	2007	Importantly, MPTP induced differential regulation of IL-1 receptors.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	13-17	interleukin 1 complex	Mus musculus	53-57
17592750-10	2007	We suggest that differential regulation of IL-1 signaling can serve as an important mechanism to modulate neuroinflammatory activity after MPTP treatment and possibly during PD.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	139-143	interleukin 1 complex	Mus musculus	43-47
17569781-7	2007	Therefore, MSCs protect lung tissue from BLM-induced injury by blocking TNF-alpha and IL-1, two fundamental proinflammatory cytokines in lung.	Bleomycin	41-44	interleukin 1 complex	Mus musculus	86-90
17393517-2	2007	Supplementation with essential omega-3 polyunsaturated fatty acids (n-3 PUFA) has been demonstrated to lower TNF-alpha and IL-1 production in mononuclear cells.	essential omega-3 polyunsaturated fatty acids	21-66	interleukin 1 complex	Mus musculus	123-127
17669273-7	2007	IL-1-induced IL-6 production was augmented by coincubation with PGE(2).	Prostaglandins E	64-67	interleukin 1 complex	Mus musculus	0-4
17669273-8	2007	The COX inhibitor ibuprofen blocked IL-1-induced IL-6 and PGE(2) production.	Ibuprofen	18-27	interleukin 1 complex	Mus musculus	36-40
17669273-8	2007	The COX inhibitor ibuprofen blocked IL-1-induced IL-6 and PGE(2) production.	Dinoprostone	58-64	interleukin 1 complex	Mus musculus	36-40
17267173-3	2007	In naive mice, poly I:C (2mg/kg) modestly increased sickness behaviors, plasma IL-6, TNF-alpha and IL-10 levels, but did not affect IL-1, IL-4, or IFN-gamma.	Poly I-C	15-23	interleukin 1 complex	Mus musculus	99-103
17391719-6	2007	Chronic ethanol exposure resulted in increased marrow TNF, IL-1, and CYP 2E1 RNA levels in ethanol-treated vs. control mice, while no significant weight differences were noted.	Ethanol	8-15	interleukin 1 complex	Mus musculus	59-63
17391719-6	2007	Chronic ethanol exposure resulted in increased marrow TNF, IL-1, and CYP 2E1 RNA levels in ethanol-treated vs. control mice, while no significant weight differences were noted.	Ethanol	91-98	interleukin 1 complex	Mus musculus	59-63
17394136-12	2007	Infiltration of CD8 T cells is the most likely mechanism of muscle injury, and IL-1, but not B cells or TNFalpha, is crucial in the development of CIM.	cim	147-150	interleukin 1 complex	Mus musculus	79-83
17393517-2	2007	Supplementation with essential omega-3 polyunsaturated fatty acids (n-3 PUFA) has been demonstrated to lower TNF-alpha and IL-1 production in mononuclear cells.	Fatty Acids, Omega-3	68-76	interleukin 1 complex	Mus musculus	123-127
17393917-2	2007	A polysaccharide-rich precipitate of noni juice (noni-ppt) also stimulates tumor necrosis factor (TNF) and interleukin 1 (IL-1) in mice.	noni-ppt	49-57	interleukin 1 complex	Mus musculus	107-126
17393917-2	2007	A polysaccharide-rich precipitate of noni juice (noni-ppt) also stimulates tumor necrosis factor (TNF) and interleukin 1 (IL-1) in mice.	Polysaccharides	2-16	interleukin 1 complex	Mus musculus	107-126
17334237-2	2007	The purpose of this study was to determine whether interleukin (IL)-1 mediates burn-induced inducible nitric oxide synthase (iNOS) expression, peroxynitrite production, and lung damage through c-Jun NH2-terminal kinase (JNK) signaling.	Peroxynitrous Acid	143-156	interleukin 1 complex	Mus musculus	51-69
17334237-18	2007	Given that the IL-1 receptor is critical in thermal injury-induced p38 MAPK phosphorylation and ROS production of neutrophils, we conclude that IL-1 mediates thermal injury-induced iNOS expression and lung damage through the JNK signaling pathway.	Reactive Oxygen Species	96-99	interleukin 1 complex	Mus musculus	15-19
17334237-18	2007	Given that the IL-1 receptor is critical in thermal injury-induced p38 MAPK phosphorylation and ROS production of neutrophils, we conclude that IL-1 mediates thermal injury-induced iNOS expression and lung damage through the JNK signaling pathway.	Reactive Oxygen Species	96-99	interleukin 1 complex	Mus musculus	144-148
17352828-3	2007	The effectiveness of IL-1 inhibition was first evaluated in a mouse model of monosodium urate crystal-induced inflammation.	Uric Acid	77-93	interleukin 1 complex	Mus musculus	21-25
17505141-11	2007	(2) AC induces IL-1 mostly in non-MCs, but this IL-1 is not a prerequisite for the induction of HDC by AC.	Charcoal	4-6	interleukin 1 complex	Mus musculus	15-19
17105669-10	2006	IL-1 levels were significantly reduced in the alcohol plus resveratrol group compared with the alcohol group (p &lt; 0.05).	Alcohols	46-53	interleukin 1 complex	Mus musculus	0-4
16899235-1	2006	BACKGROUND: Lipoteichoic acid (LTA) and lipopolysaccharide (LPS), the toxicants from bacteria, are potent inducers of inflammatory cytokines, such as tumor necrosis factor-alpha (TNF) and interleukin-1beta (IL-1).	lipoteichoic acid	12-29	interleukin 1 complex	Mus musculus	207-211
16899235-1	2006	BACKGROUND: Lipoteichoic acid (LTA) and lipopolysaccharide (LPS), the toxicants from bacteria, are potent inducers of inflammatory cytokines, such as tumor necrosis factor-alpha (TNF) and interleukin-1beta (IL-1).	lipoteichoic acid	31-34	interleukin 1 complex	Mus musculus	207-211
17105669-10	2006	IL-1 levels were significantly reduced in the alcohol plus resveratrol group compared with the alcohol group (p &lt; 0.05).	Resveratrol	59-70	interleukin 1 complex	Mus musculus	0-4
17105669-10	2006	IL-1 levels were significantly reduced in the alcohol plus resveratrol group compared with the alcohol group (p &lt; 0.05).	Alcohols	95-102	interleukin 1 complex	Mus musculus	0-4
16883582-8	2006	IL-1 treatment of cells in alginate results in increased release of PG into the conditioned media.	Alginates	27-35	interleukin 1 complex	Mus musculus	0-4
16973626-6	2006	We show that glutathione S-transferase- or polyhistidine-tagged recombinant HBeAg can interact with endogenous mIL-1RAcP in vitro.	Glutathione	13-24	interleukin 1 complex	Mus musculus	111-116
16973626-6	2006	We show that glutathione S-transferase- or polyhistidine-tagged recombinant HBeAg can interact with endogenous mIL-1RAcP in vitro.	polyhistidine	43-56	interleukin 1 complex	Mus musculus	111-116
17035503-0	2006	IL-1 resets glucose homeostasis at central levels.	Glucose	12-19	interleukin 1 complex	Mus musculus	0-4
17035503-4	2006	This effect was largely antagonized by blockade of IL-1 receptors in the brain; and (iv) when animals with an advanced Type II diabetes were treated with IL-1 and challenged with glucose, they died in hypoglycemia.	Glucose	179-186	interleukin 1 complex	Mus musculus	51-55
17035503-5	2006	However, when IL-1 receptors in the brains of these diabetic mice were blocked, they survived, and glucose blood levels approached those that these mice had before IL-1 administration.	Glucose	99-106	interleukin 1 complex	Mus musculus	14-18
17035503-6	2006	The prolonged hypoglycemic effect of IL-1 is insulin-independent and develops against increased levels of glucocorticoids, catecholamines, and glucagon.	Catecholamines	123-137	interleukin 1 complex	Mus musculus	37-41
17035503-6	2006	The prolonged hypoglycemic effect of IL-1 is insulin-independent and develops against increased levels of glucocorticoids, catecholamines, and glucagon.	Glucagon	143-151	interleukin 1 complex	Mus musculus	37-41
16965564-8	2006	MG-132 treatment resulted in lower increase in IL-1, TNF-alpha and IL-10 levels.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	0-6	interleukin 1 complex	Mus musculus	47-51
16806339-12	2006	Levels of IL-1, IL-3, IL-6, IFN-gamma, G-CSF, and KC were higher in cultures of stimulated splenocytes from either DCAC- or DCAA-treated mice than from controls.	2,2-dichloroacetyl chloride	115-119	interleukin 1 complex	Mus musculus	10-14
16806339-12	2006	Levels of IL-1, IL-3, IL-6, IFN-gamma, G-CSF, and KC were higher in cultures of stimulated splenocytes from either DCAC- or DCAA-treated mice than from controls.	dichloroacetic anhydride	124-128	interleukin 1 complex	Mus musculus	10-14
16908863-5	2006	In parallel studies, we find that TSH directly inhibits TNFalpha production, reduces the number of TNFalpha-producing osteoclast precursors, and attenuates the induction of TNFalpha expression by IL-1, TNFalpha, and receptor activator of NF-kappaB ligand.	Thyrotropin	34-37	interleukin 1 complex	Mus musculus	196-254
16886064-0	2006	MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals.	Uric Acid	90-106	interleukin 1 complex	Mus musculus	16-20
17035503-2	2006	Here, we show that this effect can be elicited by endogenous IL-1 and is related to not only the capacity of the cytokine to increase glucose uptake in peripheral tissues but also to mechanisms integrated in the brain.	Glucose	134-141	interleukin 1 complex	Mus musculus	61-65
16818675-8	2006	Our findings demonstrate that IL-1 functions upstream of IL-17 to promote pathogenic ThIL-17 cells in EAE.	thil	85-89	interleukin 1 complex	Mus musculus	30-34
16751071-6	2006	Additionally, curcumin significantly decreased mRNA expression of early responding cytokines (IL-1 IL-6, IL-18, TNF-alpha, and lymphotoxin-beta) and the fibrogenic cytokine, TGF-beta, in cutaneous tissues at 21 days postradiation.	Curcumin	14-22	interleukin 1 complex	Mus musculus	94-103
19127725-0	2006	Alkali-soluble polysaccharides of Rhizoclonium riparium alga induce IL-1 gene expression via protein kinase signaling pathways.	Polysaccharides	15-30	interleukin 1 complex	Mus musculus	68-72
16677721-15	2006	This may reflect a role for IL-6 in the tryptophan and serotonin responses to IL-1 and LPS.	Tryptophan	40-50	interleukin 1 complex	Mus musculus	78-82
16677721-15	2006	This may reflect a role for IL-6 in the tryptophan and serotonin responses to IL-1 and LPS.	Serotonin	55-64	interleukin 1 complex	Mus musculus	78-82
19127725-4	2006	Using a murine-derived macrophage cell line J774A.1, we found that polysaccharide constituents of the higher molecular-weight group of RASP were able to induce interleukin-1beta (IL-1) gene expression via protein kinase-mediated signal transduction pathways.	Polysaccharides	67-81	interleukin 1 complex	Mus musculus	179-183
19127725-6	2006	To the best of our knowledge, this is the first occasion that polysaccharides from R. riparium have been demonstrated to exert immunomodulation properties by the induction of IL-1 within macrophages.	Polysaccharides	62-77	interleukin 1 complex	Mus musculus	175-179
16203021-0	2006	Mutual augmentation of the induction of the histamine-forming enzyme, histidine decarboxylase, between alendronate and immuno-stimulants (IL-1, TNF, and LPS), and its prevention by clodronate.	Histamine	44-53	interleukin 1 complex	Mus musculus	138-142
16203021-4	2006	We reported previously that in mice, (i) the inflammatory actions of N-BPs depend on IL-1, (ii) N-BP pretreatment augments both LPS-stimulated IL-1 production and HDC induction, and (iii) the co-administration of clodronate (a non-N-BP) with an N-BP inhibits the latter"s inflammatory actions (including HDC induction).	n-bps	69-74	interleukin 1 complex	Mus musculus	85-89
16646036-9	2006	This effect also occurred in inducible nitric oxide synthase-knockout mice, revealing the involvement of a secondary IL-1-induced factor other than nitric oxide.	nitric	39-45	interleukin 1 complex	Mus musculus	117-121
16646036-9	2006	This effect also occurred in inducible nitric oxide synthase-knockout mice, revealing the involvement of a secondary IL-1-induced factor other than nitric oxide.	Nitric Oxide	39-51	interleukin 1 complex	Mus musculus	117-121
16646036-14	2006	CONCLUSION: This study demonstrates that IL-1-induced SOCS-3 expression is a novel mechanism of IGF-1 desensitization in chondrocytes; in conjunction with nitric oxide it can contribute to cartilage damage during arthritis.	Nitric Oxide	155-167	interleukin 1 complex	Mus musculus	41-45
16309985-4	2006	RANKL stimulated OCL formation in a dose-dependent manner in bone marrow cultures, and this response was significantly inhibited by IL-1 RA (100 ng/ml), a specific IL-1 antagonist.	ocl	17-20	interleukin 1 complex	Mus musculus	132-136
16309985-5	2006	Interleukin-1 further increased OCL formation in BMM cultures that were treated with M-CSF (30 ng/ml) and RANKL (1, 3, 10 and 30 ng/ml).	ocl	32-35	interleukin 1 complex	Mus musculus	0-13
16309985-6	2006	In addition, BMM cultures from IL-1 type I receptor-deficient mice, which do not respond to IL-1, demonstrated significantly less OCL formation compared to wild-type BMM cultures.	ocl	130-133	interleukin 1 complex	Mus musculus	31-35
16309985-12	2006	In addition, SP600125, a specific JNK inhibitor, markedly reduced OCL formation in BMM cultures that were treated with RANKL or the combination of RANKL and IL-1.	pyrazolanthrone	13-21	interleukin 1 complex	Mus musculus	157-161
16203021-0	2006	Mutual augmentation of the induction of the histamine-forming enzyme, histidine decarboxylase, between alendronate and immuno-stimulants (IL-1, TNF, and LPS), and its prevention by clodronate.	Alendronate	103-114	interleukin 1 complex	Mus musculus	138-142
16203021-4	2006	We reported previously that in mice, (i) the inflammatory actions of N-BPs depend on IL-1, (ii) N-BP pretreatment augments both LPS-stimulated IL-1 production and HDC induction, and (iii) the co-administration of clodronate (a non-N-BP) with an N-BP inhibits the latter"s inflammatory actions (including HDC induction).	n-bp	69-73	interleukin 1 complex	Mus musculus	85-89
16203021-4	2006	We reported previously that in mice, (i) the inflammatory actions of N-BPs depend on IL-1, (ii) N-BP pretreatment augments both LPS-stimulated IL-1 production and HDC induction, and (iii) the co-administration of clodronate (a non-N-BP) with an N-BP inhibits the latter"s inflammatory actions (including HDC induction).	n-bp	96-100	interleukin 1 complex	Mus musculus	143-147
16203021-4	2006	We reported previously that in mice, (i) the inflammatory actions of N-BPs depend on IL-1, (ii) N-BP pretreatment augments both LPS-stimulated IL-1 production and HDC induction, and (iii) the co-administration of clodronate (a non-N-BP) with an N-BP inhibits the latter"s inflammatory actions (including HDC induction).	n-bp	96-100	interleukin 1 complex	Mus musculus	143-147
16203021-6	2006	These results suggest that (1) there are mutual augmentations between alendronate and immuno-stimulants (IL-1, TNF, and LPS) in HDC induction, (2) tissue IL-1beta is important in alendronate-stimulated HDC induction, and (3) combination use of clodronate may have the potential to reduce the inflammatory effects of alendronate (we previously found that clodronate, conveniently, does not inhibit the anti-bone-resorptive activity of alendronate).	Alendronate	70-81	interleukin 1 complex	Mus musculus	105-109
16204073-9	2005	Double culture of accessory cells with CT-26/antisense KITENIN/90K cells revealed increased secretion of IL-1 and IL-6.	CT-26	39-44	interleukin 1 complex	Mus musculus	105-109
16009389-1	2006	Simultaneous exposure to lipopolysaccharide (LPS) markedly amplifies induction of proinflammatory cytokine expression as well as IL-1-driven lymphocyte apoptosis by trichothecene deoxynivalenol (DON) in the mouse.	trichothecene deoxynivalenol	165-193	interleukin 1 complex	Mus musculus	129-133
16009389-1	2006	Simultaneous exposure to lipopolysaccharide (LPS) markedly amplifies induction of proinflammatory cytokine expression as well as IL-1-driven lymphocyte apoptosis by trichothecene deoxynivalenol (DON) in the mouse.	deoxynivalenol	195-198	interleukin 1 complex	Mus musculus	129-133
16433833-0	2006	Induction of IL-1, in the testes of adult mice, following subcutaneous administration of turpentine.	Turpentine	89-99	interleukin 1 complex	Mus musculus	13-17
16433833-3	2006	In the present study we examined the effect of acute mostly localized inflammation, using turpentine, on the expression levels of testicular IL-1 system.	Turpentine	90-100	interleukin 1 complex	Mus musculus	141-145
16426146-5	2006	DHEA also significantly reduced the mitogen-induced production of the proinflammatory cytokine interleukin-1 (IL-1) as well as the Th1 cytokines IL-2 and interferon-gamma (IFN-gamma).	Dehydroepiandrosterone	0-4	interleukin 1 complex	Mus musculus	95-114
16198389-2	2005	In this study, the effects of BaV on the release of the cytokines IL-1, IL-6 and TNF-alpha and the eicosanoids LTB4 and TXA2 in the peritoneal cavity of mice were analyzed.	CHEMBL564010	30-33	interleukin 1 complex	Mus musculus	66-70
16198389-4	2005	Levels of proinflammatory cytokines IL-6 and TNF-alpha, as well as eicosanoids LTB4 and TXA2 were significantly increased after BaV injection (250 microg/kg), whereas no increment in IL-1 was observed.	CHEMBL564010	128-131	interleukin 1 complex	Mus musculus	183-187
16176557-7	2005	Alendronate produced normal bisphosphonate lines in IL-1-deficient mice, too.	Alendronate	0-11	interleukin 1 complex	Mus musculus	52-56
16176557-8	2005	These results suggest that clodronate and/or dexamethasone may be suitable for preventing or reducing the inflammatory side effects of nitrogen-containing bisphosphonates while preserving their powerful anti-bone-resorptive activities (although in practice the known side effects of dexamethasone may limit its use), and that the anti-bone resorptive activities of nitrogen-containing bisphosphonates are not influenced by IL-1.	Clodronic Acid	27-37	interleukin 1 complex	Mus musculus	423-427
16176557-8	2005	These results suggest that clodronate and/or dexamethasone may be suitable for preventing or reducing the inflammatory side effects of nitrogen-containing bisphosphonates while preserving their powerful anti-bone-resorptive activities (although in practice the known side effects of dexamethasone may limit its use), and that the anti-bone resorptive activities of nitrogen-containing bisphosphonates are not influenced by IL-1.	Dexamethasone	45-58	interleukin 1 complex	Mus musculus	423-427
16825798-1	2006	BACKGROUND: This study examined the role of glucocorticoids (GC) and interleukin-1 (IL-1) in regulating the production of brain prostaglandin E(2) (PGE(2)) in response to surgical stress.	Dinoprostone	128-146	interleukin 1 complex	Mus musculus	84-88
16825798-1	2006	BACKGROUND: This study examined the role of glucocorticoids (GC) and interleukin-1 (IL-1) in regulating the production of brain prostaglandin E(2) (PGE(2)) in response to surgical stress.	Prostaglandins E	148-151	interleukin 1 complex	Mus musculus	84-88
16825798-4	2006	IL-1 involvement in mediating PGE(2) response to surgical stress was examined in IL-1 receptor type I deficient (IL-1rKO) mice.	Prostaglandins E	30-33	interleukin 1 complex	Mus musculus	0-4
16825798-9	2006	Normal IL-1 signaling is required for the production of brain PGE(2) under basal conditions and in response to surgical stress.	Dinoprostone	62-68	interleukin 1 complex	Mus musculus	7-11
17047394-12	2006	The time courses of the IL-1- and LPS-induced increases in plasma corticosterone paralleled those in the reduction in milk drinking, however, the changes in body temperature appeared later.	Corticosterone	66-80	interleukin 1 complex	Mus musculus	24-28
17047394-14	2006	The decreased milk drinking may occur when IL-1 and LPS bind to receptors on brain endothelial cells subsequently inducing COX-2 and the production of prostanoids which elicit the reductions in milk drinking.	Prostaglandins	151-162	interleukin 1 complex	Mus musculus	43-47
15885468-2	2005	We hypothesized that the absence of the IL-1 type-1 receptor would mitigate the inflammatory response to titanium particles and decrease periprosthetic inflammatory tissue in a murine intramedullary rod model.	Titanium	105-113	interleukin 1 complex	Mus musculus	40-44
15996692-1	2005	It is well established that peripheral administration of interleukin-1 (IL-1) and lipopolysaccharide (LPS) can activate the hypothalamo-pituitary-adrenocortical (HPA) axis, alter brain catecholamine and indoleamine metabolism, and affect behavior.	Catecholamines	185-198	interleukin 1 complex	Mus musculus	57-76
15996692-1	2005	It is well established that peripheral administration of interleukin-1 (IL-1) and lipopolysaccharide (LPS) can activate the hypothalamo-pituitary-adrenocortical (HPA) axis, alter brain catecholamine and indoleamine metabolism, and affect behavior.	indolamine	203-214	interleukin 1 complex	Mus musculus	57-76
15950734-9	2005	The rF1-induced activation of p42/44 MAPK was correlated to the functional activation of macrophages by demonstrating the inhibition of actin rearrangement, IL-1, TNF-alpha and NO production caused by PD98059 in the rF1-treated macrophages.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	201-208	interleukin 1 complex	Mus musculus	157-161
16045030-7	2005	Diazepam inhibited the serum levels of ALT, AST, TNF-alpha and IL-1, and reduced levels of MDA, NO and NOS and increased levels of GR and SOD in the liver.	Diazepam	0-8	interleukin 1 complex	Mus musculus	63-67
16045030-8	2005	Modafinil decreased liver histological feature, increased the serum levels of ALT, AST, TNF-alpha and IL-1, increased level of MDA, and inhabited levels of SOD and GR in the liver.	Modafinil	0-9	interleukin 1 complex	Mus musculus	102-106
15965081-1	2005	Ceramide is a pro-apoptotic lipid messenger that induces oxidative stress and may mediate apoptosis in cerebral endothelial cells (CECs) induced by TNF-alpha/cycloheximide, lipopolysaccharide, oxidized LDL, IL-1, and amyloid peptide.	Ceramides	0-8	interleukin 1 complex	Mus musculus	207-211
16210060-0	2005	Prevention of IL-1 signaling attenuates airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma.	Toluene 2,4-Diisocyanate	105-125	interleukin 1 complex	Mus musculus	14-18
16210060-3	2005	OBJECTIVE: We sought to determine the role of IL-1 signaling in airway reactivity and inflammation by using a murine model of TDI-induced asthma.	Toluene 2,4-Diisocyanate	126-129	interleukin 1 complex	Mus musculus	46-50
16210060-6	2005	Prevention of IL-1 signaling through deletion of the IL-1 receptor type I or administration of neutralizing antibodies to both IL-1beta and IL-1alpha abrogated the development of TDI-induced asthma.	Toluene 2,4-Diisocyanate	179-182	interleukin 1 complex	Mus musculus	14-18
15691869-4	2005	2-Methyl-2-[[1-(phenylmethyl)-1H-indazol-3yl]methoxy]propanoic acid (bindarit) has been shown to preferentially inhibit MCP-1 production in vitro in monocytes and in vivo without affecting the production of the cytokines IL-1, IL-6, or the chemokines IL-8, protein macrophage inflammatory-1alpha, and RANTES.	bindarit	69-77	interleukin 1 complex	Mus musculus	221-225
15893609-0	2005	A role of IL-1 in MPTP-induced changes in striatal dopaminergic and serotoninergic transporter binding: clues from interleukin-1 type I receptor-deficient mice.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	18-22	interleukin 1 complex	Mus musculus	10-14
15885468-9	2005	CONCLUSIONS: These results implicate IL-1 as an important modulator in the local inflammatory response to intramedullary titanium particles.	Titanium	121-129	interleukin 1 complex	Mus musculus	37-41
15722456-0	2005	Aspects of dioxin toxicity are mediated by interleukin 1-like cytokines.	Dioxins	11-17	interleukin 1 complex	Mus musculus	43-56
15836969-4	2005	Morphine-induced analgesia was also extended in strains of mice genetically impaired in IL-1 signaling (mice with transgenic over-expression of IL-1 receptor antagonist, deletion of the IL-1 receptor type I, or deletion of the IL-1 receptor accessory protein).	Morphine	0-8	interleukin 1 complex	Mus musculus	88-92
15836969-4	2005	Morphine-induced analgesia was also extended in strains of mice genetically impaired in IL-1 signaling (mice with transgenic over-expression of IL-1 receptor antagonist, deletion of the IL-1 receptor type I, or deletion of the IL-1 receptor accessory protein).	Morphine	0-8	interleukin 1 complex	Mus musculus	144-148
15836969-5	2005	The finding that IL-1 produces a marked anti-analgesic effect, suggests that it may also be involved in the development of opiate tolerance.	Opiate Alkaloids	123-129	interleukin 1 complex	Mus musculus	17-21
15836969-6	2005	Indeed, genetic or pharmacological blockade of IL-1 signaling prevented the development of tolerance following repeated morphine administration.	Morphine	120-128	interleukin 1 complex	Mus musculus	47-51
15836969-7	2005	Moreover, acute administration of IL-1ra in wild type mice, either immediately following the cessation of acute morphine analgesia, or following the development of chronic morphine tolerance, re-instated the analgesia, suggesting that blockade of the IL-1 system unmasks the analgesic effect of morphine.	Morphine	112-120	interleukin 1 complex	Mus musculus	34-38
15836969-7	2005	Moreover, acute administration of IL-1ra in wild type mice, either immediately following the cessation of acute morphine analgesia, or following the development of chronic morphine tolerance, re-instated the analgesia, suggesting that blockade of the IL-1 system unmasks the analgesic effect of morphine.	Morphine	172-180	interleukin 1 complex	Mus musculus	34-38
15836969-7	2005	Moreover, acute administration of IL-1ra in wild type mice, either immediately following the cessation of acute morphine analgesia, or following the development of chronic morphine tolerance, re-instated the analgesia, suggesting that blockade of the IL-1 system unmasks the analgesic effect of morphine.	Morphine	172-180	interleukin 1 complex	Mus musculus	34-38
15836969-8	2005	These findings suggest that morphine produces an IL-1-mediated homeostatic response, which serves to limit the duration and extent of morphine analgesia and which underlies the development of tolerance.	Morphine	28-36	interleukin 1 complex	Mus musculus	49-53
15836969-8	2005	These findings suggest that morphine produces an IL-1-mediated homeostatic response, which serves to limit the duration and extent of morphine analgesia and which underlies the development of tolerance.	Morphine	134-142	interleukin 1 complex	Mus musculus	49-53
15722456-3	2005	Given their common roles in chemically induced toxicity, we asked whether interleukin 1 (IL1)-like cytokines play a role in acute aspects of the dioxin response.	Dioxins	145-151	interleukin 1 complex	Mus musculus	74-92
15862160-0	2005	[Kinetic changes of plasma IL-1 and IL-6 levels in MPTP-induced Parkinson"s disease model mice and their relationship with brain asymmetry].	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	51-55	interleukin 1 complex	Mus musculus	27-31
15862160-9	2005	Plasma IL-1 levels also increased on day 3 after last time injection of MPTP, and the level of left pawed mice was higher than that of right pawed mice.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	72-76	interleukin 1 complex	Mus musculus	7-11
15862160-10	2005	CONCLUSION: IL-6 and IL-1 probably participate in the occurrence and progress of MPTP-induced PD in model mice, and were related with brain asymmetry.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	81-85	interleukin 1 complex	Mus musculus	21-25
16046848-4	2005	Unilateral HI was induced at postnatal day 9 in IL-1beta, IL-1beta18, and IL-1alphabeta knockout and wild-type mice and brain injury was evaluated 1 week later.	hi	11-13	interleukin 1 complex	Mus musculus	48-52
15836969-3	2005	We report that administration of a neutral dose of IL-1beta abolished morphine analgesia in mice, whereas acute or chronic blockade of IL-1 signaling by various IL-1 blockers (IL-1 receptor antagonist (IL-1ra), alpha-melanocyte-stimulating hormone, or IL-1 tri-peptide antagonist) significantly prolonged and potentiated morphine analgesia.	Morphine	70-78	interleukin 1 complex	Mus musculus	51-55
15785120-7	2005	Pretreatment with DTC counteracted restraint stress-induced immunosuppression, which is expressed as partial normalisation of the total number of thymocytes, splenocytes and IL-1 production, accelerated regeneration of thymus and spleen, shorter suppressive action of restraint stress on the percentage of CD4+CD8+thymocytes and in total normalisation of the CD4+thymocytes and splenocytes.	Ditiocarb	18-21	interleukin 1 complex	Mus musculus	174-178
15785120-9	2005	The immunocorrecting action of DTC is enhanced by zinc supplementation, expressed in the increased percentage of CD4+thymocytes and splenocytes, CD19+splenocytes, proliferative activity of thymocytes stimulated with PHA and IL-1 production.	Ditiocarb	31-34	interleukin 1 complex	Mus musculus	224-228
15621690-3	2004	Many inflammatory mediators (e.g. TNF-alpha, IL-1 and IL-6) are involved in the pathogenesis of shock and, among them, nitric oxide (NO).	Nitric Oxide	119-131	interleukin 1 complex	Mus musculus	45-49
15271886-2	2004	Previously, we showed that, upon injection with turpentine, IL-1 is induced in the brain in association with the development of fever.	Turpentine	48-58	interleukin 1 complex	Mus musculus	60-64
15271886-9	2004	These observations suggest a mechanism of IL-1-induced febrile response in which IL-1 in the blood activates Cox-2, with the resulting prostaglandin E(2) inducing IL-6 in the brain, leading to the development of fever.	Dinoprostone	135-153	interleukin 1 complex	Mus musculus	42-46
15271886-9	2004	These observations suggest a mechanism of IL-1-induced febrile response in which IL-1 in the blood activates Cox-2, with the resulting prostaglandin E(2) inducing IL-6 in the brain, leading to the development of fever.	Dinoprostone	135-153	interleukin 1 complex	Mus musculus	81-85
15072850-7	2004	Investigating the signal transduction pathway responsible for the NO, TNF-alpha and IL-1 production by the UVB-irradiated macrophages, it was observed that the pharmacological inhibitors pertussis toxin, wortmannin, PD98059, SB202190 and genistein blocked NO, TNF-alpha and IL-1 production suggesting the probable involvement of G-proteins, phosphoinositol-3-kinase, p42/44, p38 mitogen activated protein kinases and tyrosine kinases in the above process.	Wortmannin	204-214	interleukin 1 complex	Mus musculus	84-88
15099528-8	2004	These results suggest that (i) in liver, lung and spleen, either the major cells supplying histamine via HDC induction in response to LPS and IL-1 are not mast cells, or mast cells are not a prerequisite for the induction of HDC; (ii) the cells in which HDC is induced by LPS and IL-1 are similar or identical in a given organ; and (iii) neither IL-1 nor TNF-alpha is a prerequisite for the induction of HDC by LPS.	Histamine	91-100	interleukin 1 complex	Mus musculus	142-146
15585847-4	2004	In contrast, reversal of Treg anergy is dependent on TLR activation of DCs, and involves the potentiation of Treg responsiveness to IL-2 by cooperative effects of IL-6 and IL-1, both of which are produced by TLR-activated, mature DCs.	treg	25-29	interleukin 1 complex	Mus musculus	172-176
15585847-4	2004	In contrast, reversal of Treg anergy is dependent on TLR activation of DCs, and involves the potentiation of Treg responsiveness to IL-2 by cooperative effects of IL-6 and IL-1, both of which are produced by TLR-activated, mature DCs.	treg	109-113	interleukin 1 complex	Mus musculus	172-176
21241555-5	2004	Compared to saline treatment, indomethacin intervention apparently down regulated the levels of IL-1, IL-6 and TNF-alpha ( P &lt; 0.05 ), and remarkably prolonged the survival of mice ( P &lt; 0.05).	Indomethacin	30-42	interleukin 1 complex	Mus musculus	96-100
15237105-10	2004	The peritoneal IL-17 levels after FFL-injection were greatly diminished in IL-1-deficient mice.	ffl	34-37	interleukin 1 complex	Mus musculus	15-19
14754758-6	2004	Inhalation of dexamethasone, an inhibitor of IL-1 production, blocked the development of AHR, BAL fluid neutrophilia, and decreased levels of IL-1 following O(3) exposure.	Dexamethasone	14-27	interleukin 1 complex	Mus musculus	45-49
14754758-6	2004	Inhalation of dexamethasone, an inhibitor of IL-1 production, blocked the development of AHR, BAL fluid neutrophilia, and decreased levels of IL-1 following O(3) exposure.	Dexamethasone	14-27	interleukin 1 complex	Mus musculus	142-146
14754758-7	2004	In summary, acute exposure to O(3) induces AHR, neutrophilic inflammation, epithelial damage, and IL-1.	Ozone	30-34	interleukin 1 complex	Mus musculus	98-102
12751959-4	2003	In addition, ginsan induced the endogenous production of cytokines such as Il1, Il6, Ifng and Il12, which are required for hematopoietic recovery, and was able to enhance Th1 function while interfering with the Th2 response in irradiated mice.	ginsan	13-19	interleukin 1 complex	Mus musculus	75-78
14764723-9	2004	IL-1 also stimulated PGE(2) production in osteoblasts and osteoclast formation in the cocultures, and the stimulation was inhibited by NS398.	Prostaglandins E	21-24	interleukin 1 complex	Mus musculus	0-4
14764723-11	2004	These results suggest that IL-1 as well as LPS stimulates osteoclastogenesis through two parallel events: direct enhancement of RANKL expression and suppression of OPG expression, which is mediated by PGE(2) production.	Prostaglandins E	201-204	interleukin 1 complex	Mus musculus	27-31
14670622-2	2004	Acetylaminofluorene inhibited IL-1 production in LPS-stimulated splenic macrophages and RAW 264.7 cells.	2-Acetylaminofluorene	0-19	interleukin 1 complex	Mus musculus	30-34
14693703-7	2004	IL-1 reportedly makes an important pathological contribution in the multidose streptozotocin model of diabetes; however, there was no difference in sensitivity to streptozotocin between NOD mice and NOD.Casp1(-/-) mice at 40 mg/kg body wt or at 25 mg/kg body wt dosage levels.	Streptozocin	78-92	interleukin 1 complex	Mus musculus	0-4
14688369-7	2004	D10 cell proliferation assay revealed MA-IL-1 bioactivity of paraformaldehyde-fixed synoviocytes and the further induction of endogenous mouse MA-IL-1 via autocrine mechanisms.	paraform	61-77	interleukin 1 complex	Mus musculus	41-45
12975454-5	2003	When IL-1Ra-/- mice were treated with monosodium glutamate (MSG), which causes obesity in wild-type mice by ablating cells in the hypothalamic arcuate nucleus, they were resistant to obesity, indicating that excess IL-1 signaling antagonizes the effect of MSG-sensitive neuron deficiency.	Sodium Glutamate	38-58	interleukin 1 complex	Mus musculus	5-9
12975454-5	2003	When IL-1Ra-/- mice were treated with monosodium glutamate (MSG), which causes obesity in wild-type mice by ablating cells in the hypothalamic arcuate nucleus, they were resistant to obesity, indicating that excess IL-1 signaling antagonizes the effect of MSG-sensitive neuron deficiency.	Sodium Glutamate	60-63	interleukin 1 complex	Mus musculus	5-9
12698271-6	2003	Following stimulation in culture, PEC from DOX-treated mice produced more TNF, IL1, and IFNgamma than PEC from untreated mice.	Doxorubicin	43-46	interleukin 1 complex	Mus musculus	79-82
14758446-8	2004	Higher IL1 expression was detected in islets of vitamin D-deficient mice and their peritoneal macrophages had an aberrant cytokine profile (low IL1 and IL6, high IL15).	Vitamin D	48-57	interleukin 1 complex	Mus musculus	7-10
14758446-8	2004	Higher IL1 expression was detected in islets of vitamin D-deficient mice and their peritoneal macrophages had an aberrant cytokine profile (low IL1 and IL6, high IL15).	Vitamin D	48-57	interleukin 1 complex	Mus musculus	144-147
15021970-5	2004	RESULTS: Thymidine incorporation into CTLL cells, induced by IL-1, was reduced dose dependently by IL-1ra and TGF-beta 1.	Thymidine	9-18	interleukin 1 complex	Mus musculus	61-65
12780687-5	2003	Interleukin (IL)-1 activity was measured by a mouse thymocyte activation assayed by MTT dye reduction and tumour necrosis factor (TNF) activity was measured by an L929 cytotoxicity bioassay.	monooxyethylene trimethylolpropane tristearate	84-87	interleukin 1 complex	Mus musculus	0-18
12743173-5	2003	Osteoblastic bone marrow stromal cells induced the expression of cyclooxygenase (COX)-2 and membrane-bound PGE2 synthase (mPGES) in response to IL-1 and lipopolysaccharide (LPS) to produce PGE2.	Dinoprostone	107-111	interleukin 1 complex	Mus musculus	144-148
12451469-2	2002	When interleukin-1alpha (IL-1) is given in a murine model, it induces acute hemorrhagic necrosis, tumor vascular injury and decreased tumor blood flow, and when given prior to carboplatin, there is enhanced antitumor activity compared to either agent alone.	Carboplatin	176-187	interleukin 1 complex	Mus musculus	25-29
12697697-1	2003	The cytokines IL-1 and IL-6 are able to induce prostaglandin (PG)-dependent activation of the hypothalamo-pituitary-adrenal axis (HPAA) and are thought to play key roles in immune-neuroendocrine interactions during inflammation.	Prostaglandins	47-60	interleukin 1 complex	Mus musculus	14-18
12697697-1	2003	The cytokines IL-1 and IL-6 are able to induce prostaglandin (PG)-dependent activation of the hypothalamo-pituitary-adrenal axis (HPAA) and are thought to play key roles in immune-neuroendocrine interactions during inflammation.	Prostaglandins	62-64	interleukin 1 complex	Mus musculus	14-18
12637202-7	2003	Prazosin, an alpha1/alpha2 adrenoreceptor antagonist, drastically increased plasma IL-10 induced by LPS, reduced plasma levels of IL-1 and abolished the effect of lateralization observed after LPS alone.	Prazosin	0-8	interleukin 1 complex	Mus musculus	83-87
12743173-4	2003	In bone marrow cultures, interleukin (IL)-1 markedly stimulated PGE2 production and osteoclast formation in wild-type mice, but not in cPLA2alpha-null mice.	Dinoprostone	64-68	interleukin 1 complex	Mus musculus	25-43
12563314-4	2003	Failure to generate ceramide-enriched membrane platforms in infected cells results in an unabated inflammatory response, massive release of interleukin (IL)-1 and septic death of mice.	Ceramides	20-28	interleukin 1 complex	Mus musculus	140-158
12631467-8	2003	Infarct volumes were significantly lower in IL-1 KO mice compared with wild-type mice 48 h after tMCAO (P&lt;0.01).	tmcao	97-102	interleukin 1 complex	Mus musculus	44-48
12631467-9	2003	The immunoreactivities of 3-nitro-L-tyrosine were determined in the neurons and microvasculature 24 h after tMCAO and were significantly decreased in the IL-1 KO mice compared to wild-type mice.	3-nitrotyrosine	26-44	interleukin 1 complex	Mus musculus	154-158
12631467-11	2003	These results indicate that IL-1 is up-regulated and may play a role in neurodegeneration by peroxynitrite production during ischemia.	Peroxynitrous Acid	93-106	interleukin 1 complex	Mus musculus	28-32
12568403-4	2003	IL-1 increased blood calcium and bone resorption in wild-type (wt), p50, and p52 single KO mice, but not in 3/4KO or dKO mice.	Calcium	21-28	interleukin 1 complex	Mus musculus	0-4
12532458-7	2003	Leflunomide (4, 12, 36 mg.kg(-1)) significantly lowered TNF-alpha and NO level in serum, and IL-1 produced by intraperitoneal macrophages(PMphi).	Leflunomide	0-11	interleukin 1 complex	Mus musculus	93-97
12485356-7	2002	It has also been found that a single hydrocortisone dose decreases interleukin (IL)-1 production by murine intraperitoneal macrophages stimulated in vitro with lipopolysaccharide (LPS) from Escherichia coli.	Hydrocortisone	37-51	interleukin 1 complex	Mus musculus	67-85
12819374-3	2002	10(-9)M TCDD increased IFNgamma and TNFalpha gene expression, but suppressed IL-1 gene expression.	Polychlorinated Dibenzodioxins	8-12	interleukin 1 complex	Mus musculus	77-81
12819374-4	2002	10(-6)M phenol inhibited IL-1, IL-6 and TNFalpha gene expression, and 10(-6)M of 2-BP downregulated TNFalpha gene expression.	Phenol	8-14	interleukin 1 complex	Mus musculus	25-29
11994463-4	2002	In normal pOCs, IL-1 induces actin ring formation and tyrosine phosphorylation of p130(Cas), a known substrate of c-Src.	Tyrosine	54-62	interleukin 1 complex	Mus musculus	16-20
12421476-5	2002	Ethanol had no significant influence on 24 h MPM IL-1 production, but it promoted the ability of resveratrol on enhancing the IL-1 release from activated MPM.	Ethanol	0-7	interleukin 1 complex	Mus musculus	126-130
12421476-5	2002	Ethanol had no significant influence on 24 h MPM IL-1 production, but it promoted the ability of resveratrol on enhancing the IL-1 release from activated MPM.	Resveratrol	97-108	interleukin 1 complex	Mus musculus	126-130
12419972-0	2002	Production of interleukin-1 activity of Kupffer cells from mice treated with the acidic mannan fraction of baker"s yeast.	Mannans	88-94	interleukin 1 complex	Mus musculus	14-27
12419972-1	2002	We investigated the production of interleukin-1 (IL-1) activity by Kupffer cells (KC) from mice treated with a neutral mannan fraction (WNM) or an acidic mannan fraction (WAM025) from baker"s yeast (Saccharomyces cerevisiae) in vivo and in vitro.	Mannans	119-125	interleukin 1 complex	Mus musculus	34-53
12419972-1	2002	We investigated the production of interleukin-1 (IL-1) activity by Kupffer cells (KC) from mice treated with a neutral mannan fraction (WNM) or an acidic mannan fraction (WAM025) from baker"s yeast (Saccharomyces cerevisiae) in vivo and in vitro.	Mannans	154-160	interleukin 1 complex	Mus musculus	34-53
12419972-4	2002	Diisopropyl fluorophosphate completely inhibited the production of IL-1 by KC from the mice administered WAM025.	Isoflurophate	0-27	interleukin 1 complex	Mus musculus	67-71
12096892-7	2002	As a substitute for the infection, mice were injected with IL-1 and/or IL-6; Pb exacerbated sickness behavior only in mice injected peripherally with IL-1 and IL-6.	Lead	77-79	interleukin 1 complex	Mus musculus	59-63
12096892-7	2002	As a substitute for the infection, mice were injected with IL-1 and/or IL-6; Pb exacerbated sickness behavior only in mice injected peripherally with IL-1 and IL-6.	Lead	77-79	interleukin 1 complex	Mus musculus	150-154
12349947-7	2002	Inhibitor studies with genistein on MCP-1-induced macrophage TNF and IL-1 production additionally supported the role of protein tyrosine phosphorylation in the process of macrophage activation with MCP-1.	Genistein	23-32	interleukin 1 complex	Mus musculus	69-73
12012430-5	2002	In contrast, the inducible nitric oxide (iNOS) immunoreactivity after global ischemia was reduced in IL-1 knockout mice as compared with wild-type mice.	Nitric Oxide	27-39	interleukin 1 complex	Mus musculus	101-105
12012430-6	2002	The levels of nitrite (NO(2) (-)) and nitrate (NO(3) (-)) in the hippocampus of wild-type mice were increased with time after ischemia-reperfusion, whereas the increase was significantly inhibited in IL-1 knockout mice.	Nitrites	14-21	interleukin 1 complex	Mus musculus	200-204
12012430-7	2002	These observations strongly suggest that endogenous IL-1 contributes to ischemic brain damage, and this influence may act through the release of nitric oxide by iNOS.	Nitric Oxide	145-157	interleukin 1 complex	Mus musculus	52-56
12529962-2	2002	In the murine colon-26 (C-26) adenocarcinoma model IL-1, secreted by tumor-infiltrating mononuclear phagocytes, has an important role in induction of cancer cachexia.	Carbon	24-25	interleukin 1 complex	Mus musculus	51-55
12115237-4	2002	RESULTS: In the presence of AdLacZ-infected FLS, titanium particle-stimulated macrophages exhibited a marked increase in secretion of tumor necrosis factor alpha (TNFalpha) (6.5-fold), IL-6 (13-fold), and IL-1 (5-fold).	Titanium	49-57	interleukin 1 complex	Mus musculus	205-209
11561079-8	2001	Oral administration of CP-424,174 to mice resulted in inhibition of IL-1 in the absence of an effect on IL-6 and TNFalpha.	cp-424	23-29	interleukin 1 complex	Mus musculus	68-72
11892896-7	2002	In contrast, quinolones inhibit both human and mouse monocytic IL-1 and TNF-alpha synthesis, an effect that is beneficial in rat experimental type II collagen induced arthritis and LPS-induced septic chock in mice.	Quinolones	13-23	interleukin 1 complex	Mus musculus	63-67
11594749-1	2001	Interleukin-1 (IL-1) regulation of tPA in hepatocytes was studied in mouse hepatocyte line AML12.	Tetradecanoylphorbol Acetate	35-38	interleukin 1 complex	Mus musculus	0-13
11594749-1	2001	Interleukin-1 (IL-1) regulation of tPA in hepatocytes was studied in mouse hepatocyte line AML12.	Tetradecanoylphorbol Acetate	35-38	interleukin 1 complex	Mus musculus	15-19
11594749-2	2001	IL-1 induced transient accumulation of tPA mRNA as high as threefold by 2 h after the start of treatment.	Tetradecanoylphorbol Acetate	39-42	interleukin 1 complex	Mus musculus	0-4
11594749-5	2001	IL-1 stimulated the uptake of (125)I-tPA by AML 12.	i-tpa	35-40	interleukin 1 complex	Mus musculus	0-4
11594749-7	2001	These results revealed that low-density lipoprotein receptor-related protein (LRP), which is known to be a receptor for tPA and to be blocked by RAP, was up-regulated by IL-1.	Tetradecanoylphorbol Acetate	120-123	interleukin 1 complex	Mus musculus	170-174
12056513-10	2002	Additional evidence for beneficial effects in osseous inflammation was provided by an in vitro assay in which bindarit inhibited the release of MCP-1 from IL-1 stimulated osteoblast cells.	bindarit	110-118	interleukin 1 complex	Mus musculus	155-159
11826401-6	2002	This increased susceptibility to APAP-induced liver injury appeared to correlate with an elevated expression of liver proinflammatory cytokines, tumor necrosis factor (TNF)-alpha, and IL-1, as well as inducible nitric oxide synthase (iNOS).	Acetaminophen	33-37	interleukin 1 complex	Mus musculus	184-188
12512557-2	2002	once and four times to mice on the phagocytic and killing ability of peritoneal macrophages, interleukin-1 (IL-1) production by murine macrophages stimulated in vitro with lipopolisaccharide of E. coli and expression of thymocyte, splenocyte and mesenteric lymphonode cell CD3+, CD4+ and CD8+ markers were studied.	lipopolisaccharide	172-190	interleukin 1 complex	Mus musculus	93-112
12579968-5	2001	IL-1, IL-2 and ConA-induced splenocyte proliferation response were determined by methods of 3H-infiltrated cell proliferation.	Tritium	92-94	interleukin 1 complex	Mus musculus	0-4
11810767-8	2001	Meanwhile, the serum level of IL-6, TNF-alpha and IL-1 in the INDT group was found to be significantly low in comparison with the NST group.	Indomethacin	62-66	interleukin 1 complex	Mus musculus	50-54
11435459-5	2001	The novel JNK inhibitor SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) completely blocked IL-1--induced accumulation of phospho-Jun and induction of c-Jun transcription in synoviocytes.	pyrazolanthrone	24-32	interleukin 1 complex	Mus musculus	86-90
11418636-3	2001	Ab production against SRBC was significantly reduced in IL-1alpha/beta-deficient (IL-1(-/-)) mice and enhanced in IL-1R antagonist(-/-) mice.	srbc	22-26	interleukin 1 complex	Mus musculus	56-60
11508495-8	2001	The results obtained here suggest that IL-1 is involved in the physiological mechanisms of stress reactions, operating at the levels of IL-1 production and its biological actions on lymphoid target cells, as well as at the level of cytokine signal transduction via the sphingomyelin pathway in nerve tissue.	Sphingomyelins	269-282	interleukin 1 complex	Mus musculus	39-43
11435459-5	2001	The novel JNK inhibitor SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) completely blocked IL-1--induced accumulation of phospho-Jun and induction of c-Jun transcription in synoviocytes.	pyrazolanthrone	34-65	interleukin 1 complex	Mus musculus	86-90
11158262-0	2001	Dexamethasone up-regulates type II IL-1 receptor in mouse primary activated astrocytes.	Dexamethasone	0-13	interleukin 1 complex	Mus musculus	35-39
11509229-7	2001	Indomethacin pretreatment almost prevented the feeding responses to IL-1 in normal and COX1ko mice.	Indomethacin	0-12	interleukin 1 complex	Mus musculus	68-72
11158262-4	2001	IL-1beta-activated mouse primary astrocytes were treated with 10(-6) M dexamethasone, and IL-1 receptors were studied at the mRNA and protein levels.	Dexamethasone	71-84	interleukin 1 complex	Mus musculus	0-4
11137713-2	2001	Protein tyrosine kinase (PTK) inhibitors attenuated the stimulated superoxide, hydrogen peroxide, and nitric oxide production in macrophages stimulated with IL-1, LPS, or fMLP.	Superoxides	67-77	interleukin 1 complex	Mus musculus	157-161
11016935-7	2001	Subsequent ATP injection to wild-type animals promotes an increase in IL-1, which in turn leads to additional IL-6 production; similar increases did not occur in ATP-treated, LPS-primed P2X(7)R(-/-) animals.	Adenosine Triphosphate	11-14	interleukin 1 complex	Mus musculus	70-74
11137713-2	2001	Protein tyrosine kinase (PTK) inhibitors attenuated the stimulated superoxide, hydrogen peroxide, and nitric oxide production in macrophages stimulated with IL-1, LPS, or fMLP.	Hydrogen Peroxide	79-96	interleukin 1 complex	Mus musculus	157-161
11137713-2	2001	Protein tyrosine kinase (PTK) inhibitors attenuated the stimulated superoxide, hydrogen peroxide, and nitric oxide production in macrophages stimulated with IL-1, LPS, or fMLP.	Nitric Oxide	102-114	interleukin 1 complex	Mus musculus	157-161
11137713-7	2001	Genistein and tyrphostin decreased the production of IL-8 and GM-CSF in macrophages activated by IL-1, whereas 2,5-dihydroxycinnamate did not affect it.	Genistein	0-9	interleukin 1 complex	Mus musculus	97-101
11137713-7	2001	Genistein and tyrphostin decreased the production of IL-8 and GM-CSF in macrophages activated by IL-1, whereas 2,5-dihydroxycinnamate did not affect it.	Tyrphostins	14-24	interleukin 1 complex	Mus musculus	97-101
11201166-5	2001	However, in the presence of indomethacin, IL-1 down-regulates the receptor by destabilizing IL-1 receptor mRNA.	Indomethacin	28-40	interleukin 1 complex	Mus musculus	42-46
11243506-11	2001	Abrogation of TNFalpha and IL-1 production in the early stages of experimental SLE by an anti-TNFalpha mAb or by PTX improves the clinical status of mice afflicted with this autoimmune disease.	Pentoxifylline	113-116	interleukin 1 complex	Mus musculus	27-31
12593702-3	2001	Previous in vivo studies have documented that administration of SR31747A in murine models of sepsis resulted in decreased proinflammatory (IL-1, IL-6, TNF-alpha) and increased anti-inflammatory (IL-10) response (serum, splenocyte).	SR 31747	64-72	interleukin 1 complex	Mus musculus	139-143
11201166-10	2001	When hepatocytes were pretreated with dexamethasone (Dex) and IL-6, the activation of IRAK was augmented in response to IL-1, indicating that IL-1 signaling is also up-regulated.	Dexamethasone	38-51	interleukin 1 complex	Mus musculus	120-124
11201166-10	2001	When hepatocytes were pretreated with dexamethasone (Dex) and IL-6, the activation of IRAK was augmented in response to IL-1, indicating that IL-1 signaling is also up-regulated.	Dexamethasone	38-51	interleukin 1 complex	Mus musculus	142-146
11201166-10	2001	When hepatocytes were pretreated with dexamethasone (Dex) and IL-6, the activation of IRAK was augmented in response to IL-1, indicating that IL-1 signaling is also up-regulated.	Dexamethasone	53-56	interleukin 1 complex	Mus musculus	120-124
11201166-10	2001	When hepatocytes were pretreated with dexamethasone (Dex) and IL-6, the activation of IRAK was augmented in response to IL-1, indicating that IL-1 signaling is also up-regulated.	Dexamethasone	53-56	interleukin 1 complex	Mus musculus	142-146
11201166-11	2001	In addition, IL-1 treatment ather combined administration of Dex and IL-6 into mice markedly increased the serum level of serum amyloid A.	Dexamethasone	61-64	interleukin 1 complex	Mus musculus	13-17
11201166-5	2001	However, in the presence of indomethacin, IL-1 down-regulates the receptor by destabilizing IL-1 receptor mRNA.	Indomethacin	28-40	interleukin 1 complex	Mus musculus	92-96
11201166-8	2001	On the other hand, the expression of cell surface IL-1RI is inhibited by tyrosine kinase inhibitors, herbimycin and genistein, resulting in reduction of the kinase activity of IRAK (IL-1 receptor associated kinase) and IL-1-induced IL-6 production from the fibroblasts.	herbimycin	101-111	interleukin 1 complex	Mus musculus	50-54
11201166-8	2001	On the other hand, the expression of cell surface IL-1RI is inhibited by tyrosine kinase inhibitors, herbimycin and genistein, resulting in reduction of the kinase activity of IRAK (IL-1 receptor associated kinase) and IL-1-induced IL-6 production from the fibroblasts.	Genistein	116-125	interleukin 1 complex	Mus musculus	50-54
11137614-2	2000	Thus, adriamycin (Dox) has been shown to enhance the activation of macrophages with associated increases of IL1 and TNF production, to stimulate the production of IL2 and the development and action of CTLs.	Doxorubicin	6-16	interleukin 1 complex	Mus musculus	108-111
11137614-2	2000	Thus, adriamycin (Dox) has been shown to enhance the activation of macrophages with associated increases of IL1 and TNF production, to stimulate the production of IL2 and the development and action of CTLs.	Doxorubicin	18-21	interleukin 1 complex	Mus musculus	108-111
11068674-4	2000	Mouse thioglycollate-elicited peritoneal macrophages showed by RT-PCR constitutive steady-state levels of mRNA for TNF-type I and -type II receptors as well as IL-1 type I receptor.	Thioglycolates	6-20	interleukin 1 complex	Mus musculus	160-164
11125308-3	2000	Concanavalin A or phorbol myristate acetate/calcium ionophore/anti-CD3 stimulation of spleen cells from H2(b) congenic mice induced less IL-1, IL-2, IFN-gamma and MIF mRNA and/or protein than the equivalent cells from H2(d) mice.	Tetradecanoylphorbol Acetate	18-43	interleukin 1 complex	Mus musculus	137-141
11125308-3	2000	Concanavalin A or phorbol myristate acetate/calcium ionophore/anti-CD3 stimulation of spleen cells from H2(b) congenic mice induced less IL-1, IL-2, IFN-gamma and MIF mRNA and/or protein than the equivalent cells from H2(d) mice.	Calcium	44-51	interleukin 1 complex	Mus musculus	137-141
11125308-6	2000	We suggest that the low IL-1 production in H2(b) spleen cultures is secondary to lower T cell activation.	Hydrogen	43-45	interleukin 1 complex	Mus musculus	24-28
10970676-6	2000	Treatment of the mice with the selective COX1 inhibitor, piroxicam, attenuated the hypophagic responses to IL-1 and LPS.	Piroxicam	57-66	interleukin 1 complex	Mus musculus	107-111
10970676-9	2000	Pretreatment of the mice with aspirin, an irreversible inhibitor of COX1 and COX2, prevented the hypophagic response to IL-1, 16 h, but not 40 h later.	Aspirin	30-37	interleukin 1 complex	Mus musculus	120-124
10970676-14	2000	Because indomethacin almost completely prevented the hypophagic response to IL-1, this additivity suggests that there are multiple mechanisms by which LPS induces hypophagia.	Indomethacin	8-20	interleukin 1 complex	Mus musculus	76-80
10823815-4	2000	Studies using cultured THP-1 monocyte/macrophages showed that the hydrophobic bile acid chenodeoxycholate, a well established potent repressor of CYP7A1, induced the expression of mRNAs encoding interleukin 1 (IL-1) and tumor necrosis factor alpha (TNFalpha).	Bile Acids and Salts	78-87	interleukin 1 complex	Mus musculus	195-214
10960082-8	2000	In addition, PKC-depleted astrocyte cultures by overnight treatment with PMA no longer responded to PMA or IL-1.	Tetradecanoylphorbol Acetate	73-76	interleukin 1 complex	Mus musculus	107-111
11022128-4	2000	The observation that addition of wortmanin, that specifically blocks Akt phosphorylation, also attenuates NFkappaB activation can be interpreted that Akt phosphorylation interacts with IL-1 signaling pathways.	Wortmannin	33-42	interleukin 1 complex	Mus musculus	185-189
10996031-3	2000	PTX also affects the production of other cytokines such as IL-1, IL-6, IL-10, IL-12, and IFN-gamma.	Pentoxifylline	0-3	interleukin 1 complex	Mus musculus	59-63
10934075-9	2000	LAM may be an important stimulator of innate immunity in infection with M. tuberculosis via mechanisms that involve endogenous IL-1 activity.	lipoarabinomannan	0-3	interleukin 1 complex	Mus musculus	127-131
10996474-5	2000	Prolonged desipramine administration (seven and 28 days) significantly increased the bioactivity of IL-1.	Desipramine	10-21	interleukin 1 complex	Mus musculus	100-104
10823815-4	2000	Studies using cultured THP-1 monocyte/macrophages showed that the hydrophobic bile acid chenodeoxycholate, a well established potent repressor of CYP7A1, induced the expression of mRNAs encoding interleukin 1 (IL-1) and tumor necrosis factor alpha (TNFalpha).	Chenodeoxycholic Acid	88-105	interleukin 1 complex	Mus musculus	195-214
10869429-6	2000	Immunohistochemical studies and electrophoretic mobility shift assays performed on bone marrow cocultures from iNOS-deficient mice showed abnormalities in IL-1-induced nuclear translocation of the p65 component of NFkappaB and in NFkappaB-DNA binding, which were reversed by treatment with the NO donor S-nitroso-acetyl penicillamine.	S-Nitroso-N-Acetylpenicillamine	303-333	interleukin 1 complex	Mus musculus	155-159
10864020-3	2000	SM-10906 concentration-dependently inhibited TNF-alpha, IL-1 and IL-6 releases from lipopolysaccharide-activated mouse PEMs, as with PGE1, PGI2 and cAMP analog.	SM 10906	0-8	interleukin 1 complex	Mus musculus	56-60
10841183-1	2000	Interleukin-1 (IL-1) stimulates prostaglandin production in bone by a rapid and transient activation of prostaglandin G/H synthase 2 (PGHS-2) gene expression.	Prostaglandins	32-45	interleukin 1 complex	Mus musculus	0-13
10820229-4	2000	Here we report that in primary mouse bone marrow-derived mast cells activated by ionomycin or IgE/Ag, the proinflammatory mediator IL-1 (alpha or beta) up-regulated production of IL-3, IL-5, IL-6, and IL-9 as well as TNF, i.e., cytokines implicated in many inflammatory processes including those associated with allergies and helminthic infections.	Ionomycin	81-90	interleukin 1 complex	Mus musculus	131-150
10928970-0	2000	Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice.	aminobisphosphonates	60-80	interleukin 1 complex	Mus musculus	15-28
10809735-7	2000	These data suggest that alpha(1)-AGP is a possible mediator in turpentine- or IL-1-induced protection because time points of maximal induction of alpha(1)-AGP by turpentine or IL-1 and of optimal protection by alpha(1)-AGP coincide.	Turpentine	63-73	interleukin 1 complex	Mus musculus	176-180
10809735-7	2000	These data suggest that alpha(1)-AGP is a possible mediator in turpentine- or IL-1-induced protection because time points of maximal induction of alpha(1)-AGP by turpentine or IL-1 and of optimal protection by alpha(1)-AGP coincide.	Turpentine	162-172	interleukin 1 complex	Mus musculus	78-82
10749768-7	2000	Endogenously produced IL-1ra plays a central role in mitigating the magnitude of the IL-1-mediated inflammatory response and, ultimately, the outcome to a turpentine abscess.	Turpentine	155-165	interleukin 1 complex	Mus musculus	22-26
10768707-7	2000	The depressed proinflammatory cytokine (IL-1 and IL-6) release seen in splenic and peritoneal macrophages was restored in the 17beta-estradiol-treated hemorrhage group.	17beta	126-132	interleukin 1 complex	Mus musculus	40-44
10768707-7	2000	The depressed proinflammatory cytokine (IL-1 and IL-6) release seen in splenic and peritoneal macrophages was restored in the 17beta-estradiol-treated hemorrhage group.	Estradiol	133-142	interleukin 1 complex	Mus musculus	40-44
10772237-2	2000	The goal of this study was to investigate whether the gaseous mediator nitric oxide (NO) plays a crucial role in the inhibition of BMP-2 effects by IL-1.	Nitric Oxide	71-83	interleukin 1 complex	Mus musculus	148-152
10759763-1	2000	Cytokines such as IL-1, tumour necrosis factor-alpha (TNF-alpha), IL-6 and IL-8 are increased in inflamed colonic mucosa after administration of mouse DSS.	dss	151-154	interleukin 1 complex	Mus musculus	18-22
10759763-4	2000	When antisense oligonucleotide was given on day 0, the disease activity index (DAI) representing clinical symptoms improved and the histological score decreased; furthermore, IL-1, IL-6, and TNF-alpha concentrations in rectal mucosa were lower compared with the control group.	Oligonucleotides	15-30	interleukin 1 complex	Mus musculus	175-179
10841183-1	2000	Interleukin-1 (IL-1) stimulates prostaglandin production in bone by a rapid and transient activation of prostaglandin G/H synthase 2 (PGHS-2) gene expression.	Prostaglandins	32-45	interleukin 1 complex	Mus musculus	15-19
10868955-2	2000	Treatment of RAW 264.7 cells and CD-1 mouse peritoneal macrophages with lipopolysaccharide (LPS) + interferon-gamma (IFN-gamma) results in inducible nitric oxide synthase (iNOS), inducible cyclooxygenase (COX-2) and interleukin-1 (IL-1) expression, increased production of nitric oxide, and the release of IL-1.	Nitric Oxide	149-161	interleukin 1 complex	Mus musculus	216-235
10839200-3	2000	Time dependent increases in DCF-fluorescence as a measure of reactive oxygen load were quantified in single cells after incubation with TNF-alpha, IL-1 and IFN-gamma.	Pentostatin	28-31	interleukin 1 complex	Mus musculus	147-151
10808526-3	2000	The IL-1 seems to participate in physiological mechanisms of realisation of stress reactions on the levels of its production and biological action on target cells as well as of the sphingomyelin pathway of its signal transduction in nerve tissue.	Sphingomyelins	181-194	interleukin 1 complex	Mus musculus	4-8
10808527-1	2000	Involvement of the sphingomyelin cascade in Interleukin 1 beta (IL-1) signal transduction pathway in membrane fraction P2 of the murine brain cortex, was found.	Sphingomyelins	19-32	interleukin 1 complex	Mus musculus	64-68
10808527-5	2000	It appears that the IL-1 beta effects on the CNS are realized via IL-1 receptor type I and activation of the nSMase as an initiating enzyme of the sphingomyelin cascade.	Sphingomyelins	147-160	interleukin 1 complex	Mus musculus	20-24
10623851-4	2000	In immunostimulated macrophages and spleen cells, inosine potently inhibited the production of the proinflammatory cytokines TNF-alpha, IL-1, IL-12, macrophage-inflammatory protein-1alpha, and IFN-gamma, but failed to alter the production of the anti-inflammatory cytokine IL-10.	Inosine	50-57	interleukin 1 complex	Mus musculus	136-140
11268389-6	2000	The HPA-activating activity of IL-1 is associated with increases in the apparent release of brain noradrenaline (NA) and serotonin (5-HT), but not dopamine, as well as with increased brain tryptophan.	Norepinephrine	98-111	interleukin 1 complex	Mus musculus	31-35
11268389-6	2000	The HPA-activating activity of IL-1 is associated with increases in the apparent release of brain noradrenaline (NA) and serotonin (5-HT), but not dopamine, as well as with increased brain tryptophan.	Serotonin	121-130	interleukin 1 complex	Mus musculus	31-35
11268389-6	2000	The HPA-activating activity of IL-1 is associated with increases in the apparent release of brain noradrenaline (NA) and serotonin (5-HT), but not dopamine, as well as with increased brain tryptophan.	Serotonin	132-136	interleukin 1 complex	Mus musculus	31-35
11268389-6	2000	The HPA-activating activity of IL-1 is associated with increases in the apparent release of brain noradrenaline (NA) and serotonin (5-HT), but not dopamine, as well as with increased brain tryptophan.	Dopamine	147-155	interleukin 1 complex	Mus musculus	31-35
11268389-6	2000	The HPA-activating activity of IL-1 is associated with increases in the apparent release of brain noradrenaline (NA) and serotonin (5-HT), but not dopamine, as well as with increased brain tryptophan.	Tryptophan	189-199	interleukin 1 complex	Mus musculus	31-35
11070407-9	2000	Progressive upregulation in the transcripts for Th1 cytokines (IL-12, IFN-gamma, IL-1, TNF-alpha) was observed with increasing dosage of DSS.	dss	137-140	interleukin 1 complex	Mus musculus	63-67
11729854-12	2000	Murine epithelial cells increased PGE2 formation in response to IL-1 and Ca Ion, but not LPS and the increased PGE2 was significantly decreased by cPLA2 enzyme inhibitors.	Dinoprostone	34-38	interleukin 1 complex	Mus musculus	64-68
10601817-0	2000	Effects of the IL-1 receptor antagonist on the IL-1- and endotoxin-induced activation of the HPA axis and cerebral biogenic amines in mice.	Amines	124-130	interleukin 1 complex	Mus musculus	15-19
10601817-1	2000	Endotoxin (lipopolysaccharide, LPS) and interleukin-1 (IL-1) are known to activate the hypothalamo-pituitary- adrenocortical (HPA) axis, as well as brain norepinephrine (NE) and indoleamine metabolism.	Norepinephrine	154-168	interleukin 1 complex	Mus musculus	40-53
10601817-1	2000	Endotoxin (lipopolysaccharide, LPS) and interleukin-1 (IL-1) are known to activate the hypothalamo-pituitary- adrenocortical (HPA) axis, as well as brain norepinephrine (NE) and indoleamine metabolism.	Norepinephrine	154-168	interleukin 1 complex	Mus musculus	55-59
10601817-1	2000	Endotoxin (lipopolysaccharide, LPS) and interleukin-1 (IL-1) are known to activate the hypothalamo-pituitary- adrenocortical (HPA) axis, as well as brain norepinephrine (NE) and indoleamine metabolism.	indolamine	178-189	interleukin 1 complex	Mus musculus	40-53
10623430-8	1999	When IL-1 was neutralized before or during the ICA using specific anti-IL-1alpha,beta antibodies, inflammation could be blocked completely.	ica	47-50	interleukin 1 complex	Mus musculus	5-9
10601817-1	2000	Endotoxin (lipopolysaccharide, LPS) and interleukin-1 (IL-1) are known to activate the hypothalamo-pituitary- adrenocortical (HPA) axis, as well as brain norepinephrine (NE) and indoleamine metabolism.	indolamine	178-189	interleukin 1 complex	Mus musculus	55-59
10500198-10	1999	In mice, it induces serum amyloid A, potentiates the induction by IL-1 of corticosterone and IL-6, and causes body weight loss and B cell hyperplasia with serum IgG and IgM increase.	Corticosterone	74-88	interleukin 1 complex	Mus musculus	66-70
10537140-0	1999	Mitogen-activated protein (MAP) kinases are involved in interleukin-1 (IL-1)-induced IL-6 synthesis in osteoblasts: modulation not of p38 MAP kinase, but of p42/p44 MAP kinase by IL-1-activated protein kinase C. We previously reported that interleukin-1alpha (IL-1alpha)-induced activation of protein kinase C (PKC) via phosphatidylcholine-specific phospholipase C (PC-PLC) limits IL-6 synthesis induced by IL-1alpha itself in osteoblast-like MC3T3-E1 cells.	Phosphatidylcholines	320-339	interleukin 1 complex	Mus musculus	71-75
10545489-3	1999	Interruption of TCR- or IL-1R-stimulated ERK cascade by PD-98059, a specific inhibitor of MAP/ERK kinase (MEK), resulted in partial suppression of nuclear factor of activated T cells activation and in complete inhibition of IL-1-stimulated NFkappaB activation.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	56-64	interleukin 1 complex	Mus musculus	24-28
10597915-8	1999	Pre-treatment of C3H/HeJ mice with dexamethasone reduced basal and induced IL-1 levels, but complete inhibition was not achieved.	Dexamethasone	35-48	interleukin 1 complex	Mus musculus	75-79
10628361-6	1999	Overall, this study showed that ponalrestat suppresses IL-1 production both in vitro and in vivo, and inhibits the cachectic symptoms induced by colon26 adenocarcinoma in mice, suggesting that ponalrestat has a therapeutic potential for the treatment of cancer cachexia.	ponalrestat	32-43	interleukin 1 complex	Mus musculus	55-59
10498828-5	1999	Administration of uridine (a precursor of UTP) prior injection of either LPS itself or interleukin-1 (IL-1) reduces the lethality of GalN+LPS.	Uridine	18-25	interleukin 1 complex	Mus musculus	87-106
10498828-5	1999	Administration of uridine (a precursor of UTP) prior injection of either LPS itself or interleukin-1 (IL-1) reduces the lethality of GalN+LPS.	Uridine Triphosphate	42-45	interleukin 1 complex	Mus musculus	87-106
10498828-5	1999	Administration of uridine (a precursor of UTP) prior injection of either LPS itself or interleukin-1 (IL-1) reduces the lethality of GalN+LPS.	Galactosamine	133-137	interleukin 1 complex	Mus musculus	87-106
9880559-2	1999	Ceramide and ceramide-activated enzymes have been implicated in responses to bacterial lipopolysaccharide (LPS) and the proinflammatory cytokines tumor necrosis factor-alpha (TNF) and interleukin-1beta (IL-1).	Ceramides	0-8	interleukin 1 complex	Mus musculus	203-207
10479400-7	1999	Surprisingly, higher concentrations of SB203580 (30 microM) potentiated the IL-1 responses.	SB 203580	39-47	interleukin 1 complex	Mus musculus	76-80
10479400-10	1999	Additional IL-1 signalling pathways can clearly compensate for the lack of p38 MAP kinase which result in potentiation of the IL-1 responses observed at high-dose SB203580.	SB 203580	163-171	interleukin 1 complex	Mus musculus	11-15
10479400-10	1999	Additional IL-1 signalling pathways can clearly compensate for the lack of p38 MAP kinase which result in potentiation of the IL-1 responses observed at high-dose SB203580.	SB 203580	163-171	interleukin 1 complex	Mus musculus	126-130
10382954-6	1999	Additional studies have shown that HC and CsA blocked con A-driven differentiation of CD8+ and CD4+ CD8+ lymph node cells (LNC) and progression of LNC to S + G2/M cell cycle phases, and inhibited IL-1, IL-2 and TGF-beta while enhancing GM-CSF gene expression in BM cells.	Cyclosporine	42-45	interleukin 1 complex	Mus musculus	196-200
10378483-5	1999	AFB1 markedly inhibited TNF-alpha interleukin-1 (IL-1) and IL-6 production by LPS-stimulated macrophages.	Aflatoxin B1	0-4	interleukin 1 complex	Mus musculus	49-53
10485327-2	1999	4-deoxypirydoxine is a potent antagonist of vitamin B6 coenzyme which depresses IL-1, TNF and IL-6 and has anti-inflammatory properties.	4-deoxypirydoxine	0-17	interleukin 1 complex	Mus musculus	80-84
10485327-2	1999	4-deoxypirydoxine is a potent antagonist of vitamin B6 coenzyme which depresses IL-1, TNF and IL-6 and has anti-inflammatory properties.	Vitamin B 6	44-54	interleukin 1 complex	Mus musculus	80-84
10433369-4	1999	On the other hand, simultaneous injection of lipopolysaccharide (LPS) as well as interleukin-1 (IL-1) was capable of interfering with the induction of tolerance to DHGG.	dhgg	164-168	interleukin 1 complex	Mus musculus	81-94
10433369-4	1999	On the other hand, simultaneous injection of lipopolysaccharide (LPS) as well as interleukin-1 (IL-1) was capable of interfering with the induction of tolerance to DHGG.	dhgg	164-168	interleukin 1 complex	Mus musculus	96-100
10678095-0	1999	Ro 31-8220 inhibits release of interleukin-1 and interleukin-6 from mouse peritoneal macrophages induced by fibrin fibrinogen degradation products.	Ro 31-8220	0-10	interleukin 1 complex	Mus musculus	31-44
10201956-5	1999	125I-labeled IL-1 binding experiment showed that the level of binding was also up-regulated by the treatment with Dex and IL-6.	Dexamethasone	114-117	interleukin 1 complex	Mus musculus	13-17
10201956-8	1999	When hepatocytes were pretreated with Dex and IL-6, the activation of IL-1R-associated kinase was augmented in response to IL-1, indicating that IL-1 signaling was also augmented.	Dexamethasone	38-41	interleukin 1 complex	Mus musculus	70-74
10201956-8	1999	When hepatocytes were pretreated with Dex and IL-6, the activation of IL-1R-associated kinase was augmented in response to IL-1, indicating that IL-1 signaling was also augmented.	Dexamethasone	38-41	interleukin 1 complex	Mus musculus	123-127
10201956-9	1999	In addition, IL-1 treatment following administration of the combination of Dex and IL-6 into mice markedly increased the serum level of serum amyloid A.	Dexamethasone	75-78	interleukin 1 complex	Mus musculus	13-17
9880559-2	1999	Ceramide and ceramide-activated enzymes have been implicated in responses to bacterial lipopolysaccharide (LPS) and the proinflammatory cytokines tumor necrosis factor-alpha (TNF) and interleukin-1beta (IL-1).	Ceramides	13-21	interleukin 1 complex	Mus musculus	203-207
9880559-3	1999	Although TNF and IL-1 cause elevation of cellular ceramide, which is thought to act as a second messenger, LPS has been proposed to signal by virtue of structural similarity to ceramide.	Ceramides	50-58	interleukin 1 complex	Mus musculus	17-21
9878816-7	1999	Pretreatment of mice with anti-IL-6 significantly attenuated the IL-1-induced increases of plasma ACTH and corticosterone at 2 h, but not at 4 h. The IL-1-induced increases of MHPG, tryptophan and 5-HIAA in hypothalamus and brain stem were not significantly altered.	Corticosterone	107-121	interleukin 1 complex	Mus musculus	65-69
9878816-7	1999	Pretreatment of mice with anti-IL-6 significantly attenuated the IL-1-induced increases of plasma ACTH and corticosterone at 2 h, but not at 4 h. The IL-1-induced increases of MHPG, tryptophan and 5-HIAA in hypothalamus and brain stem were not significantly altered.	Corticosterone	107-121	interleukin 1 complex	Mus musculus	150-154
9878816-7	1999	Pretreatment of mice with anti-IL-6 significantly attenuated the IL-1-induced increases of plasma ACTH and corticosterone at 2 h, but not at 4 h. The IL-1-induced increases of MHPG, tryptophan and 5-HIAA in hypothalamus and brain stem were not significantly altered.	Methoxyhydroxyphenylglycol	176-180	interleukin 1 complex	Mus musculus	65-69
9878816-7	1999	Pretreatment of mice with anti-IL-6 significantly attenuated the IL-1-induced increases of plasma ACTH and corticosterone at 2 h, but not at 4 h. The IL-1-induced increases of MHPG, tryptophan and 5-HIAA in hypothalamus and brain stem were not significantly altered.	Methoxyhydroxyphenylglycol	176-180	interleukin 1 complex	Mus musculus	150-154
9878816-7	1999	Pretreatment of mice with anti-IL-6 significantly attenuated the IL-1-induced increases of plasma ACTH and corticosterone at 2 h, but not at 4 h. The IL-1-induced increases of MHPG, tryptophan and 5-HIAA in hypothalamus and brain stem were not significantly altered.	Tryptophan	182-192	interleukin 1 complex	Mus musculus	65-69
9878816-7	1999	Pretreatment of mice with anti-IL-6 significantly attenuated the IL-1-induced increases of plasma ACTH and corticosterone at 2 h, but not at 4 h. The IL-1-induced increases of MHPG, tryptophan and 5-HIAA in hypothalamus and brain stem were not significantly altered.	Tryptophan	182-192	interleukin 1 complex	Mus musculus	150-154
9878816-7	1999	Pretreatment of mice with anti-IL-6 significantly attenuated the IL-1-induced increases of plasma ACTH and corticosterone at 2 h, but not at 4 h. The IL-1-induced increases of MHPG, tryptophan and 5-HIAA in hypothalamus and brain stem were not significantly altered.	Hydroxyindoleacetic Acid	197-203	interleukin 1 complex	Mus musculus	65-69
9878816-7	1999	Pretreatment of mice with anti-IL-6 significantly attenuated the IL-1-induced increases of plasma ACTH and corticosterone at 2 h, but not at 4 h. The IL-1-induced increases of MHPG, tryptophan and 5-HIAA in hypothalamus and brain stem were not significantly altered.	Hydroxyindoleacetic Acid	197-203	interleukin 1 complex	Mus musculus	150-154
10447210-6	1999	The IL-1-induced behaviors were suppressed by intraperitoneal morphine, indicating that they are nociceptive responses.	Morphine	62-70	interleukin 1 complex	Mus musculus	4-8
12205906-4	1999	The results also showed that PLGC could restore the capacity of macrophage for secreting IL-1 that had been inhibited by cyclophosphamide and PLGC could enhance the release of IL-2 from spleen cell in the experiment group (P &lt; 0.05-0.01).	Cyclophosphamide	121-137	interleukin 1 complex	Mus musculus	89-93
10022281-8	1998	The PGE2 release was inhibited by cyclooxygenase inhibitors, antioxidants, protein kinase C (PKC) inhibitors and a tyrosine kinase (TK) inhibitor, but not by antibodies against tumor necrosis factor alpha (TNF alpha) and interleukin-1 (IL-1).	Dinoprostone	4-8	interleukin 1 complex	Mus musculus	221-240
10052722-5	1998	L-NAME (0.5 g/L in drinking water) caused further enhancement of the angiogenic response produced by human recombinant bFGF (p&lt;0.001), bovine purified bFGF (p&lt;0.05) or murine recombinant IL-1 (p&lt;0.05).	NG-Nitroarginine Methyl Ester	0-6	interleukin 1 complex	Mus musculus	193-197
10097600-4	1998	We found that cord factor (TDM) and glucose monomycolate (GM) from Nocardia asteroides and Rhodococcus species with shorter chain mycolic acids also exhibited distinctive granuloma-forming activity in lungs, spleen and liver in mice and in vitro induction of prostaglandin E2 (PGE2) and interleukin 1 (IL-1) synthesis.	glucose mycolate	36-56	interleukin 1 complex	Mus musculus	287-306
9893925-5	1998	GA 1 nmol/1-10 mumol/l inhibited IL-1 production, and 100 nmol/l-10 mumol/l decreased TNF-alpha and NO production in dose-dependent manner.	Gallium	0-2	interleukin 1 complex	Mus musculus	33-37
9893925-8	1998	GB plus apafant (50 mumol/l) showed IL-1 and NO inhibitory effects, but not on TNF-alpha.	WEB 2086	8-15	interleukin 1 complex	Mus musculus	36-40
10097600-4	1998	We found that cord factor (TDM) and glucose monomycolate (GM) from Nocardia asteroides and Rhodococcus species with shorter chain mycolic acids also exhibited distinctive granuloma-forming activity in lungs, spleen and liver in mice and in vitro induction of prostaglandin E2 (PGE2) and interleukin 1 (IL-1) synthesis.	glucose mycolate	58-60	interleukin 1 complex	Mus musculus	287-306
9837778-4	1998	Northern blot analysis showed that stimulators of OCL formation such as 1,25-(OH)2D3, prostaglandin E2 (PGE2), parathyroid hormone (PTH), and interleukin 1 (IL-1) decreased OCIF mRNA levels.	ocl	50-53	interleukin 1 complex	Mus musculus	142-161
9804916-7	1998	IL-1, in contrast, induced a wide range of central monoamine alterations.	monoamine	51-60	interleukin 1 complex	Mus musculus	0-4
9795212-3	1998	In contrast, morphine reduction of splenic and thymic cell number and mitogen-induced proliferation were unaffected in MOR-KO mice, as was morphine inhibition of IL-1 and IL-6 secretion by macrophages.	Morphine	139-147	interleukin 1 complex	Mus musculus	162-166
9878126-11	1998	These results clearly demonstrate that IL-1 is involved in the development of DSS-induced colitis in mice and suggest that downregulation of IL-1 might be useful for the treatment of patients with ulcerative colitis.	Dextran Sulfate	78-81	interleukin 1 complex	Mus musculus	39-43
9878126-11	1998	These results clearly demonstrate that IL-1 is involved in the development of DSS-induced colitis in mice and suggest that downregulation of IL-1 might be useful for the treatment of patients with ulcerative colitis.	Dextran Sulfate	78-81	interleukin 1 complex	Mus musculus	141-145
9759847-0	1998	Neonatal murine B lymphocytes respond to polysaccharide antigens in the presence of IL-1 and IL-6.	Polysaccharides	41-55	interleukin 1 complex	Mus musculus	84-88
9831909-3	1998	In the present study, we examined the effect of aminoBP, 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (AHBuBP), on the production of the pro-inflammatory cytokines, IL-1 and TNFalpha, in mice.	aminobp	48-55	interleukin 1 complex	Mus musculus	171-188
9831909-3	1998	In the present study, we examined the effect of aminoBP, 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (AHBuBP), on the production of the pro-inflammatory cytokines, IL-1 and TNFalpha, in mice.	Alendronate	57-107	interleukin 1 complex	Mus musculus	171-188
9874287-1	1998	The short-term effects of silicone particles on the ability of splenic and peritoneal macrophages to produce Interleukin-1 (IL-1) were assessed.	Silicones	26-34	interleukin 1 complex	Mus musculus	124-128
9698346-0	1998	Interleukin-1 induces slow-wave sleep at the prostaglandin D2-sensitive sleep-promoting zone in the rat brain.	Prostaglandin D2	45-61	interleukin 1 complex	Mus musculus	0-13
9698346-5	1998	The SWS increase caused by IL-1 infusion into the PGD2-SZ was blocked completely by coadministered diclofenac, a nonselective cyclooxygenase (COX) inhibitor.	pgd2-sz	50-57	interleukin 1 complex	Mus musculus	27-31
9698346-5	1998	The SWS increase caused by IL-1 infusion into the PGD2-SZ was blocked completely by coadministered diclofenac, a nonselective cyclooxygenase (COX) inhibitor.	Diclofenac	99-109	interleukin 1 complex	Mus musculus	27-31
9698346-8	1998	We present a hypothesis that IL-1 induces SWS, at least in part, via COX-2-mediated PG production in the PGD2-SZ.	Prostaglandins	84-86	interleukin 1 complex	Mus musculus	29-33
9671653-4	1998	We found that interleukin-1 (IL-1), an immune response-generated cytokine that can enhance dopaminergic sprouting when exogenously applied, increased dramatically in the denervated striatum of young mice (2 months) compared with middle-aged mice (8 months) after MPTP treatment.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	263-267	interleukin 1 complex	Mus musculus	14-27
9671653-4	1998	We found that interleukin-1 (IL-1), an immune response-generated cytokine that can enhance dopaminergic sprouting when exogenously applied, increased dramatically in the denervated striatum of young mice (2 months) compared with middle-aged mice (8 months) after MPTP treatment.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	263-267	interleukin 1 complex	Mus musculus	29-33
11819306-4	1998	The serum TBIL of mice and the degree of liver necrosis increased after injection of IL-1, IL-6 with D-GAL and rTNF-alpha.CONCLUSION: Cytokines, like IL-1, IL-6, IFN&amp;agr and TNF-&amp;agr;joined in the process of hepatocyte necrosis.They can enhance the degree of liver necrosis induced by D-GAL.	Bilirubin	10-14	interleukin 1 complex	Mus musculus	85-89
9661071-8	1998	Pretreatment with indomethacin diminished the inhibitory effect of IL-1 on CAT activity and collagen synthesis, suggesting partial mediation by prostaglandins.	Indomethacin	18-30	interleukin 1 complex	Mus musculus	67-71
9637509-5	1998	ELISA data confirmed the reduced levels of IL-1 and IL-6 at disease onset in GL3-treated animals, and pathologic analysis demonstrated a marked reduction in meningeal infiltrates at the same time point.	GL3	77-80	interleukin 1 complex	Mus musculus	43-47
9728091-3	1998	At a dose of 5 mg/kg, which also caused body weight loss, leptin potentiated the induction by IL-1 of serum corticosterone and IL-6 but did not show any other activity.	Corticosterone	108-122	interleukin 1 complex	Mus musculus	94-98
9614147-9	1998	In addition, we show that the combination of poly(I-C) + IFN-gamma stimulates iNOS expression, nitrite production, IkappaB degradation, and the release of IL-1 by primary mouse macrophages, and these effects are prevented by pyrrolidinedithiocarbamate.	Poly I-C	45-54	interleukin 1 complex	Mus musculus	155-159
9614147-9	1998	In addition, we show that the combination of poly(I-C) + IFN-gamma stimulates iNOS expression, nitrite production, IkappaB degradation, and the release of IL-1 by primary mouse macrophages, and these effects are prevented by pyrrolidinedithiocarbamate.	pyrrolidine dithiocarbamic acid	225-251	interleukin 1 complex	Mus musculus	155-159
9679667-2	1998	Cytokines (IL-1, TNF alpha, TNF beta and IFN gamma) may be directly cytotoxic to beta-cells by inducing nitric oxide and oxygen free radicals in the beta-cells.	Nitric Oxide	104-116	interleukin 1 complex	Mus musculus	11-15
9679667-2	1998	Cytokines (IL-1, TNF alpha, TNF beta and IFN gamma) may be directly cytotoxic to beta-cells by inducing nitric oxide and oxygen free radicals in the beta-cells.	oxygen free radicals	121-141	interleukin 1 complex	Mus musculus	11-15
9661071-8	1998	Pretreatment with indomethacin diminished the inhibitory effect of IL-1 on CAT activity and collagen synthesis, suggesting partial mediation by prostaglandins.	Prostaglandins	144-158	interleukin 1 complex	Mus musculus	67-71
9661071-9	1998	Local in vivo injection of IL-1 (500 ng) decreased calvarial transgene mRNA after 8 h, an effect that was partially blocked by indomethacin.	Indomethacin	127-139	interleukin 1 complex	Mus musculus	27-31
9619373-9	1998	The authors show in addition, that TFG-beta blocks the IL-1 induced inhibitory effect on glycosaminoglycan (GAG) and collagen production, evaluated with [3H]glucosamine and [3H]proline incorporation studies, respectively.	Glycosaminoglycans	89-106	interleukin 1 complex	Mus musculus	55-59
9673408-2	1998	Similarly, IL-1 is reported to accelerate recovery following myelosuppressive treatment with doxorubicin (AdR), cis-platinum (DDP) and cyclophosphamide (CTx).	Doxorubicin	93-104	interleukin 1 complex	Mus musculus	11-15
9673408-2	1998	Similarly, IL-1 is reported to accelerate recovery following myelosuppressive treatment with doxorubicin (AdR), cis-platinum (DDP) and cyclophosphamide (CTx).	Cisplatin	112-124	interleukin 1 complex	Mus musculus	11-15
9673408-2	1998	Similarly, IL-1 is reported to accelerate recovery following myelosuppressive treatment with doxorubicin (AdR), cis-platinum (DDP) and cyclophosphamide (CTx).	Cisplatin	126-129	interleukin 1 complex	Mus musculus	11-15
9673408-2	1998	Similarly, IL-1 is reported to accelerate recovery following myelosuppressive treatment with doxorubicin (AdR), cis-platinum (DDP) and cyclophosphamide (CTx).	Cyclophosphamide	135-151	interleukin 1 complex	Mus musculus	11-15
9629243-5	1998	We have also compared the magnitude of the increase in corticosterone levels induced by IL-1 in 3-day-old and adult mice to that caused by acute stress.	Corticosterone	55-69	interleukin 1 complex	Mus musculus	88-92
9629247-5	1998	Even after a glucose load, IL-1-treated animals remain hypoglycemic, suggesting that central mechanisms that control the set point of glucose homeostasis are affected.	Glucose	13-20	interleukin 1 complex	Mus musculus	27-31
9629247-9	1998	On the other hand, central depletion of catecholamines exacerbates IL-1-induced hypoglycemia.	Catecholamines	40-54	interleukin 1 complex	Mus musculus	67-71
9629247-10	1998	IL-1-mediated effects on glucose levels might be directed at providing more energy supply to tissues during processes with high metabolic demands.	Glucose	25-32	interleukin 1 complex	Mus musculus	0-4
9619373-9	1998	The authors show in addition, that TFG-beta blocks the IL-1 induced inhibitory effect on glycosaminoglycan (GAG) and collagen production, evaluated with [3H]glucosamine and [3H]proline incorporation studies, respectively.	Glycosaminoglycans	108-111	interleukin 1 complex	Mus musculus	55-59
9619373-9	1998	The authors show in addition, that TFG-beta blocks the IL-1 induced inhibitory effect on glycosaminoglycan (GAG) and collagen production, evaluated with [3H]glucosamine and [3H]proline incorporation studies, respectively.	Tritium	154-156	interleukin 1 complex	Mus musculus	55-59
9619373-9	1998	The authors show in addition, that TFG-beta blocks the IL-1 induced inhibitory effect on glycosaminoglycan (GAG) and collagen production, evaluated with [3H]glucosamine and [3H]proline incorporation studies, respectively.	Glucosamine	157-168	interleukin 1 complex	Mus musculus	55-59
9619373-9	1998	The authors show in addition, that TFG-beta blocks the IL-1 induced inhibitory effect on glycosaminoglycan (GAG) and collagen production, evaluated with [3H]glucosamine and [3H]proline incorporation studies, respectively.	Tritium	174-176	interleukin 1 complex	Mus musculus	55-59
9619373-9	1998	The authors show in addition, that TFG-beta blocks the IL-1 induced inhibitory effect on glycosaminoglycan (GAG) and collagen production, evaluated with [3H]glucosamine and [3H]proline incorporation studies, respectively.	Proline	177-184	interleukin 1 complex	Mus musculus	55-59
9566020-0	1998	Esculentoside A inhibits tumor necrosis factor, interleukin-1, and interleukin-6 production induced by lipopolysaccharide in mice.	esculentoside A	0-15	interleukin 1 complex	Mus musculus	48-61
9535858-9	1998	When OCLs were pretreated with antisense oligodeoxynucleotides to p65 and p50 of NF-kappaB, the expression of respective mRNAs by OCLs was suppressed, and the IL-1-induced survival of OCLs was concomitantly inhibited.	Oligodeoxyribonucleotides	41-62	interleukin 1 complex	Mus musculus	159-163
9550472-1	1998	OBJECTIVE: To investigate the role of nitric oxide (NO) and interleukin-1 in (IL-1) joint inflammation and cartilage destruction during zymosan-induced gonarthritis (ZIA).	Zymosan	136-143	interleukin 1 complex	Mus musculus	60-76
9600709-5	1998	Co-culture with AET counteracted the down-regulatory effect of hydrocortisone on LPS-induced TNF-alpha and IL-1 secretion.	5-androstene-3,16,17-triol	16-19	interleukin 1 complex	Mus musculus	107-111
9600709-5	1998	Co-culture with AET counteracted the down-regulatory effect of hydrocortisone on LPS-induced TNF-alpha and IL-1 secretion.	Hydrocortisone	63-77	interleukin 1 complex	Mus musculus	107-111
9566020-4	1998	IL-1 and IL-6 secretion was also obviously inhibited in a concentration-dependent manner by esculentoside A from 0.01 to 10 mumol/l.	esculentoside A	92-107	interleukin 1 complex	Mus musculus	0-4
9566020-6	1998	Pretreatment of mice with 5, 10, or 20 mg/kg esculentoside A once a day for 7 consecutive days dose-dependently decreased the TNF, IL-1 and IL-6 levels in the sera of mice following LPS challenge.	esculentoside A	45-60	interleukin 1 complex	Mus musculus	131-135
9498792-9	1998	Ethacrynic acid and DIDS (4,4"-diisothiocyanato-stilbene-2,2"-disulfonic acid) block ATP-induced proteolysis of pro-IL-1 beta and prevent release of pro-IL-1 alpha/beta and LDH; they do not inhibit ATP-induced K+ (86Rb+) efflux.	Ethacrynic Acid	0-15	interleukin 1 complex	Mus musculus	116-120
9492070-5	1998	A hydroxamate inhibitor of MMPs significantly suppressed bone-resorbing activity induced by IL-1.	hydroxamate	2-13	interleukin 1 complex	Mus musculus	92-96
9498792-0	1998	Post-translational processing of murine IL-1: evidence that ATP-induced release of IL-1 alpha and IL-1 beta occurs via a similar mechanism.	Adenosine Triphosphate	60-63	interleukin 1 complex	Mus musculus	40-44
9538043-6	1998	We examined the direct induction of cox-1 and cox-2 by TCDD and the indirect induction of cox-2 via TCDD-induced IL-1.	Polychlorinated Dibenzodioxins	100-104	interleukin 1 complex	Mus musculus	113-117
9498792-9	1998	Ethacrynic acid and DIDS (4,4"-diisothiocyanato-stilbene-2,2"-disulfonic acid) block ATP-induced proteolysis of pro-IL-1 beta and prevent release of pro-IL-1 alpha/beta and LDH; they do not inhibit ATP-induced K+ (86Rb+) efflux.	dids (4,4"-diisothiocyanato-stilbene-2,2"-disulfonic acid	20-77	interleukin 1 complex	Mus musculus	116-120
9498792-9	1998	Ethacrynic acid and DIDS (4,4"-diisothiocyanato-stilbene-2,2"-disulfonic acid) block ATP-induced proteolysis of pro-IL-1 beta and prevent release of pro-IL-1 alpha/beta and LDH; they do not inhibit ATP-induced K+ (86Rb+) efflux.	Adenosine Triphosphate	85-88	interleukin 1 complex	Mus musculus	116-120
9498792-10	1998	Ethacrynic acid inhibits release of both forms of IL-1 with a similar concentration dependence; within the arrested cells, procytokines accumulate in a Triton-insoluble fraction.	Ethacrynic Acid	0-15	interleukin 1 complex	Mus musculus	50-54
9657065-3	1997	TNF and IL-1 both inhibit cAMP-stimulated testosterone production as well as mRNA and protein levels of cholesterol side chain cleavage enzyme (P450scc) and 17 alpha-hydroxylase/C17,20 lyase (P450c17) in mouse Leydig cells.	Cyclic AMP	26-30	interleukin 1 complex	Mus musculus	8-12
9452447-2	1998	We observe that hyperglycemic levels of D-glucose (8-20 mM) inhibit the release of IL-1 by lipopolysaccharide-stimulated RAW 264.7 murine macrophage cells.	Glucose	40-49	interleukin 1 complex	Mus musculus	83-87
9452447-3	1998	An inhibitor of glucose transport and metabolism, 2-deoxyglucose, prevents this inhibition of IL-1 release.	Glucose	16-23	interleukin 1 complex	Mus musculus	94-98
9452447-3	1998	An inhibitor of glucose transport and metabolism, 2-deoxyglucose, prevents this inhibition of IL-1 release.	Deoxyglucose	50-64	interleukin 1 complex	Mus musculus	94-98
9452447-4	1998	High levels (8-20 mM) of fructose and mannose (but not galactose or L-glucose) also inhibit the release of IL-1 activity, suggesting that metabolism is required for IL-1 inhibition.	Fructose	25-33	interleukin 1 complex	Mus musculus	107-111
9452447-4	1998	High levels (8-20 mM) of fructose and mannose (but not galactose or L-glucose) also inhibit the release of IL-1 activity, suggesting that metabolism is required for IL-1 inhibition.	Fructose	25-33	interleukin 1 complex	Mus musculus	165-169
9452447-4	1998	High levels (8-20 mM) of fructose and mannose (but not galactose or L-glucose) also inhibit the release of IL-1 activity, suggesting that metabolism is required for IL-1 inhibition.	Mannose	38-45	interleukin 1 complex	Mus musculus	107-111
9452447-4	1998	High levels (8-20 mM) of fructose and mannose (but not galactose or L-glucose) also inhibit the release of IL-1 activity, suggesting that metabolism is required for IL-1 inhibition.	Mannose	38-45	interleukin 1 complex	Mus musculus	165-169
9452447-5	1998	Immunoprecipitation and activity measurements demonstrate that high glucose levels block the release of IL-1 but do not inhibit IL-1 production.	Glucose	68-75	interleukin 1 complex	Mus musculus	104-108
9452447-7	1998	Phorbol 12-myristate 13-acetate, an agonist of PKC, mimics glucose-induced inhibition of IL-1 release.	Tetradecanoylphorbol Acetate	0-31	interleukin 1 complex	Mus musculus	89-93
9452447-7	1998	Phorbol 12-myristate 13-acetate, an agonist of PKC, mimics glucose-induced inhibition of IL-1 release.	Glucose	59-66	interleukin 1 complex	Mus musculus	89-93
9452447-8	1998	These results demonstrate that high glucose levels inhibit IL-1 release (but not production) by RAW 264.	Glucose	36-43	interleukin 1 complex	Mus musculus	59-63
9588325-2	1998	This short review considers some data concerning the effects of several cytokines, interleukin (IL)-1, IL-2, IL-6 and granulocyte-macrophage colony-stimulating factor on scopolamine-induced amnesia for a passive avoidance response, and on hippocampal neurotransmitter amino acid levels in mice.	Scopolamine	170-181	interleukin 1 complex	Mus musculus	83-101
9641797-3	1998	This short review considers some data concerning the effects of several cytokines, interleukin (IL)-1, IL-2, IL-6 and granulocyte-macrophage colony-stimulating factor on scopolamine-induced amnesia for a passive avoidance response, and on hippocampal neurotransmitter amino acid levels in mice.	Scopolamine	170-181	interleukin 1 complex	Mus musculus	83-101
9505144-3	1998	The suppression of heparin-releasable LPL activity produced by combinations of IL-1 and IL-11, IL-1 and TNF-alpha, IL-11 and TNF-alpha, and, IL-11 and INF-gamma was substantially lower than that expected from the additive action of the corresponding two cytokines.	Heparin	19-26	interleukin 1 complex	Mus musculus	79-83
9505144-3	1998	The suppression of heparin-releasable LPL activity produced by combinations of IL-1 and IL-11, IL-1 and TNF-alpha, IL-11 and TNF-alpha, and, IL-11 and INF-gamma was substantially lower than that expected from the additive action of the corresponding two cytokines.	Heparin	19-26	interleukin 1 complex	Mus musculus	88-92
9657065-3	1997	TNF and IL-1 both inhibit cAMP-stimulated testosterone production as well as mRNA and protein levels of cholesterol side chain cleavage enzyme (P450scc) and 17 alpha-hydroxylase/C17,20 lyase (P450c17) in mouse Leydig cells.	Testosterone	42-54	interleukin 1 complex	Mus musculus	8-12
9657065-3	1997	TNF and IL-1 both inhibit cAMP-stimulated testosterone production as well as mRNA and protein levels of cholesterol side chain cleavage enzyme (P450scc) and 17 alpha-hydroxylase/C17,20 lyase (P450c17) in mouse Leydig cells.	Cholesterol	104-115	interleukin 1 complex	Mus musculus	8-12
9657065-5	1997	In the present study, we tested the effects of TNF and IL-1 on basal testosterone production and 8-Br-cAMP-stimulated 3 beta-hydroxysteroid dehydrogenase/delta 5--&gt;delta 4 isomerase (3 beta HSD) expression in Leydig cells.	Testosterone	69-81	interleukin 1 complex	Mus musculus	55-59
9657065-5	1997	In the present study, we tested the effects of TNF and IL-1 on basal testosterone production and 8-Br-cAMP-stimulated 3 beta-hydroxysteroid dehydrogenase/delta 5--&gt;delta 4 isomerase (3 beta HSD) expression in Leydig cells.	8-Bromo Cyclic Adenosine Monophosphate	97-106	interleukin 1 complex	Mus musculus	55-59
9657065-9	1997	Both TNF and IL-1 inhibited cAMP-stimulated 3 beta HSD mRNA and protein levels, but only TNF inhibited basal 3 beta HSD expression.	Cyclic AMP	28-32	interleukin 1 complex	Mus musculus	13-17
9657065-10	1997	These results demonstrate that TNF and IL-1 have different effects on basal steroidogenesis in Leydig cells and suggest that TNF-mediated inhibition of basal testosterone production may be owing to the inhibition of basal 3 beta-HSD expression in Leydig cells.	Testosterone	158-170	interleukin 1 complex	Mus musculus	39-43
9346915-2	1997	Ceramide generated by sphingomyelinases (SMases) is known to function as an important second messenger molecule in the signaling pathway of IL-1 and tumor necrosis factor.	Ceramides	0-8	interleukin 1 complex	Mus musculus	140-144
9464752-11	1998	In contrast, testosterone-treated female mice that had experienced hemorrhage showed significant depression in splenic and peritoneal macrophage IL-1 and IL-6 production, comparable with the values seen in macrophages from male mice that had experienced hemorrhage.	Testosterone	13-25	interleukin 1 complex	Mus musculus	145-149
9328844-2	1997	Staurosporine and calphostin C, inhibitors of protein kinase C (PKC), significantly enhanced the IL-1-induced secretion of IL-6.	Staurosporine	0-13	interleukin 1 complex	Mus musculus	97-101
9328844-2	1997	Staurosporine and calphostin C, inhibitors of protein kinase C (PKC), significantly enhanced the IL-1-induced secretion of IL-6.	calphostin C	18-30	interleukin 1 complex	Mus musculus	97-101
9328844-4	1997	IL-1 produced diacylglycerol in MC3T3-E1 cells.	Diglycerides	14-28	interleukin 1 complex	Mus musculus	0-4
9328844-6	1997	On the contrary, IL-1 significantly stimulated the formation of phosphocholine dose-dependently.	Phosphorylcholine	64-78	interleukin 1 complex	Mus musculus	17-21
9328844-7	1997	D-609, an inhibitor of phosphatidylcholine-specific phospholipase C, suppressed the IL-1-induced diacylglycerol production.	tricyclodecane-9-yl-xanthogenate	0-5	interleukin 1 complex	Mus musculus	84-88
9328844-7	1997	D-609, an inhibitor of phosphatidylcholine-specific phospholipase C, suppressed the IL-1-induced diacylglycerol production.	Phosphatidylcholines	23-42	interleukin 1 complex	Mus musculus	84-88
9328844-7	1997	D-609, an inhibitor of phosphatidylcholine-specific phospholipase C, suppressed the IL-1-induced diacylglycerol production.	Diglycerides	97-111	interleukin 1 complex	Mus musculus	84-88
9328844-9	1997	These results indicate that IL-1 activates PKC via phosphatidylcholine-specific phospholipase C in osteoblast-like cells, and the PKC activation then limits IL-6 synthesis induced by IL-1 itself.	Phosphatidylcholines	51-70	interleukin 1 complex	Mus musculus	28-32
9328844-9	1997	These results indicate that IL-1 activates PKC via phosphatidylcholine-specific phospholipase C in osteoblast-like cells, and the PKC activation then limits IL-6 synthesis induced by IL-1 itself.	Phosphatidylcholines	51-70	interleukin 1 complex	Mus musculus	183-187
9317152-1	1997	Activation of macrophages by LPS and taxol results in production of IL-1, IL-6, TNF-alpha, and granulocyte-macrophage CSF (GM-CSF), which are involved in regulating hemopoiesis, inflammation, and immune responses.	Paclitaxel	37-42	interleukin 1 complex	Mus musculus	68-72
9259765-2	1997	In the present study, we investigated the mechanism by which morphine inhibits phytohemagglutinin (PHA)/interleukin-1 (IL-1)-induced thymocyte proliferation.	Morphine	61-69	interleukin 1 complex	Mus musculus	119-123
9486409-7	1998	A significant decreased expression of TNF-alpha transgene, endogenous mouse TNF-alpha and IL-1 mRNA was observed in splenocytes of mice treated for 3 or 4 weeks with CHO/IL-4 and CHO/IL-13, and, to a lesser extent, with CHO/IL-10, compared with controls.	cho	166-169	interleukin 1 complex	Mus musculus	90-94
9486409-7	1998	A significant decreased expression of TNF-alpha transgene, endogenous mouse TNF-alpha and IL-1 mRNA was observed in splenocytes of mice treated for 3 or 4 weeks with CHO/IL-4 and CHO/IL-13, and, to a lesser extent, with CHO/IL-10, compared with controls.	cho	179-182	interleukin 1 complex	Mus musculus	90-94
9566762-7	1997	These results indicate that in the responses to LPS, taxol and ceramide, MEF retain the same reactivity as that of the mouse strains from which the MEF were derived, and LPS shares the IL-6 signal transduction pathway with taxol and ceramide, but not with IL-1.	Ceramides	63-71	interleukin 1 complex	Mus musculus	256-260
9282825-1	1997	Interleukin-1alpha (IL-1), by itself, accelerates both granulopoietic and thrombopoietic recovery in the 5-fluorouracil (5-FU) myelosuppressed mouse (FUM).	Fluorouracil	105-119	interleukin 1 complex	Mus musculus	20-24
9282825-1	1997	Interleukin-1alpha (IL-1), by itself, accelerates both granulopoietic and thrombopoietic recovery in the 5-fluorouracil (5-FU) myelosuppressed mouse (FUM).	Fluorouracil	121-125	interleukin 1 complex	Mus musculus	20-24
9212744-9	1997	Zymosan caused a rapid increase in articular IL-1, IL-6, TNF, and NO levels.	Zymosan	0-7	interleukin 1 complex	Mus musculus	45-49
9237807-1	1997	We studied the role of IL-6 and nitric oxide (NO) in IL-1 and leukaemia inhibitory factor (LIF) induced suppression of proteoglycan synthesis.	Nitric Oxide	32-44	interleukin 1 complex	Mus musculus	53-89
9150077-7	1997	A significant reduction of the circulating levels of IL-1 was a consistent finding in mice treated therapeutically with CT-112.	risarestat	120-126	interleukin 1 complex	Mus musculus	53-57
9096586-0	1997	Sinusoidal endothelium release of hydrogen peroxide enhances very late antigen-4-mediated melanoma cell adherence and tumor cytotoxicity during interleukin-1 promotion of hepatic melanoma metastasis in mice.	Hydrogen Peroxide	34-51	interleukin 1 complex	Mus musculus	144-157
9165025-7	1997	The increased PGE2 synthesis by osteoblasts may play an important role in osteoclastogenesis induced by submaximal doses of IL-1 and IL-6.	Dinoprostone	14-18	interleukin 1 complex	Mus musculus	124-128
9096586-1	1997	The hepatic sinusoidal endothelium (HSE) releases large amounts of reactive oxygen species (ROS) in response to endotoxins and interleukin-1 (IL-1).	Reactive Oxygen Species	67-90	interleukin 1 complex	Mus musculus	127-140
9096586-1	1997	The hepatic sinusoidal endothelium (HSE) releases large amounts of reactive oxygen species (ROS) in response to endotoxins and interleukin-1 (IL-1).	Reactive Oxygen Species	67-90	interleukin 1 complex	Mus musculus	142-146
9096586-1	1997	The hepatic sinusoidal endothelium (HSE) releases large amounts of reactive oxygen species (ROS) in response to endotoxins and interleukin-1 (IL-1).	Reactive Oxygen Species	92-95	interleukin 1 complex	Mus musculus	127-140
9096586-1	1997	The hepatic sinusoidal endothelium (HSE) releases large amounts of reactive oxygen species (ROS) in response to endotoxins and interleukin-1 (IL-1).	Reactive Oxygen Species	92-95	interleukin 1 complex	Mus musculus	142-146
9096586-3	1997	We have investigated the involvement of ROS released by IL-1-stimulated HSE in this promoting effect.	Reactive Oxygen Species	40-43	interleukin 1 complex	Mus musculus	56-60
9096586-15	1997	Thus, the effects of IL-1 in the liver may consist of a balance between the prometastatic effect of enhanced adherence to the HSE and the antimetastatic effect of H2O2-mediated cytotoxicity.	Hydrogen Peroxide	163-167	interleukin 1 complex	Mus musculus	21-25
9091574-5	1997	IL-18 inhibited OCL formation in the presence of osteoclastogenic agents including 1alpha,25-dihydroxyvitamin D3, prostaglandin E2, parathyroid hormone, IL-1, and IL-11.	ocl	16-19	interleukin 1 complex	Mus musculus	0-4
9091574-5	1997	IL-18 inhibited OCL formation in the presence of osteoclastogenic agents including 1alpha,25-dihydroxyvitamin D3, prostaglandin E2, parathyroid hormone, IL-1, and IL-11.	Calcitriol	83-112	interleukin 1 complex	Mus musculus	0-4
9091574-5	1997	IL-18 inhibited OCL formation in the presence of osteoclastogenic agents including 1alpha,25-dihydroxyvitamin D3, prostaglandin E2, parathyroid hormone, IL-1, and IL-11.	Dinoprostone	114-130	interleukin 1 complex	Mus musculus	0-4
9070257-0	1997	Inhibition of IL-1-induced IL-6 production by synthetic retinoids.	Retinoids	56-65	interleukin 1 complex	Mus musculus	14-18
9060449-10	1997	Because amounts of IL-1 produced in leukopenic and control arthritic joints are comparable, this suggests that IL-1 is only marginally involved in PG loss in the first phase of ICA.	ica	177-180	interleukin 1 complex	Mus musculus	111-115
9001323-6	1997	Antibodies to TNF and/or IL-1 significantly reduced the nitrite or nitrite + nitrate concentrations and the concentrations of TNF and IL-1 in the M-CM correlated with nitrite concentrations in the LA-4 culture supernatant fluids (r2 = 0.848 and 0.956).	Nitrites	67-74	interleukin 1 complex	Mus musculus	25-29
9001323-6	1997	Antibodies to TNF and/or IL-1 significantly reduced the nitrite or nitrite + nitrate concentrations and the concentrations of TNF and IL-1 in the M-CM correlated with nitrite concentrations in the LA-4 culture supernatant fluids (r2 = 0.848 and 0.956).	Nitrates	77-84	interleukin 1 complex	Mus musculus	25-29
9001323-6	1997	Antibodies to TNF and/or IL-1 significantly reduced the nitrite or nitrite + nitrate concentrations and the concentrations of TNF and IL-1 in the M-CM correlated with nitrite concentrations in the LA-4 culture supernatant fluids (r2 = 0.848 and 0.956).	Nitrites	67-74	interleukin 1 complex	Mus musculus	25-29
9096241-4	1997	Supernatants collected from P388D1 cells treated with CA, VS, CS, MMC, HU or LPS demonstrated enhanced production of tumor necrosis factor (TNF) confirmed by bioassay on L929 tumor target cells and increased interleukin-1 (IL-1) production by standard thymocyte proliferation bioassay.	Cyclophosphamide	62-64	interleukin 1 complex	Mus musculus	208-227
9001323-6	1997	Antibodies to TNF and/or IL-1 significantly reduced the nitrite or nitrite + nitrate concentrations and the concentrations of TNF and IL-1 in the M-CM correlated with nitrite concentrations in the LA-4 culture supernatant fluids (r2 = 0.848 and 0.956).	Nitrites	56-63	interleukin 1 complex	Mus musculus	25-29
8968520-1	1996	The production profile of interleukin 1 (IL-1) from mouse peritoneal macrophages (M phi) was determined following their incubation with poly(DL-lactic acid) (PDLLA) granules containing ovalbumin (OVA).	poly(dl-lactic acid)	136-156	interleukin 1 complex	Mus musculus	26-45
8968520-1	1996	The production profile of interleukin 1 (IL-1) from mouse peritoneal macrophages (M phi) was determined following their incubation with poly(DL-lactic acid) (PDLLA) granules containing ovalbumin (OVA).	pdlla	158-163	interleukin 1 complex	Mus musculus	26-45
9130242-2	1997	Indomethacin can modulate the effect of IL-1, so at least part of the IL-1 effect on disease progression is due to the induction of prostaglandin synthesis.	Indomethacin	0-12	interleukin 1 complex	Mus musculus	40-44
9130242-2	1997	Indomethacin can modulate the effect of IL-1, so at least part of the IL-1 effect on disease progression is due to the induction of prostaglandin synthesis.	Indomethacin	0-12	interleukin 1 complex	Mus musculus	70-74
9130242-2	1997	Indomethacin can modulate the effect of IL-1, so at least part of the IL-1 effect on disease progression is due to the induction of prostaglandin synthesis.	Prostaglandins	132-145	interleukin 1 complex	Mus musculus	40-44
9130242-2	1997	Indomethacin can modulate the effect of IL-1, so at least part of the IL-1 effect on disease progression is due to the induction of prostaglandin synthesis.	Prostaglandins	132-145	interleukin 1 complex	Mus musculus	70-74
9492185-3	1997	The ability of oat beta-glucan (ObetaG) to stimulate IL-1 and TNF-alpha release from murine peritoneal macrophages and the murine macrophage cell line P338D1, was assessed.	beta-Glucans	19-30	interleukin 1 complex	Mus musculus	53-57
8968520-0	1996	Production of interleukin 1 from macrophages incubated with poly (DL-lactic acid) granules containing ovalbumin.	poly (dl-lactic acid)	60-81	interleukin 1 complex	Mus musculus	14-27
9024507-9	1996	NPC production of interleukin 1 (IL-1) and interleukin-6 (IL-6) in vitro was also increased threefold following treatment of mice with levamisole.	Levamisole	135-145	interleukin 1 complex	Mus musculus	18-38
9024507-11	1996	These findings suggested that IFN alpha/beta, IL-6, and IL-1 play important regulatory roles in controlling the proliferative response of murine liver-associated T lymphocytes to levamisole.	Levamisole	179-189	interleukin 1 complex	Mus musculus	56-60
9096241-4	1997	Supernatants collected from P388D1 cells treated with CA, VS, CS, MMC, HU or LPS demonstrated enhanced production of tumor necrosis factor (TNF) confirmed by bioassay on L929 tumor target cells and increased interleukin-1 (IL-1) production by standard thymocyte proliferation bioassay.	Mitomycin	66-69	interleukin 1 complex	Mus musculus	208-227
8798439-2	1996	This study demonstrates that the free radical nitric oxide (NO) is also a regulator of IL-1 bioactivity.	Nitric Oxide	46-58	interleukin 1 complex	Mus musculus	87-91
8979148-3	1996	Estradiol, for example, has been reported to regulate TNF, IL-6, IL-1 and JE expression.	Estradiol	0-9	interleukin 1 complex	Mus musculus	65-69
8898726-11	1996	Therefore, DEX blocks the induction of LIF mRNA by inhibiting both the production of IL-1 and its action on LIF gene expression.	Dexamethasone	11-14	interleukin 1 complex	Mus musculus	85-89
8931762-0	1996	Increased IL-1, IL-6 and TNF alpha secretion and mRNA levels in WEHI-3 cells exposed to cyclopiazonic acid.	cyclopiazonic acid	88-106	interleukin 1 complex	Mus musculus	10-14
8980879-12	1996	Moreover, level of IL-1 able to stimulate [3H] thymidine incorporation into mouse thymocytes, and level of IL-1 receptor antagonist (IL-1ra), as determined by ELISA, were higher in pathological than in normal fibroblasts.	Thymidine	47-56	interleukin 1 complex	Mus musculus	19-23
8858023-10	1996	U73122 and verapamil did prevent the augmentation of IL-1 release seen after LPSp.	Verapamil	11-20	interleukin 1 complex	Mus musculus	53-57
8798439-6	1996	Aminoguanidine and iodonium diphenyl, mechanistically unrelated NOS inhibitors, also prevent the release of IL-1 activity from RAW 264.7 cells.	pimagedine	0-14	interleukin 1 complex	Mus musculus	108-112
8798439-6	1996	Aminoguanidine and iodonium diphenyl, mechanistically unrelated NOS inhibitors, also prevent the release of IL-1 activity from RAW 264.7 cells.	diphenyliodonium	19-36	interleukin 1 complex	Mus musculus	108-112
8798439-9	1996	A cGMP donor, 8-bromo-cGMP, dose-dependently reverses NMMA inhibition of bioactive IL-1 release, suggesting that NO regulates IL-1 release by a cGMP-dependent mechanism.	Cyclic GMP	2-6	interleukin 1 complex	Mus musculus	83-87
8798439-9	1996	A cGMP donor, 8-bromo-cGMP, dose-dependently reverses NMMA inhibition of bioactive IL-1 release, suggesting that NO regulates IL-1 release by a cGMP-dependent mechanism.	8-bromocyclic GMP	14-26	interleukin 1 complex	Mus musculus	83-87
8798439-9	1996	A cGMP donor, 8-bromo-cGMP, dose-dependently reverses NMMA inhibition of bioactive IL-1 release, suggesting that NO regulates IL-1 release by a cGMP-dependent mechanism.	nmma	54-58	interleukin 1 complex	Mus musculus	83-87
8798439-9	1996	A cGMP donor, 8-bromo-cGMP, dose-dependently reverses NMMA inhibition of bioactive IL-1 release, suggesting that NO regulates IL-1 release by a cGMP-dependent mechanism.	Cyclic GMP	22-26	interleukin 1 complex	Mus musculus	83-87
8932982-7	1996	With mouse cells benzydamine also substantially inhibited IL-1 production in vitro.	Benzydamine	17-28	interleukin 1 complex	Mus musculus	58-62
8954596-3	1996	In 5-day-old mice, corticosterone blood levels were markedly elevated 2 h following the last injection of IL-1.	Corticosterone	19-33	interleukin 1 complex	Mus musculus	106-110
8954596-6	1996	Furthermore, an inverse correlation between ACTH and corticosterone levels in blood and between ACTH content in the pituitary gland and corticosterone levels was observed in IL-1-treated mice.	Corticosterone	53-67	interleukin 1 complex	Mus musculus	174-178
8954596-6	1996	Furthermore, an inverse correlation between ACTH and corticosterone levels in blood and between ACTH content in the pituitary gland and corticosterone levels was observed in IL-1-treated mice.	Corticosterone	136-150	interleukin 1 complex	Mus musculus	174-178
8886850-1	1996	Alkylating agents, cyclophosphamide (CY) and the related compound mechlorethamine (NM), significantly increase in vivo the blood level of IL-6 but not of IL-1.	Cyclophosphamide	19-35	interleukin 1 complex	Mus musculus	154-158
8886850-1	1996	Alkylating agents, cyclophosphamide (CY) and the related compound mechlorethamine (NM), significantly increase in vivo the blood level of IL-6 but not of IL-1.	Cyclophosphamide	37-39	interleukin 1 complex	Mus musculus	154-158
8880300-2	1996	The induction of interferon (IFN) and interleukin-1 (IL-1) production in murine macrophages by a phosphopolysaccharide, produced by a dairy lactic acid bacteria, Lactococcus lactis ssp.	phosphopolysaccharide	97-118	interleukin 1 complex	Mus musculus	38-57
8816919-6	1996	Transforming growth factor beta caused a sustained 5- to 7-fold increase in the accumulation of PAI-1 mRNA that was maximal after 2 to 4 h. The IL-1 induction of PAI-1 was inhibited by actinomycin D, but not by cycloheximide.	Dactinomycin	185-198	interleukin 1 complex	Mus musculus	144-148
8816919-6	1996	Transforming growth factor beta caused a sustained 5- to 7-fold increase in the accumulation of PAI-1 mRNA that was maximal after 2 to 4 h. The IL-1 induction of PAI-1 was inhibited by actinomycin D, but not by cycloheximide.	Cycloheximide	211-224	interleukin 1 complex	Mus musculus	144-148
8830984-2	1996	The combination of interleukin-1 beta (IL-1) and tumor necrosis factor alpha (TNF) stimulated NO production, PGE2 production, and bone resorption.	Dinoprostone	109-113	interleukin 1 complex	Mus musculus	39-43
8830984-3	1996	The increase in bone resorption was inhibited by the NO synthase inhibitor L-NG-monomethyl arginine (LMMA) and by the cyclo-oxygenase inhibitor indomethacin, indicating that both factors act as mediators of bone resorption induced by IL-1 and TNF.	Indomethacin	144-156	interleukin 1 complex	Mus musculus	234-238
9206098-1	1996	OBJECTIVE: To observe the changes of interleukin-1 (IL-1), nitric oxide (NO) and nitric oxide synthase (NOS) in mice with oleic acid-induced acute lung injury (ALI) and the protective effects of interleukin-1 receptor antagonist (IL-1ra).	Oleic Acid	122-132	interleukin 1 complex	Mus musculus	37-50
8619029-5	1996	Pretreatment with a single dose of IL-1 resulted in the death of mice treated with 5-FU provided IL-1 was given 18 h, but not 4 or 48 h, prior to administration of sublethal doses of 5-FU.	Fluorouracil	83-87	interleukin 1 complex	Mus musculus	35-39
8619029-5	1996	Pretreatment with a single dose of IL-1 resulted in the death of mice treated with 5-FU provided IL-1 was given 18 h, but not 4 or 48 h, prior to administration of sublethal doses of 5-FU.	Fluorouracil	83-87	interleukin 1 complex	Mus musculus	97-101
8619029-5	1996	Pretreatment with a single dose of IL-1 resulted in the death of mice treated with 5-FU provided IL-1 was given 18 h, but not 4 or 48 h, prior to administration of sublethal doses of 5-FU.	Fluorouracil	183-187	interleukin 1 complex	Mus musculus	35-39
8619029-7	1996	Similarly, the toxicity of 5-FU to progenitor cells was reduced when two injections of IL-1 were administered 48 h apart.	Fluorouracil	27-31	interleukin 1 complex	Mus musculus	87-91
9812752-4	1996	RESULTS: Mat (125-500 mg.L-1) obviously inhibited concanavalin A (Con A, 5 mg.L-1)- and lipopolysaccarides (LPS, 10 mg.L-1)-induced splenocyte proliferation and LPS-induced release of IL-1 and IL-6 from mouse peritoneal macrophages.	lipopolysaccarides	88-106	interleukin 1 complex	Mus musculus	184-188
8980879-10	1996	IL-1 provided a drop in HA and a rise in GAG sulfates in normal fibroblasts, but caused an opposite effect in Crouzon fibroblasts.	gag sulfates	41-53	interleukin 1 complex	Mus musculus	0-4
8980879-12	1996	Moreover, level of IL-1 able to stimulate [3H] thymidine incorporation into mouse thymocytes, and level of IL-1 receptor antagonist (IL-1ra), as determined by ELISA, were higher in pathological than in normal fibroblasts.	Tritium	43-45	interleukin 1 complex	Mus musculus	19-23
8675313-9	1996	Our previous studies of in vitro macrophage activation by Orn-L proved that strong induction of IL-1 and prostaglandin E2 generation by Orn-L occurred (Y. Kawai and K. Akagawa, Infect.	orn-l	58-63	interleukin 1 complex	Mus musculus	96-100
8675313-9	1996	Our previous studies of in vitro macrophage activation by Orn-L proved that strong induction of IL-1 and prostaglandin E2 generation by Orn-L occurred (Y. Kawai and K. Akagawa, Infect.	orn-l	136-141	interleukin 1 complex	Mus musculus	96-100
8675313-13	1996	Namely, it was caused by prostaglandin E2 being mediated by IL-1 but not by TNF-alpha.	Dinoprostone	25-41	interleukin 1 complex	Mus musculus	60-64
8661199-8	1996	PreRx with LPSp significantly inhibited cytokine gene transcription; however, messages for both TNF and IL-1 were detectable after high-dose LPSa.	lpsa	141-145	interleukin 1 complex	Mus musculus	104-108
8661207-7	1996	The results indicate that melatonin administration after trauma-hemorrhage significantly improved the depressed immune functions, as evidenced by the restoration of Mphi IL-1 and IL-6 release, as well as significantly improved splenocyte IL-2 and IL-3 release and splenocyte proliferative capacity.	Melatonin	26-35	interleukin 1 complex	Mus musculus	170-174
8661209-2	1996	Peritoneal macrophages (M phi) incubated in carbon dioxide (CO2) but not air or helium (He), had significant, reversible inhibition of lipopolysaccharide (LPS)-stimulated tumor necrosis factor (TNF) and interleukin-1 (IL-1) release.	Carbon Dioxide	44-58	interleukin 1 complex	Mus musculus	218-222
8661209-2	1996	Peritoneal macrophages (M phi) incubated in carbon dioxide (CO2) but not air or helium (He), had significant, reversible inhibition of lipopolysaccharide (LPS)-stimulated tumor necrosis factor (TNF) and interleukin-1 (IL-1) release.	Carbon Dioxide	60-63	interleukin 1 complex	Mus musculus	218-222
8661209-8	1996	Significant reversible inhibition of TNF and IL-1 was seen with CO2, but not He or air.	Carbon Dioxide	64-67	interleukin 1 complex	Mus musculus	45-49
8661209-9	1996	Inhibition of IL-1 occurred 15 min after CO2 exposure, was associated with decreased IL-1 mRNA, and was rapidly lost following incubation in the control atmosphere.	Carbon Dioxide	41-44	interleukin 1 complex	Mus musculus	14-18
9206098-1	1996	OBJECTIVE: To observe the changes of interleukin-1 (IL-1), nitric oxide (NO) and nitric oxide synthase (NOS) in mice with oleic acid-induced acute lung injury (ALI) and the protective effects of interleukin-1 receptor antagonist (IL-1ra).	Oleic Acid	122-132	interleukin 1 complex	Mus musculus	52-56
8634432-1	1996	Ciliary neurotrophic factor (CNTF) and interleukin-6 (IL-6) potentiate the elevation of serum corticosterone induced by suboptimal doses of interleukin-1 (IL-1).	Corticosterone	94-108	interleukin 1 complex	Mus musculus	140-153
8758269-4	1996	The serum total bilirubin (TBIL) and liver necrosis of mice increased more markedly by using of TNF alpha, IL-6 or IFN gamma separately with D-GAL (TBIL: 46.2 +/- 10.6 micromol/L, 44.6 +/- 12.9 micromol/L, 41.9 +/- 14.9 micromol/L), then by D-GAL alone (TBIL: 27 +/- 11 micromol/L) also the serum TBIL of mice and liver necrosis also increased after injection of IL-1, IL-6 with D-GAL and TNF alpha.	Galactosamine	141-146	interleukin 1 complex	Mus musculus	363-367
8634432-1	1996	Ciliary neurotrophic factor (CNTF) and interleukin-6 (IL-6) potentiate the elevation of serum corticosterone induced by suboptimal doses of interleukin-1 (IL-1).	Corticosterone	94-108	interleukin 1 complex	Mus musculus	155-159
8634432-3	1996	Here, we report that four other cytokines (leukemia inhibitory factor [LIF], oncostatin M [OSM], interleukin-11 and cardiotrophin-1) also potentiated the elevation of serum corticosterone and IL-6 levels induced by IL-1.	Corticosterone	173-187	interleukin 1 complex	Mus musculus	215-219
8634432-6	1996	The potentiation of IL-1-induced serum corticosterone levels is not a consequence of the increased serum IL-6 observed after IL-1 administration.	Corticosterone	39-53	interleukin 1 complex	Mus musculus	20-24
8634432-7	1996	In fact, in IL-6 deficient mice, IL-1 increased serum corticosterone to a level comparable to that observed in wild-type mice.	Corticosterone	54-68	interleukin 1 complex	Mus musculus	33-37
8852946-3	1996	IL-1 and tumor necrosis factor-alpha (TNF-alpha), both at 1-100 ng/ml, and PTH at 0.1-10 nM increased PGHS-2 and cPLA2 mRNA and medium PGE2 levels dose-dependently after 4 h of treatment.	Dinoprostone	135-139	interleukin 1 complex	Mus musculus	0-36
8852946-11	1996	We conclude that (1) IL-1, TNF-alpha, and PTH, but not IL-6 nor IL-11, can increase the expression of PGHS-2, cPLA2, and PGE2 production in cultured mouse calvariae; (2) IL-4 inhibits PGE2 production in both control and stimulated calvarial cultures by inhibiting PGHS-2 and cPLA2; and (3) IL-4 has an inhibitory effect on bone resorption which is independent of PG production.	Dinoprostone	184-188	interleukin 1 complex	Mus musculus	21-25
8852946-11	1996	We conclude that (1) IL-1, TNF-alpha, and PTH, but not IL-6 nor IL-11, can increase the expression of PGHS-2, cPLA2, and PGE2 production in cultured mouse calvariae; (2) IL-4 inhibits PGE2 production in both control and stimulated calvarial cultures by inhibiting PGHS-2 and cPLA2; and (3) IL-4 has an inhibitory effect on bone resorption which is independent of PG production.	Prostaglandins	102-104	interleukin 1 complex	Mus musculus	21-25
8596046-1	1996	The present study was conducted to determine whether endogenous IL-1 is involved as a potent mediator of PGE2-stimulated osteoclast formation in 1 alpha,25-dihydroxyvitamin D3 (1 alpha,25-(OH)2D3)-primed calvarial cells from mouse embryos.	Dinoprostone	105-109	interleukin 1 complex	Mus musculus	64-68
8596046-1	1996	The present study was conducted to determine whether endogenous IL-1 is involved as a potent mediator of PGE2-stimulated osteoclast formation in 1 alpha,25-dihydroxyvitamin D3 (1 alpha,25-(OH)2D3)-primed calvarial cells from mouse embryos.	Calcitriol	145-175	interleukin 1 complex	Mus musculus	64-68
8697140-1	1996	Studies were carried out to determine whether the combination of IL-1 + M-CSF, similar to the effect of these cytokines on neutropenia, was able to reduce the duration of thrombocytopenia in the 5-fluorouracil (5-FU)-myelosuppressed mouse.	Fluorouracil	195-209	interleukin 1 complex	Mus musculus	65-69
8697140-1	1996	Studies were carried out to determine whether the combination of IL-1 + M-CSF, similar to the effect of these cytokines on neutropenia, was able to reduce the duration of thrombocytopenia in the 5-fluorouracil (5-FU)-myelosuppressed mouse.	Fluorouracil	211-215	interleukin 1 complex	Mus musculus	65-69
8697140-8	1996	Furthermore, the data presented are consistent with the hypothesis that IL-1 + M-CSF initially acts on a multilineage, 5-FU-resistant target cell and that IL-6 (and possibly IL-3 and GM-CSF) serves as a secondary cytokine further to enhance platelet production during rebound thrombopoiesis in the 5-FU-treated mouse.	Fluorouracil	119-123	interleukin 1 complex	Mus musculus	72-76
8991541-5	1996	SK&amp;F108636 significantly inhibited proliferation of high proliferative potential (HPP)-CFC in semisolid agar cultures stimulated by stem cell factor + interleukin 3 (IL-3) + IL-1, but had no effect in cultures stimulated with M-CSF + IL-3 + IL-1.	amicloral	0-6	interleukin 1 complex	Mus musculus	245-249
8641570-11	1996	We postulate that circulating IL-1 can be translated by brain endothelial cells into other signals such as interleukin-6 or prostaglandins that have access to the brain and induce sickness symptoms.	Prostaglandins	124-138	interleukin 1 complex	Mus musculus	30-34
8683032-4	1996	Treatment with Lithospermi radix, Astragali radix, and Cnidii rhizoma significantly inhibited BBN-induced suppression chemotactic activity and production of IL-1 and TNF-alpha by macrophages.	bbn	94-97	interleukin 1 complex	Mus musculus	157-161
8852946-11	1996	We conclude that (1) IL-1, TNF-alpha, and PTH, but not IL-6 nor IL-11, can increase the expression of PGHS-2, cPLA2, and PGE2 production in cultured mouse calvariae; (2) IL-4 inhibits PGE2 production in both control and stimulated calvarial cultures by inhibiting PGHS-2 and cPLA2; and (3) IL-4 has an inhibitory effect on bone resorption which is independent of PG production.	Dinoprostone	121-125	interleukin 1 complex	Mus musculus	21-25
8739346-3	1996	In the murine air pouch model of carrageenan/IL-1-induced inflammation TSG-6 showed a dramatic inhibitory effect on the cellular infiltration of the inflammatory site by neutrophilic PMN, while hyaluronan enhanced cellular infiltration.	Hyaluronic Acid	194-204	interleukin 1 complex	Mus musculus	45-49
7498364-11	1995	We suggest that the endogenous production of cytokines such as IL-1, IL-6, IL-3, SCF, and GM-CSF in mice treated with AS101 offers protection to circulating blood elements and ameliorates the reconstitution of megakaryocytic and erythroid progenitors.	ammonium trichloro(dioxoethylene-O,O'-)tellurate	118-123	interleukin 1 complex	Mus musculus	63-67
8597057-2	1995	Pretreatment of mice with interleukin-1 beta (IL-1) resulted in elevated levels of nitrite/nitrate in serum and rendered mice insensitive towards TNF toxicity.	Nitrites	83-90	interleukin 1 complex	Mus musculus	46-50
8597057-2	1995	Pretreatment of mice with interleukin-1 beta (IL-1) resulted in elevated levels of nitrite/nitrate in serum and rendered mice insensitive towards TNF toxicity.	Nitrates	91-98	interleukin 1 complex	Mus musculus	46-50
9132179-1	1996	The feeding of cholesterol-enriched diet for 2 weeks was enough to reduce nitric oxide (NO), prostaglandin E(2) (PGE(2) and interleukin-1 (IL-1) productions in thioglycollate-elicited murine macrophages.	Cholesterol	15-26	interleukin 1 complex	Mus musculus	124-137
9132179-1	1996	The feeding of cholesterol-enriched diet for 2 weeks was enough to reduce nitric oxide (NO), prostaglandin E(2) (PGE(2) and interleukin-1 (IL-1) productions in thioglycollate-elicited murine macrophages.	Cholesterol	15-26	interleukin 1 complex	Mus musculus	139-143
9132179-1	1996	The feeding of cholesterol-enriched diet for 2 weeks was enough to reduce nitric oxide (NO), prostaglandin E(2) (PGE(2) and interleukin-1 (IL-1) productions in thioglycollate-elicited murine macrophages.	Thioglycolates	160-174	interleukin 1 complex	Mus musculus	124-137
9132179-1	1996	The feeding of cholesterol-enriched diet for 2 weeks was enough to reduce nitric oxide (NO), prostaglandin E(2) (PGE(2) and interleukin-1 (IL-1) productions in thioglycollate-elicited murine macrophages.	Thioglycolates	160-174	interleukin 1 complex	Mus musculus	139-143
8883917-2	1996	Because cerebral noradrenergic systems have been implicated in Fos induction, we studied the IL-1-induced appearance of Fos in mice pretreated with 6-hydroxydopamine (6-OHDA) which depleted cerebral norepinephrine (NE) by more than 90%, but did not significantly alter dopamine.	Oxidopamine	148-165	interleukin 1 complex	Mus musculus	93-97
8883917-4	1996	Pretreatment with 6-OHDA substantially reduced the IL-1-induced Fos increase in the PVN which was no longer statistically significant.	Oxidopamine	18-24	interleukin 1 complex	Mus musculus	51-55
8883917-5	1996	When the 6-OHDA treatment was preceded by administration of desmethylimipramine which prevents NE depletion, IL-1 treatment increased Fos in the PVN, suggesting that the effect of 6-OHDA was indeed related to the depletion of NE.	Oxidopamine	9-15	interleukin 1 complex	Mus musculus	109-113
8883917-5	1996	When the 6-OHDA treatment was preceded by administration of desmethylimipramine which prevents NE depletion, IL-1 treatment increased Fos in the PVN, suggesting that the effect of 6-OHDA was indeed related to the depletion of NE.	Desipramine	60-79	interleukin 1 complex	Mus musculus	109-113
8883917-5	1996	When the 6-OHDA treatment was preceded by administration of desmethylimipramine which prevents NE depletion, IL-1 treatment increased Fos in the PVN, suggesting that the effect of 6-OHDA was indeed related to the depletion of NE.	Oxidopamine	180-186	interleukin 1 complex	Mus musculus	109-113
8883917-7	1996	By contrast with previous experiments is rats, the IL-1-induced increase in plasma corticosterone was not significantly altered by the 6-OHDA pretreatment in mice.	Corticosterone	83-97	interleukin 1 complex	Mus musculus	51-55
8598393-5	1996	The results show that U50,488H had a suppressive effect on the production of TNF-alpha and IL-1 at concentrations as low as 1 nM, while IL-6 was suppressed at concentrations as low as 10 nM.	488h	26-30	interleukin 1 complex	Mus musculus	91-95
8597415-5	1995	Furthermore, in keeping with the effects of stress mediators to up-regulate IL-1 receptors in AtT-20 cells, ether-laparotomy stress in mice resulted in a significant increase in [125I]IL-1 alpha binding in the pituitary with no significant alterations observed in the brain; in contrast, [125I]oCRF binding in the pituitary was significantly decreased after the ether-laparotomy stress.	Ether	108-113	interleukin 1 complex	Mus musculus	76-80
8597423-3	1995	Macrophages are sensitive to stress in that cold-water stress causes increased cytokine production, either spontaneously (IL-1), or after induction with LPS (IL-6, TNF alpha).	Water	49-54	interleukin 1 complex	Mus musculus	122-126
7489995-4	1995	Pretreatment of mice with IL-1 resulted in elevated levels of nitrite/nitrate in serum and in enhanced nitric oxide synthase (NOS) activity in liver cells isolated from these animals.	Nitrites	62-69	interleukin 1 complex	Mus musculus	26-30
7489995-4	1995	Pretreatment of mice with IL-1 resulted in elevated levels of nitrite/nitrate in serum and in enhanced nitric oxide synthase (NOS) activity in liver cells isolated from these animals.	Nitrates	70-77	interleukin 1 complex	Mus musculus	26-30
7489995-5	1995	In addition, pharmacological doses of the nitric oxide (NO) donor sodium nitroprusside conferred complete protection against TNF alpha-induced liver injury in galactosamine-sensitized mice, suggesting a possible link between IL-1- and NO-induced protection.	Nitric Oxide	42-54	interleukin 1 complex	Mus musculus	225-229
7489995-5	1995	In addition, pharmacological doses of the nitric oxide (NO) donor sodium nitroprusside conferred complete protection against TNF alpha-induced liver injury in galactosamine-sensitized mice, suggesting a possible link between IL-1- and NO-induced protection.	Nitroprusside	66-86	interleukin 1 complex	Mus musculus	225-229
7489995-5	1995	In addition, pharmacological doses of the nitric oxide (NO) donor sodium nitroprusside conferred complete protection against TNF alpha-induced liver injury in galactosamine-sensitized mice, suggesting a possible link between IL-1- and NO-induced protection.	Galactosamine	159-172	interleukin 1 complex	Mus musculus	225-229
8964654-5	1995	IL-1, IL-4, and IL-6 modified cell proliferation in general, and their effects had some age-related differences, but these actions were independent of THC.	Dronabinol	151-154	interleukin 1 complex	Mus musculus	0-4
8835558-17	1995	CONCLUSION: Local production of IL-1 in ICA in knee joints seems directly responsible for inhibition of proteoglycan synthesis.	ica	40-43	interleukin 1 complex	Mus musculus	32-36
7579389-9	1995	Genistein similarly inhibited c-jun expression in stromal cells exposed to IL-1 (500 U/mL) plus TNF-alpha (500 U/mL).	Genistein	0-9	interleukin 1 complex	Mus musculus	75-79
7579389-10	1995	The potential role of a tyrosine kinase pathway in arachidonate-mediated c-jun expression was further investigated by assaying the tyrosine kinase activity of cells challenged with arachidonic acid, IL-1, and TNF-alpha.	Arachidonic Acid	51-63	interleukin 1 complex	Mus musculus	199-203
8634684-0	1995	Participation of TNF-alpha and IL-1 in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis.	Cyclophosphamide	59-75	interleukin 1 complex	Mus musculus	31-35
8706168-5	1995	IL-2 activity in the supernatants was evaluated for its ability to support IL-2 independant cell line (CTLL-2) proliferation and the results showed that DON had no marked effect on IL-2 level, but inhibited the capacity of murine peritoneal macrophages to produce IL-1 and TNF, which play very important roles in the process of inflammation and immune response.	deoxynupharidine	153-156	interleukin 1 complex	Mus musculus	264-276
7561522-5	1995	Rat and mouse fibroblasts were also found to produce nitric oxide when primed with IFN-gamma and simultaneously treated with IL-1, TNF-alpha, or LPS.	Nitric Oxide	53-65	interleukin 1 complex	Mus musculus	125-129
21597830-4	1995	Similar results demonstrating greater protection with IL-1 incubation from L-PAM were seen when murine bone marrow cells were assayed for long-term culture-initiating cells.	Melphalan	75-80	interleukin 1 complex	Mus musculus	54-58
8582784-4	1995	Intraperitoneal treatment of hydrocortisone treated aged mice with zinc-thymulin (100 ng/day x 5) resulted in mild augmentation of splenocyte but not thymocyte responses in vitro to IL-1, IL-2, and natural cytokine mixture (NCM) and to PHA and concanavalin A (Con A) (average increase 40%).	Hydrocortisone	29-43	interleukin 1 complex	Mus musculus	182-186
8582784-4	1995	Intraperitoneal treatment of hydrocortisone treated aged mice with zinc-thymulin (100 ng/day x 5) resulted in mild augmentation of splenocyte but not thymocyte responses in vitro to IL-1, IL-2, and natural cytokine mixture (NCM) and to PHA and concanavalin A (Con A) (average increase 40%).	zinc-thymulin	67-80	interleukin 1 complex	Mus musculus	182-186
21597830-5	1995	Furthermore, IL-1 protects long-term repopulating hematopoietic stem cells from L-PAM when studied using an in vivo irradiated mouse assay.	Melphalan	80-85	interleukin 1 complex	Mus musculus	13-17
8530254-8	1995	In fact, diseased, saline treated mouse plasma inhibited the cell proliferation assay in the presence of IL-1, and dilution studies showed that the endogenous inhibitors were of high titre.	Sodium Chloride	19-25	interleukin 1 complex	Mus musculus	105-109
7675040-2	1995	IL-1 synergistically enhances the stimulatory effect of TPA on AP-1-mediated gene expression in this cell line.	Tetradecanoylphorbol Acetate	56-59	interleukin 1 complex	Mus musculus	0-4
7675040-4	1995	We found that IL-1 + TPA-treated cells contain significantly higher Jun B protein levels than cells treated with TPA alone.	Tetradecanoylphorbol Acetate	21-24	interleukin 1 complex	Mus musculus	14-18
7675040-4	1995	We found that IL-1 + TPA-treated cells contain significantly higher Jun B protein levels than cells treated with TPA alone.	Tetradecanoylphorbol Acetate	113-116	interleukin 1 complex	Mus musculus	14-18
7675040-9	1995	Thus, the stimulation of AP-1-mediated gene expression by IL-1 in EL4 cells is due to the promotion of Jun B protein accumulation that, in turn, facilitates Jun B heterodimerization with TPA-induced Fra-1 protein, thereby forming an active AP-1 complex.	Tetradecanoylphorbol Acetate	187-190	interleukin 1 complex	Mus musculus	58-62
7602094-4	1995	We found that partial ADP-ribosylation of the Gi2/Gi3 proteins before stimulation with IL-1 was sufficient to obtain full inhibition of IL-2 release.	Adenosine Diphosphate	22-25	interleukin 1 complex	Mus musculus	87-91
8522354-1	1995	Muramyl dipeptide (MDP) induces NF-kappa B activation in the murine pre-B cell line 70Z/3, increases the expression of surface immunoglobulins, and potentiates the response to other inducers such as LPS or IL-1.	Acetylmuramyl-Alanyl-Isoglutamine	0-17	interleukin 1 complex	Mus musculus	206-210
8522354-1	1995	Muramyl dipeptide (MDP) induces NF-kappa B activation in the murine pre-B cell line 70Z/3, increases the expression of surface immunoglobulins, and potentiates the response to other inducers such as LPS or IL-1.	Acetylmuramyl-Alanyl-Isoglutamine	19-22	interleukin 1 complex	Mus musculus	206-210
8576539-6	1995	Potential regulation of IL-1 activity was determined by monitoring the effects of amiprilose HCl on IL-1 stimulated proliferation of murine thymocytes and human synovial cells.	amiprilose	82-96	interleukin 1 complex	Mus musculus	24-28
8576539-6	1995	Potential regulation of IL-1 activity was determined by monitoring the effects of amiprilose HCl on IL-1 stimulated proliferation of murine thymocytes and human synovial cells.	amiprilose	82-96	interleukin 1 complex	Mus musculus	100-104
7566437-0	1995	Effect of bacterial endotoxin and interleukin-1 on prostaglandin biosynthesis by the hippocampus of mouse brain: role of interleukin-1 receptors and glucocorticoids.	Prostaglandins	51-64	interleukin 1 complex	Mus musculus	34-47
7566437-2	1995	In the present study we examined the effect of the bacterial endotoxin lipopolysaccharide (LPS) and interleukin-1 (IL-1) on the ex vivo production of PGE2 by the dorsal hippocampus of the mouse which contains high levels of receptors to IL-1.	Dinoprostone	150-154	interleukin 1 complex	Mus musculus	100-119
7566437-2	1995	In the present study we examined the effect of the bacterial endotoxin lipopolysaccharide (LPS) and interleukin-1 (IL-1) on the ex vivo production of PGE2 by the dorsal hippocampus of the mouse which contains high levels of receptors to IL-1.	Dinoprostone	150-154	interleukin 1 complex	Mus musculus	115-119
7566437-3	1995	The roles of IL-1 receptors and GC in the regulation of LPS- or IL-1-induced PGE2 production were also studied.	Dinoprostone	77-81	interleukin 1 complex	Mus musculus	13-17
7566437-3	1995	The roles of IL-1 receptors and GC in the regulation of LPS- or IL-1-induced PGE2 production were also studied.	Dinoprostone	77-81	interleukin 1 complex	Mus musculus	64-68
7566437-8	1995	In mice treated with the IL-1 receptor antagonist or with the IL-1 antagonist alpha-melanocyte-stimulating hormone (alpha-MSH), the effects of LPS and IL-1 on PGE2 production were completely abolished.	Dinoprostone	159-163	interleukin 1 complex	Mus musculus	25-29
7566437-8	1995	In mice treated with the IL-1 receptor antagonist or with the IL-1 antagonist alpha-melanocyte-stimulating hormone (alpha-MSH), the effects of LPS and IL-1 on PGE2 production were completely abolished.	Dinoprostone	159-163	interleukin 1 complex	Mus musculus	62-66
7566437-8	1995	In mice treated with the IL-1 receptor antagonist or with the IL-1 antagonist alpha-melanocyte-stimulating hormone (alpha-MSH), the effects of LPS and IL-1 on PGE2 production were completely abolished.	Dinoprostone	159-163	interleukin 1 complex	Mus musculus	62-66
7566437-10	1995	In mice treated with 100 micrograms DEX/mouse, the facilitatory effect of the lower DEX does in IL-1-induced PGE2 production was abolished.	Dexamethasone	36-39	interleukin 1 complex	Mus musculus	96-100
7566437-10	1995	In mice treated with 100 micrograms DEX/mouse, the facilitatory effect of the lower DEX does in IL-1-induced PGE2 production was abolished.	Dexamethasone	84-87	interleukin 1 complex	Mus musculus	96-100
7566437-10	1995	In mice treated with 100 micrograms DEX/mouse, the facilitatory effect of the lower DEX does in IL-1-induced PGE2 production was abolished.	Dinoprostone	109-113	interleukin 1 complex	Mus musculus	96-100
7888674-9	1995	These results suggest a role for IL-1, IL-6, TNF alpha, and SCF in the radioprotective effect of AS101.	ammonium trichloro(dioxoethylene-O,O'-)tellurate	97-102	interleukin 1 complex	Mus musculus	33-37
7575351-2	1995	This kinase was identified in immunoprecipitates from IL-1 stimulated T-cells by its ability to phosphorylate exogenous substrates in the presence of radiolabeled ATP.	Adenosine Triphosphate	163-166	interleukin 1 complex	Mus musculus	54-58
7791124-5	1995	Furthermore, inhibition of IL-1 produced by the P388D1 cell line was reversed by both the classical opioid antagonist naloxone and by the kappa opioid receptor antagonist norbinaltorphimine.	Naloxone	118-126	interleukin 1 complex	Mus musculus	27-31
7791124-5	1995	Furthermore, inhibition of IL-1 produced by the P388D1 cell line was reversed by both the classical opioid antagonist naloxone and by the kappa opioid receptor antagonist norbinaltorphimine.	norbinaltorphimine	171-189	interleukin 1 complex	Mus musculus	27-31
7791343-14	1995	The combination of LPSp plus 8-bromo-cAMP blocked the augmentation of IL-1 without changing TNF inhibition.	8-Bromo Cyclic Adenosine Monophosphate	29-41	interleukin 1 complex	Mus musculus	70-74
7748039-4	1995	The authors previously have demonstrated that pretreatment with cytokines such as IL-1 or TNF can reduce the lethality of endotoxin (lipopolysaccharide), gram-negative sepsis, cancer cachexia, and oxygen toxicity.	Oxygen	197-203	interleukin 1 complex	Mus musculus	82-86
7729899-7	1995	IL-1 receptor antagonist significantly inhibited the osteoclast-like cell formation mediated by A. actinomycetemcomitans Y4 capsular-like polysaccharide in mouse marrow cultures.	Polysaccharides	138-152	interleukin 1 complex	Mus musculus	0-4
7729899-8	1995	The bioactive IL-1 was detected in the culture media of mouse bone marrow cells stimulated with A. actinomycetemcomitans Y4 capsular-like polysaccharide.	capsular-like	124-137	interleukin 1 complex	Mus musculus	14-18
7729899-8	1995	The bioactive IL-1 was detected in the culture media of mouse bone marrow cells stimulated with A. actinomycetemcomitans Y4 capsular-like polysaccharide.	Polysaccharides	138-152	interleukin 1 complex	Mus musculus	14-18
7729899-9	1995	These results indicate that IL-1 alpha is involved in the mechanism of the formation of osteoclast-like cells induced by A. actinomycetemcomitans Y4 capsular-like polysaccharide.	Polysaccharides	163-177	interleukin 1 complex	Mus musculus	28-32
7729899-13	1995	Furthermore, a correlation between IL-1 alpha and prostaglandin E2 in the osteoclast recruitment induced by A. actinomycetemcomitans Y4 capsular-like polysaccharide is discussed.	Dinoprostone	50-66	interleukin 1 complex	Mus musculus	35-39
7729899-13	1995	Furthermore, a correlation between IL-1 alpha and prostaglandin E2 in the osteoclast recruitment induced by A. actinomycetemcomitans Y4 capsular-like polysaccharide is discussed.	Polysaccharides	150-164	interleukin 1 complex	Mus musculus	35-39
7601503-4	1995	Alveolar macrophages isolated from mice challenged with SRBC released higher levels of IL-1, IL-6, and tumor necrosis factor-alpha (TNF-alpha) upon in vitro lipopolysaccharide (LPS) stimulation compared to unprimed, challenged mice or mice receiving intraperitoneal SRBC alone.	srbc	56-60	interleukin 1 complex	Mus musculus	87-91
7601503-9	1995	Blocking IL-1 or IL-2 but not TNF-alpha also resulted in a significant decrease in lung hydroxyproline increase, as well as lung granulomatous response and fibrosis.	Hydroxyproline	88-102	interleukin 1 complex	Mus musculus	9-13
7876552-0	1995	ATP induces the release of IL-1 from LPS-primed cells in vivo.	Adenosine Triphosphate	0-3	interleukin 1 complex	Mus musculus	27-31
7583520-1	1995	The time-course and pharmacological modulation of interleukin-1 (IL-1) production were investigated during zymosan induced peritonitis in mice.	Zymosan	107-114	interleukin 1 complex	Mus musculus	50-63
7583520-1	1995	The time-course and pharmacological modulation of interleukin-1 (IL-1) production were investigated during zymosan induced peritonitis in mice.	Zymosan	107-114	interleukin 1 complex	Mus musculus	65-69
7583520-4	1995	injection of zymosan induced significant IL-1 release into the peritoneal exudate.	Zymosan	13-20	interleukin 1 complex	Mus musculus	41-45
7583520-7	1995	DEX and IX 207-887 dose-dependently decreased the immunoassayable IL-1 alpha level and the IL-1 like bioactivity as well.	Dexamethasone	0-3	interleukin 1 complex	Mus musculus	66-70
7891145-9	1995	In summary, these results suggest that IS enhances biologically active IL-1 in the hypothalamus, and that hypothalamic IL-1 plays a role in the regulation of IS-induced responses including elevated monoamine release in the hypothalamus and activation of the hypothalamo-pituitary-adrenal axis.	monoamine	198-207	interleukin 1 complex	Mus musculus	119-123
7780034-0	1995	Ciliary neurotrophic factor (CNTF) induces serum amyloid A, hypoglycaemia and anorexia, and potentiates IL-1 induced corticosterone and IL-6 production in mice.	Corticosterone	117-131	interleukin 1 complex	Mus musculus	104-108
7780034-4	1995	A single intravenous injection of CNTF induced hypoglycaemia and SAA and potentiated IL-1-induced CS and IL-6.	Corticosterone	98-100	interleukin 1 complex	Mus musculus	85-89
7876552-7	1995	Adenosine 5"-O-(3-thiotriphosphate) was also effective in causing IL-1 release but not UTP or ADP.	adenosine 5'-O-(3-thiotriphosphate)	0-35	interleukin 1 complex	Mus musculus	66-70
7876552-8	1995	This suggests that the ATP-mediated release of IL-1 is a receptor-mediated phenomenon that is associated with cell lysis.	Adenosine Triphosphate	23-26	interleukin 1 complex	Mus musculus	47-51
7841193-6	1995	N-Acetylcysteine inhibited IL1-induced interleukin-2 in EL4, however, demonstrating that N-acetylcysteine was biologically active.	Acetylcysteine	0-16	interleukin 1 complex	Mus musculus	27-30
7835294-1	1995	Numerous in vivo and in vitro studies have shown the effects of interleukin-1 (IL-1) on insulin and glucagon secretion.	Glucagon	100-108	interleukin 1 complex	Mus musculus	64-77
7835294-1	1995	Numerous in vivo and in vitro studies have shown the effects of interleukin-1 (IL-1) on insulin and glucagon secretion.	Glucagon	100-108	interleukin 1 complex	Mus musculus	79-83
7841193-6	1995	N-Acetylcysteine inhibited IL1-induced interleukin-2 in EL4, however, demonstrating that N-acetylcysteine was biologically active.	Acetylcysteine	89-105	interleukin 1 complex	Mus musculus	27-30